51

Satu

rday, M

ay 15

AMERICAN TRANSPLANT CONGRESSDay-at-a-Glance, Saturday, May 15, 2004

Pre-Meeting Symposia #1:Complications of Transplantation and Infections8:00 AM – 4:30 PM

Session I: Medical Complications of TransplantationBallroom BChair: Kim Olthoff

8:00 AM Post-transplant Renal Insufficiency: Prevalence,Strategies, Dialysis vs. Transplant in the Non-renal Transplant Recipient

Alan Wilkinson8:30 AM Post-transplant Diabetes: Epidemiology,

Treatment, and Long-term EffectsDonald Hricik

9:00 AM Post-transplant Obesity: Prevalence, Effect onPharmacokinetics, Strategies for Weight Loss

John Pirsch9:30 AM Coffee Break

Session II: Strategies to Minimize Complications ofImmunosuppressionBallroom BChair: Jeffrey Crippin

10:00 AM Does the Choice of Immunosuppression AffectLong-term Complications? General Overview ofDM, HTN, CAD, CRI, Lipids

Connie Davis10:30 AM Lessons Learned from Steroid Sparing Studies

Arthur Matas11:00 AM Lessons Learned from CNI-sparing Studies

Harold Helderman11:30 AM Lessons Learned from Induction Therapy

Robert Gaston12:00 PM Lunch Break

Session III: Infection in Transplantation: State-of-the-Artand Future ChallengesBallroom BChairs: Mark D. Pescovitz and Robert H. Rubin

1:30 PM Overview: Challenges in Transplant InfectiousDisease

Jay Fishman2:00 PM Infections in VADs and Heart Transplantation

Steven Gordon2:30 PM Special Problems: Fungal Infection in

TransplantationBernie Kubak

3:00 PM Coffee Break3:30 PM Antiviral Resistance in Cytomegalovirus

Ajit Limaye4:00 PM Polyomavirus Associated Diseases in the

Transplant PatientParmjeet Randhawa

Pre-Meeting Symposia #2:Immunology Update 20048:00 AM – 5:00 PM

Session I: The Basics of Transplant Immunology for theClinicianBallroom AChair: Sheri Krams

8:00 AM Overview of T-cell Immunity in TransplantRejection

Peter Heeger8:35 AM Clinical Significance of HLA Antibodies

Peter Nickerson9:10 AM Overview of Costimulatory Pathways

Thomas Pearson9:45 AM Coffee Break10:15 AM Overview of Chemokine Function and Relevance

to TransplantationRobert Strieter

10:50 AM Regulatory Dendritic Cells and Their Potential forTransplant Tolerance

Angus Thomas11:25 AM T- and B-cell Tolerance: Overview of Tolerance

MechanismsAnita Chong

12:00 PM Lunch Break

Session II: Update in Transplantation BiologyBallroom AChair: Peter Heeger

1:30 PM Innate Immunity in TransplantationDaniel Goldstein

2:00 PM T-cell Regulation in TransplantationKathryn Wood

2:30 PM Barriers to Transplantation ToleranceLaurence Turka

3:00 PM Coffee Break3:30 PM Hepatocyte Transplantation

Ira Fox4:00 PM The Biology of Post-transplant

Lymphoproliferative DiseaseOlivia Martinez

4:30 PM New Bone Marrow Transplantation ProtocolsIncluding Transplantation

Megan Sykes

52

AMERICAN TRANSPLANT CONGRESSDay-at-a-Glance, Saturday, May 15, 2004

Pre-Meeting Symposia #3:Tissue Typing Laboratory and Its ClinicalApplications8:00 AM – 5:00 PMCo-Sponsored with the American Society for Histocompatibility &Immunogenetics (ASHI)

Session I: Antibodies and Crossmatch: Past, Present andFutureBallroom CChair: Adriana Zeevi

8:00 AM IntroductionAdriana Zeevi

8:05 AM The ABC’s of Histocompatibility Testing: HLA2004

Howard Gebel8:30 AM Basic Concepts and Historic Prospective

Ronald Kerman9:00 AM Current Approaches to HLA Antibody

IdentificationRobert Bray

9:30 AM Clinical Application and Risk ManagementPeter Nickerson

10:00 AM Coffee Break10:30 AM Problems and Problem Solving

Howard Gebel11:00 AM Laboratory Support for Desensitization Protocols

Andrea Zachary11:30 PM Clinical Significance of Post-transplant Antibody

Adriana Zeevi12:00 PM Lunch Break

Session II: Clinical Desensitization ProtocolsBallroom CChair: Mark Stegall

1:30 PM IntroductionMark Stegall

1:35 PM The Impact of Desensitization on AlloantibodyMark Stegall

2:00 PM Plasmapheresis and Low-dose IVIGJames Gloor

2:30 PM Coffee Break3:00 PM Pathology of Humoral Rejection

Robert Colvin3:30 PM Therapeutic Approaches to Managing Anti-HLA

AntibodyRobert Montgomery

4:00 PM High-dose IVIG DesensitizationStanley Jordan

4:30 PM Panel Q&A session

Pre-Meeting Symposia #4:Pediatric Symposium8:30 AM – 5:00 PMCo-Sponsored with the International Pediatric Transplant Society(IPTA)

Session I: Transplantation of the AdolescentRoom 312Chairs: Richard Fine and Deidre Kelly

8:30 AM Biological and Psychological Differences of theChildren and Adolescents

Daphne Hsu9:00 AM Gynecologic, Issues of the Adolescent Female

Solid Organ Transplant RecipientGina Sucato

9:30 AM Growing Up, Moving On: Transition from Pediatricto Adult Care Giving

Janet McDonagh10:00 AM Coffee Break

10:30 AM Tolerance Induction is the Answer to AdolescentNon-Adherence

Allan D. Kirk11:00 AM Nothing Can be Done to Impact on Adolescent

Non-Adherence - DebatePRO: Fabienne DobbelsCON: Robert Ettenger

12:00 PM Lunch Break

Session II: Use of Newer Immunosuppressive Drugs inPediatric RecipientsRoom 312Chairs: Jean-Bernard Otte and Steven Webber

1:30 PM Rituximab/IVIg/Plasmapheresis for AcuteHumoral Rejection

Stanley Jordan2:00 PM Replacing CI’s with TOR Inhibitors

Rakesh Sindhi2:30 PM Campath- 1H

Andreas Tzakis3:00 PM Coffee Break3:30 PM Anti-IL-2 AB vs. T-cell Depleting AB Induction

Sylvie Di-Fillipo4:00 PM Co-Stimulation Blockade

William Harmon4:30 PM Steroid Avoidance in Pediatric Transplantation

with Particular Reference to LiverRaymond Reding

53

Satu

rday, M

ay 15

AMERICAN TRANSPLANT CONGRESSDay-at-a-Glance, Saturday, May 15, 2004

Pre-Meeting Symposia #5:Transplant Nurses and Coordinators Program8:30 AM – 5:00 PMCo-Sponsored with the International Transplant Nurses Society(ITNS) and the National Association for Transplant Coordinators(NATCO)

Room 302/304Chairs: Beverly Kosmach-Park and Dianne LaPointe Rudow

8:30 AM Introduction and WelcomeBeverly Kosmach-Park/Dianne LaPointe Rudow

8:40 AM Where are They Now? Long-term Survivors ofSolid Organ Transplant

Marian O’Rourke9:00 AM Renal Dysfunction: A Necessary Evil?

Ravinder Wali9:30 AM Cardiovascular Health Following Solid Organ

TransplantationSandra A. Cupples

10:00 AM Malignancies in the Solid Organ TransplantRecipient

Suzanne Olbricht10:30 AM Coffee Break10:45 AM Women’s Health Issues for Transplant Recipient

Veronica Gomez-Lobo11:15 AM The National Transplantation Pregnancy Registry

(NTPR): Update and OutcomesLisa Coscia

11:45 PM Lunch Break

1:00 PM Psychosocial Aspects of the Long-term TransplantRecipient

Judy Joyce1:45 PM The Incidence, Management and Outcomes of

Hepatitis C Infections Following Solid OrganTransplantation

Dianne LaPointe Rudow2:15 PM Financial and Lifestyle Concerns of the Long-term

Transplant SurvivorJames Rodrigue

2:45 PM Coffee Break3:00 PM Psychiatric Issues Transplantation: What Are Our

Options?Sylvia Hafliger

3:45 PM Time To Grow Up: Transitioning the OlderAdolescent to an Adult Transplant Program

Beverly Kosmach-Park4:15 PM Transplant Program Longevity: Designing Your

Program for the Long HaulModerator: Beverly Kosmach-ParkPanel: William Morris, Linda Ohler, KathySchwab, Barry Friedman, Dianne LaPointeRudow

Opening Wine & Cheese Reception5:00 - 7:00 PM Exhibits Open

54

7:00 – 8:15 AM Concurrent Sunrise SymposiaPage 56 Sunrise Symposium I: Early Signs of

InflammationBallroom A

Sunrise Symposium II: The “Business”of Transplantation: Concepts andControversyBallroom B

Sunrise Symposium III: InternationalIssues in TransplantationBallroom C

8:30 – 9:30 AM Plenary Session IPage 56 Joint Plenary Session

Veterans Auditorium

9:30 AM Break

9:45 – 11:15 AM Concurrent SymposiaPage 56 Basic Science Symposium: Genomics and

Proteomics in TransplantationBallroom B

Clinical Science Symposium: AnOverview of the UNOS and SRTRVeterans Auditorium

11:30 AM-12:30 PM Joint SessionPage 57

11:30 AM AwardsVeterans Auditorium

12:00 PM State-of-the-Art AddressVeterans Auditorium

12:30 – 2:00 PM Poster Session IPresenters in AttendanceExhibits OpenExhibit Hall C

Page 57 Acute and Chronic Rejection

Page 58 Adult to Adult Living Donor LiverTransplantation (AALDLT)

Page 59 Cardiac Transplantation:Immunosuppression

Page 60 Chemokines/Cytokines

Page 61 Complications and Donors (AALDT)

Page 62 Experimental Tolerance Induction I

Page 63 Immunosuppression:Preclinical Studies I

Page 64 Infections: BK Virus, HCV, HIV and HHV

Page 65 Kidney: Complications and ProtocolBiopsies

AMERICAN TRANSPLANT CONGRESSDay-at-a-Glance, Sunday, May 16, 2004

Page 66 Kidney: Pediatrics

Page 66 Liver Transplant: Potpourri

Page 67 Low/No Steroids Trial: Other Trials,Conversion, and Scientific Studies

Page 69 Lung: All Topics

Page 70 PK Studies and Complications

Page 72 Tissue Injury I

Page 73 Xenotransplantation

12:45 – 1:45 PM Mini-Oral SessionsPage 74 Acute Rejection: Novel Mechanisms

Room 311

Page 74 Chemokines and CytokinesRoom 309

Page 74 Current Consideration with the NewerImmunosuppressantsBallroom A

Page 75 Donation, Preservation, and ProcurementRoom 302/304

Page 75 Theraputic Drug MonitoringBallroom C

2:00 – 3:30 PM Concurrent SessionsPage 76 Concurrent Session 1: Alloantibodies

and Positive Crossmatch KidneyTransplantationVeterans Ballroom

Page 76 Concurrent Session 2: CardiovascularDisease and Kidney TransplantationBallroom A

Page 77 Concurrent Session 3: Generating T-Regulatory Cells for ToleranceRoom 311

Page 77 Concurrent Session 4:Immunosuppression: Challenges andNew Combinations IRoom 302/304

Page 78 Concurrent Session 5: LiverTransplantation: Advances inImmunosuppressionBallroom B

Page 78 Concurrent Session 6: LungTransplantation: All TopicsRoom 306

Page 79 Concurrent Session 7: LymphocyteActivation: Regulatory Cells, Anergyand Inhibitory ReceptorsRoom 310

Page 80 Concurrent Session 8: Markers andMechanisms of Chronic Graft InjuryRoom 309

55

Su

nd

ay, May 16

AMERICAN TRANSPLANT CONGRESSDay-at-a-Glance, Sunday, May 16, 2004

Page 80 Concurrent Session 9: Predictors ofRejectionRoom 312

Page 81 Concurrent Session 10: Risk Factors inDeceased Donor Kidney TransplantationBallroom C

4:00 – 5:30 PM Concurrent SessionsPage 81 Concurrent Session 11:

Immunosuppression in CardiacTransplantationRoom 312

Page 82 Concurrent Session 12:Immunosuppression: Challanges andNew CombinationsBallroom C

Page 82 Concurrent Session 13:Immunosuppression: Preclinical StudiesRoom 306

Page 83 Concurrent Session 14: Infections: HCV,HIV and Opportunistic InfectionsRoom 302/304

Page 84 Concurrent Session 15: Islet Cell andStem CellRoom 309

Page 84 Concurrent Session 16: LiverTransplantation: Live Donors and Splits-ComplicationsBallroom B

Page 85 Concurrent Session 17: Sirolimus/EverolimusBallroom A

Page 85 Concurrent Session 18: SteroidCessation ProtocolsRoom 311

Page 86 Concurrent Session 19: TransplantTolerance IRoom 310

Page 86 Concurrent Session 20: Use of ExpandedCriteria Donor KidneysVeterans Ballroom

56

Sunday, May 16, 2004

Concurrent Sunrise Symposia7:00 – 8:15 AM

Sunrise Symposium I: Early Signs of InflammationBallroom AChair: Wayne Hancock

7:00 AM Graft inflammation defines the type of rejectionFadi Lakkis

7:25 AM TLRs and vascular inflammationAsrar Malik

7:50 AM Early signal of inflammation and transplantrejection

Robert Fairchild

Sunrise Symposium II: The “Business” ofTransplantation: Concepts and ControversyBallroom BChair: Michael Abecassis

7:00 AM Interative Session: Transplant finance - a practicalapproach

Michael Abecassis7:30 AM Debate: Transplantation beyond the bottom line

Does it exist?Frugality in transplantationFair price or underprice pricing in a competitive

marketTransplants as loss leaders

Pro - The bottom line is absolutely necessary forsurvival and needs to be managed like a business

Paul Kuo

Con - There should be some room for innovationand research and some sacrifice needs to be madefor advancement

Abraham Shaked

8:00 AM Panel discussion with all participantsRobert Montgomery

Sunrise Symposium III: International Issues inTransplantationBallroom CChair: Mark Ghobrial

7:00 AM Unique issues in BrazilElias David-Neto

7:25 AM Czech Republic in the context of the worldtransplant medicine

Stephen Vitko7:50 AM Unique issues in Turkey

Yaman Tokat

Plenary Session: Joint Plenary I8:30 - 9:30 AM

Veterans AuditoriumChairs: Michael Lucey and Abraham Shaked

8:30 AM DISTINCT FIBROSIS PATTERNS CHARACTERIZECAMPATH-1H PLUS RAPAMYCIN VERSUSTRADITIONAL THERAPY WITH CALCINEURININHIBITION. (Abstract #1)Steven Hoffmann, Lynn M. Jacobson, Rebecca J.Muehrer, Allan D. Kirk, Stuart Knechtle, Bryan N.Becker. Bethesda, MD; Madison, WI.

8:45 AM T-REG MEDIATED SUPPRESSION OF THEALLOGRAFT RESPONSE IN THE DRAININGLYMPH NODE. (Abstract #2)Major K. Lee IV, Daniel J. Moore, Meredith L. Chiaccio,Moh Moh Lian, Shaoping Deng, Xiaolun Huang,Muhammad Mohiuddin, Andrew J. Caton, Clyde F.Barker, James F. Markmann. Philadelphia, PA.

9:00 AM INITIAL EXPERIENCE WITH THE EXPANDEDCRITERIA DONOR KIDNEY ALLOCATIONSYSTEM: IMPACT ON UTILIZATION. (Abstract #3)Mary K. Guidinger, Randall S. Sung, Craig D. Lake,Maureen A. McBride, Stuart M. Greenstein, Francis L.Delmonico, Friedrich K. Port, Robert M. Merion, AlanB. Leichtman. Ann Arbor, MI; Richmond, VA; Bronx,NY; Boston, MA.

9:15 AM LONG-TERM (>100 DAYS) DIABETES REVERSALIN IMMUNOSUPPRESSED NONHUMAN PRIMATERECIPIENTS OF PORCINE ISLET XENOGRAFTS.(Abstract #4)Bernhard J. Hering, Tor C. Aasheim, Melanie L. Graham,Tun Jie, Jeffrey D. Ansite, Masahiko Nakano, KathleenMoran, Wei Li, Nicole Kirchhof, Martin Wijkstrom,Henk-Jan Schuurman. Minneapolis, MN; Cambridge,MA.

9:45 AM Break

Concurrent Symposia9:45 – 11:15 AM

Basic Science Symposium: Genomics and Proteomics inTransplantationBallroom BChairs: Ginny Baumgardner and Barbara Murphy

9:45 AM Single nucleotide polymorphisms and exploratorygenomics

Debbie Nickerson10:05 AM Proteomics

Ernesto Molmenti10:25 AM The prognostic utility of gene polymorphisms

Ian Hutchinson10:45 AM Clinical applications of transcription assays

Allan Kirk

Clinical Science Symposium: An Overview of the OPTNand SRTRVeterans AuditoriumChairs: James Burdick and Mark Stegall

Session I: The Organizations and Their Roles

9:45 AM Introduction and Role of HRSAJames Burdick

57

Su

nd

ay, May 16

9:50 AM Overview of the OPTNRussell Wiesner

9:57 AM Overview of the SRTRRobert Merion

10:05 AM Panel discussion/QuestionsJames Burdick, Russell Wiesner, Walter Graham,

Robert Merion, Friedrich Port

Session II: Principles and Applications of Evidence-BasedOrgan Allocation

10:15 AM Waiting List Mortality Risk as the Basis forAllocation: MELD and PELD in LiverTransplantation

Richard Freeman10:30 AM Efficient and Equitable Models of Organ

AllocationRobert Wolfe

10:45 AM Practical Application of Survival Benefit inAllocation: Proposed Lung Allocation Policy

Thomas Egan11:00 AM Panel discussion/Questions

Richard Freeman, Robert Wolfe, Thomas Egan

Joint Session11:30 AM – 12:30 PMVeterans Auditorium

11:30 AM AST Award Presentations

12:00 PM State-of-the-Art Address:Advances in Drug Delivery and Tissue Engineering

Robert Langer

Poster Session I12:30 - 2:00 PM

Poster Viewing: 8:00 AM - 5:30 PMPresenters in Attendance: 12:30 - 2:00 PMExhibit Hall C

† Those posters identified as an ATC Poster of Distinction, bythis symbol have received review scores that place them inthe top 10% of their category. The Planning Committeeencourages you to make them a priority when you visit theposter session.

Acute and Chronic RejectionP1 † REVERSAL OF RENAL ACUTE CELLULAR

REJECTION USING THE MONOCLONALANTIBODY Campath1H(C 1H). (Abstract #5)Amit Basu, Mohan Ramkumar, Henkie Tan, AkhtarKhan, Jerry McCauley, Amadeo Marcos, John Fung,Thomas Starzl, Ron Shapiro. Pittsburgh, PA.

P2 † PROTEINURIA FOLLOWING SWITCH FROMCALCINEURIN INHIBITORS TO SIROLIMUS: ARETROSPECTIVE STUDY. (Abstract #6)Emmanuel Letavernier, Marie-Noëlle Péraldi, HenriKreis, Christophe Legendre. Paris, France.

P3 † 24-HOUR MONITORING OF CALCINEURINACTIVITY IN HEALTHY SUBJECTS. (Abstract #7)Pernille B. Koefoed-Nielsen, Nikolaos Karamperis, KajA. Jørgensen. Århus N, Denmark.

P4 PRESENCE OF DNA-CHIMERISM IN URINE OFRENAL TRANSPLANT RECIPIENTS: A KINETICSTUDY. (Abstract #8)Mareen Matz, Jana Beyer, Daniela Wunsch, ConstanzeSchoenemann, Hans-Dieter Volk, Petra Reinke, KatjaKotsch. Berlin, Germany.

P5 † SIROLIMUS-BASED CALCINEURIN INHIBITOR-SPARING IMMUNOTHERAPY, 2 YEAR RESULTS.(Abstract #9)David J. Conti, Andrew Isenberg. Albany, NY.

P6 † C4d+ RENAL BIOPSIES - TREAT THE STAININGOR THE PATIENT? (Abstract #10)Massimo Asolati, Youngki Kim, Keith Melancon, TyDunn, Miguel Tan, James Harmon, Arthur Matas.Minneapolis, MN.

P7 † HIGHLY SIGNIFICANT CORRELATION OFDONOR-SPECIFIC T CELL FREQUENCIES WITH6 MONTHS RENAL FUNCTION BY IMPROVEDELISPOT TECHNIQUE. (Abstract #11)Bele J. Naether, Peter Nickel, Franziska Presber,Constanze Schoenemann, Gottfried May, Hans-DieterVolk, Petra Reinke. Berlin, Germany.

P8 LONG TERM RENAL ALLOGRAFT OUTCOME ISPREDICTED BY QUANTITATIVE IMAGE ANALYSISOF STRUCTURAL INTERSTITIAL REMODELING(AS MEASURED BY DEPOSITION OF COLLAGEN1 & 3) SUBSTANTIALLY BETTER THAN ANALYSISOF TOTAL MATRIX AREA. (Abstract #12)Paul C. Grimm, Peter Nickerson, Adam L. Merry, JohnJeffery, James Gough, David N. Rush. San Diego, CA;Winnipeg, MB, Canada; Calgary, AB, Canada.

P9 IMPACT OF ALLOSENSITIZATION ONSYNTHESIS OF DE NOVO AS WELL AS MEMORYHLA ANTIBODIES. (Abstract #13)Smita Vaidya. Galveston, TX.

P10 IMMUNOLOGICAL EVALUATION OF CYTOKINS,APOPTOSIS, AND CTL ACTIVITY FORPROMOTION OF TRANSPLANT TOLERANCE INNONHUMAN PRIMATES. (Abstract #14)Anlun Ma, Shijie Qi, Dasheng Xu, Jun Ouyang, XiaochunZhang, Yang Wang, Huijuan Gao, Pierre Daloze, HuifangChen. Montreal, QC, Canada.

P11 CLINICAL STUDY ON Lipo PGE1 INHIBITINGPLATELETS ACTIVATION IN ACUTE REJECTIONAFTER KIDNEY TRANSPLANTATION.(Abstract #15)Yong Zhang, Delin Guan, Chengqing Xia, Zhiyou Han,Jianjun Xu, Juzhong Gao, Kerang Wu. Beijing, China.

P12 CORRELATION BETWEEN HUMORALREJECTION AND C4d STAINING IN ABO-INCOMPATIBLE RENAL TRANSPLANTATION.(Abstract #16)Kazunari Tanabe, Hideki Ishida, Tadahiko Tokumoto,Nobuo Ishikawa, Naoshi Miyamoto, Tsunenori Kondo,Tomokazu Shimizu, Hiroaki Shimmura, HirokiShirakawa, Kiyoshi Setoguchi, Shigeru Horita, YutakaYamaguchi, Hiroshi Toma. Shinjuku, Tokyo, Japan;Kashiwa, Chiba, Japan.

P13 DISEASE PROGRESSION AND OUTCOMES INDIABETIC RENAL TRANSPLANT RECIPIENTSMATCHED FOR KIDNEY FUNCTION.(Abstract #17)Anand G. Desai, Peter C. Brazy, Bryan N. Becker, ArjangDjamali. Madison, WI.

58

P14 ACUTE GRAFT REJECTION ASSESSED BYBLOOD-OXYGENATION LEVEL DEPENDENT(BOLD) MRI. (Abstract #18)Arjang Djamali, Elizabeth Sadowski, R. MichaelHofmann, Rebecca Muehrer, Tom Grist, Bryan Becker.Madison, WI.

P15 DEVELOPMENT OF POST-TRANSPLANT ANTI-DONOR HLA ANTIBODIES IS ASSOCIATEDWITH ACUTE HUMORAL REJECTION ANDGRAFT DYSFUNCTION. (Abstract #19)Qiuheng Zhang, Leonard W. Liang, David W. Gjertson,Charles Lassman, Gabriel M. Danovitch, Alan H.Wilkinson, Elizabeth Kendrick, Thu Pham, Elaine F.Reed, H. Albin Gritsch. Los Angeles, CA.

P16 PROTOCOL BIOPSIES DO NOT IMPROVEOUTCOME IN KIDNEYS WITH DELAYED GRAFTFUNCTION: TOO LITTLE, TOO LATE?(Abstract #20)Jeffrey Rogers, Sylvia Odom, Muriel Labonte, DavidTaber, Greg Gilbert, Elizabeth Ashcraft, G. Mark Baillie,Kenneth Chavin, Angello Lin, Fuad Afzal, OsemwegieEmovon, Ruy Marques, Prabhakar Baliga, P. R.Rajagopalan. Charleston, SC.

P17 CLINICAL RELEVANCE OF HLA ANTIBODY(SPECIFICITY AND TITER) AND DONORSPECIFIC FLOW CYTOMETRY CROSSMATCHESIN SIROLIMUS TREATED RENAL ALLOGRAFTRECIPIENTS. (Abstract #21)Ronald H. Kerman, Ida Fernandez, Hermangshu Podder,Richard J. Knight, Stephen M. Katz, Charles T. VanBuren, Barry D. Kahan. Houston, TX.

P18 HISTOCOMPATIBILITY TESTING PREDICTSACUTE RENAL ALLOGRAFT REJECTION RISK INEARLY CORTICOSTEROID CESSATION (ECS)REGIMENS. (Abstract #22)E. S. Woodle, B. Susskind, R. R. Alloway, M. J. Hanaway,M. Thomas, J. W. Alexander, T. Merchen, M. Gupta, P.Succop, P. Roy-Chaudhry, M. Cardi, R. Boardman, C.Rogers. Cincinnati, OH.

P19 ASSOCIATION OF METHYLENTETRAHYDROFOLAT REDUCTASE 677T ALLELEWITH EARLY DEVELOPMENT OF CHRONICALLOGRAFT NEPHROPATHY. (Abstract #23)Ondrej Viklicky, Jaroslav A. Hubacek, Jan Kvasnicka, IvoMatl, Stefan Vitko. Prague, Czech Republic.

P20 ELEVATION OF CXCR3 BINDING CHEMOKINESIN URINE INDICATES ACUTE RENAL-ALLOGRAFTDYSFUNCTION. (Abstract #24)Huaizhong Hu, Brian D. Aizenstein, Alice Puchalski,Jeanine A. Burmania, Majed M. Hamawy, Stuart J.Knechtle. Madison, WI.

P21 CYTOKINE POLYMORPHISMS AND RISKS OFACUTE REJECTION AND DELAYED GRAFTFUNCTION AFTER KIDNEY TRANSPLANTATION.(Abstract #25)Noora S. Alakulppi, Lauri E. Kyllonen, Virva T. Jantti,Jukka A. Partanen, Kaija T. Salmela, Jarmo T. Laine.Helsinki, Finland.

P22 EARLY STEROID WITHDRAWAL (DAY 6) AFTERRENAL TRANSPLANTATION. (Abstract #26)David J. Conti, Andrew L. Isenberg. Albany, NY.

P23 S100 CALCIUM BINDING PROTEINS A8 AND A9,LUNG SURFACTANT PROTEIN-C, AND B CELLMARKERS IN ACUTE REJECTION OF RENALTRANSPLANTS IN RELATION TO CHRONICALLOGRAFT NEPHROPATHY. (Abstract #27)Michael Eikmans, Marian C. Roos, Yvo W. J. Sijpkens,Jan Erchen, Hans J. Baelde, Hans W. de Fijter, LeendertC. Paul, Emile de Heer, Jan A. Bruijn. Leiden,Netherlands; Muenster, Germany.

P24 IP10 mRNA EXPRESSION AS A SENSITIVEMARKER FOR ACUTE REJECTION IN URINE OFRENAL TRANSPLANT RECIPIENTS. (Abstract #28)Mareen Matz, Katja Kotsch, Jana Beyer, DanielaWunsch, Roman Klemz, Hans-Dieter Volk, Petra Reinke.Berlin, Germany.

P25 IMMUNOHISTOCHEMICAL URINALYSIS INMANAGEMENT OF RENAL TRANSPLANTPATIENTS. (Abstract #29)Maria Boratynska, Bogdan Dubinski, Marian Klinger,Dariusz Patrzalek, Piotr Szyber. Wroclaw, Poland.

P26 THE IMPACT OF ANTIVIRAL PROPHYLAXIS ONALLOGRAFT REJECTION IN RENALTRANSPLANT PATIENTS. (Abstract #30)Donnie P. Funch, Mark D. Pescovitz, Gary Schneider,Alexander M. Walker. Auburndale, MA; Indianapolis, IN.

P27 COMPARISON OF DIFFERENTIAL GENEEXPRESSION BETWEEN PREEMPTIVE AND NON-PREEMPTIVE IMMINENT RECIPIENTS OF LIVINGDONOR RENAL ALLOGRAFTS: A CLASSCOMPARISON. (Abstract #31)Kevin C. Mange, Lalitha Bandi, Mary Putt. Philadelphia,PA.

P28 ANGIOGENESIS AS A POTENTIAL THERAPEUTICTARGET IN CHRONIC ALLOGRAFTNEPHROPATHY. (Abstract #32)Lorna P. Marson, David R. Mitchell, ChristopherBellamy, John L. R. Forsythe. Edinburgh, UnitedKingdom.

P29 IMPROVED OUTCOMES AFTERPLASMAPHERESIS OF HIGHLY SENSITIZEDRECIPIENTS OF RENAL ALLOGRAFTS.(Abstract #33)James Thielke, Howard Sankary, Giuliano Testa, Philip J.DeChristopher, Kerri Kraft, Enrico Benedetti. Chicago,IL.

P30 COMPARISON OF THREE SERUM CREATININEBASED FORMULAS IN ESTIMATINGGLOMERULAR FILTRATION RATE IN SUBJECTSWITH CHRONIC ALLOGRAFT NEPHROPATHY.(Abstract #34)Ziad Zoghby, Will Thomas, Thomas O’Bryan, AbdullaSalahudeen, Mark Rosenberg, Thomas Hostetter, HassanIbrahim. Minneapolis, MN; Bethesda, MD.

P31 RECIPIENT RACE, ACUTE REJECTION (AR) ANDPOLYMORPHISMS OF GENES RELATED TO TCELL FUNCTION. (Abstract #35)Kevin C. Mange, Andrea Foulkes, Marshall M. Joffe,Tracey Hoy, Melissa Newman, Harold I. Feldman.Philadelphia, PA.

Adult to Adult Living Donor Liver Transplantation(AALDLT)P32 † GUIDELINE PROPOSAL FOR GRAFT TYPE

SELECTION WITH RIGHT LOBE GRAFT BY THENOVEL APPROACH TO VOLUMETRY IN ADULTLIVING-DONOR LIVER TRANSPLANTATION.(Abstract #36)Yasuhiro Fujimoto, Holger Bourquain, Mureo Kasahara,Takashi Ito, Yasuhiro Ogura, Kohei Ogawa, HirotoEgawa, Yasutsugu Takada, Heinz-Otto Peitgen, KoichiTanaka. Kyoto, Kyoto, Japan; Bremen, Germany.

P33 CT-ANGIOGRAM EVALUATION OF LIVINGLIVER DONORS — INTRA-OPERATIVECORRELATION WITH RADIOLOGIC FINDINGS.(Abstract #37)Galia Rosen, Maria R. Gomes, Mohamed Sfaxi, Kevin M.Williams, Rainer Gruessner, Raja Kandaswamy, WilliamPayne, Timothy Sielaff, Abhinav Humar. Minneapolis,MN.

59

Su

nd

ay, May 16

P34 RADIOGRAPHIC EVALUATION OF LIVING LIVERDONORS WITH CORRELATION OF PRE-OPERATIVE AND INTRA-OPERATIVE FINDINGS.(Abstract #38)Christoph Wald, Mary Ann Simpson, Elizabeth A.Pomfret, Nazli Erbay, Vassilios Raptopoulos, James J.Pomposelli, Roger L. Jenkins. Burlington, MA; Boston,MA.

P35 SERIAL CHANGE OF LIVER VOLUME ANDHEMODYNAMICS IN LIVER GRAFTS AFTERLIVING RELATED LIVER TRANSPLANTATION(LDLT). (Abstract #39)Kazuhiko Hashimoto, Keizo Dono, Masato Sakon,Shigeru Marubashi, Hiroaki Nagano, Koji Umeshita, ShojiNakamori, Morito Monden. Suita City, Osaka, Japan.

P36 IDENTIFICATINO OF SEGMENTAL HEPATIC VEINSFOR RIGHT LOVE GRAFT IN LIVING RELATEDLIVER TRANSPLANTATION BY INTRAVENOUSLYENHANCED THREE-DIMENSIONAL MD-CTIMAGING. (Abstract #40)Koji Okuda, Toshiro Ogata, Hisamune Sakai, MasashiYasunaga, Kei Fujiki, Nobuharu Uchida, HikoyukiHoriuchi, Hisafumi Kinoshita, Kazuo Shirozu, ShigeakiAoyagi. Kurume City, Fukuoka, Japan.

P37 RELEVANCE OF COMPUTERIZED CT BASED 3DVISUALIZATION IN LIVING RELATED LIVERTRANSPLANTATION. (Abstract #41)Josef Fangmann, Michael Bartels, H. Bourqain, H. O.Peitgen, Thomas Kahn, Johann Hauss, Jens Harms.Leipzig, Germany; Bremen, Germany.

P38 † TISSUE ENGINEERED PATCH FOR THERECONSTRUCTION OF THE PORTAL ANDHEPATIC VEINS DURING ADULT-TO-ADULTLIVING-DONOR PARTIAL LIVERTRANSPLANTATION. (Abstract #42)Takahiro Torii, Mitsuo Miyazawa, Yasuko Toshimitsu,Katsuya Okada, Isamu Koyama. Iruma-gun, Saitama,Japan.

P39 † PREDICT FACTOR FOR RECIPIENT’S RECOVERYAFTER LIVING DONOR LIVERTRANSPLANTATAION. (Abstract #43)Masahiko Taniguchi, Maeng Bong Jin, TsuyoshiShimamura, Tomomi Suzuki, Hiroyuki Furukawa, SatoruTodo. Sapporo, Hokkaido, Japan.

P40 † DRAINAGE SYSTEM OF THE SEGMENT IVASSESSED BY 3D-CT VENOGRAPHY -APPLICATION FOR EXTENDED RIGHT LOBEGRAFT WITH MIDDLE HEPATIC VEIN IN LIVINGRELATED LIVER TRANSPLANTATION.(Abstract #44)Toshiro Ogata, Koji Okuda, Hideo Matsuo, HisamuneSakai, Kei Fujiki, Masashi Yasunaga, Nubuharu Uchida,Hikoyuki Horiuchi, Hisafumi Kinoshita, Kazuo Shirozu,Shigeaki Aoyagi. Kurume-City, Fukuoka, Japan.

P41 ISCHEMIC PRECONDITIONING IN ADULTLIVING DONOR LIVER TRANSPLANTATION. APILOT STUDY. (Abstract #45)Ernest Bombuy, Josep Fuster, Ramon Charco, JoanaFerrer, Gonzalo Rodriguez-Laiz, Constantino Fondevila,Auxiliadora Amador, Guillermo Alvarez, Juan CarlosGarcia-Valdecasas. Barcelona, Barcelona, Spain.

P42 VENOUS OUTFLOW RECONSTRUCTIONWITHOUT VENO-VENOUS BYPASS ORCAVOPLASTY IN LIVE DONOR ADULT LIVERTRANSPLANTATION (LDALT) USING RIGHTLOBE GRAFTS (RLG). (Abstract #46)Mohamed E. Akoad, James J. Pomposelli, Elizabeth A.Pomfret, Mary Ann Simpson, David W. Lewis, Roger L.Jenkins. Burlington, MA.

P43 RECONSTRUCTION OF MIDDLE HEPATIC VEININ ADULT-TO-ADULT RIGHT LOBE LIVINGDONOR LIVER TRANSPLANTATION.(Abstract #47)Andreas Pascher, Tom Theruvath, Stefan G. Tullius, JanM. Langrehr, Jochen Klupp, Utz Settmacher, PeterNeuhaus. Berlin, Berlin, Germany.

P44 DEFINITION OF DONOR SURGICAL VARIANTSASSOCIATED WITH REDUCED GRAFTOUTCOMES FOLLOWING ALDLT. (Abstract #48)Constantino Fondevila, Rafik M. Ghobrial, ErnestBombuy, Sherilyn Gordon, Jose Fuster, Bob Saggi, RamonCharco, Sammy Saab, Ronald W. Busuttil, Juan C. Garcia-Valdecasas. Los Angeles, CA; Barcelona, Spain.

P45 100 CONSECUTIVE ADULT TO ADULT RIGHTLOBE LIVING DONOR LIVERTRANSPLANTATION. (Abstract #49)Hasan F. Kucuk, Murat M. Cag, Gokhan Unsal, GokhanIcoz, Deniz Nart, Zeki Karasu, Murat Zeytunlu, MuratKilic, Yildiray Yuzer, Yaman Tokat. Izmir, Turkey.

P46 IMPACT OF HEPATIC VEIN RECONSTRUCTIONIN LIVING-DONOR LIVER TRANSPLANTATIONUSING RIGHT LOBE GRAFT WITH MIDDLEHEPATIC VEIN. (Abstract #50)Mureo Kasahara, Yasutsugu Takada, Yasuhiro Fujimoto,Mikiko Ueda, Koichi Tanaka. Kyoto, Kyoto, Japan.

P47 RIGHT LOBE LIVING DONOR LIVERTRANSPLANTATION WITH SPECIAL REFERENCETO HEPATIC VENOUS RECONSTRUCTION.(Abstract #51)Maeng Bong Jin, Tsuyoshi Shimamura, Tomomi Suzuki,Masahiko Taniguchi, Masahiro Hattori, Minoru Ohta,Toshiya Kamiyama, Michiaki Matsushita, HiroyukiFurukawa, Satoru Todo. Sapporo, Japan; Sappor, Japan.

P48 LIVING DONOR LIVER TRANSPLANT WITHRENOPORTAL ANASTOMOSIS FORSPONTANEOUS SPLENORENAL SHUNT.(Abstract #52)Shigeru Marubashi, Masato Sakon, Atsushi Miyamoto,Hiroaki Nagano, Keizo Dono, Shoji Nakamori, KojiUmeshita, Morito Monden. Suita, Osaka, Japan.

P49 SURGICAL OUTCOME OF RIGHT LIVER LOBEPREPARATION IN LIVING DONORS WITH ANDWITHOUT MIDDLE HEPATIC VEIN. (Abstract #53)Tolga Demirbas, Yildiray Yuzer, Murat Zeytunlu, MuratCag, Murat Kilic, Yaman Tokat. Izmir, Turkey.

Cardiac Transplantation: ImmunosuppressionP50 THE DARK SIDE OF CORTICOSTEROID

WEANING AFTER HEART TRANSPLANTATION: ISIT WORTH IT? (Abstract #54)Jon A. Kobashigawa, Jignesh K. Patel, Greg Cogert, NinaP. Almeda, Sheryllene Go, Paul Lee, Roxella Camara,Angela Velleca, Hillel Laks. Los Angeles, CA.

P51 CORTICOSTEROID-FREEIMMUNOSUPPRESSION IN THE TACROLIMUSAND MYCOPHENOLATE MOFETIL ERA:NEUROHORMONAL AND CLINICAL BENEFITS.(Abstract #55)Patricia A. Uber, Mandeep R. Mehra, Robert L. Scott,Myung H. Park, Hector O. Ventura. New Orleans, LA.

P52 COMBINATION OF CYCLOSPORINE-A ANDRAPAMYCIN WITH KETOCONAZOLE IN HEARTTRANSPLANT RECIPIENTS WITH A HISTORY OFRECURRENT CELLULAR REJECTION.(Abstract #56)Michael Zakliczynski, Marcin Maruszewski, AnnaKrynicka, Marian Zembala. Zabrze, Poland.

60

P53 THE USE OF DEXAMETHASONE AT THE TIME OFHEART TRANSPLANTATION IS RELATED TOINCREASED EARLY CELLULAR REJECTION.(Abstract #57)Savitri E. Fedson, Adam B. Cochrane, Anthony Y. Kim,Aliya N. Husain, Cathy Murks, Jai Raman, Allen S.Anderson. Chicago, IL.

P54 † SIMULTANEOUS HEART- KIDNEY TRANSPLANTS(SHK): DOES THE KIDNEY PROTECT THE HEART?(Abstract #58)Rajendra S. Baliga, Savitri E. Fedson, Tipu S. Puri,Pradeep V. Kadambi, Adam B. Cochrane, Antony Kim,Kristen Kasza, Michelle A. Josephson, Allen S.Anderson, Basit Javaid. Chicago, IL.

P55 C0 BUT NOT C2 IS APPROPRIATE TO ASSESSIMMUOSUPPRESSIVE EFFECT OFCYCLOSPORINE-A IN HEART TRANSPLANTRECIPIENTS RECEIVING KETOCONAZOLECONCOMITANTLY. (Abstract #59)Michael Zakliczynski, Anna Krynicka, Marta Szewczyk,Marcin Maruszewski, Marian Zembala. Zabrze, Poland.

P56 DIFFERENCES IN PHARMACOKINETIC PROFILESBETWEEN LONG-TERM HEART TRANSPLANTPATIENTS RECEIVING EITHER TACROLIMUS ORCYCLOSPORINE MICROEMULSION ANDMYCOPHENOLATE MOFETIL MAINTENANCEIMMUNOSUPPRESSION. (Abstract #60)M. Cantarovich, N. Giannetti, R. Cecere, G. Fontaine,J.-G. Besner. Montréal, QC, Canada.

P57 THE ADDITION OF MYCOPHENOLATE MOFETILTO LOW-DOSE CYCLOSPORINE A-BASEDIMMUNOSUPRESSION IMPROVES RENALFUNCTION IN HEART TRANSPLANT PATIENTS.(Abstract #61)Jean-Noel Trochu, Michel Redonnet, Bernard Lelong,Agnes Sirinelli, Stephane Cleron, Michele Treilhaud,Thierry Petit, Philippe Despins. Nantes, France; Rouen,France; Rennes, France; Tours, France; Caen, France.

P58 SERUM CREATININE LEVELS ININTRATHORACIC TRANSPLANT RECIPIENTSPRIOR AND FOLLOWING THE ADDITION OFSIROLIMUS. (Abstract #62)Martin Cadeiras, Sergio D. Sevilla, Alejandro G.Bertolotti, Alicia B. Arnedo, Pablo Klin, Mirta Diez,Jorge A. Argento, Liliana E. Favaloro, Francisco Klein,Sergio V. Perrone, Roberto R. Favaloro. Argentina.

P59 REDUCED CALCINEURIN INHIBITION DURINGINDUCTION FOR HLHS TRANSPLANTATIONLEADS TO INFREQUENT REJECTION ANDIMPROVED SURVIVAL. (Abstract #63)Biagio A. Pietra, Christine Mashburn, Deborah Gilbert,Flori Legette, Erin Kunz, David D. Ivy, Henry M.Sondheimer, Max B. Mitchel, David N. Campbell, MarkM. Boucek. Denver, CO.

P60 RETROSPECTIVE REVIEW OF SIROLIMUS USEFOR CHRONIC REJECTION AND RENALDYSFUNCTION IN HEART TRANSPLANTRECIPIENTS. (Abstract #64)Jennifer B. Lehneman, Gregory A. Smallwood, CorbyD’Amico, David Vega, Andrew Smith. Atlanta, GA.

P61 THYMOGLOBULINE INDUCTION THERAPYCREATES EXCELLENT LONG-TERM OUTCOME INPATIENTS WITH POSITIVE LYMPHOCYTECROSSMATCH AFTER CARDIACTRANSPLANTATION. (Abstract #65)Andreas Zuckermann, Daniela Dunkler, BettinaHaidbauer, Anna Muehlbauer, Emese Szent-Ivanyi, ErnstWolner, Wolfgang Mayr, Michael Grimm. Vienna,Austria.

P62 ALLOGRAFT REJECTION IN PEDIATRIC HEARTTRANSPLANT RECIPIENTS ON TACROLIMUS ORCYCLOSPORINE PRIMARYIMMUNOSUPPRESSION: RESULTS OF ARANDOMIZED TRIAL AT MEAN 25 MONTHFOLLOW-UP. (Abstract #66)Stacey M. Pollock-BarZiv, Anne I. Dipchand, Brian W.McCrindle, Nadya Nalli, Lori J. West. Toronto, ON,Canada.

P63 SIROLIMUS USE IN CHILDREN FOLLOWINGHEART TRANSPLANTATION. CLINICAL ANDMETABOLIC EFFECTS. (Abstract #67)Eba Hathout, Tamara Shankel, Drew Cutler, Robert Tan,James Fitts, Joyce Johnston, Leonard Bailey, RichardChinnock. Loma Linda, CA.

P64 INFLUENCE OF IMMUNOSUPPRESSIVE THERAPYWITH CYCLOSPORINE-A OR TACROLIMUS ONPRESENCE OF ANTI-INSULIN (IAA), ANTI-ISLETCELL (ICA), AND ANTI-GAD ANTIBODIES(GADA) IN DIABETIC HEART TRANSPLANTRECIPIENTS. (Abstract #68)Michael Zakliczynski, Teresa Zielinska, Marta Szewczyk,Marian Zembala. Zabrze, Poland.

P65 NOVEL IMMUNOSUPPRESSIVE EFFECTS OFTHIAZOLIDINEDIONE AGENTS IN POSTCARDIAC TRANSPLANT DIABETIC PATIENTS.(Abstract #69)Preethi Srikanthan, W. A. Hsueh, Jon A. Kobashigawa.Los Angeles, CA.

P66 INTRINSIC PERIPHERAL BLOOD MYELOIDDENDRITIC CELL DEPLETION DURING ACUTEREJECTION AFTER HUMAN HEARTTRANSPLANTATION. (Abstract #70)Petros Athanassopoulos, Leonard M. B. Vaessen, Alex P.W. M. Maat, Aggie H. M. M. Balk, Ad J. J. C. Bogers,Willem Weimar. Rotterdam, Netherlands.

Chemokines/CytokinesP67 † IFN-γγγγγ LIMITS CTL GENERATION DURING

ALLOIMMUNE RESPONSES BY INHIBITING IL-2PRODUCTION: A MAJOR FEEDBACK LOOP INEFFECTOR HOMEOSTASIS. (Abstract #71)Luis G. Hidalgo, Philip F. Halloran. Edmonton, AB,Canada.

P68 † INTERLEUKIN-1 RECEPTOR ANTAGONISTSECRETING HEPATOCYTES FOR THE TREATMENTOF FULMINANT HEPATIC FAILURE. (Abstract #72)Masahiro Shinoda, Arno W. Tilles, Go Wakabayashi,Naoki Kobayashi, François Berthiaume, MotohideShimazu, Nobuyoshi Shimizu, Noriaki Tanaka, MasakiKitajima, Ronald G. Tompkins, Mehmet Toner, MartinL. Yarmush. Boston, MA; Tokyo, Japan; Okayama,Japan.

P69 CRITICAL ROLE OF G-PROTEIN-COUPLEDPI3Kγγγγγ IN ALLOGRAFT REJECTION. (Abstract #73)Tao Wang, Bao Lu, Andrew D. Wells, Wayne W.Hancock. Philadelphia, PA; Boston, MA.

P70 THE CLINICAL IMPACT OF CHEMOKINE ANDRECEPTOR GENE EXPRESSION DURINGISCHEMIA/REPERFUSION INJURY IN RENALALLOGRAFTS. (Abstract #74)Motoo Araki, Nader Fahmy, Lingmei Zhou, HiromiKumon, Venkatesh Krishnamurthi, David Goldfarb,Charles Modlin, Stuart Flechner, Andrew Novick, RobertFairchild. Cleveland, OH; Okayama, Okayama, Japan.

61

Su

nd

ay, May 16

P71 SYNERGISM BETWEEN CCR5 BLOCKADE ANDCSA IN PRIMATE CARDIACALLOTRANSPLANTATION. (Abstract #75)Richard N. Pierson, Bao N. Nguyen, C. Schroeder, G.Wu, M. Springer, K. Lyons, L. Peterson, A. Azimzadeh,J. DeMartino. Baltimore, MD; Rahway, NJ.

P72 REJECTION OF MOUSE ALLOGRAFTS IN THEABSENCE OF THE CHEMOKINE RECEPTORCCR7. (Abstract #76)Hans-Günter Zerwes, Barbara Nüsslein-Hildesheim, Jian-Ping Li, Grazyna Wieczorek, Uta Höpken, Martin Lipp.Basel, Switzerland; Berlin, Germany.

P73 MIGRATORY RESPONSES OF MURINE LIVERMYELOID, ‘LYMPHOID-RELATED’ ANDPLASMACYTOID DENDRITIC CELLS TO CCCHEMOKINES. (Abstract #77)Masanori Abe, Alan F. Zahorchak, Alison J. Logar,Angus W. Thomson. Pittsburgh, PA.

P74 A CHEMOKINE RECEPTOR ANTAGONIST, TAK-779, AND CYCLOSPORIN A SYNERGISTICALLYPROLONGS SURVIVAL OF FULLY MHC-MISMATCHED CARDIAC ALLOGRAFTS IN MICE.(Abstract #78)Masayoshi Miura, Naohiko Shimoda, Ken Morita,Yoshihiko Watarai, Hiromi Fujiwara, Katsuya Nonomura.Sapporo, Hokkaido, Japan; Suita, Osaka, Japan.

P75 REGULATION OF INTERLEUKIN 14 MRNA LEVELSIN VITRO BY ALLOANTIGEN AND IN VIVOFOLLOWING RENAL TRANSPLANTATION.(Abstract #79)Nicolae Leca, Julian L. Ambrus, Rabie Stephan, KristinMatteson, Fadi Dagher, Mark R. Laftavi, OlehPankewycz. Buffalo, NY.

P76 TRAFFIC AND MOBILITY OF THE MEMBRANE-ANCHORED CHEMOKINE, FRACTALKINE.(Abstract #80)Lisa A. Robinson, Guang-Ying Liu, Alan M. Fong,Dhavalkumar D. Patel. Toronto, ON, Canada; Durham,NC; Chapel Hill, NC.

P77 T CELL EXPRESSION OF CCR5 IS REQUIREDFOR ACUTE ALLOGRAFT REJECTION.(Abstract #81)Hiroyuki Amano, Eun-Jee Oh, Hiroshi Toma, Andrew C.Novick, Robert L. Fairchild. Cleveland, OH; Tokyo,Tokyo, Japan.

P78 MIG/CXCL9 INDUCED T-LYMPHOCYTEPROLIFERATION IS INDEPENDENT OF IL-2.(Abstract #82)David Whiting, George R. Hsieh, Gabriel T. Schnickel,Anamika Banerji, Ali Shefizadeh, Abbas Ardehali. LosAngeles, CA.

Complications and Donors (AALDT)P79 THE PATHOLOGIC END OF THE SPECTRUM OF

SMALL-FOR-SIZE GRAFT SYNDROME IN ADULTLIVING DONOR LIVER TRANSPLANTATION(ALDLT). (Abstract #83)Dympna M. Kelly, Anthony J. Demetris, Bijan Eghtesad,Wallis Marsh, Kusum Patel, Paula Novelli, RaymondPlaninsic, John J. Fung, Amadeo Marcos. Pittsburgh, PA.

P80 PROLONGED POSTOPERATIVEHYPERBILIRUBINEMIA FOLLOWING ADULT-TO-ADULT LIVING DONOR LIVERTRANSPLANTATION – A MULTIVARIATEANALYSIS OF ASSOCIATED RISK FACTORS.(Abstract #84)Roberto Troisi, Roberto Montalti, Salvatore Ricciardi,Isabelle Colle, Hans Van Vlierberghe, Bernard deHemptinne. Ghent, Belgium.

P81 THERE IS NO ROLE FOR EPIDURAL ANALGESIAIN THE POSTOPERATIVE MANAGEMENT OFLIVING LIVER DONORS. (Abstract #85)Alan J. Koffron, Mario Ferrario, Johnathan J. Fryer,Lori Clark, Michael Abecassis. Chicago, IL.

P82 ASYMPTOMATIC THROMBOCYTOPENIA AFTERDONOR RIGHT HEPATECTOMY: EVIDENCE FOROCCULT PORTAL HYPERTENSION EXISTS.(Abstract #86)Dianne LaPointe Rudow, Robert S. Brown, Jr., DouglasMarratta, Janet Lee, Jean C. Emond, Milan Kinkhabwala.New York, NY.

P83 BILIARY COMPLICATIONS IN SIXTY-ONEADULT LIVING-DONOR LIVER TRANSPLANTS.(Abstract #87)Ryan A. McTaggart, Sandy Feng, Jon T. Carter, AndrewVardanian, Dulce MacLeod, Abdel Rahmaoui, Nancy L.Ascher, Chris E. Freise, John P. Roberts. San Francisco,CA.

P84 A SIMPLIFIED TECHNIQUE FOR HEPATICVENOUS OUTFLOW RECONSTRUCTION IN THERIGHT LOBE DONOR WITH MULTIPLE HEPATICVEINS SHORTENS WARM ISCHEMIA TIME ANDPROTECTS THE ALLOGRAFT FROM INJURY.(Abstract #88)Howard N. Sankary, Giuliano Testa, Diego Bogetti, JoseOberholzer, Enrico Benedetti. Chicago, IL.

P85 COMPLICATIONS IN THE DONOR AFTER RIGHT-LOBE ADULT LIVING DONOR LIVERTRANSPLANTATION (LDLT). (Abstract #89)Joana Ferrer, Josep Fuster, Ramon Charco, ErnestBombuy, Constantino Fondevila, Guillermo Alvarez,Gonzalo Rodriquez-Laiz, Auxiliadora Amador, JosepMaria Llovet, Miquel Navasa, Antoni Rimola, JordiBruix, Juan Carlos Garcia-Valdecasas. Barcelona,Barcelona, Spain.

P86 PRO- AND ANTI-INFLAMMATORY CYTOKINEPRODUCTION DURING ISCHEMIAREPERFUSION INJURY IN A CASE OF IDENTICALTWIN LIVING DONOR LIVERTRANSPLANTATION USING NOIMMUNOSUPPRESSION. (Abstract #90)Xiangdong Zhao, Yasuhiro Fujimoto, Takaaki Koshiba,Jacques Pirenne, Atsushi Yoshizawa, Takashi Ito, HideyaKamei, Kanta Jobara, Kohei Ogawa, Kenji Uryuhara,Yasutsugu Takada, Koichi Tanaka. Kyoto, Kyoto, Japan;Leuven, Leuven, Belgium.

P87 COMPARING RIGHT HEPATECTOMIES FORADULT LIVING DONATION WITH THOSE FORMETASTATIC DISEASE. IS THERE A DIFFERENCE?(Abstract #91)Gonzalo P. Rodriguez-Laiz, Ernest Bombuy, AuxiliadoraAmador, Joana Ferrer, Ramon Charco, Jose Fuster,Antonio Rimola, Miguel A. Navasa, Ramon Bataller,Javier Forns, Juan C. Garcia-Valdecasas. Barcelona, Spain.

P88 POSTOPERATIVE LIVER REGENERATION ANDCOMPLICATION IN LIVE LIVER DONOR AFTERPARTIAL HEPATECTOMY FOR LIVING DONORLIVER TRANSPLANTATION. (Abstract #92)Jin S. Choi, Soon I. Kim, Kyung S. Kim, Soon H. Nam,Woo J. Lee. Seoul, Republic of Korea.

P89 A NEW APPROACH IN ABO-INCOMPATIBLELIVING DONOR LIVER TRANSPLANTATIONS INADULTS: SELECTIVE APHERESIS USINGGLYCOSORB® AB WITH DACLIZUMAB ANDMYCOPHENOLATE MOFETIL INDUCTIONWITHOUT SPLENECTOMY. (Abstract #93)Roberto Troisi, Lucien Noens, Roberto Montalti,Salvatore Ricciardi, Pasquale F. Conoscitore, MicheleCentra, Bernard de Hemptinne. Ghent, Belgium; SanGiovanni Rotondo, Italy.

62

Experimental Tolerance Induction IP93 JANUS TYROSINE KINASE (JAK3) INHIBITOR,

NC1153, INDUCES APOPTOSIS OF T CELLS ANDDONOR-SPECIFIC TRANSPLANTATIONTOLERANCE. (Abstract #97)Stanislaw M. Stepkowski, Lucrezia Furian, SlawaJanczewska, Ye Zhang, Neelam Tajpal, Mouer Wang,Robert Kirken, Johnathan Dimmock, Barry D. Kahan.Houston, TX; Saskatoon, SK, Canada.

P94 CD1d-RESTRICTED NATURAL KILLER T (NKT)CELLS PROVIDE HELP TO ALLOREACTIVECD4+CD25+ REGULATORY T CELLS. (Abstract #98)Shuiping Jiang, David S. Game, Robert I. Lechler.London, United Kingdom.

P95 SIGNALING THROUGH THE T CELL RECEPTORAND CD25 REGULATES SMAD7 EXPRESSION INREGULATORY T CELLS. (Abstract #99)Tina L. Sumpter, Allison T. Thiele, Yan Zheng, David S.Wilkes. Indianapolis, IN.

P96 B LYMPHOCYTES FACILITATE ISLETALLOGRAFT REJECTION ARE NOT REQUIREDFOR TOLERANCE RESISTANCE IN NOD MICE.(Abstract #100)Ronald G. Gill, Jeffrey Rawson, Marilyne Coulombe.Denver, CO.

P97 TOLERANCE INDUCTION USING IL-21ANTAGONIZING FUSION PROTEIN.(Abstract #101)Sophoclis Alexopoulos, Douglas Hanto, Terry Strom,Xin Xiao Zheng. Boston, MA.

P98 TOLERANCE TO MYOBLAST TRANSPLANTATION(MT) REQUIRES A NOVEL PROTOCOL (ANTI-CD45RB, ANTI-CD154 AND MIXED CHIMERISM)THAT PROMOTES TOLERANCE THROUGHPERSISTENCE OF PERIPHERAL AND CENTRALMECHANISMS. (Abstract #102)Geoffrey Camirand, Joël Rousseau, Marie-Ève Ducharme,Jaques Tremblay, David Rothstein. New Haven, CT;St.Foy, QC, Canada.

P99 THE PROGRAMMED DEATH-1 (PD1) NEGATIVECOSTIMULATORY PATHWAY PLAYS ACRITICAL ROLE IN FETOMATERNALTOLERANCE. (Abstract #103)Indira Guleria, Arezou Khosroshahi, Jaime Imitola,Mohammed Javeed Ansari, Miyuki Azuma, Samia J.Khoury, Mohamed H. Sayegh. Boston, MA.

P100 PERIPHERAL B CELL TOLERANCE TOTRANSPLANTATION ANTIGENS. (Abstract #104)Anita S. Chong, Huasong Zeng, Lianli Ma, Jikun Shen,Guerard W. Byrne, Dengping. Chicago, IL; Rochester,MN.

MICE TREATED WITH T CELL DEPLETION (TCD),SIROLIMUS (SIR) AND DONOR BONE MARROW(BM). (Abstract #105)Khairul Anam, Alfred Black, Douglas A. Hale. Bethesda,MD.

P102 DETERMINATION OF THE MOST APPROPRIATEDENDRITIC CELL FOR A TOLERANCE INDUCINGREGIMEN IN THE BABOON. (Abstract #106)Joanna Ashton-Chess, Gilles Blancho. Nantes, France.

P103 PROFOUND T CELL HYPORESPONSIVENESS INRENAL TRANSPLANT PATIENTS TREATED WITHCAMPATH-1H. (Abstract #107)Debra D. Bloom, Huaizhong Hu, John H. Fechner, StuartJ. Knechtle. Madison, WI.

P104 SHORT TANDEM REPEAT ANALYSIS TOMONITOR BONE MARROW ENGRAFTMENT INNONHUMAN PRIMATES. (Abstract #108)Macy Lau, Tamara Vayntrub, Carl Grumet, RobertLowsky, Samuel Strober, Bruce Reitz, Dominic Borie.Stanford, CA.

P105 DEVELOPMENT OF POTENTIMMUNOREGULATORY T CELLS AFTER LOCALCTLA4IG GENE TRANSFER TO PANCREATICALLOGRAFT. (Abstract #109)Gang Miao, Toshinori Ito, Fumihiro Uchikoshi, YusukeAkamaru, Tetsuma Kiyomoto, Hiroshi Komoda, JinghaiSong, Masumi Nozawa, Hikaru Matsuda. Osaka, Japan.

P106 OPTIMUM PERIPHERAL TOLERANCE ISMAINTAINED BY MULTIPLE T CELL SUBSETS.(Abstract #110)Dengping S. Yin, Lianli Ma, Jikun Shen, Anita Chong.Chicago, IL.

P107 C-KIT+ LIN+ FRACTION OF DONOR BONEMARROW (BM) POSSESSES SUPERIORPOTENCY COMPARED TO WHOLE BM INPROLONGING SKIN ALLOGRAFT SURVIVAL INMICE TREATED WITH ANTILYMPHOCYTE SERUM(ALS) AND SIROLIMUS. (Abstract #111)Edip Akpinar, Nancy Craighead, Khairul Anam, DouglasSmoot, Douglas Hale. Bethesda, MD.

P108 CTLA4Ig-INDUCED TRANSPLANTATIONTOLERANCE: NOT ONLY IDO COUNTS.(Abstract #112)Marcelo Hill, Cécile Voisine, Rachid Zagani, LaurentTesson, Régis Josien, Ignacio Anegon. Nantes, France.

P109 RADIATION-SENSITIVE MECHANISMS IN RATRECIPIENTS OF ALLOGENEIC HEART.(Abstract #113)Tetsuma Kiyomoto, Atsunori Nakao, HideyoshiToyokawa, Takashi Kaizu, Anthony J. Demetris,Thomas E. Starzl, Noriko Murase. Pittsburgh, PA.

P110 FUNCTIONAL ANALYSIS OF INFECTIOUSTOLERANCE MEDIATED BY HUMAN CADAVERDONOR BONE MARROW CELLS. (Abstract #114)James M. Mathew, Teresa Vallone, Silvia Alvarez,Laphalle Fuller, Bonnie Blomberg, Camillo Ricordi,Andreas G. Tzakis, Violet Esquenazi, Joshua Miller.Miami, FL.

P111 DENDRITIC CELLS TREATED WITH INHIBITORSOF NFkappaB ABROGATE RESPONSES TOALLOANTIGEN VIA INDUCTION OFREGULATORY CELL POPULATIONS.(Abstract #115)Ana Hernandez, William A. Ross, Bonnie B. Blomberg,Inna Lindner, James M. Mathew, Manuel Carreno,Rolando Garcia-Morales, Camilo Ricordi, Andreas G.Tzakis, Kelvin P. Lee, Joshua Miller, Violet Esquenazi.Miami, FL.

P90 MINIMAL MODELING ANALYSIS OF GLUCOSEMETABOLISM IN LIVING-DONOR LIVERTRANSPLANTATION REVEALED NO INFLUCENCEOF IMMUNOSUPPRESSION DURING 1-YEARFOLLOW UP. (Abstract #94)Martin Stockmann, Sabine Nolting, Thomas Konrad,Diana Hünerbein, Helena Döbling, Thomas Steinmüller,Peter Neuhaus. Berlin, Germany; Frankfurt, Germany.

P91 INFLUENCE OF HLA COMPATIBILITY ONLIVING-RELATED PEDIATRIC LIVERTRANSPLANTATION. (Abstract #95)Ozgur Basaran, Aydin Dalgic, Sema Pehlivan, MunireTuran, Mehmet Haberal. Ankara, Turkey.

P92 COMPARISON OF CYCLOSPORINEMICROEMULSION AND TACROLIMUS IN 39RECIPIENTS OF LIVING DONOR LIVERTRANSPLANTATION. (Abstract #96)Koichi Tanaka, John Lake, Federico Villamil, Gary Levy,Paul Marotta, Sergio Mies, Bernard de Hemptinne, GerdOtto. Kyoto, Japan.

P101 LOW DOSE BUSULFAN (BU) FACILITATESINDUCTION OF TITRATABLEMACROCHIMERISM IN FULLY ALLOGENIC

63

Su

nd

ay, May 16

Brent Koehn, Rafi Ahmed, Christian Larsen. Atlanta,GA.

Immunosuppression: Preclinical Studies IP113 † CTLA4IG IMMUNOSUPPRESSION ALLOWS

PRESERVATION OF CD8+ T CELL MEMORYRESPONSE TO TUMOR ANTIGENS; A POTENTIALADVANTAGE IN THE TRANSPLANT SETTING.(Abstract #117)Andrew E. Gelman, Peter Abt, Dong Xin, GuodongWang, Fotini Debonera, Kim Olthoff, Andrew Wells,Abraham Shaked. Philadelphia, PA.

P114 TACROLIMUS DECREASES, CYCLOSPORINEINCREASES, AND RAPAMYCIN HAS NO EFFECTON PROFIBROTIC GENE MRNA EXPRESSION INRENAL TISSUE. (Abstract #118)Nicholas R. Brook, Julian R. Waller, Gareth R. Bicknell,Michael L. Nicholson. Leicester, United Kingdom.

P115 REDUCTION OF PECAM-1 AT GRAFTENDOTHELIUM AFTER CARDIACTRNASPLANTATION IS ACCOMPANIED BY THEREDUCTION OF LEUKOCYTE INFILTRATIONINTO THE PERIVASCULAR SPACE OF ARTERIES.A COMPARATIVE STUDY WITH CsA, Fk506 ANDMMF. (Abstract #119)Markus Richter, Markus Barten, Hartmut Bittner, JanGummert, Friedrich Mohr. Leipzig, Germany.

P116 THE EFFECT OF CSA, FK506 AND MMF ON THEEXPRESSION OF INDUCIBLE CELL ADHESIONMOLECULES (iCAMs), TRANSPLANTVASCULOPATHY AND LEUKOCYTEINFILTRATION. (Abstract #120)Markus Richter, Hartmut Bittner, Markus Barten, JanGummert, Friedrich Mohr. Leipzig, Germany.

P117 ANTI-TGF-beta ANTIBODY LIMITS CsA-MEDIATED RENAL TOXICITY IN A RAT CARDIACALLOGRAFT MODEL: POTENTIAL OFTHERAPEUTIC APPLICATIONS. (Abstract #121)Ashwani K. Khanna, Matthew S. Plummer, Gail Hilton,Galen M. Pieper, Steve Ledbetter. Milwaukee, WI;Framingham, MA.

P118 THE NEW IMMUNOSUPPRESSANT, RAPAMYCINACTS IN A DOSE DEPENDENT MANNER TOREDUCE CYCLOSPORINE INDUCED KIDNEYDAMAGE. (Abstract #122)Nicholas R. Brook, Julian R. Waller, Bin Yang, Peter N.Furness, Gareth R. Bicknell, Michael L. Nicholson.Leicester, United Kingdom.

P119 † FK506 IMMUNOSUPPRESSION INHIBITSCOLLAR-INDUCED ATHEROSCLEROTICPLAQUE DEVELOPMENT IN ApoE DEFICIENTMICE. (Abstract #123)Marjo Donners, Sylvia Heeneman, Ilze Bot, Johannesvan Hooff, Leon de Windt, Theo van Berkel, MatDaemen, Eric Biessen. Maastricht, Netherlands; Leiden,Netherlands; Utrecht, Netherlands.

P120 † PG490-88, A NOVEL IMMUNOSUPPRESSANT,EFFECTIVELY PREVENTS ACUTE AND CHRONICREJECTION IN RAT RENAL ALLOGRAFTS.(Abstract #124)Fan Pan, Ogert Fisniku, Carmen Wynn, Laurie M.Erickson, Gladys Crews, Mei-Shiang Jang, Yuji Sudo,Kouichi Tamura, Masakazu Kobayashi, HallgrimurBenediktsson, Hongsi Jiang. Evanston, IL; Calgray, AB,Canada.

P121 COMBINATION OF PG490-88 AND LOW DOSEFK506 SIGNIFICANTLY PROLONGED RENALALLOGRAFT SURVIVAL IN MONKEYS.(Abstract #125)Gang Chen, Ximo Wang, Frank Sun, Weihua Liu, XuyanHuang, Bertha Garcia, Yuji Sudo, Kouichi Tamura, RobertZhong. London, ON, Canada.

P122 EVALUATION OF PG490-88, A NOVELIMMUNOSUPPRESSANT IN A DOG RENALALLOGRAFT MODEL. (Abstract #126)Ximo Wang, Gang Chen, Frank Sun, Weihua Liu, BerthaGarcia, Chenlin Yung, Yuji Sudo, Kouichi Tamura, RobertZhong. London, ON, Canada.

P123 PTERIDINE DERIVATES ACT AS POWERFULIMMUNOSUPPRESSANTS IN A MURINECARDIAC TRANSPLANT MODEL. (Abstract #127)Gerald Brandacher, Manuel Maglione, StefanSchneeberger, Peter Obrist, Guntram Thoni, GabrieleWerner-Felmayer, Raimund Margreiter, Ernst R. Werner.Innsbruck, Austria.

P124 THE NOVEL CYCLOPHILIN-BINDING DRUGSANGLEFEHRIN-A SPECIFICALLY AFFECTSANTIGEN UPTAKE RECEPTOR EXPRESSION ANDENDOCYTIC ACTIVITY OF HUMAN DENDRITICCELLS. (Abstract #128)Cees van Kooten, Nicole Schlagwein, Sandra W. van derKooij, Johan W. de Fijter, Andrea M. Woltman. Leiden,Netherlands.

P125 SANGLIFEHRIN A, A NOVEL CYCLOPHILIN-BINDING IMMUNOSUPPRESSANT BLOCKSBIOACTIVE IL-12 PRODUCTION BY HUMANDENDRITIC CELLS. (Abstract #129)Christoph Steinschulte, Timucin Taner, Angus W.Thomson, Gregor Bein, Holger Hackstein. Giessen,Germany; Pittsburgh, PA.

P126 FARNESYLTRANSFERASE INHIBITOR ABT-100ABROGATES ACUTE REJECTION. (Abstract #130)Ming-Sing Si, Ping Ji, Michael Lee, Jennifer Kwok, JamieKusumoto, Eric Naasz, Shi-Chung Ng, David K. Imagawa.San Francisco, CA; Orange, CA; Abbott Park, IL.

P127 CURCUMIN INHIBITS MIXED LYMPHOCYTEREACTION (MLR) STIMULATED CELLPROLIFERATION VIA INHIBITION OF IL-2PATHWAY. (Abstract #131)Dinesh Ranjan, Changguo Chen, Hoonbae Jeon, ThomasD. Johnston. Lexington, KY.

P128 IMMUNOSUPPRESSIVE EFFECT OF A NEWIMMUNOSUPPRESSANT, BAOHUOSIDE-1 (B1)ON LYMPHOCYTE ACTIVATION IN VITRO ANDIN VIVO. (Abstract #132)Anlun Ma, Shijie Qi, Dasheng Xu, Xiaochun Zhang, YangWang, Huifang Chen. Montreal, QC, Canada.

P129 THYMOSIN BETA-4 SULPHOXIDE - AN ANTI-INFLAMMATORY PEPTIDE WITH NOVELIMMUNOSUPPRESSANT PROPERTIES.(Abstract #133)Mohantha D. Dooldeniya, Peter J. Dupont, Lyn R.Ambrose, Paul E. Herbert, Alexios Tzivanikis, HenrietaFazekasova, Giovanna Lombardi, Anthony N. Warrens.London, United Kingdom.

P130 CD26/DIPEPTIDYL PEPTIDASE IV-TARGETEDTHERAPY OF ACUTE LUNG ALLOGRAFTREJECTION IN RATS. (Abstract #134)Florian J. Jung, Lin Yang, Ingrid De Meester, KoenAugustyns, Sven Hillinger, Didier Lardinois, Peter Vogt,Simon Scharpe, Walter Weder, Stephan Korom. Zurich,Switzerland; Antwerp, Belgium.

P112 † EFFECTS OF HEMATOPOIETIC CHIMERISM ONPROTECTIVE IMMUNITY. (Abstract #116)

64

P131 PRENYLATION INHIBITOR L-778,123SELECTIVELY BLOCKS SIGNAL 3 OF THEIMMUNE RESPONSE. (Abstract #135)Ming-Sing Si, Bruce A. Reitz, Dominic C. Borie.Stanford, CA.

P132 MIZORIBINE REVEALED A SYNERGIC EFFECTWITH CYCLOSPORINE IN MICE HEARTTRANSPLANT MODEL, AND THAT WAS MUCHSTRONGER THAN MYCOPHENOLATE MOFETIL.(Abstract #136)Naohiko Fukami, Mamoru Kusaka, Toru Higuchi, HitomiSasaki, Kiyohito Ishikawa, Ryoichi Shiroki, KiyotakaHoshinaga. Toyoake, Aichi, Japan.

P133 PROSTAGLANDIN E2 AND SELECTIVE EPRECEPTOR AGONISTS PROLONGEDALLOGRAFT SURVIVAL THROUGH Th2 SHIFT INRAT SKIN TRANSPLANTATION MODEL.(Abstract #137)Yoshimi Fujimoto, Takahito Yagi, Hiroshi Sadamori,Hiroyoshi Matsukawa, Susumu Shinoura, Hiroshi Murata,Aya Kunitomi, Takanori Oyama, Sun Dong Sheng,Hiromi Iwagaki, Noriaki Tanaka. Okayama City,Okayama Prefecture, Japan.

P134 FK778 DIRECTLY PREVENTS AND SUPPRESSESALLOSPECIFIC CELLULAR IMMUNO RESPONSEAFTER RAT CARDIAC TRANSPLANTATION - INVIVO AND IN VITRO STUDIES. (Abstract #138)Tobias Deuse, Sonja Schrepfer, Friedrich Koch-Nolte,Hans-Jörg Schäfer, Edzard Schwedhelm, Rainer Böger,Hermann Reichenspurner. Hamburg, Germany.

P135 SUPERARRAY ANALYSIS OF TRACHEALALLOGRAFTS UNDER JAK3-TARGETEDIMMUNOSUPPRESSION REVEALS A ROLE FORTHE B-CELL CHEMOATTRACTANT BLC-BCA 1.(Abstract #139)Macy Lau, Sally Zhang, Michael Larson, Mona Flores,Ming-Sing Si, Geraldine Rousvoal, Jennifer Hawkins, BariHolm, Gerald Berry, Randall Morris, Bruce Reitz,Dominic Borie. Stanford, CA.

P136 4-AMINO-TETRAHYDROBIOPTERIN, A NOVELiNOS- INHIBITOR, ACTS AS POWERFULIMMUNOSUPPRESSANT: GENE EXPRESSIONANALYSES USING cDNA MICROARRAYTECHNOLOGY. (Abstract #140)Gerald Brandacher, Manuel Maglione, StefanSchneeberger, Peter Obrist, Gabriele Werner-Felmayer,Walter Mark, Raimund Margreiter, Ernst R. Werner.Innsbruck, Austria.

Infections: BK Virus, HCV, HIV and HHVP137 † THYMOGLOBULIN INDUCTION THERAPY DOES

NOT INCREASE RISK OF BK VIRUSREPLICATION IN KIDNEY TRANSPLANTRECIPIENTS. (Abstract #141)Waichi Wong, Hans H. Hirsch, Kumiko Fujimoto,Manuel Pascual, Maureen T. Doran, Angela M.Delvecchio, A. Benedict Cosimi, Nina Tolkoff-Rubin.Boston, MA; Basel, Switzerland; Lausanne, Switzerland.

P138 † JC VIRAL DISEASE IN RENALTRANSPLANTATION. (Abstract #142)Pradip Manna, Velma Scantlebury, Abhay Vats. KansasCity, MO; Mobile, AL; Pittsburgh, PA.

P139 † CMV INFECTION AND HLA CLASS I MISMATCHARE SIGNIFICANT RISK FACTORS FORPOLYOMA VIRUS BK NEPHROPATHY.(Abstract #143)Dechu P. Puliyanda, Nurmamet Amet, Lara Hilo, DollyTyan, Asha Moudgil, Raju K. Radha, Alice Peng,Suphamai Bunnapradist, Stanley C. Jordan, MiekoToyoda. Los Angeles, CA; Washington, DC.

P140 † EPIDEMIOLOGY OF BK VIRUS REPLICATION INRENAL ALLOGRAFT RECIPIENTS ANDIDENTIFICATION OF CORTICOSTEROIDMAINTENANCE THERAPY AS AN INDEPENDENTRISK FACTOR. (Abstract #144)D. Dadhania, T. Muthukumar, C. Snopkowski, R. Ding,B. Li, M. Aull, D. Thomas, N. Shakibai, V. Sharma, D.Serur, C. Hartono, S. Kapur, M. Suthanthiran. New York,NY.

P141 † PROSPECTIVE BIOPSY FOR EARLY DIAGNOSISOF POLYOMA VIRUS ASSOCIATEDNEPHROPATHY (PVAN). (Abstract #145)Emilio Ramos, Cinthia B. Drachenberg, Ravinder Wali,Joseph Nogueira, Charles B. Cangro, David K. Klassen,John C. Papadimitriou. Baltimore, MD.

P142 † REDUCED BK VIRUS NEPHROPATHY BUTINCREASED ACUTE REJECTION WITHMYCOPHENOLATE MOFETIL DOSE REDUCTIONIN KIDNEY TRANSPLANTATION. (Abstract #146)David Shaffer, Anthony Langone, William A. Nylander,A. Tarik Kizilisik, J. Harold Helderman. Nashville, TN.

P143 † PREVENTION OF BKV NEPHRITIS BYMONITORING BK VIREMIA IN RENALTRANSPLANT RECIPIENTS-A PROSPECTIVESTUDY. (Abstract #147)Syed A. Hussain, Rimus Orentas, Joanne Walczak, Eric P.Cohen, Sundaram Hariharan. Milwaukee, WI.

P144 MEASUREMENT OF ANTI-BK VIRUS VP-1ANTIBODIES IN KIDNEY TRANSPLANTRECIPIENTS BY VIRUS-LIKE PARTICLE-BASEDELISA. (Abstract #148)Parmjeet S. Randhawa, Karen Weck, Ron Shapiro,Raphael Viscidi. Pittsburgh, PA; Baltimore, MD.

P145 URINARY CELL mRNA PROFILES PREDICTALLOGRAFT OUTCOME IN PATIENTS WITH BKVNEPHROPATHY. (Abstract #149)R. Ding, D. Dadhania, T. Muthukumar, V. K. Sharma, B.Li, S. V. Seshan, M. Suthanthiran. New York, NY.

P146 PREEMPTIVE WITHDRAWAL OF AZA OR MMFPREVENTS PROGRESSION OF BK VIREMIA TOBK NEPHROPATHY: A PROSPECTIVERANDOMIZED CONTROLLED TRIAL OF BKVIRUS INFECTION AFTER RENALTRANSPLANTATION. (Abstract #150)I. A. Agha, K. L. Hardinger, D. Bohl, A. Ansari, P. Dyk,M. Koch, B. Miller, M. Jendrisak, S. Shenoy, N. Desai, D.Beffa, J. Lowell, M. Schnitzler, G. Storch, D. C. Brennan.St. Louis, MO.

P147 CYTOKINE GENE POLYMORPHISMS AND RISKOF BK VIRUS NEPHROPATHY IN RENALTRANSPLANTATION. (Abstract #151)Ish Singla, Demetrius Ellis, Ron Shapiro, Parmjeet S.Randhawa, Michael Barmada, Robert E. Ferrell, AbhayN. Vats. Pittsburgh, PA.

P148 BLOOD AND URINE PROTEOMIC PROFILES OFBK VIRUS ASSOCIATED NEPHROPATHY(BKVAN) IN RENAL TRANSPLANTATION.(Abstract #152)Abhay N. Vats, Parmjeet S. Randhawa, Ish Singla, ReenaRai, Cherie P. Dhar, Ron Shapiro. Pittsburgh, PA.

P149 LIMITED BENEFITS FROM CIDOFOVIR THERAPYCOMBINED WITH REDUCEDIMMUNOSUPPRESSION IN CLINICALLY-EVIDENT BK NEPHROPATHY IN RENALTRANSPLANTS. (Abstract #153)Adit S. Mahale, Hasan A. Khamash, Christopher K.Buehrig, Mark Espy, Thomas R. Schwab, James M.Gloor, Donna J. Lager, Mary E. Fidler, Fernando C.Cosio, Robin Patel, Mark D. Stegall, Timothy S. Larson,Matthew D. Griffin. Rochester, MN.

65

Su

nd

ay, May 16

P150 OUTCOME OF BK VIRUS ASSOCIATEDNEPHROPATHY FOLLOWING REDUCTION INIMMUNOSUPPRESSION. (Abstract #154)Abraham Thomas, Duvuru Geetha. Baltimore, MD.

P151 ONE YEAR FOLLOW-UP OF RENAL ALLOGRAFTRECIPIENTS WITH BK VIRUS ASSOCIATED-NEPHROPATHY TREATED WITH INTRAVENOUSIMMUNOGLOBULIN. (Abstract #155)Patrick P. W. Luke, Anthony M. Jevnikar, Vivian C.McAlister, Norman Muirhead, Neil Boudville, FaiselRehman, Andrew A. House. London, ON, Canada.

P152 HLA MISMATCHING: A RISK FOR POST-TRANSPLANT BK VIRUS NEPHRITIS.(Abstract #156)Yehia A. Awadalla, Parmjeet S. Randhawa, Kris Ruppert,Adriana Zeevi, Rasha Y. Khalil, Rene J. Duquesnoy.Pittsburgh, PA; Cairo, Egypt.

P153 † DOES HISOTOLOGICAL SEVERITY OF LIVERDISEASE PREDICT CLINICAL OUTCOME INRENAL ALLOGRAFT RECIPIENTS WITHHEPATITIS-C INFECTION? (Abstract #157)Mukut Minz, Munish K. Heer, Randeep Kashyap, AshishSharma, Navalkishor Udgiri, Ranjana W. Minz, AshimDas. Chandigarh, UT, India.

P154 OUTCOME OF RENAL TRANSPLANTATION INHCV POSITIVE HEMODIALYSIS PATIENTSTREATED WITH INTERFERON-ALFA.(Abstract #158)Tadahiko Tokumoto, Kazunari Tanabe, Hideki Ishida,Naoshi Miyamoto, Hiroaki Shimmura, Nobuyuki Goya,Takashi Akiba, Hiroshi Toma. Tokyo, Japan.

P155 EVOLUTION OF THE HYPERVARIABLE REGION-1 OF HEPATITIS C VIRUS AND LIVER FIBROSISPROGRESSION IN RENAL-TRANSPLANTRECIPIENTS. (Abstract #159)Nassim Kamar, Janik Selves, Karine Sandres-Saune,Laurent Alric, Dominique Durand, Lionel Rostaing,Jacques Izopet. Toulouse, France.

P156 INCREASED MORTALITY IN HEPATITIS C VIRUS(HCV)+ KIDNEY RECIPIENTS IS ASSOCIATEDWITH PREEXISTING DIABETES (DM).(Abstract #160)Roy D. Bloom, Gabriel T. Sayer, Serban Constantinescu,Kosunarty Fa, Simin Goral, Alden M. Doyle, Ali Naji,James Markman, Robert A. Grossman, Marty Sellers.Philadelphia, PA.

P157 HCV+ DONOR TO HCV+ RECIPIENT: IMPACT OFINDUCTION METHOD AND VIRAL LOAD ANDOUTCOME. (Abstract #161)Mark S. Burke, Rabie N. Stephan, Merril T. Dayton,Oleh Pankewicz, Mark R. Laftavi, Lisa Kilmer, Fadi Y.Dagher. Buffalo, NY.

P158 HCV INFECTION IN RENAL TRANSPLANTRECIPIENTS WITH BENIGN LIVER HISTOLOGY.(Abstract #162)Rana Muzaffar, Ejaz Ahmed, Javed I. Kazi, Mirza NaqiZafar, Fazal Akhtar, Anwar Naqvi, Adib Rizvi. Karachi,Sindh, Pakistan.

P159 IMPACT OF SHORT-TERM CALCINEURININHIBITORS (CI) ON GLUCOSE TOLERANCE INHEPATITIS C (HCV)+ AND HCV- PATIENTSAWAITING KIDNEY TRANSPLANTATION.(Abstract #163)Kosunarty Fa, Roy D. Bloom, Raymond Townsend,Serban Constantinescu, Debbie L. Cohen. Philadelphia,PA.

P160 HEPATIC IRON DEPOSITION IN HEPATITIS CVIRUS-POSITIVE (HCV+) KIDNEY TRANSPLANTCANDIDATES: ASSOCIATION WITHINTRAVENOUS (IV) IRON AND LIVERHISTOLOGY. (Abstract #164)Gabriel T. Sayer, Jeffrey Berns, Serban Constantinescu,Kevin C. Mange, Emma E. Furth, Rajender Reddy, RoyD. Bloom. Philadelphia, PA.

P161 † LAMIVUDINE FOR TREATMENT OF HEPATITIS BAFTER KIDNEY TRANSPLANT: METANALYSIS OFCLINICAL TRIALS. (Abstract #165)Paul Martin, Vivek Dixit, Gareth Dulai, SuphamaiBunnapradist, Fabrizio Fabrizi. Los Angeles, CA.

P162 HIV SEROPOSITIVE PATIENTS AND RENALTRANSPLANTATION: TRANSPLANTLABORATORY EVALUATIONS. (Abstract #166)Robert F. McAlack, Anil M. Kumar, Billie S. Fyfe,Elizabeth Tecza. Philadelphia, PA.

P163 RITONAVIR USE IN HIV+ KIDNEY TRANSPLANTRECIPIENTS SIGNIFICANTLY ALTERSCYCLOSPORINE PHARMACOKINETICS WITH AHIGH POTENTIAL FOR OVER- AND UNDER-DOSING. (Abstract #167)Michael Heifets, Mysore S. Anil Kumar, Debra Sierka,Susan Stabler. Philadelphia, PA.

P164 INFECTION WITH HUMAN HERPESVIRUS 6 INRENAL TRANSPLANTATION: A SINGLE CENTEREXPERIENCE. (Abstract #168)Milagros Samaniego, Richard M. Ugarte, Lesia Dropulic,Aruna Subramanian, Edward Kraus. Baltimore, MD.

P165 † ULTRA-LOW DOSE ALPHA-INTERFERON PLUSRIBAVIRIN FOR THE TREATMENT OF ACTIVEHEPATITIS C IN RENAL TRANSPLANTRECIPIENTS. (Abstract #169)Kuo-Hsiung Shu, Joung-Liang Lan, Ming-Ju Wu, Chi-Hung Cheng, Chen-Hsu Chen, Wen-Chin Lee, Horng-Rong Chang, Jong-Da Lian. Taichung, Taiwan.

Kidney: Complications and Protocol BiopsiesP166 EFFICACY AND SAFETY OF PALMAZ STENT

IMPLANTATION IN THE TREATMENT OF RENALARTERY STENOSIS IN RENALTRANSPLANTATION. (Abstract #170)Elisabetta Bertoni, Lorenzo Di Maria, Alberto Rosati,Maria Zanazzi, Paola Becherelli, Rosa Piperno, MaurizioSalvadori. Florence, Tuscany, Italy.

P167 RECIPIENT HISTORY OF CANCER ISINDEPENDENTLY ASSOCIATED WITHINCREASED POST-TRANSPLANT DE NOVOMALIGNANCIES AND DECREASED SURVIVAL.(Abstract #171)H. M. Kauffman, Y. Cheng, W. S. Cherikh, M. A.McBride, D. W. Hanto, F. L. Delmonico. Richmond, VA;Boston, MA.

P168 UROLOGIC COMPLICATIONS IN 402CONSECUTIVE RENAL TRANSPLANTS USING ASTENTED LICH-GREGOIRURETERONEOCYSTOSTOMY. (Abstract #172)Richard S. Mangus, Brian W. Haag. Indianapolis, IN.

P169 SAFETY AND SPECIMEN ADEQUACY OFAMBULANT RENAL TRANSPLANT BIOPSIES.(Abstract #173)Anke Schwarz, Wilfried Gwinner, Markus Hiss, JoergRadermacher, Michael Mengel, Hermann Haller.Hannover, Germany.

66

P170 DETECTION OF SUBCLINICAL HUMORAL AND/OR VASCULAR REJECTION BY PROTOCOLBIOPSIES IN HIGHLY SENSITIZED RENALTRANSPLANT RECIPIENTS. (Abstract #174)Tomokazu Shimizu, Kazunari Tanabe, Hideki Ishida,Miyuki Furusawa, Tsutomu Ishizuka, TadahikoTokumoto, Naoshi Miyamoto, Nobuo Ishikawa, HiroakiShimmura, Hiroki Shirakawa, Hiroshi Toma. Tokyo,Japan.

P171 PROTOCOL BIOPSY FINDINGS IN HIVPOSITIVE RENAL TRANSPLANT RECIPIENTS.(Abstract #175)Billie S. Fyfe, Lisa C. Veith, Michael S. Heifets, Anil M.Kumar. Philadelphia, PA.

Kidney: PediatricsP172 † A MULTICENTRE, PROSPECTIVE, OPEN LABEL

STUDY OF CYCLOSPORIN A MONITORING BYTWO HOURS LEVELS IN DE NOVO PAEDIATRICKIDNEY TRANSPLANT RECIPIENTS : INTERIMANALYSIS. (Abstract #176)Mariano Ferraresso, Luciana Ghio, Fabrizio Ginevri,Francesco Perfumo, Bruno Ginoglio, Luisa Murer,Graziella Zacchello, Laurent Piazza, Sara Viganò, LucaDello Strologo, Paola Pedotti. Italy.

P173 EVEROLIMUS CLINICAL PHARMACOKINETICSIN PEDIATRIC DE NOVO KIDNEY TRANSPLANTPATIENTS. (Abstract #177)J. M. Kovarik, P. F. Hoyer, R. Ettenger, V. Moeller.Basel, Switzerland and East Hanover, NJ; Essen,Germany; Los Angeles, CA.

P174 DONOR AND RECIPIENT EPSTEIN-BARR VIRUSSERO-STATUS, VIRAL PROPHYLAXIS, VIRALLOAD MONITORING, AND CLINICAL DISEASEIN PEDIATRIC RENAL TRANSPLANT RECIPIENTS.(Abstract #178)Lorraine Bell, Daniela Toffoli, Chantal Cassis, AngelaBurns. Montreal, QC, Canada.

P175 PREDICTION OF LONG TERM SUCCESSFULSTEROID WITHDRAWL BY CTLA4 AND OTHERPOLYMORPHISMS -PEDIATRIC RENALTRANSPLANT EXPERIENCE. (Abstract #179)Juergen Strehlau, Jan Kwant, Bernd Klare. Hannover,Germany; Munich, Germany.

P176 CYCLOSPORIN A ABSORPTION PROFILES INPEDIATRIC RENAL TRANSPLANT RECIPIENTSPREDICT THE RISK OF ACUTE REJECTION.(Abstract #180)Burkhard Toenshoff, Lutz T. Weber, Victor W.Armstrong, Lothar B. Zimmerhackl, Michael Oellerich.Heidelberg, Germany; Göttingen, Germany; Innsbruck,Austria.

P177 ADVANTAGES OF CICLORPORIN A (CsA)DOSING BASED ON CsA MONITORING BY TWOHOUR LEVELS IN PEDIATRIC KIDNEYTRANSPLANTATION. (Abstract #181)Lars Pape, Jochen H. H. Ehrich, Gisela Offner.Hannover, Germany.

P178 STEROID WITHDRAWAL FIVE DAYS AFTERPEDIATRIC RENAL TRANSPLANTATION.(Abstract #182)Jose Oberholzer, Eunice John, Adisorn Lumpaopong,Leslie Briars, Giuliano Testa, Howard Sankary, KerryKraft, Priya Verghese, Enrico Benedetti.

P179 CYTOMEGALOVIRUS (CMV) HIGH RISK STATUSHAS INFLUENCE ON LONGTERM OUTCOME OFKIDNEYTRANSPLANTED CHILDREN ANDADOLESCENTS ASIDE FROM ACUTE REJECTIONEPISODES. (Abstract #183)Therese Christina Jungraithmayr, Günter Kirste, LotharBernd Zimmerhackl. Innsbruck, Tirol, Austria; Freiburg,Germany.

P180 PEDIATRIC RENAL TRANSPLANT: RESULTSUSING A STEROID-FREE MAINTENANCEREGIMEN. (Abstract #184)Clotilde D. Garcia, Viviane R. Barros, Eleonora Salles,Felipe Hertz, Fernanda Caraver, Fernanda Weber, OscarKirst, Valter D. Garcia. Porto Alegre, RS, Brazil.

P181 UROLOGIC COMPLICATIONS ARE INCREASEDIN CHILDREN AFTER KIDNEYTRANSPLANTATION FOR OBSTRUCTIVE ANDREFLUX UROPATHY. (Abstract #185)Blanche M. Chavers, Varvara Askiti, SookkasemKhositseth, Elizabeth Ingulli, Leo Fung, KristenGillingham, Thomas Nevins. Minneapolis, MN.

P182 BONE MINERAL DENSITY CHANGES AFTERRENAL TRANSPLANTATION IN CHILDREN.(Abstract #186)Marina Charbit, Genevieve Guest, Marie-FranceGagnadoux, Patrick Niaudet. Paris, France.

P183 C2 AS AN AGE-INDIPENDENT MARKER FOROPTIMAL CYCLOSPORINE EXPOSURE IN LONGTERM KIDNEY TRANSPLANT RECIPIENTS.(Abstract #187)Luciana Ghio, Franco Citterio, Mariano Ferraresso,Mariolina Scatà, Alberto Edefonti, Luisa Berardinelli,Marco Castagneto. Milan, Italy; Rome, Italy.

P184 IS A SINGLE PRE-TRANSPLANT C REACTIVEPROTEIN PREDICTIVE OF LONG-TERM RENALALLOGRAFT SURVIVAL OR REJECTION INCHILDREN? (Abstract #188)Lavjay Butani, Jeremy Johnson, Christoph Troppmann,John McVicar, Richard V. Perez. Sacramento, CA.

P185 RENAL FUNCTION IN HEART TRANSPLANTEDCHILDREN ON CYCLOSPORINE TREATMENT:DETERIORATION IS NOT MANDATORY.(Abstract #189)L. Dello Strologo, F. Parisi, C. Pontesilli, A. Pastore, A.E. Tozzi, G. Rizzoni. Rome, Italy.

Liver Transplant: PotpourriP186 † A TISSUE-ENGINEERED ARTIFICIAL BILE DUCT

CAN BE A SUBSTITUTE FOR THE NATIVE BILEDUCT. (Abstract #190)Mitsuo Miyazawa, Takahiro Torii, Yasuko Toshimitsu,Katsuya Okada, Isamu Koyama, Yoshito Ikada. Iruma-gun, Saitama, Japan; Suzuka, Mie, Japan.

P187 EVIDENCE OF B CELL TOLERANCE TO BLOODGROUP ANTIGENS AFTER ABO-INCOMPATIBLELIVER TRANSPLANTATION. (Abstract #191)Hideki Ohdan, Wendy Zhou, Yuka Tanaka, YasushiFuchimoto, Toshimasa Asahara. Hiroshima-City,Hiroshima, Japan; Setagaya-ku, Tokyo, Japan.

P188 CHILD-PUGH CLASS AND MELD SCOREPOORLY PREDICT THE SHORT-TERM SURVIVALIN PATIENTS TREATED WITH TIPS FORREFRACTORY ASCITES OR HYDROTHORAX.(Abstract #192)Angelo Luca, Roberto Miraglia, Adele D’Antoni,Giovanni Vizzini, Bruno Gridelli. Palermo, Italy.

P189 A SPOT OF TEA FOR STEATOSIS? (Abstract #193)Ryan N. Fiorini, Jennifer Donovan, Zachary Evans,Ronald E. Reyna, Michael G. Schmidt, Crystal Campbell,Harold D. May, Charles Milliken, John Markowitz,Kenneth D. Chavin. Charleston, SC.

P190 THE SAFETY AND EFFICACY OF rVIIa INORTHOTOPIC LIVER TRANSPLANTATION.(Abstract #194)Ruthann M. Conoley, Robert E. Dupuis, Jeffrey H. Fair,David A. Gerber, Kenneth Andreoni, Mark W. Johnson,Anthony Passannante. Chapel Hill, NC.

67

Su

nd

ay, May 16

P191 OUTCOMES OF HBV TRANSPLANTATION WITHCOMBINATION LAMIVUDINE &&&&& LOW DOSE/HIGH DOSE HEPATITIS B IMMUNE GLOBULIN(HBIG). (Abstract #195)Jin Kee Ho, Nilu Partovi, Siegfried R. Erb, Charles H.Scudamore, Urs P. Steinbrecher, Stephen W. Chung,Andrez Buczkowski, Eric M. Yoshida. Vancouver, BC,Canada.

P192 SYSTEMIC HYPERGLYCEMIA INDUCESISCHEMIA-LIKE CHANGES IN THETRANSPLANTED LIVER. (Abstract #196)Anna Gillispie, Johan Ungerstedt, Grzegorz Nowak.Huddinge University Hospital, Stockholm, Sweden.

P193 RECIPIENT RACE AND OUTCOME AFTERCADAVERIC LIVER TRANSPLANTATION.(Abstract #197)Pierpaolo Sileri, Antonio Manzelli, Diego Bogetti,Thomasz Jarzembowski, Howard Sankary, Giuliano Testa,Enrico Benedetti. Chicago, IL.

P194 INFLUENCING FACTORS ON LIVERTRANSPLANT PATIENT’S QUALITY OF LIFE.(Abstract #198)Bok Nyeo Kim. Seoul, Korea.

P195 OPTIMAL APPLICATION AND MONITORING OFNEORAL IN ADULT LIVING DONOR LIVERTRANSPLANTATION. (Abstract #199)Shigeyuki Kawachi, Motohide Shimazu, Go Wakabayashi,Ken Hoshino, Minoru Tanabe, Masashi Yoshida,Yasuhide Morikawa, Kiyoshi Mihara, Kunihiko Morita,Yusuke Tanigawara, Masaki Kitajima. Tokyo, Japan.

P196 ABLATION OF PIMARY LIVER MALIGNANCIESAS PRIMARY THERAPY: ONE CENTERSEXPERIENCE. (Abstract #200)Mark J. Thomas, David Barnasi, Ann Cho, AndrewRaheim, Manish Gupta, Todd Merchen, Steve Rudich,Micheal Hanaway, E. Steve Woodle, Joseph Buell.Cincinnati, OH.

P197 TECHNIQUES FOR LAPAROSCOPICEVALUATION AND MANAGEMENT OF PRIMARYLIVER TUMORS IN PROSPECTIVE LIVERTRANSPLANT CANDIDATES. (Abstract #201)T. Merchen, M. Gupta, M. J. Thomas, C. Schneider, A.Reheim, A. Choe, M. J. Hanaway, S. M. Rudich, E. S.Woodle, J. F. Buell. Cincinnati, OH.

P198 HEPATOCELLULAR ULTRASTRUCTURE AFTERISCHEMIA/REPERFUSION INJURY IN HUMANORTHOTOPIC LIVER TRANSPLANTATION.(Abstract #202)Satish Nadig, Basker Periyasamy, Ryan Fiorini, DavidRodwell, Stephen Shafizadeh, Carmen Polito, DanaDunkelberger, Michael Schmidt, Sally Self, KennethChavin. Charleston, SC; Columbia, SC.

P199 INFRARENAL AORTIC GRAFTS INCREASE RISKOF CHYLOUS ASCITES AFTER LIVERTRANSPLANTATION. (Abstract #203)Silvania P. Cauduro, Sara DiCecco, Nickie Francisco-Ziller, David J. Brandhagen, Patrick S. Kamath, CharlesB. Rosen. Rochester, MN.

P200 ADENOVIRUS INFECTION DETECTED BY PCR INLIVER AND BOWEL TRANSPLANT RECIEPIENTS:DEMONSTRATION OF INFECTION BYSCREENING TISSUE BIOPSIES. (Abstract #204)Robert E. Cirocco, Debbie Weppler, Tamoko Kato,Genaro Selvaggi, Navine Mital, S. Nishida, J. Moon,Violet Esquenazi, Joshua Miller, Andreas Tzakis. Miami,FL.

P201 ONCE DAILY DOSING WITH NEORAL UTILIZINGC2 MONITORING IN DE NOVO LIVERTRANSPLANT PATIENTS. (Abstract #205)Gary A. Levy, Leslie B. Lilly, Nigel T. Girgrah, Mark S.Cattral, Paul D. Greig, Robert Smith, David R. Grant.Toronto, ON, Canada.

P202 THE INFLUENCE OF PROCUREMENT TECHNIQUEON EARLY LIVER ALLOGRAFT FUNCTION.(Abstract #206)Jang I. Moon, Hee Chul Yu, David M. Levi, SeigoNishida, Debbie Weppler, Gennaro Selvaggi, JuanMadariaga, Susan Ganz, Tomoaki Kato, Andreaas G.Tzakis. Miami, FL.

P203 SUCCESSFUL PORTAL VEIN ARTERIALIZATIONFOR FULMINANT HEPATIC FAILURE.(Abstract #207)Bruno Nardo, Roberto Montalti, Paolo Beltempo,Riccardo Bertelli, Lorenza Puviani, Paolo Caraceni,Mauro Bernardi, Cristina Rossi, Gerardo Martinelli,Antonino Cavallari. Bologna, Italy.

P204 UTILITY OF PRE-LIVER TRANSPLANT MAGNETICRESONANCE IMAGING TO DETECT MEDIANARCUATE LIGAMENT COMPRESSIONSYNDROME. (Abstract #208)M. Gupta, K. A. Choe, T. D. Merchen, J. F. Buell, M. J.Hanaway, E. S. Woodle, S. M. Rudich. Cincinnati, OH.

P205 THE EFFICACY OF BRIDGING THERAPY FORHEPATOCELLULAR CARCINOMA ON SURVIVALFOLLOWING LIVER TRANSPLANTATION.(Abstract #209)Hideo Yoshida, Tomoaki Kato, David M. Levi, Juan R.Madariaga, Jang I. Moon, Seigo Nishida, GennaroSelvaggi, Eugene R. Schiff, Andreas G. Tzakis. Miami,FL.

P206 LAPAROSCOPIC EVALUATION OF MASSES INEND STAGE LIVER DISEASE PATIENTS.(Abstract #210)J. F. Buell, M. J. Thomas, C. R. Schneider, F. Weber, M.Gupta, T. D. Merchen, M. Bass, D. Flannery, T. C. Doty,M. J. Hanaway, S. M. Rudich, E. S. Woodle. Cincinnati,OH.

P207 ACCURACY OF PREOPERATIVE VSINTRAOPERATIVE IMAGING OF PRIMARY LIVERMALIGNANCY. (Abstract #211)Mark J. Thomas, David Barnasi, Steve Rudich, ManishGupta, Todd Merchan, Micheal J. Hanaway, E. S.Woodle, Joeseph F. Buell. Cincinnati, OH.

Low/No Steroids Trial: Other Trials, Conversion, andScientific StudiesP208 A PROSPECTIVE RANDOMIZED STUDY TO

COMPARE THE EFFICACY AND SAFETY OFSIROLIMUS(SLR) AND MYCOPHENOLATEMOFETIL(MMF) MONITORED BY PROTOCOLBIOPSIES IN TACROLIMUS(TAC) BASEDSTEROID FREE IMMUNOSUPPRESSION.(Abstract #212)Mysore S. Anil Kumar, Michael Heifets, Billie Fyfe,Debra Sierka, Mohammed I. Saeed, Mithen Parekh,Michael J. Moritz, Susan Stabler, Aparna Kumar.Philadelphia, PA.

P209 THE EFFECT OF 2-GRAM VS. 1-GRAMCONCENTRATION CONTROLLEDMYCOPHENOLATE MOFETIL ON TRANSPLANTOUTCOMES USING SIROLIMUS BASEDCALCINEURIN INHIBITOR DRUG-FREEIMMUNOSUPPRESSION. (Abstract #213)Stuart M. Flechner, Mahesh Goel, Jing Feng, BarbaraMastroianni, Kathy Savas, Jeffrey Arnovitz, Charles S.Modlin, David Goldfarb, Daniel J. Cook, Andrew Novick.Cleveland, OH.

68

P210 † SAFETY AND EFFICACY OF TACROLIMUS(TAC)BASED STEROID FREE IMMUNOSUPPRESSIONIN AFRICAN AMERICAN KIDNEY RECIPIENTS: APROSPECTIVE CONTROLLED STUDY.(Abstract #214)Mysore S. Anil Kumar, Billie Fyfe, Sheng G. Xiao, DebraSierka, Michael Heifets, Muhammed I. Saeed, Michael J.Moritz, Aparna Kumar. Philadelphia, PA.

P211 A META-ANALYSIS OF STEROID WITHDRAWALTRIALS IN RENAL TRANSPLANT PATIENTS ONTRIPLE THERAPY WITH A CALCINEURININHIBITOR AND MYCOPHENOLATE MOFETIL.(Abstract #215)Julio Pascual, Carlos Quereda, Javier Zamora, DomingoHernández, Spanish Group for Evidence Based Medicinein Renal Transplantation. Madrid, Spain; Santa Cruz deTenerife, Spain.

P212 ARE STEROID-SPARING IMMUNOSUPPRESSIONREGIMENS IMPACTING POSITIVELY ON CO-MORBIDITIES AFTER RENALTRANSPLANTATION? (Abstract #216)M. J. Aull, D. Dadhania, D. Serur, C. Hartono, D.Thomas, W. T. Stubenbord, M. Suthanthiran, S. Kapur.New York, NY.

P213 COMPARISON OF MYCOPHENOLATEMOFETIL(MMF) AND SIROLIMUS(SLR) INAFRICAN AMERICAN KIDNEY RECIPIENTSUSING STEROID FREE CALCINEURIN BASEDIMMUNOSUPPRESSION. (Abstract #217)Aparna Kumar, Michael Heifets, Debra Sierka, BillieFyfe, Muhammed I. Saeed, Michael J. Moritz, Miten H.Parikh, Mysore S. Anil Kumar. Philadelphia, PA.

P214 SHORT TERM ALLOGRAFT BIOPSY FINDINGS INKIDNEY RECIPIENTS AFTER STEROIDAVOIDANCE. (Abstract #218)Raymond L. Heilman, Marek J. Mazur, Adyr A. Moss,James W. Williams, K. Sudhakar Reddy, David Post,Savas Petrides, David C. Mulligan. Phoenix, AZ.

P215 COMPARISON OF TACROLIMUS(TAC) ANDSIROLIMUS(SLR) VERSUSCYCLOSPORINE(CSA) AND SLR IN KIDNEYTRANSPLANT RECIPIENTS MAINTAINED ONSTEROID FREE IMMUNOSUPPRESSION.(Abstract #219)Muhammed I. Saeed, Mysore S. Anil Kumar, MichaelHeifets, Debra Sierka, Sheng G. Xiao, Michael J. Moritz,Miten H. Parikh, Billie Fyfe. Philadelphia, PA.

P216 ENTERIC-COATED MYCOPHENOLATE SODIUMIN COMBINATION WITH OPTIMIZED NEORALDOSING, BASILIXIMAB, AND STEROIDSRESULTS IN GOOD EFFICACY AND RENALFUNCTION IN RENAL TRANSPLANT RECIPIENTSIN THE FIRST 6 MONTHS. (Abstract #220)D. M. Cibrik, S. Jensik, H.-U. Meier-Kriesche, B.Bresnahan, B. Lieberman for the Myfortic-US01 RenalTransplant Study Group. Ann Arbor, MI; Chicago, IL;Gainesville, FL; Milwaukee, WI; East Hanover, NJ.

P217 SIROLIMUS (RAP) PLUS CYCLOSPORINEMICROEMULSION (CSA) IS ASSOCIATED WITHA GREATER RISK FOR RENAL FUNCTIONDETERIORATION VS. MYCOPHENOLATEMOFETIL (MMF) PLUS CSA. (Abstract #221)Herwig-Ulf Meier-Kriesche, Jacqueline J. Loveland,Bettina J. Steffen, Alice H. Chu, Vincent Gotz, Robert D.Gordon, Jonathan A. Morris, Bruce Kaplan. Gainesville,FL; La Jolla, CA; Nutley, NJ.

P218 SAFETY AND TOLERABILITY OF ENTERIC-COATED MYCOPHENOLATE SODIUM INCOMBINATION WITH STEROIDS AND TWOREGIMEN OF NEORAL®, IN DE NOVO KIDNEYTRANSPLANT RECIPIENTS : 6 MONTHS INTERIMRESULTS. A RANDOMIZED, MULTICENTRE,OPEN, PROSPECTIVE CONTROLLED STUDY.(Abstract #222)Lionel Rostaing, Georges Mourad, Christophe Legendre.Toulouse, France; Montpellier, France; Paris, France.

P219 SIROLIMUS TREATMENT PATTERNS AND FIRSTYEAR OUTCOMES IN RENAL TRANSPLANTRECIPIENTS UNDER CONDITIONS OF NORMALPRACTICE: THE RAPAMUNE® OUTCOMESASSESSMENT REGISTRY (ROAR™).(Abstract #223)Bertram Kasiske, the ROAR Study Group. Minneapolis,MN.

P220 ASSESSMENT OF TWO NEORAL®ADMINISTRATION STRATEGIES ON RENALFUNCTION AND EFFICACY IN DE NOVO RENALTRANSPLANT PATIENTS RECEIVING ENTERIC-COATED MYCOPHENOLATE SODIUM, STEROIDSAND ANTI-IL2R ANTIBODIES: 6 MONTHSINTERIM ANALYSIS OF A RANDOMIZED,MULTICENTRE, OPEN, PROSPECTIVECONTROLLED STUDY. (Abstract #224)Georges Mourad, Lionel Rostaing, Christophe Legendre.Montpellier, France; Toulouse, France; Paris, France.

P221 Abstract #225 has been withdrawn.P222 CONVERSION FROM CYCLOSPORINE/

SIROLIMUS (CsA/SRL) TO MYCOPHENOLATEMOFETIL/SIROLIMUS (MMF/SRL) IN PATIENTSWITH CHRONIC ALLOGRAFT DYSFUNCTION.(Abstract #226)Carla C. Fonseca, Cláudia R. Felipe, Sofia A. Motegi,Beatriz H. Hosaka, Márcia K. Tanaka, Luciana A.Kamura, Sung I. Park, Paula G. Machado, Riberto Garcia,Hélio Tedesco-Silva, Jr., José O. Medina-Pestana. SãoPaulo, SP, Brazil.

P223 SIX MONTH INTERIM ANALYSIS OF A PHASE IIIPROSPECTIVE, RANDOMISED STUDY TOCOMPARE CONVERSION FROM CALCINEURININHIBITORS TO RAPAMYCIN IN ESTABLISHEDRENAL ALLOGRAFT RECIPIENTS WITH MILDTO MODERATE RENAL INSUFFICIENCY.(Abstract #227)Keshwar Baboolal. Cardiff, United Kingdom.

P224 LONG-TERM EFFECTS OF THE CONVERSIONFROM AZATHIOPRINE (AZA) TOMYCOPHENOLATE MOFETIL (MMF) IN PATIENTSWITH CHRONIC ALLOGRAFT DYSFUNCTION(CAD). (Abstract #228)Ednelson C. Alves, Cláudia R. Felipe, Sung I. Park,Luciene A. Silva, Paula G. Machado, Riberto Garcia,Hélio Tedesco-Silva, Jr., José O. Medina-Pestana. SãoPaulo, SP, Brazil.

P225 SUPERIOR RENAL FUNCTION FOLLOWINGCONVERSION TO SIROLIMUS AFTER RENALTRANSPLANTATION – PRELIMINARY RESULTSFROM A RANDOMISED TRIAL. (Abstract #229)Christopher J. Watson, John Firth, John Bradley, Paul F.Williams, Jane C. Smith, Christopher R. Palmer, AndrewJ. Bradley. Cambridge, United Kingdom.

P226 LATE CONVERSION TO SIROLIMUS IN AKIDNEY TRANSPLANT POPULATION : IS ITWORTH? (Abstract #230)Hélène Lord, Anne Boucher, Michel Morin, RaymondDandavino. Montréal, QC, Canada.

69

Su

nd

ay, May 16

P227 DENDRITIC CELL KINETICS IN PERIPHERALBLOOD OF PATIENTS UNDERGOING RENALTRANSPLANTATION. (Abstract #231)Dennis A. Hesselink, Martijn A. Verkade, PetrosAthanassopoulos, Michiel G. H. Betjes, Wim C. J. Hop,Thea van Dam, Wenda Schoordijk, Lennaert M. B.Vaessen, Carla C. Baan, Willem Weimar. Rotterdam,Netherlands.

P228 IMMUNOSUPPRESSION DOES NOT ALTER THEPROPORTION OF RECENT THYMUS EMIGRANTSIN RENAL TRANSPLANT PATIENTS.(Abstract #232)Peter Nickel, Gantuja Bold, Stephanie Kreutzer, AstridFriebe, Christian Meisel, Gottfried May, Hans-DieterVolk, Petra Reinke. Berlin, Germany.

P229 BASILIXIMAB LOWERS THE THERAPEUTICTHRESHOLD FOR CYCLOSPORINE EXPOSUREIN THE EARLY POST KIDNEY TRANSPLANTPERIOD. (Abstract #233)Felipe G. Balbontin, Bryce Kiberd, Philip Belitsky,Dharm Singh, Albert Fraser, Joseph G. Lawen. Halifax,NS, Canada; Santiago, Chile.

P230 ASSESSING IMMUNE RECONSITUTION:MONITORING LYMPHOCYTE IMMUNEFUNCTION FOLLOWING DEPLETIONALTHERAPY USING THE IMMUNKNOW™ ASSAY.(Abstract #234)Roslyn B. Mannon, D. Post, R. Kowalski, A. D. Kirk, D.Hale, J. Britz. Columbia, MD; Betheda, MD.

P231 TAPERING OF IMMUNOSUPPRESSIVE DRUGSLEADS TO RECOVERY OF IN VIVO DELAYEDCUTANEOUS HYPERSENSITIVITY RESPONSES.(Abstract #235)Barbara J. van der Mast, Jacqueline van de Wetering,Nicole M. van Besouw, Jacqueline Rischen-Vos, WillemWeimar. Rotterdam, Netherlands.

P232 HYPOMAGNESEMIA AND OUTCOMES IN RENALTRANSPLANT RECIPIENTS WITH CALCINEURININHIBITOR TOXICITY. (Abstract #236)Ryan D. Holzmacher, Christina Kendziorski, Michael R.Hofmann, Brazy Peter, Becker N. Bryan, ArjangDjamali. Madison, WI.

P233 CLINICAL SIGNIFICANCE OF ROUTINE GRAFTBIOPSY PERFORMED ON 14TH

POSTTRANSPLANT DAY IN LIVING DONORRENAL TRANSPLANTATION. (Abstract #237)Chul Woo Yang, Bum Soon Choi, Suk Joon Shin, YongSoo Kim, Suk Young Kim, In Sung Moon, Yong BokKoh, Byung Kee Bang. Seoul, Korea.

P234 INTRACELLULAR CYTOKINE RESPONSE TOIMMUNOSUPPRESSIVE AGENTS IN PATIENTSWITH END STAGE RENAL FAILURE ONHAEMODIALYSIS AWAITINGTRANSPLANTATION. (Abstract #238)Aurelia Zamauskaite, Peter Amlot, Andrew Davenport,Stephen H. Powis. London, United Kingdom.

P235 EVALUATION OF IMMUNOSUPPRESION USINGA REPORTER GENE ASSAY IN KIDNEYTRANSPLANT RECIPIENT. (Abstract #239)Lionel Couzi, Jean-Luc Taupin, Jean-Francois Moreau,Pierre Merville. Bordeaux, France; Bordeaux, France.

P236 TRANSFORMING GROWTH FACTOR-beta INFOLLOW-UP KIDNEY PROTOCOL BIOPSIESFROM A RANDOMIZED TRIAL COMPARINGCYCLOSPORINE-BASED AND TACROLIMUS-BASED IMMUNOSUPPRESSIVE REGIMENS.(Abstract #240)Michael Eikmans, Marian C. Roos, Hans J. Baelde,Eduard Scholten, Ingeborg M. Bajema, Sandrine Florquin,Ajda T. Rowshani, Emile de Heer, Hans W. de Fijter, JanA. Bruijn. Leiden, Netherlands; Amsterdam, Netherlands.

P237 ACCURACY OF CIMETIDINE-CORRECTEDSERUM CREATININE, CREATININE CLEARANCEAND CALCULATED CREATININE CLEARANCE TOASSESS THE GLOMERULAR FILTRATION RATE INLONG-TERM KIDNEY-PANCREAS AND LIVERTRANSPLANT PATIENTS. (Abstract #241)M. Cantarovich, J. Barkun, J. Tchervenkov, S.Paraskevas, J. Schiff, R. Mangel, M. Deschenes, G.Fontaine, C. Coursol, P. Metrakos. Montreal, QC,Canada.

P238 EFFICACY OF BASILIXIMAB INDUCTIONTHERAPY IN ABO-INCOMPATIBLE KIDNEYTRANSPLANTATION: A RAPID STEROIDWITHDRAWAL PROTOCOL. (Abstract #242)Kotaro Kai, Tamotsu Tojimbara, Sumihiko Sato, MichiroNakamura, Tomonori Kawase, Ichiro Nakajima, ShouheiFuchinoue, Satoshi Teraoka. Tokyo, Japan.

P239 A PROSPECTIVE MULTICENTER NATIONALSTUDY TO ASSESS THE FEASIBILITY ANDBENEFITS OF STEROID WITHDRAWAL INKIDNEY TRANSPLANT PATIENTS UNDER AMYCOPHENOLATE MOFETIL ANDTACROLIMUS-BASED REGIMEN. (Abstract #243)Antonio Alarcon, Domingo Del Castillo, Miguel A.Gentil, Pablo Gomez, Luis Capdevilla, Rafael Romero.Palma de Mallorca, Spain; Cordoba, Spain; Sevilla, Spain;Bilbao, Spain; Barcelona, Spain; Santiago de Compostela,Spain.

P240 THE EFFECT OF RAPAMYCIN ON SEXHORMONES OF MALE RENAL TRANSPLANTPATIENTS. (Abstract #244)Suji Lee, Maria Coco, Stuart Greenstein, RichardSchechner, Vivian Tellis, Daniel Glicklich. Bronx, NY.

P241 INCREASED RISK OF POST-TRANSPLANTDIABETES MELLITUS DESPITE EARLY STEROIDWITHDRAWAL IN HISPANIC KTX RECIPIENTS.(Abstract #245)Debra Walczak, Denise Calvert, Tomasz M.Jarzembowski, Giuliano Testa, Howard N. Sankary, JoseOberholzer, Enrico Benedetti. Chicago, IL.

P242 A RACIAL COMPARISON OF THE ADVERSEEFFECTS OF SIROLIMUS IN KIDNEYTRANSPLANT RECIPIENTS. (Abstract #246)David J. Taber, G. Mark Baillie, Elizabeth E. Ashcraft,Suzanne Berkman, Angello Lin, Kenneth D. Chavin,Prabhakar K. Baliga, Jeffrey Rogers, P. R. Rajagopalan.Charleston, SC.

Lung: All TopicsP243 † CHRONIC KIDNEY DISEASE AFTER LUNG

TRANSPLANTATION. (Abstract #247)Ana Thereza C. Rocha, Paulo N. Rocha, Stephen R.Smith, Scott Palmer. Durham, NC.

P244 † LUNG TRANSPLANTATION FOR IDIOPATHICPULMONARY FIBROSIS: WHICH PATIENTSSHOULD BE TRANSPLANTED FIRST?(Abstract #248)Alessandro Bertani, Diana A. Zaldonis, Julianne Ristich,James D. Dauber, Kenneth R. McCurry. Pittsburgh, PA.

P245 † IMMUNE RECOVERY IN LUNG TRANSPLANTRECIPIENTS FOLLOWING T CELL DEPLETIONCOMBINED WITH TACROLIMUS THERAPY.(Abstract #249)Adriana Zeevi, Alin L. Girnita, Kathy Spichty, DianaZaldonis, Kevin McDade, Aldo T. Iacono, Samuel A.Yousem, Kenneth R. McCurry. Pittsburgh, PA.

70

P246 INFECTIOUS COMPLICATIONS AT SIX MONTHSIN LUNG TRANSPLANT RECIPIENTSUNDERGOING PRETRANSPLANT T-CELLDEPLETION. (Abstract #250)Shahid Husain, Eun J. Kwak, David L. Paterson, DianaZaldonis, Adriana Zeevi, Thomas E. Starzl, Kenneth R.McCurry. Pittsburgh, PA.

P247 EVEROLIMUS PHARMACOKINETICS AND WELL-TOLERATED TROUGH CONCENTRATION RANGEIN MAINTENANCE LUNG TRANSPLANT PATIENTS.(Abstract #251)J. M. Kovarik, R. B. Love, R. Aris, C. K. Chan, L.McMahon. Basel, Switzerland; Madison, WI; Chapel Hill,NC; Toronto, ON, Canada.

P248 MARKED DECREASE IN PTLD WITH A PTLDPREVENTION PROGRAM IN ADULT LUNGTRANSPLANT RECIPIENTS UTILIZING EBV-DNAMONITORING. (Abstract #252)Robin K. Avery, Jeffrey T. Chapman, Atul C. Mehta,Omar A. Minai, Tracy Evans-Walker, Holli Blazey,Marcus Haug, Steven M. Gordon, Lara Danziger-Isakov,Steven K. Schmitt, Marie Budev, Dan Culver, MalcolmM. DeCamp. Cleveland, OH.

P249 MDR1 HAPLOTYPE/GENOTYPE ANDSEQUENTIAL TACROLIMUS DOSING ANALYSISIN ADULT LUNG TRANSPLANT PATIENTS.(Abstract #253)HongXia Zheng, Erin Schuetz, Adriana Zeevi, KennethMcCurry, Aldo Iacono, Steven Webber, Jatinder Lamba,Gilbert Burckart. Los Angeles, CA; Pittsburgh, PA;Memphis, TN.

P250 DOES LUNG TRANSPLANTATION IMPROVEHEALTH-RELATED QUALITY OF LIFE? THEUNIVERSITY OF FLORIDA EXPERIENCE.(Abstract #254)James R. Rodrigue, Maher A. Baz, William F. Kanasky,Kathleen L. MacNaughton. Gainesville, FL; Chicago, IL.

P251 SEIZURES COMPLICATING ADULT LUNGTRANSPLANTATION. (Abstract #255)Erik A. Beyer, Gonzalo V. Gonzalez-Stawinski, Jing Feng,Patrick E. Parrino, Peter A. Walts, O. Minai, MalcolmM. Decamp. Cleveland, OH.

P252 EARLY REFLUX MONITORING FOLLOWINGLUNG TRANSPLANTATION MAY UNDERESTIMATETHE INCIDENCE OF GASTROESOPHAGEALREFLUX. (Abstract #256)Matthew G. Hartwig, James Z. Appel, Ed Cantu, R.Duane Davis. Durham, NC.

P253 EFFICACY OF RABBIT ANTITHYMOCYTEGLOBULIN IN PEDIATRIC CARDIOTHORACICTRANSPLANT RECIPIENTS WITH STEROIDRESISTANT OR SEVERE REJECTION.(Abstract #257)Albert Faro, Brandon K. Knott, F. Jay Fricker, KennethO. Schowengerdt, Gary A. Visner, Deborah A. Kahler.Gainesville, FL.

PK Studies and ComplicationsP254 THE NIGHTTIME MYCOPHENOLIC ACID AREA

UNDER THE CURVE INFLUENCES THEOCCURRENCE OF ACUTE REJECTION IN THEEARLY STAGE IN RENAL TRANSPLANTRECIPIENTS. (Abstract #258)Shigeru Satoh, Hitoshi Tada, Norihiko Tsuchiya, MihoMurakami, Zhenhua Li, Yukitoshi Hayase, ToshioSuzuki, Tomonori Habuchi. Akita, Japan; Otaru, Japan.

P255 WOUND HEALING COMPLICATIONS AFTERKIDNEY TRANSPLANTATION: A PROSPECTIVE,RANDOMIZED COMPARISON OF SIROLIMUSAND TACROLIMUS. (Abstract #259)Patrick G. Dean, William J. Lund, Timothy S. Larson,Mikel Prieto, Scott L. Nyberg, Michael B. Ishitani,Walter K. Kremers, Mark D. Stegall. Rochester, MN.

P256 EARLY ACUTE REJECTION IN AFRICANAMERICANS IS NOT DUE TO RELATIVELY POORDRUG ABSORPTION IN A CYCLOSPORINEBASED REGIMEN. (Abstract #260)John J. Curtis, Thomas C. Pearson, Jimmy A. Light,Flavio Vincenti, Robert Mendez, You Min Wu.Birmingham, AL; Atlanta, GA; Washington, DC; SanFranscisco, CA; Los Angeles, CA; Iowa City, IA.

P257 STEADY-STATE PHARMACOKINETICS OFENTERIC-COATED MYCOPHENOLATE SODIUM(MYFORTIC®) IN STABLE RENAL TRANSPLANTPATIENTS DIFFER DURING CONCOMITANTTREATMENT WITH NEORAL® OR TACROLIMUS.(Abstract #261)Bruce Kaplan, Marie-Claude Bastien, Meier-KriescheHerwig-Ulf, Paula Minnick, Romain Sechaud, Ching-Ming Yeh, Sebastien Balez, Franck Picard, RobertSchmouder. Gainsville, FL; East Hanover, NJ.

P258 CONVERSION OF STABLE KIDNEY TRANSPLANTRECIPIENTS FROM A TWICE DAILY PROGRAFBASED REGIMEN TO A ONCE DAILY MODIFIEDRELEASE TACROLIMUS BASED REGIMEN.(Abstract #262)Rita Alloway. Cincinnati, OH.

P259 RENAL FUNCTION AND ALBUMINCONCENTRATIONS ARE DETERMINANTS OFMYCOPHENOLIC ACID PHARMACOKINETICS.(Abstract #263)Reinier vanHest, Teun vanGelder, Arnold Vulto, RonMathot. Rotterdam, Netherlands.

P260 FTY720 PHARMACOKINETICS ARE SIMILARACROSS ETHNIC-RACIAL GROUPS.(Abstract #264)J. M. Kovarik, A. Slade, Y. Sugita, G. J. Riviere, R. L.Schmouder. Basel, Switzerland; Tokyo, Japan; EastHanover, NJ.

P261 DIFFERENTIAL EFFECT OF CSA/FK 506/RAPA ONHEPATIC AND INTESTINAL CYP3A4 AND PGPACTIVITY IN VIVO. (Abstract #265)Wim Lemahieu, Bart Maes, Kristin Verbeke, YvesVanrenterghem. Leuven, Belgium.

P262 FTY720 PHARMACOKINETICS AREPREDICTABLE AND LINEAR OVER AN EXTENDEDEXPOSURE RANGE. (Abstract #266)J. M. Kovarik, A. Slade, G. J. Riviere, R. L. Schmouder.Basel, Switzerland; East Hanover, NJ.

P263 PHARMACOKINETICS OF AN EVEROLIMUS-CYCLOSPORINE REGIMEN YIELDING GOODEFFICACY AND RENAL FUNCTION IN DE NOVOKIDNEY TRANSPLANTATION. (Abstract #267)J. M. Kovarik, H. Tedesco, J. Pascual, G. Civati, J.Geissler. Basel, Switzerland; Sao Paulo, Brazil; Madrid,Spain; Milan, Italy.

P264 CONCENTRATION OF TOTAL MYCOPHENOLICACID (MPA), MYCOPHENOLIC ACIDGLUCURONIDE (MPAG) AND UNBOUND MPA INDIABETIC KIDNEY TRANSPLANT RECIPIENTS.(Abstract #268)Fatemeh Akhlaghi, Chirag G. Patel, Patricia Zuinga,Sonia Lin, Angelito Yango, Reginald Gohh. Kingston, RI;Providence, RI.

71

Su

nd

ay, May 16

P265 C2 MONITORING ALLOWS A REDUCTION INCYCLOSPORINE DOSE AND COSTS IN RENALTRANSPLANT RECIPIENTS RECEIVINGQUADRUPLE IMMUNOSUPPRESSIVE THERAPYWITH THYMOGLOBULIN. (Abstract #269)Karen L. Hardinger, Mark A. Schnitzler, Brent Miller,Jeffrey A. Lowell, Surendra Shenoy, Niraj Desai, MartinJendrisak, Matthew J. Koch, Daniel C. Brennan. St.Louis, MO.

P266 C2 MONITORING REVISITED. (Abstract #270)

G. Einecke, M. Schuetz, I. Mai, L. Fritsche, H. H.Neumayer, K. Budde. Berlin, Germany.

P267 ORAL PHARMACOKINETICS OF FK 506 ARESIGNIFICANTLY ALTERED IN RENALTRANSPLANT PATIENTS SUFFERING FROMPERSISTENT DIARRHEA. (Abstract #271)Wim Lemahieu, Bart Maes, Kristin Verbeke, YvesVanrenterghem. Leuven, Belgium; Leuven.

P268 LOWER INCIDENCE OF REJECTION AFTERKIDNEY TRANSPLANTATION WITH NEORAL C2MONITORING. (Abstract #272)Tudor Bîrsan, Christiane Loinig, Martin Bodingbauer,Thomas Wekerle, Susanne Rockenschaub, GabrielaBerlakovich, Thomas Soliman, Ferdinand Mühlbacher,Rudolf Steininger. Vienna, Austria.

P269 REDUCED PLASMA LEVELS OFIMMUNOGLOBULINS AND MANNOSE-BINDING-PROTEIN AFTER RENAL TRANSPLANTATIONUNDER MMF THERAPY: A LONGITUDINALSTUDY. (Abstract #273)Nilufer Emine Broeders, Marc Hazzan, Martin Wissing,Christian Noel, Francoise Mascart, Daniel Abramowicz.Brussels, Belgium; Lille, France.

P270 NEORAL C2 REMAINS A ROBUST MARKER OFCYCLOSPORINE EXPOSURE REGARDLESS IF ITUSED IN REGIMENS WITH MMF, AZATHIOPRINE,EVEROLIMUS, OR FTY720. (Abstract #274)J. M. Kovarik, M. Rouilly, M. Soergel, C. Cornu-Artis.Basel, Switzerland.

P271 THE USEFULNESS OF THERAPEUTIC DRUGMONITORING OF MYCOPHENOLATE MOFETIL:A COMPUTER SIMULATION. (Abstract #275)Reinier M. van Hest, Teun van Gelder, Arnold G. Vulto,Ron A. A. Mathot. Rotterdam, Netherlands.

P272 THE ABSORPTION PHASE OF CYCLOSPORINE(NEORAL®) IS VASTLY DIFFERENT BETWEENMORNING AND EVENING DOSING:IMPLICATIONS FOR CYCLOSPORINEMONITORING. (Abstract #276)John J. Curtis, Patsy Jones, Ralph Barbeito. Birmingham,AL; East Hanover, NJ.

P273 THERAPEUTIC DRUG MONITORING INCLINICAL RENAL TRANSPLANTATION:EXPERIENCES WITH TWO-HOURCYCLOSPORINE LEVELS (C2) IN THE LONGTERM. (Abstract #277)Jan Carstens, Melvin Madsen. Aarhus, Denmark.

P274 MDR-1 C3435T POLYMORPHISM HAS NOEFFECT ON CYCLOSPORINE ABSORPTION ANDTACROLIMUS DOSAGE OR CLINICALOUTCOME IN STABLE RENAL TRANSPLANTRECIPIENTS. (Abstract #278)G. Einecke, M. Goldammer, I. Mai, P. Glander, C.Lorkowski, L. Fritsche, H. H. Neumayer, K. Budde.Berlin, Germany.

P275 † INTERIM ANALYSIS OF THE MODIFY STUDY INRENAL TRANSPLANTATION (MODIFICATION OFDOSES TO IMPROVE FUNCTION THROUGH THEYEARS). (Abstract #279)Elias David-Neto, Lilian M. Pereira, Maria Cristina R. deCastro, Renata M. Mattos, Nairo M. Sumita, Maria E.Mendes, Paschoalina Romano, William C. Nahas, Luiz E.Ianhez. Sao Paulo, SP, Brazil.

P276 FACTORS INFLUENCING 12 HOUR TROUGHMYCOPHENOLIC ACID LEVELS IN RENALTRANSPLANTATION. (Abstract #280)Richard Borrows, Gary Chusney, Jen van Tromp,Anthony James, Jose Stichbury, Thomas Cairns, MeganGriffith, Nadey Hakim, Adam McLean, Andrew Palmer,Vassilios Papalois, David Taube. London, UnitedKingdom.

P277 LONG-TERM RESULTS OF CONVERSION TONEORAL C2 MONITORING OF STABLE KIDNEYTRANSPLANT RECIPIENTS. (Abstract #281)Franco Citterio, Maria Carmela Scatà, JacopoRomagnoli, Giuseppe Nanni, Marco Castagneto. Rome,Italy.

P278 THE ROLE OF THERAPEUTIC DRUGMONITORING (TDM) OF MYCOPHENOLATEMOFETILE UNDER TACROLIMUS BASED ANDCNI FREE IMMUNOSUPPRESSION.(Abstract #282)Yoshihiko Watarai, Ken Morita, Naohiko Shimoda,Tomoaki Usuki, Katsuya Nonomura, Hiroyasu Shiga,Harumi Takada, Katsumi Miyazaki. Sapporo, Hokkaido,Japan.

P279 THE CYP3A5*3 ALLELE WHICH PREDICTS NON-EXPRESSION OF CYP3A5 IS ASSOCIATED WITHHIGHER DOSE-NORMALISED TACROLIMUSBLOOD CONCENTRATIONS IN SOUTH ASIANAND WHITE PATIENTS. (Abstract #283)Iain A. M. MacPhee, Salim Fredericks, Maha Mohamed,Michelle Moreton, Nick D. Carter, Lawrence Goldberg,David W. Holt. London, United Kingdom; Brighton,United Kingdom.

P280 OUTCOME OF NEORAL C2 LEVEL MONITORINGIN ASIAN KIDNEY TRANSPLANT RECIPIENT.(Abstract #284)Kearkiat Praditpornsilpa, Yingyos Avihingsanon,Talerngsak Kansanabuch, Somchai Eiam-Ong, SauwaluckChusil, Kriang Tungsanga. Bangkok, Thailand.

P281 AUC-GUIDED DOSING OF TACROLIMUSVERSUS CYCLOSPORINE: SUPERIORREJECTION RATES AT THE COST OF HIGHINCIDENCE OF POST TRANSPLANT DIABETESMELLITUS. (Abstract #285)Ajda T. Rowshani, Eduard M. Scholten, SandrineFlorquin, Ingeborg Bajema, Frederike Bemelman, JantoSurachno, Leendert C. Paul, Ineke ten Berge, Johan W.de Fijter. Amsterdam; Leiden, Netherlands.

P282 ONE YEAR RANDOMIZED STUDY COMPARINGCYCLOSPORINE MICROEMULSION WITH C2MONITORING AND TACROLIMUS IN DE NOVOKIDNEY TRANSPLANTATION. (Abstract #286)Felipe G. Balbontin, Bryce Kiberd, Philip Belistky,Dharm Singh, Albert Fraser, Joseph G. Lawen. Halifax,NS, Canada; Santiago, Chile.

72

P283 INVESTIGATION OF THE OPTIMALMONITORING OF MYCOPHENOLATE MOFETILAND TACROLIMUS IN RENAL TRANSPLANTIMMUNOSUPPRESSIVE THERAPY: — IS THEREREALLY NO PROBLEM WITH TROUGHMONITORING? (Abstract #287)Kazuharu Uchida, Yoshihiro Tominaga, Toshihito Haba,Akio Katayama, Susumu Matsuoka, Norihiko Goto,Tsuneo Ueki, Asami Takeda, Kunio Morozumi, TsukasaKimata, Takuto Nagai, Yoshimitsu Goto, Hiroshi Takagi,Takaaki Kobayashi, Akimasa Nakao. Nagoya, Aichi,Japan.

P284 C2 MONITORING FOR TACROLIMUS, MPA ANDCyA. A SINGLE APPROACH TO THERAPEUTICDRUG MONITORING. (Abstract #288)Lilian M. Pereira, Maria Cristina R. de Castro, Renata M.Mattos, Nairo M. Sumita, Maria E. Mendes, PaschoalinaRomano, William C. Nahas, Luiz E. Ianhez, Elias David-Neto. Sao Paulo, SP, Brazil.

P285 PHARMACOKINETIC PROFILE OF ASIANPEDIATRIC RENAL TRANSPLANT RECIPIENTS BYSPARSE SAMPLING AUC. (Abstract #289)Anwar Naqvi, Adib Rizvi, Zafar Hussain, Altaf Hashmi,Fazal Akhtar, Mirza Naqi Zafar, Ejaz Ahmed, ManzoorHussain. Karachi, Sindh, Pakistan.

P286 † TACROLIMUS WITHIN THE THERAPEUTICWINDOW REDUCES βββββ-CELL FUNCTION BUT ISNOT ASSOCIATED WITH HIGHER INCIDENCEOF GLUCOSE METABOLISM ABNORMALITIES.(Abstract #290)Elias David-Neto, Christiano S. Cocuzza, Lilian M.Pereira, Maria Cristina R. de Castro, Renata M. Mattos,Jose A. Marcondes, Valeria S. Lando, William C. Nahas,Luiz E. Ianhez. Sao Paulo, SP, Brazil.

P287 † PHARMACOKINETICS OF TACROLIMUS INKIDNEY TRANSPLANT RECIPIENTS: TWICEDAILY VERSUS ONCE DAILY DOSING.(Abstract #291)Karen L. Hardinger, Jeong M. Park, Mark A. Schnitzler,Matthew J. Koch, Brent W. Miller, Daniel C. Brennan.St. Louis, MO; Ann Arbor, MI.

P288 † EVALUATION OF THE OPTIMUM METHOD FORCYCLOSPORINE ADMINISTRATION BASED ONTHE BLOOD CALCINEURIN ACTIVITY, USING ANEW ASSAY PROCEDURE. (Abstract #292)Michio Nakamura, Tsutomu Ishizuka, Tetsuo Hayashi,Mineko Yasuo, Kotaro Kai, Sumihiko Sato, TamotsuTojimbara, Ichiro Nakajima, Shohei Fuchinoue, SatoshiTeraoka. Shinjuku, Tokyo, Japan.

P289 † FTY720 HIGH DOSE: LYMPHOCYTE RESPONSEAT SINGLE DOSES UP TO 40 MG. (Abstract #293)Alan Slade, John M. Kovarik, Thomas L. Hunt, RobertSchmouder. East Hanover, NJ; Basel, Switzerland; Austin,TX.

P290 † EXCELLENT EFFICACY AND TOLERABILITY OFC2-MONITORING FOR CYCLOSPORINEMICROEMULSION (CsA-ME, NEORAL): RESULTSOF MO2ART, A 12-MONTH RANDOMIZEDINTERNATIONAL STUDY. (Abstract #294)Sergio Stefoni, Karsten Midtvedt, Edward Cole, EricThervet, Sandra Cockfield, Mathias Buchler, LorenzoToselli, Luis Pallardo, Francesco Paolo Schena, HelenPilmore, Michèle Kessler, Steven Chadban, César AgostCarreño. Bologna, Italy.

Tissue Injury IP291 RENOPROTECTIVE EFFECT OF RECOMBINANT

HUMAN ERYTHROPOIETIN ON CHRONICCYCLOSPORINE NEPHROPATHY. (Abstract #295)Chul Woo Yang, Can Li, Bum Soon Choi, Sun Woo Lim,Bo Kyoung Sun, Yong Soo Kim, Byung Kee Bang. Seoul,Republic of Korea.

P292 MILD HYPOTHERMIA PROVIDES SIGNIFICANTPROTECTION AGAINST ISCHEMIA/REPERFUSION INJURY IN FATTY LIVERS.(Abstract #296)Soojinna Choi, Joonhwa Noh, Claus U. Niemann, NatalieJ. Serkova, John P. Roberts, Ryutaro Hirose. Gwangju,Korea; San Francisco, CA; Denver, CO.

P293 A RADICAL SCAVENGER, EDARAVONE,PROTECTS RENAL FUNCTION FROM ISCHEMIA-REPERFUSION INJURY IN 72 HOURS CANINEKIDNEY COLD PRESERVATION ANDAUTOTRANSPLANTATION. (Abstract #297)Munenori Tahara, Masato Nakayama, Maeng Bong Jin,Miri Fujita, Tomomi Suzuki, Masahiko Taniguchi,Tsuyoshi Shimamura, Hiroyuki Furukawa, Satoru Todo.Sapporo, Hokkaido, Japan; Muroran, Hokkaido, Japan.

P294 BOTH REACTIVE OXYGEN AND REACTIVENITROGEN AUGMENT TGF-BETA, CTGF AND HIF-1 ALPHA mRNA EXPRESSION IN RENAL CELLS.(Abstract #298)Ashwani K. Khanna, Matthew S. Plummer, Galen M.Pieper. Milwaukee, WI.

P295 † RAPAMYCIN SPECIFICALLY INHIBITS IL-12-MEDIATED STAT4 PHOSPHORYLATION INDENDRITIC CELLS, NOT T CELLS. (Abstract #299)Lianfu Wang, Po-Hui Chiang, Xiaoyan Liang, Ran Tao,John J. Fung, Shiguang Qian, Lina Lu. Pittsburgh, PA.

P296 DYNAMIC ASSESSMENT OF OXYGEN CONTENTOF PFC AND UW SOLUTIONS OVER TIMEDURING 2-LAYER METHOD OF PANCREASPRESERVATION. (Abstract #300)Marc R. Garfinkel, Patrick Zhou, Ryan Skarbek.Chicago, IL.

P297 FTY720: A NOVEL USE OF A NEW AGENT TOAMELIORATE ISCHEMIA/REPERFUSION INJURYIN THE LIVER. (Abstract #301)Daniel F. Tentori, David J. Post, Shawn St. Peter, JeffPerumen, Hector Rodriguez-Luna, Adyr A. Moss, DavidC. Mulligan. Phoenix, AZ.

P298 SURFACTANT PRE-TREATMENT IMPROVES LUNGFUNCTION BUT NOT CELLULAR INFILTRATIONAFTER ISCHEMIA-REPERFUSION-INJURY OFTHE LUNG. (Abstract #302)Niels P. van der Kaaij, Jack J. Haitsma, Jolanda Kluin,Bart N. Lambrecht, Burkhard Lachmann, Ron W. F. deBruin, Ad J. J. C. Bogers. Rotterdam, Netherlands.

P299 INCREASED EXPRESSION OF P16(INK4a), P21(WAF1/CIP1)

AND P27(Kip1) CDKI GENES AFTER RENALISCHEMIA AND EX-VIVO HEMOPERFUSION.(Abstract #303)Archil B. Chkhotua*, Hubert Schelzig*, Peter Hajmassy,Dirk Koglin, Dietmar Abendroth, Shared first authorship.Tbilisi, Georgia; Ulm, Germany.

P300 N-ACETYLCYSTEIN DECREASES RENAL INJURYDAMAGED TRIGGERED BY ISCHEMIA ANDREPERFUSION. (Abstract #304)Cristiane Di Giorno, Helady S. Pinheiro, Nelson Z.Galante, Marcos A. Cenedeze, Alvaro Pacheco-Silva,Niels O. S. Camara. Sao Paulo, Brazil; Juiz de Fora, SP,Brazil.

73

Su

nd

ay, May 16

P301 BRAIN DEATH IN THE MOUSE -CHARACTERIZATION OF SURVIVAL ANDHEMODYNAMICS IN A NEW MODEL OF BRAINDEATH. (Abstract #305)Andreas Lundgren, Daniel J. Lukes, Henrik Krook,Ulrika Johnsson, Johan Mölne, Elmir Omerovic, TomasLorant, Michael Olausson. Göteborg, Sweden; Uppsala,Sweden.

P302 EXPRESSION OF STATHMIN (A NOVEL MARKERFOR TUBULAR PROLIFERATION/INJURY) INRENAL TRANSPLANT PATIENTS WITH DELAYEDGRAFT FUNCTION. (Abstract #306)P. Roy-Chaudhury, A. Jain, J. Trofe, R. Alloway, M.Clippard, L. McKee, S. Heffelfinger, S. Petrovic, L. Ma,K. Zahedi, S. Rudich, S. Woodle, M. Soleimani.Cincinnati, OH.

XenotransplantationP303 ACUTE REJECTION OF XENOGRAFTS IS T CELL

DEPENDENT AND IS INITIATED OUTSIDESECONDARY LYMPHOID ORGANS.(Abstract #307)Daniel R. Goldstein, Bethany M. Tesar, Fadi G. Lakkis.New Haven, CT.

P304 ROLE OF CD40-CD154 PATHWAY INCONCORDANT AND DISCORDANT ISLETXENOGRAFT REJECTION. (Abstract #308)Gang Mai, Pascal Bucher, Philippe Morel, DomenicoBosco, Axel Andres, Zoltan Mathe, Thomas Wekerle,Thierry Berney, Leo H. Buhler. Geneva, Geneva,Switzerland; Vienna, Austria.

P305 † ABROGATION OF HYPERACUTE PULMONARYXENOGRAFT DYSFUNCTION BY PASSENGERMACROPHAGE DEPLETION. (Abstract #309)Edward Cantu, Jeffery G. Gaca, Daniel J. Lukes, DanielPalestrant, Kamran Baig, Gonzalo V. Gonzalez-Stawinski,William Parker, R. Duane Davis. Durham, NC.

P306 PORCINE ANNEXIN IV: A LECTIN THAT MEDIATESXENOGENEIC RECOGNITION OF HUMANERYTHROCYTES. (Abstract #310)Christopher Burlak, Lisa M. Twining, Michael A. Rees.Toledo, OH.

P307 ELIMINATION OF ααααα-GAL EPITOPES ONXENOGENEIC PORCINE CELLS REDUCESCYTOLYTIC, BUT NOT PHAGOCYTOTICACTIVITY OF HUMAN RETICULO-ENDOTHELIALMACROPHAGE. (Abstract #311)Kentaro Ide, Hideki Ohdan, Hidetaka Hara, TakaakiKobayashi, Daisuke Tokita, Takashi Onoe, Wendy Zhou,Kohei Ishiyama, Hiroshi Mitsuta, Yuka Tanaka,Toshimasa Asahara. Hiroshima, Japan; Nagoya, Japan.

P308 N-ACETYLNEURAMINIC ACID IS A TARGETEPITOPE RECOGNIZED BY PORCINE KUPFFERCELLS ON THE SURFACE OF XENOGENEICHUMAN ERYTHROCYTES. (Abstract #312)Christopher Burlak, Michael A. Rees. Toledo, OH.

P309 TRANSPLANTATION OF ααααα1,3-GALACTOSYLTRANSFERASE GENE-KNOCKOUTPIG BONE MARROW IN BABOONS.(Abstract #313)Yau-Lin Tseng, Frank J. M. F. Dor, Kenji Kuwaki, DerekPrabharasuth, Amy Alt, David Ryan, Maria Denaro,Maria Giovino, James Wood, Kazuhiko Yamada, RobertHawley, Michel Awwad, Clive Patience, Henk-JanSchuurman, David H. Sachs, David K. C. Cooper. Boston,MA; Cambridge, MA.

P310 SURVIVAL ADVANTAGE OF DISCORDANT ISLETXENOGRAFTS IN DIABETIC BDC2.5/NOD MICE.(Abstract #314)Adam M. Frank, Yong Suk Bae, Moh Moh Lian,Thavachenthan Thambi-Pillai, Daniel Moore, HoomanNoorchasm, James F. Markmann, Shaoping Deng.Philadelphia, PA.

P311 INDUCTION OF STABLE TOLERANCE TOCONCORDANT AND DISCORDANT ISLETXENOGRAFTS BY INHIBITION OF SIGNALS 2AND 3. (Abstract #315)Gang Mai, Pascal Bucher, Philippe Morel, DomenicoBosco, Axel Andres, Zolzan Mathe, Thierry Berney,Christoph Heusser, Thomas Wekerle, Leo H. Buhler.Geneva, Switzerland; Basel, Switzerland; Vienna, Austria.

P312 SUCCESSFUL FUNCTION OFMICROENCAPSULATED PORCINE ISLETS INSTREPTOZOTOCIN-DIABETICIMMUNOCOMPETENT MICE. (Abstract #316)Alexander Szabo, Ingrid Stuiver, Dagmar Meissner,Gabriel Evanoff, Edilaine Miller, Daniel Salomon. LaJolla, CA; San Diego, CA.

P313 † SIMULTANEOUS GENE SILENCING OF PIG CD80AND CD86 BUT NOT SINGLE CD80, CD86 ORCD40 BY RNAI PREVENTS COSTIMULATION OFHUMAN ANTI-PIG T CELL RESPONSES.(Abstract #317)Jae-Young Kim, Donghee Kim, Inho Choi, Jae-SeokYang, Dong-Sup Lee, Jeong-Ryul Lee, Shuji Miyagawa,Katsuyoshi Matsunami, Woo-Suk Hwang, SuhnggwonKim, Jung-Sang Lee, Curie Ahn. Seoul, Korea; Osaka,Japan.

P314 INVESTIGATION OF THE IMMUNOGLOBULINRESPONSE AND VH GENE USAGE IN RHESUSMONKEYS INJECTED WITH PORCINEHEPATOCYTES AND ENDOTHELIAL CELLS.(Abstract #318)Joanne L. Zahorsky-Reeves, Clare R. Gregory, Donald V.Cramer, Andrew E. Kyles, Dominic C. Borie, Kari L.Christe, Vaughn A. Starnes, Mary K. Kearns-Jonker. LosAngeles, CA; Davis, CA; Stanford, CA.

P315 CRITIACL ROLE FOR CR2 IN THE MECHANISMOF B CELL TOLERANCE TO αααααGAL IN GALTKNOCKOUT MICE VIA INDUCTION OF MIXEDCHIMERISM. (Abstract #319)Ichiro Shimizu, Yoshiyasu Kawahara, Philip D. Bardwell,Megan Sykes. Boston, MA.

P316 THE USE OF LENTIVIRAL VECTORS TO ACHIEVECHIMERISM AND INHIBIT XENOANTIBODYRESPONSES WITHOUT LETHAL CONDITIONING.(Abstract #320)Noboru Mitsuhashi, Jacqueline Fischer-Lougheed,Stephanie Weston, Aya Jang, Donald B. Kohn, KennethWeinberg, Vaughn A. Starnes, Mary Kearns-Jonker. LosAngeles, CA.

P317 COAGULATION PROFILE IN PRIMATERECIPIENTS OF PORCINE XENOGRAFTSEXPOSED TO LONG-TERM TREATMENT WITHHIGH-DOSE RECOMBINANT HUMANANTITHROMBIN. (Abstract #321)M. Boldrin, S. Gavasso, M. Seveso, G. Tognin, N. Baldan,A. Katopodis, Y. Echelard, T. Rice, A. Pagnan, P.Simioni, E. Cozzi, E. Ancona. Padua, Italy; Basel,Switzerland.

74

Mini-Oral: Acute Rejection: Novel Mechanisms12:45 - 1:45 PM

Room 306Chairs: Dianne B. McKay and Stanislaw M. Stepkowski

12:45 PM AGING IMPAIRS T CELL ACTIVATION AND TH1IMMUNITY LEADING TO A REDUCED ABILITY TOREJECT FULLY MHC MISMATCHED SKINALLOGRAFTS. (Abstract #322)Bethany M. Tesar, Cesar Cruz, Daniel R. Goldstein. NewHaven, CT.

12:52 PM EARLY AND SUSTAINED DOWN-REGULATION OFANGIOPOETIN-1 AND VEGF IN REJECTINGKIDNEY: THE MECHANISM OF VASCULARPERMEABILITY IN T CELL MEDIATEDREJECTION? (Abstract #323)Adis Tasanarong, Attapong Vongwiwatana, Konrad S.Famulski, Vido Ramassar, David C. Rayner, Philip F.Halloran. Edmonton, AB, Canada.

12:59 PM PERFORIN AND FAS-L (CD95L) FORMPARALLEL, COMPLEMENTARY PATHWAYS OFCD8 T CELL MEDIATED ISLET ALLOGRAFTREJECTION. (Abstract #324)Michelle Sleater, Andrew S. Diamond, Amy Bolwerk,Ronald G. Gill. Denver, CO.

1:06 PM EFFECT OF ANTI-TUMOR NECROSIS FACTOR-αααααADMINISTRATION IN MURINE CARDIACALLOGRAFTS. (Abstract #325)Emanuela Binello, Yasushi Uchida, Jessica A. Allen,Xiao-yu Song, Richard N. Mitchell. Cambridge, MA;Boston, MA; Malvern, PA.

1:13 PM SECONDARY LYMPHOID ORGANS AND THEIMMUNE RESPONSE TO INTESTINALALLOGRAFTS. (Abstract #326)Jun Wang, Ying Dong, Zhong Guo, Marvin Newton-West, Marisa Alegre, Kenneth A. Newell. Atlanta, GA;Chicago, IL.

1:20 PM TIM-3 mRNA IN URINARY CELLS IS HIGHLYEXPRESSED IN ACUTE REJECTION IN KIDNEYTRANSPLANT RECIPIENTS. (Abstract #327)Paulo G. Renesto, Niels O. S. Camara, Marcos Cenedeze,Alvaro Pacheco-Silva. Sao Paulo, SP, Brazil.

1:27 PM ANTIBODIES TO LIVER SINUSOIDALENDOTHELIAL CELLS MODULATE IMMUNERESPONSES IN LIVER TRANSPLANTATION.(Abstract #328)Xupeng Ge, Azza Karrar, Bo-Goran Ericzon, UlrikaBroome, Suchitra Sumitran-Holgersson. Stockholm,Sweden.

Mini-Oral: Chemokines and Cytokines12:45 - 1:45 PM

Room 309Chairs: Wayne W. Hancock and Stuart J. Knechtle

12:45 PM CXCL9 ANTAGONISM FURTHER EXTENDSPROLONGED ALLOGRAFT SURVIVAL IN CCL19/CCL21-DEFICIENT MICE. (Abstract #329)B. L. Colvin, Z. Wang, H. Nakano, T. Kakiuchi, R. L.Fairchild, A. W. Thomson. Pittsburgh, PA; Tokyo,Japan; Cleveland, OH.

12:52 PM TYPE-1 INTERFERON-DEPENDENT HEPATOCYTEPRODUCTION OF IP-10. (Abstract #330)Qiao Bo, Yuan Zhai, Wei Gao, Feng Gao, Ronald W.Busuttil, Genhong Cheng, Jerzy W. Kupiec-Weglinski.Los Angeles, CA.

12:59 PM ASSOCIATION OF URINARY EXCRETION OF THEIP-10, MIG, AND I-TAC WITH ACUTEALLOGRAFT REJECTION IN BABOON KIDNEYTRANSPLANTATION. (Abstract #331)Turan Kanmaz, Ping Feng, Jose Torrealba, Jean Kwun,John H. Fechner, Jacqueline M. Schultz, Yinchen Dong,Hyoung Tae Kim, Wasim Dar, Majed M. Hamawy, StuartJ. Knechtle, Huaizhong Hu. Madison, WI.

1:06 PM INHIBITION OF TRANSENDOTHELIAL TLYMPHOCYTE MIGRATION BY P-FTY720 ANDSPHINGOSINE 1-PHOSPHATE (S1P).(Abstract #332)Adam C. Yopp, Shuang Fu, Jordi C. Ochando, Nancy R.Krieger, Jonathan S. Bromberg. Brooklyn, NY; NewYork, NY.

1:13 PM CCR AND CC CHEMOKINE EXPRESSION INRELATION TO Flt3 LIGAND-INDUCED DENDRITICCELL ACCUMULATION WITHIN THE KIDNEY.(Abstract #333)P. Toby H. Coates, Bridget L. Colvin, Anju Ranganathan,F. Jason Duncan, Yuk Y. Lan, Alan F. Zahorchak, AngusW. Thomson. Pittsburgh, PA.

1:20 PM NK CELLS RECRUITED TO LIVER ALLOGRAFTSARE A SOURCE OF IFN-γγγγγ. (Abstract #334)Hideaki Obara, Olivia M. Martinez, Yasuhiro Ogura,Christine L. Hsieh, Carlos O. Esquivel, Sheri M. Krams.Stanford, CA.

1:27 PM FORMATION OF TERTIARY (ECTOPIC)LYMPHOID ORGANS IN MURINE CARDIACALLOGRAFTS UNDERGOING CHRONIC ORDELAYED ACUTE REJECTION. (Abstract #335)Isam W. Nasr, Barbara Wrobel, Nancy H. Ruddle, Fadi G.Lakkis, Fady K. Baddoura. New Haven, CT; Buffalo, NY.

Mini-Oral: Current Consideration with theNewer Immunosuppressants12:45 - 1:45 PM

Ballroom BChairs: David C. Cronin, III and Todd Pesavento

12:45 PM ACUTE RAPAMYCIN NEPHROTOXICITY INPROTEINURIC PATIENTS WITH CHRONICGLOMERULOPATHIES. (Abstract #336)F. C. Fervenza, P. M. Fitzpatrick, J. Mertz, S. Liggett, S.Popham, T. S. Larson, D. N. Wochos, J. A. Velosa.Rochester, MN.

12:52 PM BONE PAIN IN RENAL TRANSPLANTATION: DOESSIROLIMUS PLAY A ROLE? (Abstract #337)R. E. Boardman, J. Trofe, R. R. Alloway, C. Rogers, P.Roy-Chaudhury, M. Cardi, S. Safdar, E. S. Woodle.Cincinnati, OH.

12:59 PM MYCOPHENOLIC ACID METABOLITE PROFILEIN RENAL TRANSPLANT PATIENTS RECEIVINGENTERIC-COATED MYCOPHENOLATE SODIUM(EC-MPS, MYFORTIC®). (Abstract #338)Helio Tedesco-Silva, Marie-Claude Bastien, Les Choi,Claudia Felipe, Joelle Campestrini, Frank Picard, RobertSchmouder. Sao Paulo, Brazil; East Hanover.

1:06 PM EBV-RELATED PTLD AFTER KIDNEYTRANSPLANTATION: SUCCESSFUL TREATMENTWITH A TAILORED REGIMEN INCLUDINGAUTOLOGOUS EBV-SPECIFIC CYTOTOXIC TLYMPHOCYTES. (Abstract #339)Patrizia Comoli, Rita Maccario, Umberto Valente,Massimo Labirio, Giancarlo Basile, Alberto Garaventa,Arcangelo Nocera, Francesco Perfumo, Franco Locatelli,Fabrizio Ginevri. Pavia, Italy; Genova, Italy.

75

Su

nd

ay, May 16

1:13 PM A PROSPECTIVE, RANDOMIZED COMPARATIVETRIAL OF MIZORIBINE VERSUSMYCOPHENOLATE MOFETIL FOR EFFICACYAND SAFETY IN RENAL TRANSPLANTATION.(Abstract #340)Ye Tian, Xu-ren Xiao, Yu-hai Zhang, Jian-hua Ao, Ya-wang Tang, Lei Zhang. Beijing, China.

1:20 PM PHARMACOKINETICS, SAFETY AND EFFICACYOF MYCOPHENOLATE MOFETIL INCOMBINATION WITH SIROLIMUS VSCYCLOSPORINE IN RENAL TRANSPLANTPATIENTS. (Abstract #341)Mark Pescovitz, Flavio Vincenti, Marquis Hart, LarryMelton, John Whelchel, Shamkant Mulgaonkar, DianeMcKay, Mimi Leung, Elizabeth Calleja, ParvizGhahramani.

1:27 PM OLDER GRAFTS ELICIT A STRONGER IMMUNERESPONSE IN THE EARLY PERIOD POSTTRANSPLANTATION. (Abstract #342)Anja Reutzel-Selke, Alexander Filatenkov, Anke Jurisch,Paulo N. A. Martins, Andreas Pascher, Sven Jonas,Johann Pratschke, Peter Neuhaus, Stefan G. Tullius.Berlin, Germany.

Mini-Oral: Donation, Preservation, andProcurement12:45 - 1:45 PM

Ballroom CChairs: Bartley P. Griffith and Alan Langnas

12:45 PM CONTINUOUS PERFUSION DURING DONORHEART TRANSPORT: RISK/BENEFITASSESSMENT. (Abstract #343)Robert S. Poston, Deyanira Prastein, Junyan Gu, FredGage, Richard N. Pierson III, Bartley P. Griffith.Baltimore, MD; Chicago, IL.

12:52 PM IMPROVING PULMONARY FUNCTION ANDLUNG RECOVERY FOR TRANSPLANTATIONUSING THE LINK™ DURING ORGAN DONORMANAGEMENT. (Abstract #344)Susan S. Ganz, David M. Levi, Seigo Nishida, Jeffrey K.Raines, Mary-Ellen Anton, Michael Osorio, KimberlyHollingsworth, Ellyn L. Bellinger, Si M. Pham. Miami,FL.

12:59 PM ELIMINATION OF THE HEMODYNAMICSEQUELAE OF BRAIN DEATH PREVENTSSYSTEMIC INFLAMMATORY RESPONSESYNDROME (SIRS) AND ACUTE LUNG INJURY(ALI) IN THE TRANSPLANT DONOR.(Abstract #345)Vassilios S. Avlonitis, Christopher H. Wigfield, John A.Kirby, John H. Dark. Newcastle upon Tyne, UnitedKingdom.

1:06 PM THYMOGLOBULIN (TG) INDUCTION PROTECTSLIVER ALLOGRAFTS FROM ISCHEMIA/REPERFUSION INJURY (IRI). (Abstract #346)Diego Bogetti, Howard N. Sankary, Gregorio Chejfec,Scott Cotler, Giuliano Testa, Enrico Benedetti. Chicago,IL.

1:13 PM EXTENDED CRITERIA DONORS SHORTEN LIVERTRANSPLANT WAIT TIMES. (Abstract #347)J. G. Drewett, J. E. Martin, L. Trumbull, M. Gupta, T.Merchen, M. J. Hanaway, J. F. Buell, E. S. Woodle, S. M.Rudich. Cincinnati, OH.

1:20 PM STANDARDIZED GRAFT PROCUREMENTTECHNIQUE FOR LIVING RELATED SMALLBOWEL TRANSPLANTATION: SINGLE CENTEREXPERIENCE. (Abstract #348)Giuliano Testa, Stefano Schena, Fabrizio Panaro, MarkHolterman, Herand Abcarian, Howard N. Sankary, JoseOberholzer, Enrico Benedetti. Chicago, IL.

1:27 PM HYPOTHERMIC MACHINE PERFUSION OFLIVER GRAFTS FOR TRANSPLANTATION:PRECLINICAL ASSESSMENT IN HUMANDISCARD AND MINIATURE SWINE MODELS.(Abstract #349)James V. Guarrera, Max Polyak, Ben O’Mar Arrington,John Estevez, William T. Stubenbord, Jean C. Emond,Milan Kinkhabwala. New York, NY.

Mini-Oral: Theraputic Drug Monitoring12:45 - 1:45 PM

Ballroom AChairs: Bruce Kaplan and Kathleen D. Lake

12:45 PM 12 HOUR TROUGH MYCOPHENOLIC ACIDLEVELS PREDICT REJECTION, BONE MARROWSUPPRESSION, VIRAL INFECTIONS ANDDIARRHOEA IN RENAL TRANSPLANTRECIPIENTS IMMUNOSUPPRESSED WITHMYCOPHENOLATE MOFETIL AND TACROLIMUS.(Abstract #350)Richard Borrows, Gary Chusney, Jen van Tromp,Anthony James, Jose Stichbury, Thomas Cairns, MeganGriffith, Nadey Hakim, Adam McLean, Andrew Palmer,Vassilios Papalois, David Taube. London, UnitedKingdom.

12:52 PM PREDICTIVE VALUE OF PRETRANSPLANT IMPDHACTIVITY FOR MMF DOSING. (Abstract #351)K. Budde, P. Glander, P. Hambach, L. Fritsche, J. Waiser,K. P. Braun, H. H. Neumayer. Berlin, Germany.

12:59 PM PHARMACOKINETICS OF MYCOPHENOLATEMOFETIL IN RENAL GRAFT RECIPIENTS TREATEDWITH SIROLIMUS. (Abstract #352)Matthias Buchler, Maud Beneton, Yann Lemeur, PierreF. Westeel, Anne E. Heng, Isabelle Idier, YvonLebranchu, Gilles Paintaud. Tours, France; Limoges,France; Amiens, France; Clermont Ferrand, France;Paris, France.

1:06 PM THERAPEUTIC LEVELS OF MYCOPHENOLICACID UNDER FIXED DOSES OF MMF ON THEFIRST TWO MONTHS AFTER KIDNEYTRANSPLANTATION. (Abstract #353)Lilian M. Pereira, Maria Cristina R. de Castro, Renata M.Mattos, Carlucci G. Ventura, Nairo M. Sumita, Maria E.Mendes, Paschoalina Romano, William C. Nahas, Luiz E.Ianhez, Elias David-Neto. Sao Paulo, SP, Brazil.

1:13 PM BLINDED NEORAL C2 MONITORING IN DENOVO RENAL TRANSPLANT RECIPIENTS.(Abstract #354)Kathleen D. Lake, John C. Magee, Jacob Stodart,Darlene Mclean, Thomas M. Annesley, Diane M. Cibrik.Ann Arbor, MI.

1:20 PM NEORAL® THERAPY OPTIMIZED BY C2MONITORING AND SIMULECT® INDUCTIONCAN RESULT IN A LOW ACUTE REJECTION RATEIN RENAL TRANSPANT RECIPIENTS.(Abstract #355)Robert Mendez, Jimmy Light, Thomas C. Pearson, YouMin Wu, John Curtis, Flavio Vincenti. Los Angeles, CA;Washington, DC; Atlanta, GA; Iowa City, IA;Birmingham, AL; San Francisco, CA.

76

1:27 PM PITFALLS OF CYCLOSPORINE C2 MONITORINGIN DE NOVO RENAL TRANSPLANT PATIENTS.(Abstract #356)Barry J. Browne, Robert L. Madden, AlexanderKurbanov, George S. Lipkowitz. Springfield, MA.

Concurrent Session 1: Alloantibodies andPositive Crossmatch Kidney Transplantation2:00 - 3:30 PM

Veterans BallroomChairs: Enver Akalin and Yolanda Tri Becker

2:00 PM A FOUR YEAR FOLLOW-UP OF REJECTIONPATTERNS, TREATMENT AND OUTCOMES INHIGHLY-HLA-SENSITIZED CROSSMATCH (CMX)POSITIVE PATIENTS TRANSPLANTED WITH IVIGDESENSITIZATION. (Abstract #357)Stanley C. Jordan, Ashley A. Vo, Cynthia C. Nast, RajuRadha, Dolly Tyan, Mieko Toyoda, SuphamaiBunnapradist, Alice Peng. Los Angeles, CA.

2:10 PM KIDNEY TRANSPLANTATION FOLLOWINGADMINISTRATION OF HIGH DOSEINTRAVENOUS IMMUNOGLOBULIN IN PATIENTSWITH POSITIVE FLOW CYTOMETRIC /NEGATIVE ENHANCED CYTOTOXICITYCROSSMATCH. (Abstract #358)James M. Gloor, Martin L. Mai, Steven R. DeGoey,Timothy S. Larson, Thomas A. Gonwa, Howard M.Gebel, Robert A. Bray, S. Breanndan Moore, Petrina V.Genco, Mark D. Stegall. Rochester, MN; Jacksonville,FL; Atlanta, GA.

2:20 PM THE DEVELOPMENT OF CHRONIC INTERSTITIALFIBROSIS AND GLOMERULOPATHY INPOSITIVE CROSSMATCH AND ABOINCOMPATIBLE KIDNEY ALLOGRAFTS.(Abstract #359)Mark D. Stegall, Patrick G. Dean, David J. Rea, FernandoG. Cosio, James M. Gloor. Rochester, MN.

2:30 PM PRE-TRANSPLANT ANTI-HLA CLASS IANTIBODIES OF IgG ISOTYPE SKEWED SOLELYTOWARDS THE IgG

1 SUBCLASS ARE

ASSOCIATED WITH POORER RENALALLOGRAFT SURVIVAL. (Abstract #360)Peter J. Dupont, Emmet J. Griffiths, Ruth E. Nelson,Anthony N. Warrens. London, United Kingdom.

2:40 PM CLINICAL RELEVANCE OF HLA ANTIBODIESBEFORE AND AFTER RENAL TRANSPLANTATION.(Abstract #361)Ronald H. Kerman, Hal Gibson, Noriel Acorda, ChrisBallew, Natalie Guidry, Hermangshu Podder, Richard J.Knight, Charles T. Van Buren, Stephen M. Katz, BarryD. Kahan. Houston, TX.

2:50 PM CLASS II DONOR SPECIFIC ANTIBODIES AREPATHOGENIC IN PRIMARY RENALALLOGRAFTS. (Abstract #362)Peter Nickerson, Denise Pochinco, Martin Karpinski,Howard Gebel, Robert Bray, Ian Gibson, David Rush,John Jeffery. Winnipeg, MB, Canada; Atlanta, GA.

2:50 PM HLA DR MISMATCHING AND DONOR SPECIFICANTIBODIES ARE RISK FACTORS FOR ACUTEREJECTION EVEN IN THE ERA OF MODERNIMMUNOSUPPRESSION. (Abstract #363)Peter Nickerson, Martin Karpinski, Ian Gibson, JohnJeffery, David Rush. Winnipeg, MB, Canada.

3:00 PM LIVING DONOR KIDNEY TRANSPLANTATIONWITH AND WITHOUT SPLENECTOMY INPOSITIVE CROSSMATCH PATIENTS.(Abstract #364)James M. Gloor, Steven R. DeGoey, Matthew D. Griffin,Timothy S. Larson, Donna J. Lager, Mary E. Fidler, S.Breanndan Moore, Mark D. Stegall. Rochester, MN.

3:10 PM ANTI-CD 20 RESCUE THERAPY FOR KIDNEYSUNDERGOING ANTIBODY-MEDIATEDREJECTION. (Abstract #365)Robert A. Montgomery, Christopher E. Simpkins,Andrea A. Zachary, Laura Lees, Daniel S. Warren,Matthew Cooper, Milagros Samaniego. Baltimore, MD.

3:20 PM HIGH ANTI-ENDOTHELIAL CELL ANTIBODY(AECA) LEVELS DECREASE TRANSPLANTABILITYAND GRAFT SURVIVAL IN HIGHLY HLA-SENSITIZED ESRD PATIENTS. (Abstract #366)Gail S. Rodich, Anna Petrosyan, Matthew McIntosh,Stanley C. Jordan, Mieko Toyoda. Los Angeles, CA;Rockville, MD.

Concurrent Session 2: Cardiovascular Diseaseand Kidney Transplantation2:00 - 3:30 PM

Ballroom AChairs: Bruce Kaplan and Rosemary Ouseph

2:00 PM CHRONIC KIDNEY DISEASE: DO RENALTRANSPLANT RECIPIENTS RECEIVECOMPARABLE CARE TO NON-TRANSPLANTPATIENTS WITH CHRONIC RENAL FAILURE?(Abstract #367)Naser Hussain, Vanji Karthikeyan, Ayub Akbari, JolantaKarpinski, Greg Knoll. Ottawa, ON, Canada.

2:10 PM OBESITY: INCIDENCE, PREVALENCE ANDOUTCOME OF RENAL TRANSPLANTATION.(Abstract #368)Sali Aswad, Umakant Khetan, Rafael G. Mendez, FredAswad, Thomas Bogaard, Robert Mendez. Los Angeles,CA.

2:20 PM ELEVATED PLASMA TOTAL-HOMOCYSTEINEPREDICTS PATIENT AND ALLOGRAFT SURVIVALIN KIDNEY TRANSPLANT RECIPIENTS.(Abstract #369)Wolfgang C. Winkelmayer, Manuela Födinger, AnilChandraker, Reinhard Kramar, Gere Sunder-Plassmann.Boston, MA; Vienna, Austria; Wels, Austria.

2:30 PM A NOVEL TECHNIQUE OF DETECTION OFMYOCARDIAL ISCHEMIA IN POTENTIAL RENALTRANSPLANT RECIPIENTS USING CONTRASTENHANCED CARDIAC MRI. (Abstract #370)Patrick B. Mark, Nicola Johnston, Thomas N. Martin,Kevin G. Blyth, Tracey Steedman, John Foster, R. S. C.Rodger, Henry J. Dargie, Alan G. Jardine. Glasgow,Scotland, United Kingdom.

2:40 PM CARDIAC INVESTIGATIONS IN KIDNEYTRANSPLANT WAIT LIST CANDIDATES -RELIANCE ON CLINICAL INDICATIONS IS NOTEFFECTIVE. (Abstract #371)Irene W. Y. Ma, John S. Gill, Nathan L. Johnson, DavidLandsberg, Adeera Levin. Vancouver, BC, Canada;Boston, MA.

77

Su

nd

ay, May 16

2:50 PM PULSE PRESSURE, RENAL ALLOGRAFTFUNCTION AND ANTIHYPERTENSIVEMEDICATION: RESULTS FROM MOST, AMULTICENTER OBSERVATIONAL STUDY.(Abstract #372)Joachim Beige, Marianne Soergel, Gerd Offermann,Walter Zidek. Bern, Switzerland; Basel, Switzerland;Berlin, Germany.

3:00 PM RAPID PROGRESSION OF SUBCLINICALCORONARY ATHEROSCLEROSIS IN INCIDENTRENAL TRANSPLANT RECIPIENTS.(Abstract #373)Sylvia E. Rosas, Korlei Mensah, Katharine Schankel,Daniel J. Rader, Marshall Joffe. Philadelphia, PA.

3:10 PM DOES KIDNEY TRANSPLANTATION HALTCARDIOVASCULAR DISEASE PROGRESSION INPATIENTS WITH ESRD? (Abstract #374)Herwig-Ulf Meier-Kriesche, Jesse D. Schold, Titte R.Srinivas, Alan I. Reed, Bruce Kaplan. Gainesville, FL.

3:20 PM INFLUENCE OF RENAL TRANSPLANT FUNCTIONON CARDIOVASCULAR DISEASE AND ALLCAUSE MORTALITY IN THE ALERT TRIAL.(Abstract #375)Bengt C. Fellstrom, Hallvard Holdaas, Alan Jardine,Edward Cole, Gudrun Nyberg, Carola Gronhagen-Riska,Soren Madsen, Hans Neumayer, Bart Maes, PatrichAmbuhl. Uppsala, Sweden; Oslo, Norway; Glasgow,United Kingdom.

Concurrent Session 3: Generating T-RegulatoryCells for Tolerance2:00 - 3:30 PM

Room 311Chairs: Allan D. Kirk and Nancy R. Krieger

2:00 PM DONOR APOPTOTIC CELLS PROLONG GRAFTSURVIVAL VIA PRESENTATION OFALLOPEPTIDES BY SEMI-MATURE CD8ααααα+

DENDRITIC CELLS AND DEFICIENT ACTIVATIONOF ALLOSPECIFIC CD4+ T CELLS. (Abstract #376)Adrian E. Morelli, Zhiliang Wang, William J. Shufesky,Adriana T. Larregina, Marcelo J. Perone, Angus W.Thomson. Pittsburgh, PA.

2:10 PM REGULATION OF DISTINCT IL-2R SIGNALINGPATTERN IN CD4+CD25+ REGULATORY T CELLSBY THE TUMOR SUPPRESSOR GENE PTEN.(Abstract #377)Patrick T. Walsh, Steven J. Bensinger, Jidong Zhang,Jessica Wang, Nicole Dalton, Laurence A. Turka.Philadelphia, PA.

2:20 PM CHARACTERIZATION OF RHESUS MACAQUE TREGULATORY CELLS: ROLE IN LONG-TERMTRANSPLANT TOLERANCE INDUCED BY ANTI-CD3 IMMUNOTOXIN AND DEOXYSPERGUALIN.(Abstract #378)Clement K. Asiedu, Balgansuren Gansuvd, AnneHutchings, Stacie Jenkins, Karen J. Goodwin, KristenByars, Judith M. Thomas. Birmingham, AL.

2:30 PM HIGH-DOSE CALCINEURIN INHIBITOR BLOCKSTHE GENERATION OF REGULATORY CELLS,WHEREAS LOW-DOSE PROMOTES THEIRDEVELOPMENT. (Abstract #379)M. Kawai, H. Kitade, C. Mathieu, M. Waer, J. Pirenne.Leuven, Vlaams-Brabant, Belgium.

2:40 PM ADOPTIVE CELL THERAPY WITH CULTURED,DONOR-SPECIFIC REGULATORY T CELLS TOPROMOTE TRANSPLANTATION TOLERANCE.(Abstract #380)Dela Golshayan, Shuiping Jiang, Marina I. Garin, RobertI. Lechler. London, United Kingdom.

2:50 PM REGULATORY T CELL PROLIFERATION ANDGENE EXPRESSION IN RESPONSE TOALLOANTIGEN STIMULATION. (Abstract #381)Sophoclis P. Alexopoulos, Alberto Sanchez-Fueyo,Douglas Hanto, Xin Xiao Zheng, Terry B. Strom.Boston, MA.

3:00 PM CD8+ CD28- T SUPPRESSOR TOLERIZEENDOTHELIAL CELLS BY UPREGULATING THEEXPRESSION OF THE INHIBITORY RECEPTORILT4. (Abstract #382)John S. Manavalan, Afzal J. Naiyer, Seunghee Kim-Shulze, Luigi Scotto, Raffaello Cortesini, Nicole Suciu-Foca. New York, NY.

3:10 PM INDUCTION OF T-REGS BY INTRATHYMICINOCULATION OF ANTIGEN BEARINGSPLENOCYTES. (Abstract #383)Daniel J. Moore, Beth P. Jarrett, Xiaolun Huang, JosephW. Markmann, Major K. Lee IV, Moh Moh Lian,Meredith Chiaccio, Shaoping Deng, Andrew J. Caton,James F. Markmann. Philadelphia, PA.

3:20 PM CALCINEURIN INHIBITORS BUT NOTRAPAMYCIN ABROGATE ACTIVATION OF THEIMMUNOMODULATORY ENZYME INDOLEAMINE2,3-DIOXYGENASE. (Abstract #384)Gerald Brandacher, Christiana Winkler, StefanSchneeberger, Raimund Margreiter, Dietmar Fuchs.Innsbruck, Austria.

Concurrent Session 4: Immunosuppression:Challenges and New Combinations I2:00 - 3:30 PM

Room 302/204Chairs: Angelo M. de Mattos and Lorenzo Gallon

2:00 PM BASILIXIMAB INDUCTION REDUCES ACUTEREJECTIONS IN THE 6 MONTHS AFTERTRANSPLANATION AND FACILITATES STEROIDFREE IMMUNOSUPPRESSION IN NONSENSITIZED PRIMARY KIDNEY TRANSPLANTRECIPIENTS. (Abstract #385)Mysore S. Anil Kumar. Philadelphia, PA.

2:10 PM LONG TERM RISKS OF ANTIBODY INDUCTIONTHERAPY IN KIDNEY TRANSPLANTATION.(Abstract #386)Herwig-Ulf Meier-Kriesche, Jesse D. Schold, Titte R.Srinivas, Karl Womer, Alan W. Hemming, Bruce Kaplan.Gainesville, FL.

2:20 PM ANTIBODY INDUCTION THERAPY AND THEIRASSOCIATED OUTCOMES IN CADAVERICKIDNEY TRANSPLANTS. (Abstract #387)Suphamai Bunnapradist, Eimear Nic Lochlainn, StevenK. Takemoto. Los Angeles, CA.

2:30 PM ANTIBODY INDUCTION IMMUNOSUPPRESSIONAND GRAFT SURVIVAL IN HIGH RISKRECIPIENTS OF EXPANDED CRITERIA DONORKIDNEY. (Abstract #388)Wida S. Cherikh, H. M. Kauffman, Sandy Feng.Richmond, VA; San Fransisco, CA.

2:40 PM SIMULTANEOUS CORTICOSTEROIDAVOIDANCE AND MINIMIZATION OFCALCINEURIN INHIBITORS IN KIDNEYTRANSPLANTATION. (Abstract #389)J. W. Alexander, T. J. Metze, H. Goodman, M. Cardi, J.Austin, S. Goel, S. Safdar, S. Huang, R. Munda, J. Fidler, J.Buell, M. Hanaway, B. Suskind, N. Greenburg, R. Alloway,E. Woodle. Cinti, OH; St. Louis Park, MN.

78

2:50 PM LONG-TERM EFFECT OF ZENAPAX VERSUS OKT-3 PROPHYLAXIS IN IMMUNOLOGICALLYHIGH-RISK KIDNEY TRANSPLANT RECIPIENTS.(Abstract #390)Jiri Lacha, Katerina Bartosova, Ladislava Lyerova,Marcela Burgelova, Vladimir Teplan, Stefan Vitko.Prague, Czech Republic.

3:00 PM THYMOGLOBULIN VERSUS NO INDUCTION INADULT PRIMARY DECEASED-DONOR RENALTRANSPLANT RECIPIENTS ON MAINTENANCETACROLIMUS, MYCOPHENOLATE MOFETIL,AND PREDNISONE: A SINGLE-CENTERLONGITUDINAL STUDY. (Abstract #391)Richard M. Ugarte, Lorraine Racusen, Mark Haas, MaryS. Leffell, Andrea Zachary, Milagros Samaniego-Picota,Ernesto Molmenti, Matthew Cooper, RobertMontgomery, Hamid Rabb, Edward S. Kraus. Baltimore,MD.

3:10 PM RANDOMIZED TRIAL OF THREE DIFFERENTINDUCTION REGIMENS TO PREVENT ACUTERENAL ALLOGRAFT REJECTION: EARLYRESULTS. (Abstract #392)Gaetano Ciancio, George W. Burke, Jeff J. Gaynor, AdelaD. Mattiazzi, Manuel R. Carreno, Anne Rosen, RamirRoohipour, David Roth, Warren Kupin, Joshua Miller.Miami, FL.

3:20 PM DETERMINANTS OF LONG-TERM PRESERVATIONOF RENAL FUNCTIONAL AFTER CONVERSIONTO SIROLIMUS IN PATIENTS WITH CHRONICALLOGRAFT NEPHROPATHY. (Abstract #393)Antonio Guasch, Mitzi Near, Sasi Selvaraj. Atlanta, GA.

Concurrent Session 5: Liver Transplantation:Advances in Immunosuppression2:00 - 3:30 PM

Ballroom BChairs: Marlon F. Levy and James F. Markmann

2:00 PM A MULTI-CENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PARALLELGROUP, DOSE-FINDING STUDY TO EVALUATETHE SAFETY, TOLERABILITY ANDPHARMACOKINETICS OF EVEROLIMUS (E) INDE NOVO LIVER TRANSPLANT RECIPIENTS: 12AND 36 MONTH ANALYSIS. (Abstract #394)Gary Levy, Virginia Moeller, Jonathan Jaffe, JeffreyPunch, David Mayer, Peter Neuhaus. Toronto, ON,Canada; East Hanover, NJ; Ann Arbor, MI; Edgbaston,Birmingham, United Kingdom; Berlin, Germany.

2:10 PM EFFICACY OF TRIPLE THERAPY WITHMYCOPHENOLATE MOFETIL (MMF),TACROLIMUS (TACRO) ANDCORTICOSTEROIDS (CS) COMPARED TOTACRO AND CS IMMUNOSUPPRESSION INLIVER TRANSPLANTATION: AN ANALYSIS OFTHE US LIVER TRANSPLANT EXPERIENCE.(Abstract #395)John R. Lake, Alice H. Chu, Bettina J. Steffen, VincentP. Gotz, Jonathan A. Morris, Robert D. Gordon, RussellH. Wiesner. Minneapolis, MN; La Jolla, CA; Nutley, NJ;Rochester, MN.

2:20 PM CAMPATH-1H IN ADULT LIVER ALLO-TRANSPLANTATION: INDUCTION WITHLASTING BENEFITS. (Abstract #396)Panagiotis Tryphonopoulos, Juan R. Madariaga, SeigoNishida, David M. Levi, Jang Moon, Gennaro Selvaggi,Arie Regev, Pablo Bejarano, Amr Khaled, KamranSafdar, Phillip Ruiz, Tomoaki Kato, Andreas G. Tzakis.Miami, FL.

2:30 PM CAMPATH–1H (ALEMTUZUMAB) INDUCTION INLIVER TRANSPLANTATION– A SINGLE CENTEREXPERIENCE. (Abstract #397)Alan Koffron, Juan Carlos Caicedo, Irma Dixler, LauraKulik, Patrice Al-Saden, Eileen DeMayo, JonathanFryer, Micheal Abecassis. Chicago, IL.

2:40 PM EVALUATION OF RENAL FUNCTION IN LIVERTRANSPLANT RECIPIENTS RECEIVINGDACLIZUMAB (ZENAPAX®) ANDMYCOPHENOLATE MOFETIL (CELLCEPT®) ANDA DELAYED AND LOW-DOSE TACROLIMUSREGIMEN VERSUS A STANDARD-DOSETACROLIMUS-BASED REGIMEN: PRELIMINARYRESULTS. (Abstract #398)Eric Yoshida, Paul Marotta, Paul Greig, NormanKneteman, Denis Marleau, Kevork Peltekian, MarceloCantarovich, Giovanni Facciponte, Bryan Simpson,Robert Balshaw, Jeffrey Barkun. Vancouver, BC, Canada;London, ON, Canada; Toronto, ON, Canada; Edmonton,AB, Canada; Montreal, QC, Canada; Halifax, NS, Canada;Mississauga, ON, Canada.

2:50 PM REJECTION IS DECREASED AMONG ADULTRECIPIENTS OF LIVING VS. DECEASED DONORLIVER ALLOGRAFTS. (Abstract #399)Abraham Shaked, Tempie E. Hulbert-Shearon, JamesEverhart, Robert M. Merion, A2ALL Study Group.Philadelphia, PA; Ann Arbor, MI; Bethesda, MD.

3:00 PM 12-MONTH FOLLOW-UP DATA FROM ARANDOMIZED, MULTICENTRE, PROSPECTIVESTUDY OF CYCLOSPORINE C2 MONITORINGVERSUS TACROLIMUS IN LIVERTRANSPLANTATION (LIS2T). (Abstract #400)Gian Luca Grazi, Gary Levy, You Wu, Paul Marotta,Olivier Boillot, Fernando San Juan, Didier Samuel,Ferdinand Muehlbacher, Federico Villamil. Bologna, Italy.

3:10 PM CONVERSION OF STABLE LIVER TRANSPLANTRECIPIENTS FROM A TWICE DAILY PROGRAFBASED REGIMEN TO A ONCE DAILY MODIFIEDRELEASE TACROLIMUS BASED REGIMEN.(Abstract #401)Sander Florman. New Orleans, LA.

3:20 PM PREVALENCE AND RISK FACTORS FOR ACUTECELLULAR REJECTION IN LIVERTRANSPLANTATION: RESULTS FROM MOST, ANINTERNATIONAL OBSERVATIONAL TRIAL.(Abstract #402)Federico G. Villamil, Patrizia Burra, Juan Figueras, RobertJones. Piso, Argentina.

Concurrent Session 6: Lung Transplantation:All Topics2:00 - 3:30 PM

Room 306Chairs: Mark L. Barr and Marshall I. Hertz

2:00 PM EVEROLIMUS (RAD) SHOWS SUPERIORITYOVER AZATHIOPRINE TO INHIBIT THE DECLINEOF PULMONARY FUNCTION IN STABLE LUNGTRANSPLANT RECIPIENTS - 24-MONTH RESULTSOF A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY. (Abstract #403)Vincent G. Valentine, Robert B. Love, Gregory I. Snell,Patrizio Vitulo, Allan R. Glanville, Ulrich Pirron. NewOrleans, LA; Madison, WI; Melbourne, Australia; Pavia,Italy; Sydney, Australia; Basel, Switzerland.

79

Su

nd

ay, May 16

2:10 PM OUTCOMES FOLLOWING PRETRANSPLANT T-CELL DEPLETION WITH THYMOGLOBULIN ORCAMPATH IN HUMAN LUNG TRANSPLANTATION.(Abstract #404)Kenneth R. McCurry, Adrianna Zeevi, Diana B. Zaldonis,Carol Bentlejewski, Kathy Spichty, Diana Metes, NorikoMurase, Samuel Yousem, Thomas E. Starzl. Pittsburgh,PA.

2:20 PM IN VIVO P-GP ACTIVITY IS DOWN-MODULATEDIN PROLIFERATING CD4 GRAFT INFILTRATING TCELLS OF LUNG ALLOGRAFT RECIPIENTS.(Abstract #405)Vera S. Donnenberg, Gilbert J. Burckart, Adriana Zeevi,Kenneth R. McCurry, Aldo Iacono, James D. Luketich,Albert D. Donnenberg. Pittsburgh, PA; Los Angeles, CA.

2:30 PM ACUTE RENAL FAILURE AFTER LUNGTRANSPLANTATION: INCIDENCE, RISKFACTORS, AND IMPACT ON PERIOPERATIVEMORBIDITY AND MORTALITY. (Abstract #406)Paulo N. Rocha, Ana Thereza C. Rocha, Scott Palmer,Stephen R. Smith. Durham, NC.

2:40 PM A PROSPECTIVE TRIAL OF VALGANCICLOVIRPROPHYLAXIS FOR CYTOMEGALOVIRUS(CMV) PREVENTION IN LUNG TRANSPLANTRECIPIENTS. (Abstract #407)Atul Humar, Deepali Kumar, Jutta Preiksaitis, JayneFenton, Sarah Nia, Kathy Jackson, Susan Chernenko,Dale Lien. Toronto, ON, Canada; Edmonton, AB,Canada.

2:50 PM EVEROLIMUS EXPOSURE-RESPONSERELATIONSHIPS TO INHIBIT PULMONARYFUNCTION DECLINE IN MAINTENANCE LUNGTRANSPLANTATION. (Abstract #408)J. M. Kovarik, G. Snell, V. Valentine, P. Vitulo, H.Schmidli, U. Pirron. Basel, Switzerland; Prahran, VIC,Australia; New Orleans, LA; Pavia, Italy.

3:00 PM ANALYSIS OF CIRCULATING T CELL MEMORYCELLS IN LUNG TRANSPLANT RECIPIENTSTREATED WITH T CELL DEPLETION THERAPIES.(Abstract #409)Adriana Zeevi, Carol Bentlejewski, Kathy Spichty, DavidGuaspari, Diana Zaldonis, Richard Kowalski, JulieWoodcock, Judy Britz, Kenneth McCurry. Pittsburgh,PA; Columbia, MD.

3:10 PM A PROSPECTIVE STUDY OF COMMUNITYACQUIRED RESPIRATORY VIRUS INFECTIONSIN LUNG TRANSPLANT RECIPIENTS AND THEIRCLINICAL IMPACT ON GRAFT FUNCTION.(Abstract #410)Deepali Kumar, Dean Erdman, Teresa Peret, ShafKeshavjee, Lianne Singer, Atul Humar. Toronto, ON,Canada; Atlanta, GA.

3:20 PM A MULTIFACTORIAL ANALYSIS OF RISKFACTORS ASSOCIATED WITH CHRONIC LUNGALLOGRAFT REJECTION. (Abstract #411)Alin L. Girnita, Rene Duquesnoy, Aldo T. Iacono, GilbertBurckart, Timothy E. Corcoran, Samuel A. Yousem,Bruce Johnson, James H. Dauber, Bartley P. Griffith,Kenneth R. McCurry, Adriana Zeevi. Pittsburgh, PA;Baltimore, MA.

Concurrent Session 7: Lymphocyte Activation:Regulatory Cells, Anergy and InhibitoryReceptors2:00 - 3:30 PM

Room 310Chairs: Elizabeth H. Field and Andrew D. Wells

2:00 PM SPECIFICITY OF CD4+ CD25+ REGULATORY TCELLS IN A NOVEL TCR TRANSGENIC MODELOF ALLOIMMUNITY. (Abstract #412)Sigrid E. Sandner, Alberto Sanchez-Fueyo, ChristophDomenig, Xin Xiao Zheng, Laurence A. Turka, Terry B.Strom, Mohamed H. Sayegh. Boston, MA; Philadelphia,PA.

2:10 PM ALLOCHIMERIC THERAPY INDUCES UNIQUEREGULATORY T CELLS THAT MITIGATECHRONIC REJECTION. (Abstract #413)Natalya V. Semiletova, Samuel J. Slomowitz, KaushikMukherjee, Xiu-Da Shen, Feng Gao, M. C. Fishbein,Ronald W. Bussuttil, Jerzy W. Kupiec-Weglinski, RafikM. Ghobrial. Los Angeles, CA.

2:20 PM SIGNALING REQUIREMENTS OF CD4+CD25+REGULATORY T CELLS DURING HOMEOSTATICPROLIFERATION. (Abstract #414)Somia N. Perdow-Hickman, Laurence A. Turka.Philadelphia, PA.

2:30 PM REGULATION OF THE IL-2/IL-2R PATHWAY INTARGET T CELLS BY CD4+CD25+ HYBRIDOMAS.(Abstract #415)Mohamed E. Nasr, Todd Rouse, Elizabeth H. Field. IowaCity, IA.

2:40 PM EPIGENETIC SILENCING OF THE IL-2 GENE AS APOTENTIAL MOLECULAR BASIS FOR ANERGYIN NAIVE CD4+ T CELLS. (Abstract #416)Rajan Thomas, Andrew Wells. Philadelphia, PA.

2:50 PM CTLA-4 ENHANCES ENDOCYTOSIS OF CD28AND ABROGATES PHOSPHORYLATION OF TCRPROXIMAL TYROSINE KINASES IN CD8+ TCELLS. (Abstract #417)Martina Berg, Nicholas Zavazava. Iowa City, IA.

3:00 PM DICHOTOMY OF PD-L1 AND PD-L2 PATHWAYSIN NEGATIVELY REGULATING ALLOREACTIVECD4+ AND CD8+ T CELLS. (Abstract #418)Reshma Kewalramani, Minh Diem Vu, Miyuki Azuma,Mohamed H. Sayegh, Xian Chang Li. Boston, MA;Tokyo, Japan.

3:10 PM PD-L2 (B7-DC) IS UPREGULATED IN CLINICALAND EXPERIMENTAL ALLOGRAFTS ANDFUNCTIONS AS A NEGATIVE REGULATOR OF TCELL ALLORESPONSES IN VIVO. (Abstract #419)Iris Lee, Engin Ozkaynak, Liqing Wang, Andrew D.Wells, Tahiro Shin, Anthony J. Coyle, Drew M. Pardoll,Wayne W. Hancock. Philadelphia, PA; Cambridge, MA;Baltimore, MD.

80

Concurrent Session 8: Markers andMechanisms of Chronic Graft Injury2:00 - 3:30 PM

Room 309Chairs: Anil Chandrakar and Bruno Watschinger

2:00 PM IDENTIFICATION OF PROTEINS ASSOCIATEDWITH FREEDOM FROM CARDIAC ALLOGRAFTVASCULOPATHY. (Abstract #420)Ayesha I. De Souza, Emma McGregor, Andrew Mitchell,Nicholas R. Banner, Mike J. Dunn, Marlene L. Rose.London, United Kingdom; Harefield, United Kingdom.

2:10 PM HUMAN NEUTROPHIL DEFENSINS: ABIOMARKER OF CHRONIC LUNG ALLOGRAFTREJECTION. (Abstract #421)Tereza M. Cervenka, Gary L. Nelsestuen, MichealMartinez, Marshall I. Hertz, Christine H. Wendt.Minneapolis, MN.

2:20 PM INCREASED EXPRESSION OF SENESCENCEASSOCIATED CELL CYCLE INHIBITOR P16INK4A

IN FAILING KIDNEY TRANSPLANTS: PROOFTHAT FAILING TRANSPLANTS MANIFESTACCELERATED SENESCENCE. (Abstract #422)Anette Melk, Bernhard M. W. Schmidt, AttapongVongwiwatana, David C. Rayner, Philip F. Halloran.Edmonton, AB, Canada; Heidelberg, Germany.

2:30 PM TUBULAR EPITHELIAL CELL TO FIBROBLASTTRANSITION IN CHRONIC RENAL ALLOGRAFTDYSFUNCTION. (Abstract #423)John A. Kirby, Helen Robertson. Newcastle upon Tyne,Tyne and Wear, United Kingdom.

2:40 PM FURTHER INSIGHT OF ICOS-B7h PATHWAYINTO ALLOIMMUNE RESPONSE. (Abstract #424)Hisanori Kashizuka, Masayuki Sho, Yukiyasu Kuzumoto,Naoya Ikeda, Satoru Akashi, Yoshikazu Tsurui, TakashiMizuno, Hideo Yagita, Yoshiyuki Nakajima, MohamedH. Sayegh. Nara, Japan; Tokyo, Japan; Boston, MA.

2:50 PM GRAFT ARTERIAL DISEASE REQUIRES B CELLAS ANTIGEN PRESENTING CELLS IN MURINEHEART TRANSPLANTATION. (Abstract #425)Koichi Shimizu, Peter Libby, Richard N. Mitchell.Boston, MA.

3:00 PM ALTERED ALLOANTIBODY RESPONSES BYALLOCHIMERIC CLASS I MHC MOLECULESORCHESTRATES INHIBITION OF CHRONICREJECTION. (Abstract #426)Natalya V. Semiletova, K. Mukherjee, Xiu-Da Shen, F.Gao, S. J. Slomowitz, M. C. Fishbein, B. Baibakov, R. W.Busuttil, J. W. Kupiec-Weglinski, R. M. Ghobrial. LosAngeles, CA; Baltimor, MD.

3:10 PM MICE DEFICIENT IN DENDRITIC CELLS (Flt3L-/-)SHOW MARKED REDUCTIONS IN TRANSPLANTVASCULAR SCLEROSIS. (Abstract #427)Z. Wang, A. E. Morelli, A. W. Thomson. Pittsburgh, PA.

3:20 PM EFFECT OF A NOVEL INDUCIBLE NITRIC OXIDESYNTHASE INHIBITOR IN PREVENTION OF RATCHRONIC AORTIC REJECTION. (Abstract #428)Huifang Chen, Jun Ouyang, Dasheng Xu, XiaochunZhang, Shijie Qi, Anlun Ma, Wenlei Jiang, Noboru Chida,Yuji Sudo, Kouichi Tamura, Pierre Daloze, Huifang Chen.Montreal, QC, Canada; Osaka, Japan.

Concurrent Session 9: Predictors of Rejection2:00 - 3:30 PM

Room 312Chairs: Diane M. Cibrik

2:00 PM DIFFERENTIAL GENE EXPRESSION PROFILES OFCHRONIC ALLOGRAFT NEPHROPATHY BYMICROARRAYS: UPREGULATION OFTRANSFORMING GROWTH FACTOR-b INDUCEDFACTOR, AND DOWNREGULATION OFVASCULAR ENDOTHELIAL GROWTH FACTOR.(Abstract #429)Hilary Hotchkiss, Tea-Hua T. Chu, Yuexun Liu, BethZavilowitz, Enver Akalin. New York, NY.

2:10 PM PREDICTING THE FUTURE: CONNECTIVE TISSUEGROWTH FACTOR (CTGF), A SURROGATE FORTHE DEVELOPMENT OF CHRONIC ALLOGRAFTNEPHROPATHY (CAN) IN MAN. (Abstract #430)Roslyn B. Mannon, O. H. Cheng, S. C. Hoffmann, A. D.Kirk, G. Grottendorst. Bethesda, MD; Miami, FL.

2:20 PM VASCULAR ENDOTHELIAL GROWTH FACTORGENE POLYMORPHISM INFLUENCES RENALGRAFT SURVIVAL IN LIVING DONORTRANSPLANTS. (Abstract #431)Francine B. C. Lemos, Wendy Mol, Joke Roodnat, AndreUitterlinden, Jan IJzermans, Willem Weimar, Carla Baan.Rotterdam, Netherlands.

2:30 PM MACROPHAGE ACTIVATION PREDICTS LONG-TERM GRAFT SURVIVAL. (Abstract #432)Thomas F. Mueller, Uwe Kuhlmann, Scott O. Grebe.Boston, MA; Marburg, Germany.

2:40 PM REGULATORY PHENOTYPE IS ENRICHED IN THECD25 ‘HIGH’ SUB-POPULATION OF CD4+CD25+

CELLS EXPANDED FROM RENAL TRANSPLANTRECIPIENTS. (Abstract #433)Michael R. Clarkson, Alan D. Salama, Thomas Mueller,Stacy Fernandes, William E. Harmon, Mohamed H.Sayegh, Nader Najafian. Boston, MA.

2:50 PM IS IT POSSIBLE TO IDENTIFY RENALTRANSPLANT RECIPIENTS AT RISK FORSUBCLINICAL REJECTION? (Abstract #434)Muralikrishna Golconda, Angelo de Mattos, KimberlyDewey, Donald Houghton, Jonathan Prather, YugoShibagaki, Douglas Keith, Gautham Mogilishetty, AliOlyaei, John Barry, Douglas Norman. Portland, OR.

3:00 PM THE CHANGING PRESENTATION OF ACUTEREJECTION IN LOW RISK PATIENTS TREATEDWITH ANTI-CD25 ANTIBODY AND EARLYSTEROID ELIMINATION. (Abstract #435)Yook M. Woo, John S. Gill, Gary Nussbaumer, DavidLandsberg. Vancouver, BC, Canada.

3:10 PM DEVELOPMENT OF CHRONIC ALLOGRAFTNEPHROPATHY (CAN) IN “LOW RISK” KIDNEYTRANSPLANT RECIPIENTS. (Abstract #436)Fernando G. Cosio, Matthew D. Griffin, Joseph P.Grande, Donna J. Lager, James M. Gloor, Jorge A.Velosa, Timothy S. Larson, Mark D. Stegall. Rochester,MN.

3:20 PM HIGH PRE-TRANSPLANT SERUM LEVELS OF IP-10 PREDICT EARLY RENAL ALLOGRAFTFAILURE. (Abstract #437)Elisabetta Bertoni, Paola Romagnani, Mario Rotondi,Alberto Rosati, Mario Serio, Maurizio Salvadori.Florence, Tuscany, Italy.

3:30 PM Break

81

Su

nd

ay, May 16

Concurrent Session 10: Risk Factors inDeceased Donor Kidney Transplantation2:00 - 3:30 PM

Ballroom CChairs: L. Thomas Chin and James F. Whiting

2:00 PM RISK FACTORS FOR EARLY MORTALITYFOLLOWING DECEASED DONOR KIDNEYTRANSPLANT. (Abstract #438)Maureen A. McBride, Francis L. Delmonico, H. MyronKauffman. Richmond, VA; Boston, MA.

2:10 PM THE OUTCOME OF RENAL ALLOGRAFTSPROCURED FROM 192 NON-HEART BEATINGCADAVERS AT A SINGLE CENTER AND THE RISKFACTORS AFFECTING LONG-TERM GRAFTSURVIVAL. (Abstract #439)Yusuke Kubota, Hitomi Sasaki, Tamio Fujita, MamoruKusaka, Naohiko Fukami, Ryoichi Shiroki, KiyohitoIshikawa, Tetsuo Kanno, Kiyotaka Hoshinaga. Toyoake,Aichi, Japan; Nagoya, Aichi, Japan.

2:20 PM IMPACT OF WEST NILE VIRUS SCREENING ONSOLID ORGAN AND TISSUE PROCUREMENTPROGRAM – A LOCAL EXPERIENCE. (Abstract #440)Jutta K. Preiksaitis, Julie Fox, Linda Chui, Peter Tilley,Jayne Fenton, Bonita E. Lee. Edmonton, AB, Canada;Calgary, AB, Canada; AB, Canada.

2:30 PM SHORT AND LONG TERM OUTCOMES OFKIDNEY TRANSPLANTS FROM DONORS AFTERCARDIAC DEATH (DCD). (Abstract #441)Mona D. Doshi, John D. Rosendale, Lawrence G.Hunsicker. Iowa City, IA; Richmond, VA.

2:40 PM KIDNEY TRANSPLANTATION FROMUNCONTROLLED NON-HEART-BEATINGDONORS: A UNOS ANALYSIS. (Abstract #442)Yong W. Cho, Tse-Ling Fong, Rick Selby, Yuichi Iwaki,James Cicciarelli. Los Angeles, CA.

2:50 PM BLACKS AS DONORS FOR TRANSPLANTATION:SUBOPTIMAL OUTCOMES OVERCOME BYTRANSPLANTATION INTO OTHER MINORITIES.(Abstract #443)Clive O. Callender, Wida S. Cherikh, Patrice V. Miles,Alan Hermesch, Gwendolyn D. Maddox, Margruetta B.Hall. Washington, DC; Richmond, VA.

3:00 PM THE FATE OF 435 RENAL ALLOGRAFTSPROCURED FROM NON-HEART BEATINGCADAVERS USING MODIFIED IN SITUREGIONAL COOLING TECHNIQUE AT A SINGLECENTER. (Abstract #444)Kiyotaka Hoshinaga, Yusuke Kubota, Tamio Fujita,Hitomi Sasaki, Tohru Higuchi, Mamoru Kusaka,Kiyohito Ishikawa, Ryoichi Shiroki, Tetsuo Kanno.Toyoake, Aichi, Japan; Nagoya, Aichi, Japan.

3:10 PM SUCCESSFUL OUTCOME AFTERTRANSPLANTATION OF KIDNEYS FROMCADAVER(CAD) DONORS WITH ACUTE RENALFAILURE(ARF) - A PROSPECTIVE CONTROLLEDSTUDY. (Abstract #445)Mysore S. Anil Kumar, Billie Fyfe, Michael Heifets,Muhammed I. Saeed, Michael J. Moritz, Miten H.Parikh, Sheng G. Xiao, Aparna Kumar. Philadelphia, PA.

3:20 PM ZERO MISMATCHED NONHEARTBEATINGDONOR KIDNEYS SHOULD BE EXCLUDED FROMMANDATORY SHARING REQUIREMENTS.(Abstract #446)Randall S. Sung, Laura L. Christensen, Mary K.Guidinger, James J. Wynn, Stuart M. Greenstein,Friedrich K. Port, Alan B. Leichtman. Ann Arbor, MI;Augusta, GA; Bronx, NY.

Concurrent Session 11: Immunosuppression inCardiac Transplantation4:00 - 5:30 PM

Room 312Chairs: Stuart D. Russell and Randall C. Starling

4:00 PM SIROLIMUS PROVIDES PROTECTION FROMGRAFT VASCULOPATHY AT 2 YEARS AFTERHEART TRANSPLANTATION. (Abstract #447)Anne Keogh, David Muller, Steve Faddy, Peter Ruygrok,Meroula Richardson, Andrew Galbraith. Sydney,Australia; Auckland, New Zealand; Melbourne, Australia;Brisbane, Australia.

4:10 PM ENTERIC-COATED MYCOPHENOLATE SODIUM(EC-MPS) VS MYCOPHENOLATE MOFETIL (MMF)IN DE NOVO HEART TRANSPLANT PATIENTS: 6-MONTH EFFICACY AND SAFETY RESULTS.(Abstract #448)J. A. Kobashigawa, S. F. Davis, D. G. Renlund, H. Eisen,L. Miller, H. Lehmkuhl, A. Gambino, R. Brambilla. LosAngeles; Nashville; Salt Lake City; Philadelphia;Minneapolis; Berlin, Germany; Padova, Italy; Basel,Switzerland.

4:20 PM CALCINEURIN-INHIBITOR-FREEIMMUNOSUPPRESSION 1WITHMYCOPHENOLATE MOFETIL AND SIROLIMUSAFTER CARDIAC TRANSPLANTATION IS SAFEAND IMPROVES RENAL FUNCTIONSIGNIFICANTLY: 1 YEAR FOLLOW UP.(Abstract #449)J. Groetzner, I. Kaczmarek, M. Mueller, J. Adamidis, M.Vogeser, P. Ueberfuhr, S. Daebritz, B. Meiser, B.Reichart. Munich, Germany.

4:30 PM A RANDOMISED, DOUBLE-BLIND, PLACEBOCONTROLLED TRIAL OF ANTI INTERLEUKIN-2RECEPTOR MONOCLONAL ANTIBODY(DACLIZUMAB) INDUCTION THERAPY AFTERHEART TRANSPLANTATION. (Abstract #450)Teun van Gelder, Marike Wabbijn, Ron van Domburg,Pascal Vantrimpont, Lex Maat, Carla Baan, WillemWeimar, Aggie Balk. Rotterdam, Netherlands.

4:40 PM A RANDOMIZED, PROSPECTIVE, MULTICENTERCOMPARISON OF TACROLIMUS,MYCOPHENOLATE MOFETIL (MMF) ANDSTEROIDS VS. CYCLOSPORINE (MODIFIEDUSP), MMF AND STEROIDS VS. TACROLIMUS,SIROLIMUS AND STEROIDS IN DE NOVOCARDIAC TRANSPLANT RECIPIENTS-6 MONTHREPORT. (Abstract #451)Stuart D. Russell, Jon A. Kobashigawa, Leslie W. Miller,Gregory A. Ewald, Mark Zucker, L. R. Goldberg, HowardJ. Eisen, Kimberly A. Salm, Rhonda Washington,William E. Fitzsimmons. Durham, NC; Los Angeles, CA;Minneapolis, MN; St. Louis, MO; Newark, NJ;Philadelphia, PA; Deerfield, IL.

4:50 PM A 12-MONTH, MULTICENTER, RANDOMIZED,ADAPTIVE DESIGN, OPEN-LABEL STUDY TOEVALUATE THE BENEFIT OF C2 HOURMONITORING OF NEORAL ON SAFETY ANDEFFICACY OUTCOMES IN DE NOVO CARDIACTRANSPLANT RECIPIENTS RECEIVINGBASILIXIMAB INDUCTION. (Abstract #452)M. Cantarovich, H. Ross, J. Arizon, J. Orus, L.Straatman, J. Howlett, E. Lage, M. Crespo, S. Wang, H.Haddad, L. Pulpon, I. Andres, W. Hauck, the MotownStudy Group. Montreal, QC, Canada.

82

5:00 PM 24 MONTH SAFETY RESULTS OF ARANDOMIZED, MULTICENTER, DOUBLE-BLINDSTUDY OF EVEROLIMUS VS AZATHIOPRINE INDE NOVO HEART TRANSPLANT RECIPIENTS.(Abstract #453)H. Eisen, J. Kobashigawa, R. C. Starling, N. Cretin, J.Jaffe, J. Murphy. Philadelphia, PA; Los Angeles, CA;Cleveland, OH; E. Hanover, NJ.

5:10 PM C0h / C2h- PHARMACODYNAMIC MONITORINGOF CYCLOSPORIN PLUS MYCOPHENOLATEMOFETIL IN HUMAN HEART TRANSPLANTRECIPIENTS. (Abstract #454)Markus J. Barten, Axel Rahmel, Markus H. C. Richter,Jens Garbade, Stefan Dhein, Hartmuth B. Bittner,Friederich W. Mohr, Jan F. Gummert. Leipzig, Germany.

5:20 PM MANAGEMENT OF THE SENSITIZED CARDIACRECIPIENT: THE ROLE OF IVIG ANDPLASMAPHERESIS. (Abstract #455)Stephen H. Leech, Mayra Lopez-Cepero, William M.LeFor. Philadelphia, PA; Tampa, FL.

Concurrent Session 12: Immunosuppression:Challenges and New Combinations I4:00 - 5:30 PM

Ballroom CChairs: Martha Pavlakis and Ron Shapiro

4:00 PM ESTIMATED 1-YEAR GLOMERULAR FILTRATIONRATE (GFR) IS THE BEST PREDICTOR OF LONGTERM GRAFT FUNCTION : RESULTS FROM THENEORAL-MOST OBSERVATIONAL STUDY.(Abstract #456)Maurizio Salvadori, Alberto Rosati, Andreas Bock,Jeremy Chapman, Bertrand Dussol, Lutz Fritsche, JohnJeffery, Volker Kliem, Yvon Lebranchu, FedericoOppenheimer, Erich Pohanka, Gunnar Tufveson.Florence, Tuscany, Italy.

4:10 PM VIRAL TUBULOINTERSTITIAL NEPHRITIS (TIN)OR VIRUS INFECTION AND ACUTE REJECTION(AR)? AN ANALYSIS OF TEMPORAL CHANGESIN TUBULAR POLYOMA VIRUS (PV)INFECTION,TIN, AND FIBROSIS IN SEQUENTIAL RENALALLOGRAFT (RA) BIOPSIES WITH POLYOMAVIRUS NEPHROPATHY (PVN). (Abstract #457)M. A. Josephson, P. V. Kadambi, B. Javaid, R. S. Baliga,J. Williams, J. Manaligod, S. M. Meehan. Chicago, IL.

4:20 PM CONCENTRATION-CONTROLLED USE OFSIROLIMUS (SRL) ASSOCIATED WITH REDUCEDEXPOSURE OF CYCLOSPORINE (CSA) INBLACK PATIENTS: 12-MONTH RESULTS.(Abstract #458)Alexandra N. Ferreira, Paula G. Machado, Cláudia R.Felipe, Sofia A. Motegi, Beatriz H. Hosaka, Márcia K.Tanaka, Luciana A. Kamura, Sung I. Park, RibertoGarcia, Marcello Franco, Fernando Alfieri, Dulci E.Casarini, Hélio Tedesco-Silva, Jr., José O. Medina-Pestana. São Paulo, SP, Brazil.

4:30 PM A REGIMEN OF SIROLIMUS AND REDUCED-DOSE CYCLOSPORINE RESULTS IN IMPROVEDRENAL ALLOGRAFT FUNCTION: COMBINEDANALYSIS OF THE U.S. AND EUROPEANSIROLIMUS-CYCLOSPORINE TRIALS.(Abstract #459)David J. Cohen, Ferdinand Muehlbacher, for the U.S. andEuropean Sirolimus CsA Study Groups. New York, NY;Vienna, Austria.

4:40 PM FK-506 (TACROLIMUS)-RESISTANCE AMONGAFRICAN AMERICANS: BLUNTED INHIBITIONOF CALCINEURIN ACTIVITY,INTERFERON γγγγγ ANDTRANSFORMING GROWTH FACTOR βββββPRODUCTION WITHIN ACTIVATED CD4+ TCELLS. (Abstract #460)J. Tumlin, M. Shakir, S. Savage, B. Roberts. Atlanta, GA.

4:50 PM PRESERVING RENAL FUNCTION BY AVOIDINGCALCINEURIN-INHIBITORS IN RENALTRANSPLANTATION: A RANDOMIZED TRIAL OFSIROLIMUS VS. TACROLIMUS. (Abstract #461)Timothy S. Larson, Patrick G. Dean, Matthew D.Griffin, Mikel Prieto, Thomas R. Schwab, Fernando G.Cosio, Scott L. Nyberg, Stephen C. Textor, James M.Gloor, Mark D. Stegall. Rochester, MN.

5:00 PM RENAL FUNCTION EVALUATION AFTER HALFDOSE REDUCTION OF NEORAL® INCOMBINATION WITH CELLCEPT® IN RENALTRANSPLANT PATIENTS WITH ALTERED RENALFUNCTION : PRELEMINARY 2 YEAR SAFETY ANDEFFICACY RESULTS OF THE MMF - REFERENCESTUDY : A RANDOMISED, OPEN, MULTICENTRE,PROSPECTIVE, CONTROLLED STUDY.(Abstract #462)M. Kessler, L. Frimat, B. Charpentier, A. Durrbach, C.Noel, F.-R. Pruvot, D. Glotz, R. Fraoui, E. Cassuto-Viguier, D. Durand, O. Cointault, J.-D. Sraer, K. Akposso,B. Bourbigot, M.-C. Moal, B. Moulin, S. Caillard, P.Lang, G. Fruchaud, J.-M. Chalopin, D. Ducloux, C.Pouteil-Noble, L. Bergougnoux, S. Biguenet. Vandoeuvreles Nancy, France.

5:10 PM PRELIMINARY RESULTS OF A RANDOMIZEDTRIAL COMPARING SIROLIMUS (SRL) VERSUSCYCLOSPORINE (CsA) IN 150 TRANSPLANTPATIENTS RECEIVING A CADAVERIC RENALGRAFT. (Abstract #463)Yvon Lebranchu, Isabelle Etienne, Olivier Toupance,Pierre-Francois Westeel, Christophe Legendre, BrunoHurault de Ligny, Yann Le Meur, Bruno Moulin, GuyTouchard, Patrice Deteix, Florence Villemain, Patrick LePogamp, Christian Noel, Isabelle Idier. Tours; Rouen;Reims; Amiens; Paris; Caen; Limoges; Strasbourg;Poitiers; Clermont Ferrand; Angers; Rennes; Lille; Paris,France.

5:20 PM PHASE III PROSPECTIVE, RANDOMIZZED STUDYTO EVALUATE THE SAFETY AND EFFICACY OFCONCENTRATION CONTROLLED RAPAMUNE(SIROLIMUS) WITH CICLOSPORIN DOSEMINIMISATION OR ELIMINATION IN DE NOVORENAL ALLOGRAFT RECIPIENTS AT 12 MONTHS.(Abstract #464)Alan G. Jardine. Glasgow, United Kingdom.

Concurrent Session 13: Immunosuppression:Preclinical Studies4:00 - 5:30 PM

Room 306Chairs: M. Wayne Flye and Kenneth A. Newell

4:00 PM SELECTIVE JANUS KINASE 3 (JAK3)ANTAGONIST ACTS SYNERGISTICALLY WITHCYCLOSPORINE (CsA) BUT LACKS SIDEEFFECTS ASSOCIATED WITH CsA/SIROLIMUSCOMBINATION. (Abstract #465)Hemangshu Podder, Stanislaw M. Stepkowski, MouerWang, Regina Verani, Jonathan Dimmock, RobertKirken, Barry D. Kahan. Houston, TX; Saskatoon, SK,Canada.

83

Su

nd

ay, May 16

4:10 PM OBLITERATIVE BRONCHIOLITIS IS PREVENTEDBY JAK3 INHIBITION WITH THE NEWIMMUNOSUPPRESSANT CP-690,550.(Abstract #466)Geraldine Rousvoal, Sally Zhang, Michael Larson, GeraldBerry, Ming-Sing Si, Bari Holm, Ricardo Paniagua,Jennifer Hawkins, Macy Lau, Mona Flores, RandallMorris, Bruce Reitz, Dominic Borie. Stanford, CA.

4:20 PM A NUCLEAR FACTOR-κκκκκB INHIBITOR, BAY 11-7082, INHIBITS INTERACTIONS BETWEENHUMAN ENDOTHELIAL CELLS, T-CELLS, ANDMONOCYTES. (Abstract #467)He Xu, Xiao-Jie Zhang, Roslyn B. Mannon, Allan D.Kirk. Bethesda, MD.

4:30 PM SMALL MOLECULE LCK INHIBITORS PROMOTELONG TERM ALLOGRAFT SURVIVAL.(Abstract #468)Michelle Hart, Robert Stachlewitz III, Michael Perkins,Michelle Babineau, Gavin Hirst, Wendy Waegell.Worcester, MA.

4:40 PM INHIBITION OF TERMINAL COMPLEMENT WITHA FUNCTIONALLY BLOCKING ANTI-C5MONOCLONAL ANTIBODY COMBINED WITHCYCLOSPORINE PREVENTS ACUTE VASCULARREJECTION IN A MOUSE CARDIAC ALLOGRAFTTRANSPLANTATION MODEL. (Abstract #469)Hao Wang, Jifu Jiang, Bertha Garcia, Russell P. Rother,Robert Zhong. London, ON, Canada; Cheshire, CT.

4:50 PM BENEFICIAL EFFECTS OF TARGETING THECXCR3 CHEMOKINE RECEPTOR IN NON-HUMAN PRIMATE RENAL ALLOGRAFTRECIPIENTS. (Abstract #470)Wayne W. Hancock, Turan Kanmaz, Yinchen Dong,Wasim Dar, Jean Kwun, James R. Rottman, Shixin Qin,Walter Newman, Qunrui Ye, Jose R. Torrealba, John H.Fechner, Stuart J. Knechtle. Philadelphia, PA;Cambridge, MA; Madison, WI.

5:00 PM A NOVEL SMALL MOLECULE CCR5ANTAGONIST INHIBITS ALLOIMMUNERESPONSE IN VIVO. (Abstract #471)Satoru Akashi, Masayuki Sho, Yukiyasu Kuzumoto,Naoya Ikeda, Yoshikazu Tsurui, Hisanori Kashizuka,Takashi Mizuno, Yoshiyuki Nakajima. Kashihara, Nara,Japan.

5:10 PM IMMUNOMODULATION BY STATINS INVOLVESALTERED INTERLEUKIN-2 SIGNALING IN HUMANT CELLS. (Abstract #472)Jens Goebel, Barbara Logan, Kathy Forrest, Thomas L.Roszman. Cincinnati, OH; Lexington, KY.

5:20 PM HISTAMINE RECEPTOR ANTAGONISTSPROLONGED SURVIVAL OF FULLY ALLOGENICCARDIAC GRAFT IN MICE. (Abstract #473)Fumihiko Inoue, Nozomu Shirasugi, Takurin Akiyoshi,Katsunori Tanaka, Osamu Aramaki, Qi Zhang, MotohideShimazu, Kenji Matsumoto, Masaki Kitajima, MasanoriNiimi. Shinjuku-ku, Tokyo, Japan; Itabashi-ku, Tokyo,Japan.

Concurrent Session 14: Infections: HCV, HIVand Opportunistic Infections4:00 - 5:30 PM

Room 302/304Chairs: Roy D. Bloom and John D. Pirsch

4:00 PM IDENTIFICATION OF HHV8-SPECIFIC CD8+ TCELL RESPONSES IN KIDNEY TRANSPLANTRECIPIENTS USING HLA-A2 TETRAMERS.(Abstract #474)Alexandre Karras, Marion Lambert, Monique Gannage,Christophe Legendre, Celeste Lebbe, Sophie Caillat-Zucman. Paris, France.

4:10 PM PREVALENCE AND SEVERITY OFTUBERCULOSIS AMONG RENAL TRANSPLANTRECIPIENTS. (Abstract #475)Amy L. Friedman, Jeanine A. DeLucia, Richard N.Formica, Frank J. Bia, Fadi G. Lakkis, Douglas Smith,Thomas Eisen, David Rothstein, Margaret J. Bia, Marc I.Lorber. New Haven, CT.

4:20 PM HEPATITIS C IN HAEMODIALYSED PATIENTSAWAITING KIDNEY TRANSPLANTATION: THEROLE OF IL-10 AND TGF-βββββ

1 IN THE EVALUATION

OF LIVER DISEASE. (Abstract #476)Annalisa Masier, Vincenza Di Leo, Filomena Morisco,Francesco Marchini, Attilio Cecchetto, Paolo Rigotti,Remo Naccarato, Patrizia Burra. Padova, Italy; Napoli,Italy.

4:30 PM HHV-8 INFECTION IN KIDNEY DONORS ANDKIDNEY TRANSPLANT RECIPIENTS: A NATIONALPROSPECTIVE STUDY ON EPIDEMIOLOGY ANDRISK FACTORS FOR KAPOSI SARCOMA.(Abstract #477)Céleste Lebbé, Christophe Legendre, Anne GenevièveMarcellin, Sylvie Chevret, Felix Agbalika, AnnickBigorie, Vincent Calvez, Camille Francès. Paris, France.

4:40 PM LONG-TERM IMPACT OF HCV ON CLINICALOUTCOMES AND LIVER HISTOLOGY IN KIDNEYRECIPIENTS. (Abstract #478)David Roth, Rajender Reddy, Warren Kupin, GeorgeBurke, Gaetano Ciancio, Galo Garces, Jane Colona, DavidPetrin, Joshua Miller. Miami, FL; Philadelphia, PA.

4:50 PM DOES DONOR HCV STATUS REALLY MATTER TOTHE HCV+ RENAL TRANSPLANT RECIPIENT? A10 YEAR FOLLOW-UP. (Abstract #479)Jimmy A. Light, Diana Y. Barhyte, Muhammad K. Ali.Washington, DC; Elizabethtown, KY.

5:00 PM URINARY TRACT INFECTIONS INCREASES THERISK OF MORTALITY AFTER RENALTRANSPLANTATION. (Abstract #480)Peale Chuang, Jacqueline Ray, Beatrice Edmundson,Kristen Heins, Elizabeth Bleecker, Chirag Parikh, DavidShaffer, William A. Nylander, A. Tarik Kizilisik, J.Harold Helderman, Anthony Langone. Nashville, TN;Denver, CO.

5:10 PM UNEXPECTEDLY HIGH REJECTION RATES INHIV-POSITIVE RECIPIENTS OF RENALTRANSPLANTS. (Abstract #481)Kenzo Hirose, Lee Ann Baxter-Lowe, Laurie Carlson,Chris E. Freise, Ryutaro Hirose, Kelly Cunniffe, MichelleRoland, Nancy L. Ascher, Peter G. Stock. San Francisco,CA.

5:20 PM KIDNEY TRANSPLANTATION AMONG HIVINFECTED PATIENTS IN THE US MEDICAREPOPULATION. (Abstract #482)Bertram L. Kasiske, Jon J. Snyder. Minneapolis, MN.

84

Concurrent Session 15: Islet Cell and Stem Cell4:00 - 5:30 PM

Room 309Chairs: Ginny L. Bumgardner and Jon S. Odorico

4:00 PM A NOVEL STRATEGY FOR ABROGATION OFRECURRENT AUTOIMMUNE DESTRUCTION OFISLET TRANSPLANTS. (Abstract #483)Qixin Shi, Donghua Wang, Adam Bingaman, Donna L.Farber, Gregg A. Hadley, Stephen T. Bartlett. Baltimore,MD.

4:10 PM ADMINISTRATION OF PLASMACYTOIDDENDRITIC CELLS PROPAGATED FROM NODMICE PREVENTS DIABETES IN NOD MICE.(Abstract #484)Xiaoyan Liang, Shiguang Qian, Jennifer E. Woodward,John J. Fung, Lina Lu. Pittsburgh, PA.

4:20 PM PREVENTION OF ISLET ALLOGRAFT REJECTIONBY CO-TRANSPLANT WITH ACTIVATED HEPATICSTELLATE CELLS WITHOUT SYSTEMICIMMUNOSUPPRESSION. (Abstract #485)Cheng-Hsu Chen, Yigang Chang, John J. Fung, ShiguangQian, Lina Lu. Pittsburgh, PA.

4:30 PM BLOCKADE OF THE CD40-CD154 PATHWAYUSING A CHIMERIC ANTI-HUMAN CD40MONOCLONAL ANTIBODY SYNERGIZED WITHCD28 BLOCKADE TO PROLONG ISLETALLOGRAFT SURVIVAL. (Abstract #486)Andrew B. Adams, Nozomu Shirasugi, Thomas R. Jones,Elizabeth Strobert, Megan M. Durham, DianeHollenbaugh, David Haggerty, Robert Townsend, ThomasC. Pearson, Christian P. Larsen. Atlanta, GA; Princeton,NJ.

4:40 PM FIVE-YEAR DRUG-FREE SURVIVAL OF JUVENILENONHUMAN PRIMATE (NHP) ISLET ALLOGRAFTRECIPIENTS WITH NORMAL GLYCEMICPARAMETERS. (Abstract #487)Francis T. Thomas, Juan L. Contreras, Anne Hutchings,Devin E. Eckhoff, Judith M. Thomas. Birmingham, AL.

4:50 PM SUCCESSFUL ISLET TRANSPLANTATION FROMONE DONOR TO ONE RECIPIENT BY TARGETINGAT NKT CELLS. (Abstract #488)Yohichi Yasunami, Atsushi Toyofuku, Masahiko Nakano,Yoshiichiroh Nakamura, Masayuki Satoh, KentarohNabeyama, Seiyo Ikeda, Junko Ono, ToshinoriNakayama, Masaru Taniguchi. Fukuoka, Japan; Chiba,Japan; Yokohama, Japan.

5:00 PM MESENCHYMAL STEM CELL-ENHANCEDALLOGENEIC ENGRAFTMENT IS IMPEDED BY NKCELL ACTIVITY. (Abstract #489)D. Polchert, E. Ho, P. Napoles, A. Moadsiri, J. Turian,Z. Yu, P. Witte, A. Bartholomew. Chicago, IL;Maywood, IL.

5:10 PM ENHANCED PANCREATIC ISLET (PI) RECOVERYAND ISLET FUNCTIONALITY IN RATS BY 17b-ESTRADIOL (E

2) TREATMENT TO BRAIN-DEAD

(BD) DONORS. (Abstract #490)Devin E. Eckhoff, Christopher Eckstein, GuadalupeBilbao, Cheryl Smyth, Carlton Young, Firoz G.Rahemtulla, Irshad H. Chaudry, Juan L. Contreras.Birmingham, AL.

5:20 PM SYSTEMIC PLASMID DNA GENE TRANSFER INTODIABETIC MICE CAUSES GLUCOSE-DEPENDENTHEPATIC INSULIN EXPRESSION AND REDUCESHYPERGLYCEMIA. (Abstract #491)Tausif Alam, Philipp C. Nett, Hans W. Sollinger.Madison, WI.

Concurrent Session 16: Liver Transplantation:Live Donors and Splits-Complications4:00 - 5:30 PM

Ballroom BChairs: Christoph E. Broelsh and James Trotter

4:00 PM DRAMATIC IMPROVEMENT IN THE OUTCOMEOF ABO-INCOMPATIBLE LIVERTRANSPLANTATION FROM LIVING DONOR BYHEPATIC ARTERIAL INFUSION THERAPY.(Abstract #492)Fumitaka Oike, Hiroto Egawa, Koichi Kozaki, KenjiUryuhara, Kohei Ogawa, Mureo Kasahara, YasuhiroOgura, Yasutsugu Takada, Tetsuya Kiuchi, KoichiTanaka. Kyoto, Kyoto, Japan; Nagoya, Aichi, Japan.

4:10 PM BILIARY AND VASCULAR COMPLICATIONSFOLLOWING SPLIT LIVER TRANSPLANTATION.(Abstract #493)Neal R. Barshes, Timothy C. Lee, Beth A. Carter, W.Kenneth Washburn, Glenn A. Halff, John A. Goss.Houston, TX; San Antonio, TX.

4:20 PM BILIARY COMPLICATIONS AFTER LIVINGDONOR ADULT LIVER TRANSPLANTATION.(Abstract #494)J. E. Verbesey, E. A. Pomfret, J. J. Pomposelli, M.Akoud, M. A. Simpson, F. D. Gordon, W. D. Lewis, R. L.Jenkins. Burlington, MA.

4:30 PM HIGHER RESOURCE UTILIZATION IN ADULTLIVING DONOR LIVER TRANSPLANTRECIPIENTS COMPARED TO DECEASED DONORLIVER TRANSPLANT RECIPIENTS. (Abstract #495)Jason D. Conway, Mark W. Russo, Mark Johnson,Roshan Shrestha. Chapel Hill, NC.

4:40 PM LIVING DONOR LIVER TRANSPLANTATIONFROM HEPATITIS B CORE ANTIBODY POSITIVEDONORS. (Abstract #496)Arzu Celebi, Sinan Akay, Gokhan Unsal, Tijen Ozacar,Murat Akyildiz, Zeki Karasu, Deniz Nart, CigdemArikan, Sema Aydogdu, Murat Zeytunlu, Murat Kilic,Yildiray Yuzer, Yaman Tokat. Izmir, Turkey.

4:50 PM HEPATITIS C VIRUS (HCV) RECURRENCE IS ANEARLY AND SEVERE EVENT IN LIVING DONORLIVER TRANSPLANTATION (LDLT).(Abstract #497)Montserrat Garcia-Retortillo, Xavier Forns, Josep M.Llovet, Miquel Navasa, Anna Massaguer, Anna Feliu,Miquel Bruguera, Josep Fuster, Juan C. Garcia-Valdecasas,Antoni Rimola. Barcelona, Barcelona, Spain.

5:00 PM COMPARISONS OF REJECTION AND HEPATITISC RECURRENCE IN LIVE DONOR ANDDECEASED DONOR LIVER TRANSPLANTATION.(Abstract #498)Shi-Hui Pan, Nicholas N. Nissen, Colquhoun D. Steven,Noghreian Neda, Tram T. Tran, Fred F. Poordad, PaulMartin, Walid Ayoub, John M. Vierling, Christopher R.Shackleton. Los Angeles, CA.

5:10 PM LONGITUDINAL ANALYSIS OF DONORQUALITY OF LIFE AFTER LIVING DONOR LIVERTRANSPLANTATION. (Abstract #499)Jennifer E. Verbesey, Mary Ann Simpson, Eric Richman,Alyson Nixon, Fredric D. Gordon, James J. Pomposelli,W. David Lewis, Roger L. Jenkins, Elizabeth A. Pomfret.Burlington, MA.

85

Su

nd

ay, May 16

5:20 PM RISK FACTORS FOR GRAFT DYSFUNCTIONAFTER ADULT-TO-ADULT LIVING DONOR LIVERTRANSPLANTATION. (Abstract #500)Shigeru Marubashi, Keizo Dono, Hidenori Takahashi,Kunihito Gotoh, Kazuhiko Hashimoto, Masaru Kubota,Atsushi Miyamoto, Hiroaki Nagano, Shoji Nakamori,Koji Umeshita, Masato Sakon, Morito Monden. Suita,Osaka, Japan.

Concurrent Session 17: Sirolimus/Everolimus4:00 - 5:30 PM

Ballroom AChairs: Yaman Tokat and Carlton J. Young

4:00 PM CHRONIC ALLOGRAFT DAMAGE INDEX (CADI)a

SCORING AT CONVERSION FROMCALCINEURIN INHIBITORS (CI) TO SIROLIMUSPREDICTS RENAL OUTCOME IN KIDNEYTRANSPLANT RECIPIENTS. (Abstract #501)Niranjan Sankaranarayanan, Fabiola Balarezo, KimAlleman, Matthew Brown, Kevin Charpentier, AnneLally, David Hull, Kasturi V. Ranga. Farmington, CT;Hartford, CT.

4:10 PM KIDNEY TRANSPLANTATION WITH SIROLIMUSAND MYCOPHENOLATE MOFETIL BASEDIMMUNOSUPPRESSION PRESERVES RENALSTRUCTURE AND FUNCTION COMPARED TOCALCINEURIN INHIBITOR (CNI) DRUGS.(Abstract #502)Stuart M. Flechner, Kim Solez, Daniel J. Cook, James T.Burke, Hank Rollin, Barbara Mastoianni, Kathy Savas,Sunil Kurian, Steven Head, Daniel R. Salomon.Cleveland, OH; Edmonton, AB, Canada; La Jolla, CA;Paris, France.

4:20 PM SIROLIMUS (RAP) IN COMBINATION WITHCYCLOSPRINE MICROEMULSION (CSA) VS.MYCOPHENOLATE MOFETIL (MMF) WITH CSAIS ASSOCIATED WITH DECREASED GRAFTSURVIVAL (GS) IN RENAL TRANSPLANT (TX)RECIPIENT. (Abstract #503)Herwig-Ulf Meier-Kriesche, Jacqueline J. Loveland,Bettina J. Steffen, Alice H. Chu, Vincent Gotz, Robert D.Gordon, Jonathan A. Morris, Bruce Kaplan. Gainesville,CA; La Jolla, CA; Nutley, NJ.

4:30 PM EFFICACY AND SAFETY OF 2 DOSES OFEVEROLIMUS COMBINED WITH REDUCED DOSENEORAL® IN DE NOVO KIDNEY TRANSPLANTRECIPIENTS: 12 MONTHS ANALYSIS. (Abstract #504)John Magee, Helio Tedesco, Julio Pascual, GiovanniCivati, Gentil Filho, Valter Garcia, Tomas Haas, JohannaGeissler, Nathalie Cretin. Ann Arbor, MI; Sao Paulo,Brazil; Madrid, Spain; Milano, Italy; Campinas, Brazil;Porto Alegre, Brazil; Basel, Switzerland.

4:40 PM MAINTENANCE IMMUNOSUPPRESSION WITHTOR INHIBITORS IS ASSOCIATED WITH AREDUCED INCIDENCE OF DE NOVOMALIGNANCIES. (Abstract #505)H. M. Kauffman, W. S. Cherikh, Y. Cheng, D. W. Hanto,B. D. Kahan. Richmond, VA; Boston, MA; Houston, TX.

4:50 PM SIROLIMUS-RELATED INTERSTITIALPNEUMONITIS : REPORT OF 21 CASES IN RENALTRANSPLANT RECIPIENTS. (Abstract #506)Laure Champion, Emmanuel Morelon, Marc Stern,Marie-France Mamzer, Jean-Philippe Rerolle, Marie-Noelle Peraldi, Henri Kreis. Paris, France; Suresnes,France.

5:00 PM EXCELLENT GRAFT FUNCTION IN DE NOVOKIDNEY TRANSPLANT RECIPIENTS TREATEDWITH CERTICAN®, SIMULECT® AND REDUCEDNEORAL® EXPOSURE : 12-MONTH RESULTS.(Abstract #507)John Whelchel, Stefan Vitko, Josette Eris, ScottCampbell, Bernhardt Burbigott, John Leone, PaoloRigotti, Tomas Haas, Annette Jappe, Nathalie Cretin.Atlanta, GA; Prague, Czech Republic; Sidney, Australia;Brisbane, Queensland, Australia; Brest, France; Tampa,FL; Padua, Italy; Basel, Switzerland.

5:10 PM EVEROLIMUS THERAPEUTIC CONCENTRATIONRANGE DERIVED FROM A PROSPECTIVECONCENTRATION-CONTROLLED TRIAL IN DENOVO KIDNEY TRANSPLANTATION.(Abstract #508)J. M. Kovarik, H. Tedesco, J. Pascual, G. Civati, H.Schmidli, J. Geissler. Basel, Switzerland; Sao Paulo, Brazil;Madrid, Spain; Milan, Italy.

5:20 PM DELAYED GRAFT FUNCTION AND SIROLIMUS.(Abstract #509)A. Lo, M. F. Egidi, L. Gaber, H. Amiri, S. Vera, B. Gross,C. Dye, B. Duhurt, E. D. Clark, A. O. Gaber. Memphis,TN.

Concurrent Session 18: Steroid CessationProtocols4:00 - 5:30 PM

Room 311Chairs: Elmahdi A. Elkhammas and David A. Laskow

4:00 PM FIVE YEAR FOLLOW-UP AFTER STEROIDWITHDRAWAL DEMONSTRATES NO EVIDENCEOF WORSENING RENAL FUNCTION. (Abstract #510)Baris Akin, Ronald M. Ferguson, Ronald P. Pelletier.Columbus, OH.

4:10 PM LONG TERM RENAL ALLOGRAFT SURVIVALAND FUNCTION AFTER STEROID WITHDRAWALIN AFRICAN AMERICANS RECEIVINFSIROLIMUS AND TACROLIMUS. (Abstract #511)Donald E. Hricik, Thomas C. Knauss, Kenneth A.Bodziak, Christopher T. Siegel, James A. Schulak.Cleveland, OH.

4:20 PM IMPACT OF EARLY CORTICOSTEROIDCESSATION ON BODY WEIGHT ALTERATIONSIN RENAL TRANSPLANT RECIPIENTS.(Abstract #512)C. C. Rogers, R. R. Alloway, M. J. Hanaway, J. F. Buell, J.W. Alexander, M. Gupta, T. D. Merchen, M. J. Thomas,P. Roy-Chaudhury, J. Trofe, M. Cardi, R. Munda, E. S.Woodle. Cincinnati, OH.

4:30 PM GLOBAL CARDIOVASCULAR RISK UNDEREARLY STEROID CESSATION DECREASESPROGRESSIVELY IN THE FIRST YEAR POSTTRANSPLANT. (Abstract #513)C. C. Rogers, R. R. Alloway, R. E. Boardman, J. Trofe,M. J. Hanaway, J. W. Alexander, P. Roy-Chaudhury, J. F.Buell, M. J. Thomas, M. Cardi, B. Susskind, E. S. Woodle.Cincinnati, OH.

86

4:40 PM ANTI CD25 MONOCLONAL ANTIBODYINDUCTION REDUCES ACUTE REJECTION INADULT RENAL TRANSPLANT RECIPIENTSIMMUNOSUPPRESSED WITH TACROLIMUS ANDMYCOPHENOLATE IN A STEROID AVOIDANCEREGIME. (Abstract #514)Richard Borrows, Marina Loucaidou, Jen van Tromp,Thomas Cairns, Megan Griffith, Nadey Hakim, AdamMcLean, Andrew Palmer, Vassilios Papalois, DavidTaube. London, United Kingdom.

4:50 PM STEROID WITHDRAWAL IS ASSOCIATED WITHIMPROVED PATIENT SURVIVAL IN STABLERENAL TRANSPLANT RECIPIENTS.(Abstract #515)Gautham Mogilishetty, Jonathan C. Prather, Ali J.Olyaei, Murali S. Golconda, John M. Barry, Douglas J.Norman, Jae S. Chung, Angelo M. de Mattos. Portland,OR.

5:00 PM FIVE-YEAR FOLLOW-UP AFTER PREDNISONEWITHDRAWAL USING SIROLIMUS-CYCLOSPORINE IMMUNOSUPPRESSION FORRENAL TRANSPLANTATION. (Abstract #516)Richard J. Knight, Zsolt Csapo, Carlos Benavides-Viveros, Linda Schoenberg, Ronald H. Kerman,Hemangshu Podder, Stephen M. Katz, Charles T. VanBuren, Barry D. Kahan. Houston, TX.

5:10 PM A MULTICENTER, OPEN LABEL PILOT STUDY OFEARLY (5 DAY) CORTICOSTEROID CESSATIONIN DE NOVO RENAL TRANSPLANT RECIPIENTSUNDER SIMULECT, TACROLIMUS, ANDSIROLIMUS THERAPY: ONE YEAR RESULTS.(Abstract #517)E. S. Woodle, F. Vincenti, M. Lorber, A. Gritsch, D.Hricik, K. Washburn, A. Matas, M. Gallichio.

5:20 PM IS STEROID AVOIDANCE BENEFICIAL IN KIDNEYTRANSPLANTATION? (Abstract #518)Sumaiya W. Siddiqi, Hans W. Sollinger, Stuart J.Knechtle, Anthony M. D’Alessandro, Jon S. Odorico,Yolanda T. Becker, L. Thomas Chin, John D. Pirsch.Madison, WI.

Concurrent Session 19: Transplant Tolerance I4:00 - 5:30 PM

Room 310Chairs: John Iacomini and Laurence Turka

4:00 PM WHY DO SOME NONHUMAN PRIMATES (NHP)DEVELOP DRUG-FREE, ENDURING (>5-10 YEAR)TOLERANCE TO MHC-INCOMPATIBLEALLOGRAFTS? (Abstract #519)Devin E. Eckhoff, Francis T. Thomas, Juan L.Contreras, William Hubbard, Anne Hutchings, CarlHaisch, Jill K. Moore, David M. Neville, Jr., Judith M.Thomas. Birmingham, AL; Flat Rock, NC; Bethesda,MD.

4:10 PM IDENTIFICATION OF PERIFERIAL BLOOD-BASEDGENE EXPRESSION PROFILES HIGHLY-PREDICTIVE OF PARTIAL AND COMPLETEIMMUNE TOLERANCE IN LONG-TERM RENALALLOGRAFT RECIPIENTS. (Abstract #520)E. S. Mansfield, S. Brouard, A. Dupont, M. Giral, F.Hsieh, S. Z. Hsieh, R. Liu, J. P. Soulillou, M. M. Sarwal.Stanford, CA; Nantes, Cedex, France; Nantes, France;Palo Alto, CA.

4:20 PM IMMUNOLOGIC ASSAYS IN PATIENTSSUCCESSFULLY WITHDRAWN FROMIMMUNOSUPPRESSION (IS) AFTER LIVERTRANSPLANTATION (LTx). (Abstract #521)G. V. Mazariegos, A. Zahorchak, J. Reyes, H. Chapman,A. Girnita, K. McDade, A. Zeevi, A. Thompson.Pittsburgh, PA.

4:30 PM THE CYCLIN-DEPENDENT KINASE INHIBITORp18ink4c INHIBITS T CELL APOPTOSIS ANDOPPOSES TRANSPLANTATION TOLERANCEINDUCED BY COSTIMULATORY BLOCKADE.(Abstract #522)Emily Rowell, Liqing Wang, Grigoriy Kovalev, Lishan Su,Wayne Hancock, Andrew Wells. Philadelphia, PA;Chapel Hill, NC.

4:40 PM INTRAVENOUS ADMINISTRATION OF DONORSPLENOCYTES IN EARLY STAGES OFAPOPTOSIS AMELIORATES CHRONICALLOGRAFT ARTERIOPATHY. (Abstract #523)Zhiliang Wang, William J. Shufesky, Angus W. Thomson,Adrian E. Morelli. Pittsburgh, PA.

4:50 PM EFFECT OF LATENT INFECTION ONCOSTIMULATION BLOCKADE-INDUCEDTOLERANCE. (Abstract #524)Shivaprakash Gangappa, Phyllis Rees, Cullen Laclair,Andrew B. Adams, Eric Heiss, Samuel H. Speck, ThomasC. Pearson, Christian P. Larsen. Atlanta, GA.

5:00 PM AGGRESSIVE LYMPHOCYTE DEPLETION DOESNOT ELIMINATE IMMUNE MEMORY.(Abstract #525)Jonathan P. Pearl, He Xu, Kevi L. Christopher, FrankLeopardi, Edwin Preston, Linda Cendales, Douglas Hale,Allan D. Kirk. Bethesda, MD.

5:10 PM MECHANISMS OF DONOR-SPECIFICUNRESPONSIVENESS IN TOLERANT RECIPIENTOF COMBINED NON-MYELOABLATIVE HLA-MISMATCHED BONE MARROW AND KIDNEYTRANSPLANTATION. (Abstract #526)Juanita M. Shaffer, Tatsuo Kawai, Yasuhiro Fudaba, A. B.Cosimi, Susan Saidman, Frederic Preffer, DavidDombkowski, Francis Delmonico, Steven McAfee, NinaRubin-Tolkoff, Bimalangshu Dey, Thomas R. Spitzer,David H. Sachs, Megan Sykes. Boston, MA.

5:20 PM IMMUNOCOMPETENT MEMORY T-CELLS ARETHE DOMINANT CELL TYPE FOLLOWINGANTIBODY-MEDIATED T-CELL DEPLETION ANDMAY BE A BARRIER TO ACHIEVINGTOLERANCE. (Abstract #527)Jonathan P. Pearl, Jeremy Parris, Kelly L. McCoy,Steven C. Hoffman, Kevi L. Christopher, He Xu, RosylnB. Mannon, Douglas Hale, S. John Swanson, Allan D.Kirk. Bethesda, MD.

Concurrent Session 20: Use of ExpandedCriteria Donor Kidneys4:00 - 5:30 PM

Veterans BallroomChairs: Edward J. Alfrey and Robert J. Stratta

4:00 PM ECD MORTALITY: OPO WAITING TIME BY RACEAND AGE. (Abstract #528)Dale A. Distant, Valarie B. Ashby, Friedrich K. Port,Alan B. Leichtman, Robert A. Wolfe, Robert M. Merion.Brooklyn, NY; Ann Arbor, MI.

87

Su

nd

ay, May 16

4:10 PM INITIAL EXPERIENCE WITH THE EXPANDEDCRITERIA DONOR KIDNEY ALLOCATIONSYSTEM: IMPACT ON LISTED CANDIDATES.(Abstract #529)Randall S. Sung, Mary K. Guidinger, Alan B. Leichtman,Craig D. Lake, Robert A. Metzger, Friedrich K. Port,Robert M. Merion. Ann Arbor, MI; Orlando, FL.

4:20 PM RISK FACTORS FOR GRAFT LOSS FOLLOWINGEXPANDED CRITERIA DONOR KIDNEYTRANSPLANTS. (Abstract #530)Kunam S. Reddy, Wida S. Cherikh, Timothy Baker,Robert J. Stratta, Raymond Heilman, Adyr Moss, MarekMazur, David C. Mulligan. Pheonix, AZ; Richmond, VA;Winston-Salem, NC.

4:30 PM UNOS EXPANDED CRITERIA DONORS: ISSTRATIFICATION USEFUL? (Abstract #531)Edwina Baskin-Bey, Walter Kremers, Mark Stegall, ScottNyberg. Rochester, MN.

4:40 PM DONOR SCORE, RESISTIVE INDEX, OREXPANDED CRITERIA STATUS: WHICH IS THEBEST PREDICTOR OF OUTCOME AFTERDECEASED DONOR RENAL TRANSPLANTATION?(Abstract #532)Scott Nyberg, Edwina Baskin-Bey, Walter Kremers, MarkStegall, Mitchell Henry. Rochester, MN; Columbus, OH.

4:50 PM IMPACT OF EXPANDED CRITERIA DONORKIDNEY TRANSPLANTATION ON YOUNGMINORITY PATIENTS. (Abstract #533)Ruth A. McDonald, Valarie B. Ashby, John Rosendale,William E. Harmon, Winfred W. Williams, Cindy M.Sommers, Robert A. Wolfe, Friedrich K. Port. Seattle,WA; Ann Arbor, MI; Richmond, VA; Boston, MA.

5:00 PM UNOS EXPANDED CRITERIA DONORS: HOW DOBRAIN DEAD AND NON-HEART BEATINGDONORS COMPARE? (Abstract #534)Edwina Baskin-Bey, Walter Kremers, Mark Stegall, ScottNyberg. Rochester, MN.

5:10 PM SHOULD KIDNEYS FROM MARGINAL DONORSBE USED AS DOUBLE OR SINGLETRANSPLANTS? (Abstract #535)Rushi Deshpande, Robert Smith, Carl Cardella, DanielCattran, Stanley Fenton, Michael Robinette, DavidGrant, Mark Cattral, Paul Greig, Ian McGillvary, EdwardCole. Toronto, ON, Canada.

5:20 PM ANALYSIS OF THE EXPANDED CRITERIA DONORKIDNEYS; HOW GOOD IS YOUR ECD GOINGTO BE? (Abstract #536)Herwig-Ulf Meier-Kriesche, Edward H. Cole, Jesse D.Schold, Pamela R. Patton, Richard J. Howard, BruceKaplan. Gainesville, FL; Toronto, ON, Canada.

88

AMERICAN TRANSPLANT CONGRESSDay-at-a-Glance, Monday, May 17, 2004

7:00 – 8:15 AM Concurrent Sunrise SymposiaPage 90 Sunrise Symposium I: New

Costimulatory MoleculesBallroom A

Sunrise Symposium II: Ethics inTransplantationBallroom C

Sunrise Symposium III: ClinicalResearch Primer: Trials and TribulationsBallroom B

8:30 – 9:30 AM Plenary Session IIPage 90 Basic Science I

Ballroom B

Page 90 Clinical Science IVeterans Auditorium

9:45 – 11:15 AM Concurrent SymposiaPage 90 Basic Science Symposium:

The Science of Complex Systems as itRelates to TransplantationBallroom B

Page 91 Clinical Trials Symposium:Pre-transplant Risk Factors andEffect on Post-transplantation OutcomesVeterans Auditorium

11:30 AM – 12:30 PM Concurrent SessionsPage 91 In-Depth Reviews: Basic

Ballroom B

In-Depth Reviews: ClinicalVeterans Auditorium

12:30 – 2:00 PM Poster Session IIPresenters in AttendanceExhibits OpenExhibit Hall C

Page 91 Acute Rejection: Basic

Page 92 Allorecognition/Antigen Presentation

Page 93 Deceased Donor Kidney Transplantation

Page 94 Experimental Tolerance Induction II

Page 95 Immunosuppression:Preclinical Studies II

Page 97 Infection and Non-Organ SpecificImmunosuppression

Page 98 Kidney Immunosuppression:Complications

Page 99 Kidney Immunosuppression: NewChal lenges

Page 100 Liver Transplantation: DiseaseRecurrence

Page 101 Liver Transplantation: Management ofImmunosuppression

Page 103 Living Donor Kidney Transplantation

Page 104 Pancreas and Islet Transplantation

Page 105 Pediatric Liver Transplant: Advances inTechnique and Immunosuppression

Page 106 Tissue Injury II

12:45 – 1:45 PM Mini-Oral SessionsPage 108 Antigen Presentation and Alloimmunity

Room 306

Page 108 Donation, Preservation, and OutcomeBallroom A

Page 108 Ischemia-Reperfusion InjuryRoom 309

Page 109 Liver Transplantation: ControversiesBarllroom B

2:00 – 3:30 PM Concurrent SessionsPage 109 Concurrent Session 21: ABO-

Incompatible Kidney TransplantationBallroom A

Page 110 Concurrent Session 22: CampathVeterans Ballroom

Page 110 Concurrent Session 23: ExperimentalImmunosuppression: New Insights IRoom 310

Page 111 Concurrent Session 24: LiverTransplantation: Hepatitis CBallroom B

Page 111 Concurrent Session 25: Mechanisms ofAcute Graft InjuryRoom 309

Page 112 Concurrent Session 26: OrganAllocation and Public PolicyBallroom C

Page 113 Concurrent Session 27: PediatricCardiac Transplantation and Post-Transplant ComplicationsRoom 306

Page 113 Concurrent Session 28: Pediatric Liverand Intestinal TransplantationRoom 312

Page 114 Concurrent Session 29: T-Reulatory CellFunction in ToleranceRoom 311

Page 114 Concurrent Session 30: Viral InfectionsRoom 302/304

89

Mo

nd

ay, May 17

4:00 – 5:30 PM Concurrent SessionsPage 115 Concurrent Session 31: Early Post-

Transplant and Donor IssuesBallroom A

Page 115 Concurrent Session 32: ExperimentalImmunosuppression: New Insights IIRoom 311

Page 116 Concurrent Session 33:Immunosuppression Complications andMedical ComplicationsBallroom C

Page 116 Concurrent Session 34: Innate andAdaptive Immunity and Cytokines inIschemia-ReperfusionRoom 306

Page 117 Concurrent Session 35: LiverTransplantation: Public Policy andEconomicsBallroom B

Page 117 Concurrent Session 36: LymphocyteActivation: Costimulatory Moleculesand Costimulatory BlockadeRoom 309

Page 118 Concurrent Session 37: New Agents inImmunosuppressionVeterans Ballroom

Page 118 Concurrent Session 38: TranslationalResearch in Liver TransplantationRoom 312

Page 119 Concurrent Session 39: TransplantRelated MalignanciesRoom 302/304

Page 119 Concurrent Session 40:XenotransplantationRoom 310

5:45 PM ASTS Business MeetingBallroom A

AMERICAN TRANSPLANT CONGRESSDay-at-a-Glance, Monday, May 17, 2004

90

Monday, May 17, 2004

Concurrent Sunrise Symposia7:00 – 8:15 AM

Sunrise Symposium I: New Costimulatory Molecules

Ballroom AChair: Laurence Turka

7:00 AM Lymphotoxin and LIGHT in autoimmune diseaseJ. Browning

7:25 AM New data on iCTLA4Vijay Kuchroo

7:50 AM New costimulatory molecules in transplantrejection

Mohamed Sayegh

Sunrise Symposium II: Ethics in Transplantation

Ballroom CChair: Robert Stratta

7:00 AM Transplanting illegal aliens/non-citizensRoss Isaacs

7:25 AM Organ trafficking: How extensive is the problemand how do we monitor it?

Nancy Scheper-Hughes7:50 AM Paying for organs: A social assessment of the

questionDavid J. Rothman

Sunrise Symposium III: Clinical Research Primer:Trials and Tribulations

Ballroom BChair: Flavio Vincenti

7:00 AM Overview of study designs: What is best suited toyour practice?

David Gerber7:25 AM Surrogate and alternate endpoints

Kevin Mange7:50 AM Clinical trial and medical-legal issues: A

changing landscapeJeffrey Gibbs

Plenary Session: Basic Plenary I8:30 - 9:30 AM

Ballroom BChairs: David M. Briscoe and Ginny L. Baumgardner

8:30 AM B LYMPHOCYTE MEDIATED ANTIGENPRESENTATION PROMOTES OPTIMAL IN VIVOALLOREACTIVE CD4 T CELL ACTIVATION ANDCARDIAC ALLOGRAFT REJECTION.(Abstract #537)Hooman Noorchashm, Amy J. Reed, Susan Y. Rostami,Jessica Dias, Arjun Jeganathan, Brigitte Koeberlein,Andrew J. Caton, Ali Naji. Philadelphia, PA.

8:45 AM GENERATION OF REGULATORY CD8+ T CELLSBY ICOS-B7H SIGNAL BLOCKADE IN VIVO.(Abstract #538)Atsushi Izawa, Michael R. Clarkson, Alan D. Salama,Takuya Ueno, Hideo Yagita, Arlene H. Sharpe, Gordon J.Freeman, Mohamed H. Sayegh, Nader Najafian. Boston,MA; Tokyo, Japan.

9:00 AM LOW TOLL-LIKE RECEPTOR 4 EXPRESSION ONLIVER DENDRITIC CELLS CORRELATES WITHREDUCED CAPACITY TO ACTIVATEALLOGENEIC T CELLS IN RESPONSE TOENDOTOXIN. (Abstract #539)An De Creus, F. J. Duncan, Audrey Lau, HolgerHackstein, Angus W. Thomson. Pittsburgh, PA; Giessen,Germany.

9:15 AM SOCS3 and c-maf ARE INVOLVED INGENERATION AND MAINTENANCE OF Th2REGULATORY (Th2reg) CELLS INTRANSPLANTATION TOLERANCE. (Abstract #540)Ye Zhang, Robert Kirken, Slawa Janczewska, LucreziaFurian, Xiumei Qu, Mouer Wang, Ronald Kerman,Stanislaw M. Stepkowski. Houston, TX.

Plenary Session: Clinical Plenary I8:30 - 9:30 AM

Veterans AuditoriumChairs: William E. Harmon and James A. Schulak

8:30 AM DEATH AND DESTRUCTION: THE MOLECULARAND CELLULAR EVENTS OF POLYOMAVIRUSNEPHROPATHY (PVN). (Abstract #541)Roslyn B. Mannon, S. C. Hoffman, R. Kampen, O. H.Cheng, D. Hale, A. D. Kirk, D. E. Kleiner. Bethesda,MD.

8:45 AM ABO INCOMPATIBLE KIDNEYTRANSPLANTATION WITH AND WITHOUTSPLENECTOMY USING NON-A2 BLOOD GROUPDONORS. (Abstract #542)James M. Gloor, Timothy S. Larson, Donna J. Lager,Mary E. Fidler, S. Breanndan Moore, Jeffrey L. Winters,Mark D. Stegall. Rochester, MN.

9:00 AM INSULINOTHERAPY AT AN EARLY STAGE AFTERKIDNEY TRANSPLANTATION : EFFECT ON TOTALRADICAL-TRAPPING ANTIOXIDANT PARAMETER(TRAP). (Abstract #543)Matthieu Monge, Jean-Claude Maziere, Hakim Mazouz,Jean-Daniel Lalau, Claire Presne, Gabriel Choukroun,Albert Fournier, Pierre-Francois Westeel. Amiens,France.

9:15 AM THE SURVIVAL BENEFIT OF LIVERTRANSPLANTATION. (Abstract #544)Robert M. Merion, Douglas E. Schaubel, Dawn M.Dykstra, Richard B. Freeman, Friedrich K. Port, RobertA. Wolfe. Ann Arbor, MI; Boston, MA.

9:30 AM Break

Concurrent Symposia9:45 - 11:15 AM

Basic Science Symposium: The Science of ComplexSystems as it Relates to TransplantationBallroom BChairs: Philip Halloran and Andrew Wells

9:45 AM An introduction to complexity theory and systemsthinking transplant investigators

Charles Orosz

91

Mo

nd

ay, May 17

10:05 AM The art of the probable: System control in theadaptive immune system

Ronald Germain10:25 AM Meta- immunology

Martin Zand

10:45 AM Modeling the kinetics of HCV post-transplantliver reinfection

Alan Perelson

Clinical Science Symposium: Pre-transplant Risk Factorsand Effect on Post-transplantation outcomesVeterans AuditoriumChairs: G. William Dec and Jon Kobashigawa

9:45 AM KidneyBruce Kaplan

10:15 AM LiverJohn P. Roberts

10:35 AM LungBruce Rosengard

10:55 AM HeartMario C. Deng

Concurrent Session: In-Depth Reviews11:30 AM - 12:30 PM

In-Depth Reviews: BasicBallroom BChairs: Mark Pescovitz and Hugo Rosen

11:30 AM Pathogenesis of HCVBruce Walker

12:00 PM T-bet, A transcription factory that controls Type Iimmunity

Laurie Glimcher

In-Depth Reviews: ClinicalVeterans AuditoriumChairs: Stuart Knechtle and Donald Hricik

11:30 AM Use of registry-based evidence for clinicians andpolicy makers

Friedrich Port12:00 PM Donor Management

Bruce Rosengard

Poster Sesson II12:30 - 2:00 PM

Poster Viewing: 8:00 AM - 5:30 PMPresenters in Attendance: 12:30 - 2:00 PMExhibit Hall C

† Those posters identified as an ATC Poster of Distinction, bythis symbol have received review scores that place them inthe top 10% of their category. The Planning Committeeencourages you to make them a priority when you visit theposter session.

Acute Rejection: BasicP1 GENE EXPRESSION PROFILES IN A RAT HEART

TRANSPLANT MODEL OF ACUTE CELLULARREJECTION. (Abstract #545)Katherine J. Deans, Peter C. Minneci, Adrienne E.Hergen, Carol Logun, Kelly J. Sittler, Jennifer J. Barb,Peter J. Munson, Robert L. Danner, Michael A.Solomon. Bethesda, MD; Boston, MA.

P2 TIME-DEPENDENT CHANGES IN GENEEXPRESSION IN A RAT CARDIAC TRANSPLANTMODEL. (Abstract #546)Katherine J. Deans, Peter C. Minneci, Adrienne E.Hergen, Carol Logun, Kelly J. Sittler, Jennifer J. Barb,Peter J. Munson, Robert L. Danner, Michael A.Solomon. Bethesda, MD; Boston, MA.

P3 TRANSCRIPTIONAL PROFILING SPECIFICALLYDISCRIMINATES BETWEEN CHRONIC ANDACUTE REJECTION IN NON-HUMAN PRIMATE(NHP) RENAL ALLOGRAFT RECIPIENTS.(Abstract #547)Marc Bigaud, Grazyna Wieczorek, Klaus Menninger,Sabine Riesen, Friedrich Raulf, Jeanne Kehren. Basel,Switzerland.

P4 REJECTION OF FULLY MHC MISMATCHEDALLOGRAFTS IS INDEPENDENT OF MYD88, ATOLL/IL-1 SIGNAL ADAPTOR. (Abstract #548)Bethany Tesar, Jiasheng Zhang, Qi Li, Daniel R.Goldstein. New Haven, CT.

P5 MYD88 DEFICIENCY PROLONGSVASCULARIZED SOLID ORGAN GRAFTSURVIVAL. (Abstract #549)Kenneth Christopher, Yurong Liang, Mollie M. Jurewicz,Rachel DeFina, Thomas F. Mueller, David L. Perkins.Boston, MA.

P6 T CELL MEDIATED KIDNEY REJECTION ALTERSEPITHELIAL FUNCTION BEFORE TUBULITISDEVELOPS: EVIDENCE THAT EARLY T CELLEFFECTS ARE INSTRUCTIVE RATHER THANDESTRUCTIVE. (Abstract #550)G. Einecke, R. Nelson, V. Ramassar, A. Melk, K.Famulski, L. F. Zhu, P. F. Halloran. Edmonton, Canada.

P7 SECOND WAVE INFILTRATION OF PMNS INTOCARDIAC ALLOGRAFTS AMPLIFIES T CELLACTIVITY AND PROMOTES GRAFT REJECTION.(Abstract #551)Tarek El-Sawy, Robert L. Fairchild. Cleveland, OH.

P8 GRAFT SPECIFIC IL-6 DEFICIENCY PROLONGSVASCULARIZED SOLID ORGAN GRAFTSURVIVAL. (Abstract #552)Yurong Liang, Kenneth Christopher, Rachel DeFina,Thomas F. Mueller, David L. Perkins. Boston, MA.

P9 ααααα-PHENYL-N-tert-BUTYLNITRONE, A FREERADICAL SPIN-TRAPPING AGENT, HAS POTENTEFFECTS ON CYTOKINE GENE EXPRESSION INACUTE CARDIAC ALLOGRAFT REJECTION.(Abstract #553)Galen M. Pieper, Vani Nilakantan, Aswhani K. Khanna,Xianghua Zhou, Christopher C. Felix, Mark B. Adams,Allan M. Roza, Christopher P. Johnson. Milwaukee, WI.

P10 THE SELECTIVE ESTROGEN-RECEPTOR-BETAAGONIST BIOCHANIN A SHOWSIMMUNOMODULATING EFFECTS INEXPERIMENTAL TRANSPLANTATION WITHOUTAFFECTING THE REPRODUCTIVE SYSTEM – INVIVO AND IN VITRO STUDIES. (Abstract #554)Sonja Schrepfer, Tobias Deuse, Friedrich Koch-Nolte,Hans-Jörg Schäfer, Hermann Reichenspurner. Hamburg,Germany.

P11 INCREASED INCIDENCE OF ACUTE REJECTIONAMONG CARDIAC TRANSPLANT RECIPIENTSPOSSESSING THE GLN12STOP VARIANT OFADENOSINE MONOPHOSPHATE DEAMINASE – 1.(Abstract #555)Anne B. Taegtmeyer, Jane B. Breen, John D. Smith,Nicholas R. Banner, Margaret M. Burke, Alex D. Bell,Magdi H. Yacoub, Paul J. R. Barton. Harefield,Middlesex, United Kingdom.

92

P13 † PIOGLITAZONE SUPPRESSES ACUTE ANDCHRONIC ALLOGRAFT REJECTION.(Abstract #557)Hisanori Kosuge, Jun-ichi Suzuki, Go Haraguchi, NoritakaKoga, Ryo Gotoh, Mitsuaki Isobe. Tokyo, Japan.

P14 HLA CLASS I LIGATION ACTIVATES FAK ANDMEDIATES ASSOCIATION OF ADAPTERPROTEINS WITH FAK VIA PHOSPHORYLATIONOF FAK AT TYROSINE 925 IN ENDOTHELIALCELLS. (Abstract #558)Yi-ping Jin, Michael S. Bennett, Elaine F. Reed. LosAngeles, CA.

P15 LIGATION OF HLA CLASS I MOLECULESTRIGGERS ACTIN REORGANIZATION IN ARHOA DEPENDENT MANNER. (Abstract #559)Eric J. Lepin, Yi-ping Jin, Elaine F. Reed. Los Angeles,CA.

P16 CELL TRAFFICKING IN MURINE CARDIACTRANSPLANTATION. (Abstract #560)Kenneth Christopher, Thomas F. Mueller, Yurong Liang,Rachel DeFina, David L. Perkins. Boston, MA.

P17 ANTIGEN LOCATION INDEPENDENTLYDETERMINES THE PATHOLOGIC FEATURES OF ATRANSPLANTED ORGAN. (Abstract #561)Yifa Chen, Yilmaz Demir, Anna Valujskikh, Peter S.Heeger. Cleveland, OH.

P18 † TUBULAR CHIMERISM OCCURS REGULARLY INRENAL ALLOGRAFTS AND IS NOT RELATED TOTHE OUTCOME. (Abstract #562)Michael Mengel, Danny Jonigk, Wolfram Kleeberger,Wilfried Gwinner, Hermann Haller, Hans Kreipe.Hannover, Germany.

P19 LOW ACCUMULATION OF FOXP3TRANSCRIPTS IN BLOOD CD4+ T CELLS OFPATIENTS WITH CHRONIC REJECTION.(Abstract #563)Cecile Braudeau, Stephanie Louis, Alexandre Dupont,Magali Giral, Jean-Paul Soulillou, Sophie Brouard.Nantes, France.

P20 NON-INVASIVE IMMUNE MONITORING OFPERFORIN/GRANZYME B IN PERIPHERALBLOOD PREDICTS RENAL ALLOGRAFTREJECTION. (Abstract #564)Leonard W. Liang, Qiuheng Zhang, David Gjertson,Elizabeth Kendrick, Phuong-Thu T. Pham, Alan H.Wilkinson, Gabriel M. Danovitch, Elaine F. Reed, H.Albin Gritsch. Los Angeles, CA.

P21 UP-REGULATION OF AIF-1 EXPRESSION INKUPFFER CELLS BY Th1 CYTOKINE IN LIVERALLOGRAFTS AFTER TRANSPLANTATION.(Abstract #565)Yuichi Nagakawa, Zhaoli Sun, Shuji Nomoto, YukihikoKato, Andrew Klein. Baltimore, MD.

P22 TRANSIENT TELOMERASE EXPRESSION INNORMAL SOMATIC CELLS ALTERS TELOMERELENGTH. (Abstract #566)Annie T. L. Young, Jonathan R. T. Lakey, ShaheedMerani, Erik Johnson, John C. Mullen, Ronald B. Moore.Edmonton, AB, Canada.

Allorecognition/Antigen PresentationP23 † DIFFERENTIAL ROLES OF RENAL CELLS IN

REGULATION OF EOSINOPHIL RECRUITMENT INALLOGRAFT REJECTION. (Abstract #567)Charles R. Nolan, James D. Hernandez, Hanna E.Abboud. San Antonio, TX.

P24 † COMBINED TERATMENT OF PRAVASTATIN ANDLOSARTAN HAS SYNERGISTIC EFFECT ONCHRONIC CYCLOSPORINE NEPHROPATHY.(Abstract #568)Chul Woo Yang, Can Li, Bum Soon Choi, Sun Woo Lim,Bo Kyoung Sun, Yong Soo Kim, Byung Kee Bang. Seoul,Republic of Korea.

P25 † CYTOMEGALOVIRUS MODULATES SOLUBLEHLA-RELEASE FROM ACTIVATED ENDOTHELIALCELLS. (Abstract #569)Yuri Bushkin, Jaroslava Lieskovska, William J.Burlingham, Sergey Smirnov, Sergei V. Kotenko. Newark,NJ; Madison, WI.

P26 POLYCLONAL CD8 T CELLS CAN REJECTMAJOR HISTOCOMPATILIBILITY COMPLEXCLASS I DEFICIENT SKIN ALLOGRAFTS VIA ANINDIRECT EFFECTOR MECHANISM.(Abstract #570)Chunshui He, Peter S. Heeger. Cleveland, OH.

P27 CD103 EXPRESSION DURING DIFFERENTIATIONOF ALLOREACTIVE CELLS IN VITRO AND INVIVO. (Abstract #571)Elena Uss, Natalia Nikolaeva, Rene A. W. van Lier,Ineke J. M. ten Berge. Amsterdam, Netherlands.

P28 TYPE-1 POLARIZATION OF CD8+ T CELLRESPONSES AGAINST EBV ANTIGENS ISPRESERVED IN STABLE SOLID ORGANTRANSPLANT RECIPIENTS. (Abstract #572)Iulia Popescu, Camila Macedo, Adriana Zeevi, RonShapiro, Kareem Abu-Elmagd, Walter Storkus, JohnFung, Diana Metes. Pittsburgh, PA.

P29 IDENTIFICATION OF HLA-DR4 RESTRICTEDBMLF1-DERIVED PEPTIDES RECOGNIZED BYEBV-SPECIFIC CD4+ T CELLS. (Abstract #573)Iulia Popescu, Camila Macedo, Ron Shapiro, John Fung,Walter Storkus, Diana Metes. Pittsburgh, PA.

P30 SELF-LIGAND DEPRIVATION LEADS TO ADEFECT IN THE ABILITY OF CD4 T CELLS TOINTERACT WITH DENDRITIC CELLS.(Abstract #574)Ursula Fischer, Alexander Khoruts, Elizabeth Ingulli.Minneapolis, MN.

P31 HLAMATCHMAKER AS A PREDICTOR OF POSTRENAL TRANSPLANTATION SENSITISATION.(Abstract #575)Judith E. Worthington, Susan Martin. Manchester,United Kingdom.

P32 A LACK OF INDIRECT ALLOREACTIVITY ISASSOCIATED WITH RENAL ALLOGRAFTTOLERANCE IN A NONHUMAN PRIMATE MODEL.(Abstract #576)Ognjenka Nadazdin, Siewlin Wee, Tatsuo Kawai, SvetlanBoskovic, Ichiro Koyama, Henry Winn, David Sachs, A.Benedict Cosimi. Boston, MA; Charlestown, MA.

P33 VASCULAR ENDOTHELIAL GROWTH FACTOR(VEGF) REGULATES THE IMMUNE RESPONSETHROUGH INHIBITION OF DENDRITIC CELLFUNCTION. (Abstract #577)Stuart W. Robertson, Sreenivas Laxmanan, DebarataMukhopadhyay, David M. Briscoe. Boston, MA;Rochester, MN.

P12 GROWTH FACTOR INDUCED INHIBITION OFALLOSENSITIZATION IN SKINTRANSPLANTS.(Abstract #556)Bart M. Stubenitsky, Lauren Brasile, Moshe Kon.Utrecht, Netherlands.

93

Mo

nd

ay, May 17

P34 LFA-1 INHIBITORS BLOCK NATURAL KILLERCELLS IN HUMAN BLOOD, AND MAY HAVE APOTENTIAL FOR A NEW CLASS OFTHERAPEUTIC AGENTS IN SOLID ORGANTRANSPLANTATION. (Abstract #578)Gabriele Weitz-Schmidt, Simone Schmutz, OraneGuillaume-Gentil. Basel, Switzerland.

P35 INDIRECT ALLORECOGNITION OF MHC CLASSI PEPTIDES ACCELERATES PULMONARYALLOGRAFT REJECTION IN MINIATURE SWINE.(Abstract #579)Tsuyoshi Shoji, Douglas R. Johnston, Ruediger Hoerbelt,John C. Wain, Stuart L. Houser, Louis C. Benjamin,Richard S. Lee, Dax A. Guenther, Ashok Muniappan,Rebecca S. Hasse, Levi G. Ledgerwood, Marjory A.Bravard, Mohamed H. Sayegh, Joren C. Madsen, James S.Allan. Boston, MA.

P36 PEPTIDES CORRESPONDING TOHYPERVARIABLE REGION OF CLASS I MHC INCONJUNCTION WITH SELF EPITOPS INDUCEDONOR-SPECIFIC TOLERANCE IN TWODISTINCT RAT STRAINS. (Abstract #580)Xiu-Da Shen, N. V. Semiletova, F. Gao, Q. Jiao, S. J.Slomowitz, R. W. Bussuttil, J. W. Kupiec-Weglinski, R.M. Ghobrial. Los Angeles, CA.

P37 TCR DIVERSITY AND THE MOUNTING OFALLOIMMUNE RESPONSES. (Abstract #581)Cristina Joao, Brenda M. Ogle, Jeffrey L. Platt, MariliaCascalho. Rochester, MN.

P38 MOLECULAR IDENTIFICATION OF A NOVELGENE PRODUCT INVOLVED IN SOLUBLE HLA-RELEASE BY THE METALLOPROTEINASEPATHWAY. (Abstract #582)Yuri Bushkin, Hidehiro Watanabe, Jaroslava Lieskovska,Peter Tolias, Sandra Demaria. Newark, NJ; New York,NY.

P39 ALLOANTIGEN-SPECIFIC CD8+ T CELL PRIMINGIS MORE DEPENDENT ON ICAM-1INTERACTIONS THAN CD4+ T CELL PRIMING.(Abstract #583)John C. Rabets, Qi-Wei Zhang, Tarek El-Sawy, Robert L.Fairchild. Cleveland, OH.

P40 NOVEL, HIGHLY POTENT, ORALLYBIOAVAILABLE CCR5 ANTAGONISTS AREPOTENTIAL IMMUNOMODULATORY AGENTSFOR PRIMATE TRANSPLANTATION MODELS.(Abstract #584)Gebhard Thoma, Francois Nuninger, Marc Schaefer,Kayhan Akyel, Rainer Albert, Christian Beerli, EricFrancotte, Marcel Luyten, Duncan McKenzie, LukasOberer, Markus B. Streiff, Trixie Wagner, Hans-RudolfWalter, Gisbert Weckbecker, Hans-Guenter Zerwes.Basel, Switzerland.

P41 DONOR TREATMENT FOR THE INDUCTION OFHO-1 IS ASSOCIATED WITH REDUCEDINTRAGRAFT AND PERIPHERAL DONOR-SPECIFIC DC. (Abstract #585)Paulo N. A. Martins, Henriette Kessler, Anke Jurisch,Anja Reutzel-Selke, Andreas Pascher, Johann Pratschke,Peter Neuhaus, Hans-Dieter Volk, Stefan G. Tullius.Berlin, Germany.

P42 RELATIVE CONTRIBUTION OF DIRECT ANDINDIRECT PATHWAY OF ALLORECOGNITIONAFTER DIFFERENT ALLOGENIC CELLS ORORGAN TRANSPLANTATION. (Abstract #586)Hideyoshi Toyokawa, Robert J. Bailey, Atsunori Nakao,Kei Kimizuka, Jerome L. Lemoine, Glenn D. Papworth,Leaf Huang, Noriko Murase. Pittsburgh, PA.

P43 VASCULAR ENDOTHELIAL CELLS ESCAPEFROM APOPTOSIS TRIGGERED BY HLA-DRLIGATION MEDIATED BY ALLOSPECIFICANTIBODIES. (Abstract #587)Stéphanie Le Bas-Bernardet, Stéphanie Coupel, Jean-PaulSoulillou, Béatrice Charreau. Nantes, France.

P44 HLA-E IS AN ENDOTHELIAL-SPECIFIC NONCLASSICAL CLASS I MOLECULE EXPRESSED INVASCULARIZED ORGANS: UPREGULATION ANDSHEDDING UPON INFLAMMATION.(Abstract #588)Stéphanie Coupel, Anne Moreau, Vaclav Horesji,Béatrice Charreau. Nantes, France; Praha, CzechRepublic.

P45 IN VIVO GENERATION ANDCHARACTERIZATION OF TWO DISTINCTDENDRITIC CELL SUBPOPULATIONS IN THELIVER. (Abstract #589)Yalan Wang, Zhengbin Lu, Lianfu Wang, Xiaoyan Liang,John J. Fung, Lina Lu, Shiguang Qian. Pittsburgh, PA.

Deceased Donor Kidney TransplantationP46 † LONG-TERM RESULTS (OVER 15 YEARS) OF

KIDNEY TRANSPLANTATION FROM NON-HEART-BEATING DONORS. A SINGLE CENTEREXPERIENCE. (Abstract #590)Hiroaki Shimmura, Kazunari Tanabe, Hideki Ishida,Tadahiko Tokumoto, Nobuo Ishikawa, NaoshiMiyamoto, Kiyoshi Setoguchi, Satoshi Teraoka, HiroshiToma. Shinjuku, Tokyo, Japan.

P47 AN ASSESSMENT OF THE EFFECTIVENESS OF ACOMMUNITY BASED TRANSPLANT EDUCATIONPROGRAM FOR HIGH SCHOOL YOUTH.(Abstract #591)Clive O. Callender, Margruetta B. Hall, Patrice V. Miles,Kay L. Butler, Phyllis Daen, Phyllis Ermann, RhondaGaines, Rhonda DeLaremore. Washington, DC.

P48 † HISTOLOGICAL CRITERIA FOR MARGINALKIDNEY ALLOCATION. IS THERE ROOM TOFURTHER EXPAND THE DONORS POOL?(Abstract #592)B. Infante, G. Stallone, A. Schena, G. Grandaliano, S. DiPaolo, M. Battaglia, P. Ditonno, F. P. Selvaggi, L.Gesualdo, F. P. Schena. Italy.

P49 BENEFITS OF USING PULSATILE PERFUSIONPUMP FOR CADAVERIC KIDNEYS.(Abstract #593)Hamid Shidban, Jim Locke, Tom Mone, Robert Mendez,Shirley Mirador, Ramaiah Indudhara, Sali Aswad. LosAngeles, CA.

P50 CLINICAL RESULTS OF A REGION-WIDEPROGRAM TO INCREASE UTILIZATION OFDONORS AFTER CARDIAC DEATH (DCD).(Abstract #594)James F. Whiting, Francis Delmonico, Paul Morrissey,Giacomo Basadonna, Scott Johnson, W. David Lewis,Richard Rohrer, Kevin O’Connor, James Bradley,Tammy D. Lovewell, George Lipkowitz. Portland, ME;Boston, MA; Providence, RI; Worcester, MA;Burlington, MA; Newton, MA; Springfield, MA.

P51 DISPARITIES IN THE QUALITY OF DECEASEDDONOR KIDNEYS BY RECIPIENT RACE.(Abstract #595)Jesse D. Schold, Herwig-Ulf Meier-Kriesche, Titte R.Srinivas, Michael Bucci, Bruce Kaplan. Gainesville, FL.

P52 RENAL TRANSPLANTATION FROM NON- HEART-BEATING DONORS (NHBD): A SINGLE CENTRE10 – YEAR EXPERIENCE. (Abstract #596)Angel Alonso, Constantino Fernandez, Pedro Villaverde,Rafael Garcia, Juan Oliver, Francisco Valdes. A Coruna,Spain.

94

P53 THE CELL POPULATION IN PRESERVATIONSOLUTION AND IT’S INFLUENCE ON DELAYEDKIDNEY ALLOGRAFT FUNCTION. (Abstract #597)P. Malanowski, G. Korczak-Kowalska, P. Wierzbicki, M.Kosieradzki, A. Kwiatkowski, M. Wszola, J.Pliszczynski, R. Danielewicz, L. Adadynski, L. Paczek,M. Durlik, W. Rowinski. Warsaw, Poland.

P54 OUTCOME OF SOLITARY PEDIATRIC (13MONTH-5 YEAR) DONOR KIDNEY TRANSPLANTIN ADULT RECIPIENTS. (Abstract #598)Shafiq Cheema, Rafik El-Sabrout, Kahlid Butt, PatriciaHanson, Veronica Delaney. Valhalla, NY.

P55 PROSPECTIVE ANALYSIS OF A DONORSCORING SYSTEM FOR DECEASED DONORRENAL TRANSPLANTATION. (Abstract #599)Edwina Baskin-Bey, John Franco, Meg Rogers, MarkStegall, Scott Nyberg. Rochester, MN; Minneapolis, MN.

P56 CORRECTION OF BASE DEFICIT IN DECEASEDDONORS FACILITATES FLUID MANAGEMENTAND IMPROVES IMMEDIATE RENAL ALLOGRAFTFUNCTION. (Abstract #600)Gary K. Shen, John F. Recicar, Jeffrey A. Salisbury,Timothy D. Browder, Patricia A. Niles. Las Vegas, NV.

P57 TRANSPLANTATION OF ADULT RECIPIENTSWITH SINGLE CADAVERIC KIDNEYS FROMPEDIATRIC DONORS WEIGHING ≤≤≤≤≤25 KG IS ARELIABLE OPTION. (Abstract #601)Douglas P. Slakey, A. K. Sharma, Scott Meier, SanderFlorman, Sunil Geevarghese, Philippe Gauthier. NewOrleans, LA.

P58 MOST ZERO HLA-MISMATCHED KIDNEYTRANSPLANTS OCCUR SOON AFTER LISTINGLEAVING A WAITING LIST OF PATIENTS WITHINCREASINGLY UNCOMMON HLAPHENOTYPES. (Abstract #602)Michael Cecka, David Gjertson, Gabriel Danovitch, ErickEdwards. Los Angeles, CA; Richmond, VA.

P59 NON-HEART-BEATING DONOR KIDNEYS IN THENETHERLANDS, ALLOCATION AND OUTCOMEOF TRANSPLANTATION. (Abstract #603)Karin M. Keizer, Hans W. de Fijter, Bernadette J. J .M.Haase-Kromwijk. Leiden, Netherlands.

P60 UPDATE ON ORGAN DONATION AFTERCARDIOPULMONARY DEATH USINGEXTRACORPOREAL MEMBRANE OXYGENATIONSUPPORT. (Abstract #604)Juan D. Arenas, Mark T. Gravel, Richard S. Chenault,John C. Magee, Randy S. Sung, Shawn J. Pelletier, MeelieA. Debroy, Jeffrey D. Punch. Ann Arbor, MI.

P61 ROLE OF RECOMBINANT PLASMINOGENACTIVATOR IN KIDNEYS WITH DISSEMINATEDINTRA VASCULAR COAGULATION.(Abstract #605)Dai D. Nghiem, Peter R. Olson, Kalathil K. Sureshkumar,Richard J. Marcus. Pittsburgh, PA.

P62 CADAVERIC RENAL TRANSPLANTATION ANDEXPANDED CRITERIA DONORS: SHOULD WEREASSESS THEIR USE? (Abstract #606)Jean Tchervenkov, Marcelo Cantarovich, StevenParaskevas, Myriam Fernandez, Dana Baran, RomanMangel, Jeffrey Schiff, Marc Lipman, Peter Metrakos.Montreal, QC, Canada.

P63 OUTCOME OF RENAL TRANSPLANTS FROMPEDIATRIC DONORS <5 YEARS OF AGE.(Abstract #607)Rafik A. El-Sabrout, Veronica A. Delaney, Linda E.Bonini, Pat E. Hanson, Shafiq Cheema, Khalid M. H.Butt. Valhalla, NY.

P64 RISK FACTORS FOR DEATH ON THE KIDNEYWAITING LIST. (Abstract #608)Maureen A. McBride, Francis L. Delmonico, H. MyronKauffman. Richmond, VA; Boston, MA.

P65 FACTORS ASSOCIATED WITH SURVIVAL OFKIDNEYS FROM NON-HEART-BEATINGDONORS. (Abstract #609)P. Abt, A. Frank, G. R. Stephenson, M. Sellers.Philadelphia, PA.

Experimental Tolerance Induction IIP66 † MOBILIZED PERIPHERAL BLOOD STEM CELLS

SHOW LOWER TOLEROGENIC POTENTIALTHAN BONE MARROW CELLS IN RECIPIENTSOF COSTIMULATION BLOCKADE.(Abstract #610)Zvonimir Koporc, Sinda Bigenzahn, Peter Blaha,Friedrich Wrba, Ferdinand Muehlbacher, Megan Sykes,Thomas Wekerle. Austria.

P67 † INDIRECT ANTIGEN PRESENTATION BY LIVERSINUSOIDAL ENDOTHELIAL CELLSCONTRIBUTES TO ALLOREACTIVE T CELLTOLERANCE INDUCED BY PORTAL INJECTIONOF DONOR SPLENOCYTES. (Abstract #611)Daisuke Tokita, Hideki Ohdan, Toshimasa Asahara.Hiroshima, Hiroshima, Japan.

P68 † VIRAL IL-10 GENE THERAPY VIA AUTOLOGOUSHSC PRIOR TO ORGAN TRANSPLANTATIONCAN PREVENT ALLOGRAFT REJECTION.(Abstract #612)Shashikumar Salgar, Dinghua Yang, Phillip Ruiz, JoshuaMiller, Andreas Tzakis. Miami, FL.

P69 † DIFFERENTIATION OF CD25- REGULATORY TCELLS IN LONG TERM SURVIVORS RATSFOLLOWING DONOR-SPECIFIC TRANSFUSION(DST) IN RATS. (Abstract #613)Nicolas Degauque, David Lair, Cecile Braudeau,Alexandre Dupont, Fabienne Haspot, Fabien Sebille,Sophie Brouard, Jean-Paul Soulillou. Nantes, France.

P70 † THE ROLE OF B CELLS IN TOLERENCE INDUCEDBY ANTI-CD45RB. (Abstract #614)Muhammad M. Mohiuddin, Daniel J. Moore, XiaolunHuang, Ergun Velidedeoglu, Moh M. Lian, Major K. Lee,Yong Suk Bae, Adam M. Frank, Meredith Chiaccio,Haiying Chen, James F. Markmann, Shaoping Deng.Philadelphia, PA.

P71 † THE ROLE OF CTLA-4 ENGAGEMENT IN THEINDUCTION OF PROLONGED ALLOGRAFTSURVIVAL BY COSTIMULATION BLOCKADE.(Abstract #615)Luuk B. Hilbrands, Jeroen J. A. Coenen, Hans J. P. M.Koenen, Esther van Rijssen, Irma Joosten. Netherlands.

P72 † SENSITIZATION VS. ANGERY/REGULATION: ACOMPARISON OF THE IMPACT OF EXPOSURETO NON-INHERITED MATERNAL ANTIGENS(NIMA) IN FOUR MOUSE MODELS.(Abstract #616)J. Andrassy, M. L. Molitor, B. R. Marthaler, L. D.Haynes, K. W. Jauch, H. W. Sollinger, W. J. Burlingham.Madison, WI; Munich, Germany.

P73 † PERIPHERAL CD4 T CELL TOLERANCE INDUCEDBY GENE THERAPY. (Abstract #617)Daron Forman, Eun-Suk Kang, Chaorui Tian, JohnIacomini. Boston, MA.

P74 † RATIONAL DESIGN OF DONOR DERIVEDDENDRITIC CELLS FOR TOLERANCEINDUCTION. (Abstract #618)Kym R. Garrod, Todd V. Brennan, Sang-Mo Kang. SanFrancisco, CA.

95

Mo

nd

ay, May 17

P75 THE ROLE OF HOST THYMIC FUNCTION IN THEINDUCTION OF TOLERANCE ACROSS FULLMHC BARRIERS BY FK506. (Abstract #619)Hanzhou Hong, Kazuhiko Yamada, Akira Shimizu,Chisako Kamano, Hitoshi Arakawa, Emma Samelson-Jones, Shannon Moran, David H. Sachs, Martin Hertl.Boston, MA.

P76 BLOCKADE OF PD-1 LIGATION REVERSESINHIBITION OF T CELL RESPONSES BY HEPATICSTELLATE CELLS. (Abstract #620)Cheng-Hsu Chen, Lina Lu, John J. Fung, Shiguang Qian.Pittsburgh, PA.

P77 MECHANISTIC STUDIES ON T CELL APOPTOSISTRIGGERED BY ALLOGENEIC LIVER B220+

DENDRITIC CELLS. (Abstract #621)Xiaoyan Liang, Lina Lu, Lianfu Wang, John J. Fung,Shiguang Qian. Pittsburgh, PA.

P78 MECHANISMS OF CD8+ T CELL TOLERANCEAFTER BONE MARROW TRANSPLANTATIONWITH NON-MYELOABLATIVE CONDITIONINGUSING ANTI-CD40 LIGAND AND DAY-1 TBI.(Abstract #622)Thomas Fehr, Yasuo Takeuchi, Josef Kurtz, MeganSykes. Boston, MA.

P79 DETERMINING THE DEVELOPMENTAL FATE OF BCELLS PRODUCING ANTI-αααααGAL ANTIBODIESUSING IMMUNOGLOBULIN KNOCK-IN MICE.(Abstract #623)Joel Kaye, Nathalie Cretin, Denise Malkowski, JohnIacomini. Boston, MA.

P80 INTERLEUKIN-10 BUT NOT TRANSFORMINGGROWTH FACTOR-βββββ ESSENTIAL FOR BOTHINDUCTION AND MAINTENANCE OFREGULATORY CELLS BY INTRATRACHEALDELIVERY OF ALLOANTIGEN. (Abstract #624)Osamu Aramaki, Nozomu Shirasugi, TadatoshiTakayama, Ko Okumura, Hideo Yagita, Masanori Niimi.Tokyo, Japan.

P81 COMBINING LFA-1 BLOCKADE WITHEVEROLIMUS OR CD40L BLOCKADE FORALLOGENEIC BONE MARROWTRANSPLANTATION INDUCES HEMATOPOIETICCHIMERISM AND CENTRAL TOLERANCE TOSOLID TISSUES IN MICE. (Abstract #625)Barbara Metzler, Patrick Gfeller, Marc Bigaud, JianpingLi, Grazyna Wieczorek, Christoph Heusser, Philip Lake,Andreas Katopodis. Basel, Switzerland.

P82 LIVER SINUSOIDAL ENDOTHELIAL CELLSCONSTITUTIVELY EXPRESSING FAS LIGANDS INLIVER ALLOGRAFTS TOLERIZE HOST-REACTIVET CELLS BY DIRECT RECOGNITION.(Abstract #626)Takashi Onoe, Hideki Ohdan, Daisuke Tokita, HidetakaHara, Yuka Tanaka, Wendy Zhou, Kohei Ishiyama,Hiroshi Mitsuta, Kentaro Ide, Toshimasa Asahara.Hiroshima, Japan.

P83 T CELL DEPLETION BUT NOT T CELLREGULATION PLAYS A ROLE INTRANSPLANTATION TOLERANCE IN MICE WITHREDUCED T CELL-INTRINSIC NF-kBACTIVATION. (Abstract #627)Ping Zhou, Mona Mashayekhi, Samuel J. Balin, David A.Palucki, Maria-Luisa Alegre. Chicago, IL.

P84 CD25+ REGULATORY T CELLS ARE INVOLVED INLIVER TRANSPLANT TOLERANCE INDUCTION INMICE. (Abstract #628)Wei Li, Xin Xiao Zheng, James D. Perkins. Seattle, WA;Boston, MA.

P85 ANTI-γγγγγC AND ANTI-IL-2Rβββββ MONOCLONALANTIBODIES INHIBIT T-CELL PROLIFERATIONAND INDUCE APOPTOSIS AND H-Y SKIN GRAFTACCEPTANCE IN MURINE MODELS. (Abstract #629)Sheng Chang, Bicheng Chen, Dunfeng Du, HongminZhou, Jie Zhou, Zhonghua Klaus Chen. Wuhan, Hubei,China.

P86 ESTABLISHMENT OF A BONE MARROW (BM)EXPANSION SYSTEM FOR EX VIVO GENERATIONOF CELLS WITH POTENT CAPACITY TOPROLONG SKIN GRAFT SURVIVAL.(Abstract #630)Edip Akpinar, Jenny Park, Douglas A. Hale. Bethesda,MD.

P87 PROMOTION OF ORGAN TRANSPLANTTOLERANCE BY A SINGLE PREOPERATIVEINFUSION OF IN VIVO-MOBILIZED PRE-PLASMACYTOID DENDRITIC CELLS, INCOMBINATION WITH ANTI-CD154 mAb.(Abstract #631)Angus W. Thomson, P. Toby H. Coates, Zhiliang Wang,F. Jason Duncan, Pia Bjorck. Pittsburgh, PA.

P88 LONGTERM REGULATION OF CD8+ T CELLS BYSHORT-TERM IMMUNOTHERAPY TARGETINGLFA-1 AND CD40/CD40L COSTIMULATION.(Abstract #632)Keri E. Lunsford, Anna M. Eiring, Mitchel A. Koester,Donghong Gao, Ginny L. Bumgardner. Columbus, OH.

P89 DEVELOPMENT OF A MIXED CHIMERISM-TOLERANCE INDUCING NONMYELOABLATIVEREGIMEN RELEVANT TO CADAVER DONORTRANSPLANTATION. (Abstract #633)Ichiro Koyama, Tatsuo Kawai, Siew-Lin Wee, SvetlanBoskovic, Ognjenka Nadazdin, Rex-Neal Smith, MeganSykes, Robert B. Colvin, David H. Sachs, A. BenedictCosimi. Boston, MA; Charlestown, MA.

P90 BLOOD T CELL POPULATIONS PHENOTYPES INDRUG-FREE “OPERATIONALLY TOLERANT”HUMAN KIDNEY RECIPIENTS. (Abstract #634)Stephanie Louis, Magali Giral, Alexandre Dupont, Jean-Paul Soulillou, Sophie Brouard. Nantes, France.

P91 METASTABLE TOLERANCE IN THE LIVERTRANSPLANT —TGFΒΒΒΒΒ LATENT+ CD4 T CELLSINFILTRATING THE HEPATIC PARENCHYMACORRESPOND TO ALLOPEPTIDE (DONOR HLA-B)- SPECIFIC T-REG CELLS IN PERIPHERALBLOOD. (Abstract #635)William J. Burlingham, Ewa Jankowska-Gan, JunglimLee, Hans W. Sollinger, Munci Kalayoglu, Stuart J.Knechtle, Jose Torrealba. Madison, WI.

P92 B CELLS ARE ASSOCIATED WITH INCREASEDSERUM IL-10 IN THE EARLY STAGES OF PRIMATETOLERANCE. (Abstract #636)Anne Hutchings, Jianguo Wu, Clement Asiedu, StacieJenkins, Jin He, Karen J. Goodwin, Stephanie Le Bas-Bernardet, Francis T. Thomas, Richard L. George, JudithM. Thomas. Birmingham, AL.

Immunosuppression: Preclinical Studies IIP93 EXTRACORPOREAL PHOTOPHORESIS

ALLOWS RECIPIENT SPECIFIC TRANSFUSION(RST) TO PROLONG CARDIAC ALLOGRAFTSURVIVAL. (Abstract #637)T. Gonzalez, S. Prange, D. Zhou, D. Lian, C. Du, Z. Yin,Q. Guan, P. J. O’Connell, R. Zhong, A. House, A. M.Jevnikar. London, ON, Canada.

96

P94 RENAL TRANSPLANTATION IN SWINE:TOLERANCE AND RENAL FUNCTION UNDERSHORT TERM CYA TREATMENT. SYNERGISTICEFFECT OF DONOR SPLEEN TX. (Abstract #638)Marcello O. Maestri, Johannes Rademacher, AnnalisaGaspari, Stefania Crespi, Luca M. Lenti, LauraCansolino, Giuseppe Novelli, Domenico Agoglitta, SaraSegreti, Paolo Dionigi. Pavia, PV, Italy.

P95 THE NEW STANDARD OF CARE: ALEMTUZUMABINDUCTION WITH TACROLIMUS ANDSIROLIMUS MAINTENANCEIMMUNOSUPPRESSION TO LIMIT ACUTE ANDCHRONIC ALLOGRAFT REJECTION.(Abstract #639)Steven C. Hoffmann, Robert L. Kampen, Jonathan P.Pearl, Douglas A. Hale, Lynn M. Jacobson, David E.Kleiner, Roslyn B. Mannon, Rececca J. Muehrer, S. J.Swanson, Bryan N. Becker, Allan D. Kirk. Bethesda,MD; Madison, WI; Washington, DC.

P96 ALLOANTIBODY DEVELOPS COINCIDENT WITHREJECTION OF SKIN AND RENAL ALLOGRAFTSIN NON-HUMAN PRIMATES TREATED WITH THEANTI CD-154 MONOCLONAL ANTIBODY IDEC-131 COMBINED WITH DONOR SPECIFICTRANSFUSION (DST) AND SIROLIMUS.(Abstract #640)Kiran K. Dhanireddy, He Xu, Edwin H. Preston, John P.Pearl, Frank V. Leopardi, Lynt B. Johnson, Allan D.Kirk. Bethesda, MD; Washington, DC.

P97 † ASSESSMENT OF IMMUNOLOGIC RISK BYACCURATE, SENSITIVE AND QUANTITATIVEMEASUREMENT OF ANTI-HLA ANTIBODY IN ASINGLE TUBE ASSAY. (Abstract #641)Brian Susskind, Paul Brailey, Prabir Roy-Chaudhury,Michael Cardi, Joseph Buell, Rino Munda, Sharad Goel,Joseph Austin, Michael Hanaway, E. Steve Woodle.Cincinnati, OH.

P98 DONOR SPECIFIC ANTI-HLA CLASS IANTIBODY DETECTION BY AN ELISA-BASEDTRANSPLANT MONITORING SYSTEM (TMS®).(Abstract #642)Brian Susskind, Rubina Karim, Paul Brailey, Prabir Roy-Chaudhury, Michael Hanaway, Michael Cardi, E. SteveWoodle. Cincinnati, OH.

P99 DRB GENOTYPING OF CYNOMOLGUS AS AWAY TO SELECT HISTOINCOMPATIBLERECIPIENT-DONOR PAIRS INVOLVED INTHERAPEUTIC ASSAYS FOR PREVENTION, ORTREATMENT, OF ALLOGRAFT REJECTION.(Abstract #643)Antoine Blancher, Pierre Tisseyre, Marianne Dutaur,Pol-André Apoil, Claudine Maurer, Valérie Quesniaux,Marc Bigaud, Michel Abbal. Toulouse, France; Bale,Switzerland.

P100 MEASUREMENT OF CHIMERISM INCYNOMOLGUS MONKEYS USING HUMANSPECIFIC SHORT TANDEM REPEAT (STR) BASEDASSAY. (Abstract #644)Edip Akpinar, Jodie M. Keary, Roger Kurlander, DouglasA. Hale. Bethesda, MD.

P101 A NOVEL AND RAPID PHARMACODYNAMIC(PD) ASSAY MEASURES COMPLEXIMMUNOSUPPRESSIVE DRUG EFFECTS IN RATS,MONKEYS AND HUMANS. (Abstract #645)Christoph Burkhart, Marc Bigaud, Christoph Heusser,Randall E. Morris, Friedrich Raulf, Gisbert Weckbecker,Gabriele Weitz-Schmidt, Welzenbach Karl. Basel,Switzerland.

P102 IN VITRO EVALUATION OF THE EFFECTS OFCANDIDATE IMMUNOSUPPRESSIVE DRUGS:FLOW CYTOMETRY AND QUANTITATIVE REAL-TIME PCR AS TWO INDEPENDENT ANDCORRELATED READ-OUTS. (Abstract #646)Mona Flores, Sally Zhang, Ann Ha, Bari Holm, RandallMorris, Bruce Reitz, Dominic Borie. Stanford, CA.

P103 PHARMACODYNAMIC MONITORING OF I.V.AND ORAL CYCLOSPORINE THERAPY INRENAL TRANSPLANTATION. (Abstract #647)Paul A. Keown, Vivien Wu, Olaf Heisel, Jean Shapiro,John Gill. Vancouver, BC, Canada.

P104 † INHIBITORY ROLE OF CYCLOSPORIN A ANDITS DERIVATIVES ON REPLICATION OFHEPATITIS C VIRUS. (Abstract #648)Kunitada Shimotohno, Koichi Watashi. Kyoto, Japan.

P105 † TROPISM OF BK VIRUS TO RENAL CELLS ANDTHE EFFECT OF IMMUNOSUPPRESSANTS ONVIRAL CYTOPATHIC EFFECT IN A TISSUECULTURE MODEL. (Abstract #649)Brahm Vasudev, Rimas Orentas, Joanna Walczak,Sundaram Hariharan. Milwaukee, WI.

P106 REGULATION OF ANTI-EBV AND ANTI-CMVCYTOTOXIC T-CELL RESPONSES BYIMMUNOSUPPRESSIVE MEDICATIONS.(Abstract #650)Raju K. Radha, Tetsu Sado, Andy Pao, Stanley C. Jordan,Mieko Toyoda. Los Angeles, CA.

P107 GANCICLOVIR (GCV) PROPHYLAXIS AGAINSTBABOON CYTOMEGALOVIRUS (BCMV)INFECTION IN PIG-TO-NON HUMAN PRIMATE(NPH) ISLET XENOTRANSPLATION.(Abstract #651)Tun Jie, Melanie G. Thompson, Tor C. Aasheim, MartinWijkstrom, Sue Clemmings, Henk Schuurman, BernhardJ. Hering. Minneapolis, MN; Boston, MA.

P108 † RAPAMYCIN-INDUCES ENDOTHELIAL CELLDEATH, LEADING TO TUMOR-VESSELTHROMBOSIS AND ANTITUMOR ACTIVITY.(Abstract #652)Edward K. Geissler, Gudrun E. Koehl, Markus Guba,Markus Steinbauer, Karl-Walter Jauch, Christiane J.Bruns. Regensburg, Germany; Munich, Germany.

P109 RAPAMYCIN AMELIORATES THE EFFECT OFCOLD ISCHEMIA IN EXPERIMENTALTRANSPLANT ARTERIOSCLEROSIS.(Abstract #653)Felipe G. Balbontin, Jim R. Write, Weimin You, Bao YouXu, Ping Wu, Rasha Salih, Albert Fraser, Joseph G.Lawen. Halifax, NS, Canada; Santiago, Chile.

P110 DIRECT PORTACAVAL SHUNTING AT THE TIMEOF 95% HEPATECTOMY PREVENTSHYPERPERFUSION INJURY IN THE RAT MODEL.(Abstract #654)Tao Liu, Ryan A. McTaggart, John P. Roberts, Sang-MoKang. San Francisco, CA.

P111 EX VIVO PROTEIN TRANSDUCTION:SUCCESSFUL DELIVERY OF A BIOLOGICALLYACTIVE PROTEIN INTO DONOR LIVER.(Abstract #655)Takashi Kaizu, Khaja K. Rehman, Paul D. Robbins,David A. Geller, Noriko Murase. Pittsburgh, PA.

97

Mo

nd

ay, May 17

Infection and Non-Organ Specific ImmunosuppressionP112 † SEROLOGIC IMMUNITY TO DIPHTHERIA,

TETANUS, AND MEASLES AFTER PEDIATRICSOLID ORGAN TRANSPLANTATION.(Abstract #656)Camille Sabella, Lara A. Danziger-Isakov, Robert J.Cunningham III, Richard Sterba, Deepa Chand, CarlaSaracusa, Julie H. Corder, Johanna Goldfarb. Cleveland,OH.

P113 † EFFECTIVENESS OF LOW DOSEVALGANCICLOVIR IN KIDNEY AND LIVERTRANSPLANT RECIPIENTS. (Abstract #657)Robert Dupuis, Derrick Van Beuge, Ruthann Conoley,Kenneth Andreoni, David Gerber, Jeffrey Fair, RandyDetwiler, Roshan Shrestha, Robert Watson, MarkJohnson. Chapel Hill, NC.

P114 ORAL GANCICLOVIR AND VALGANCICLOVIRPROPHYLAXIS MAY PREVENT REACTIVATIONOF NON-βββββ HERPESVIRUSES INCYTOMEGALOVIRUS (CMV) D+/R- SOLIDORGAN TRANSPLANT (SOT) PATIENTS.(Abstract #658)Raymund R. Razonable, Robert A. Brown, Atul Humar,Emma Covington, Emma Alecock, Carlos V. Paya, thePV16000 Study Group. Rochester, MN; Toronto, ON,Canada; Welwyn Garden City, United Kingdom.

P115 USE OF VALGANCYCLOVIR IN THEPROPHYLAXIS; PREEMPTIVE AND DIRECTEDTHERAPY FOLLOWING SOLID ORGANTRANSPLANTATION. (Abstract #659)Hugo Bonatti, Ferguel Cakar, Daniel Hoefer, ClaudiaBoesmueller, Elfriede Ruttmann, Herwig Antretter,Ludwig Mueller, Wolfgang Steurer, Paul Hengster,Christian Geltner, Clara Larcher, Guenther Laufer,Raimund Margreiter. Innsbruck, Austria.

P116 SCREENING FOR WEST NILE VIRUS INDECEASED ORGAN DONORS. (Abstract #660)Bryce Kiberd, Kevin Forward. Halifax, NS, Canada.

P117 REACTIVITY OF PLATELIA™ ASPERGILLUSGALACTOMANNAN (GM) WITH PIPERACILLIN-TAZOBACTAM: CLINICAL IMPLICATIONSBASED ON ACHIEVABLE SERUMCONCENTRATIONS. (Abstract #661)N. Singh, A. Obman, S. Husain, S. Mietzner, J. E. Stout.Pittsburgh, PA.

P118 HUMAN POLYOMAVIRUS INFECTION ISCOMMON IN CYTOMEGALOVIRUS (CMV) D+/R-SOLID ORGAN TRANSPLANT (SOT) PATIENTS.(Abstract #662)Raymund R. Razonable, Robert A. Brown, Atul Humar,Emma Covington, Emma Alecock, Carlos V. Paya, thePV16000 Study Group. Rochester, MN; Toronto, ON,Canada; Welwyn Garden City, United Kingdom.

P119 THE CLINICAL VALUE OF QUANTITATIVEPOLYMERASE CHAIN REACTION INCYTOMEGALOVIRUS INFECTION AFTER SOLIDORGAN TRANSPLANTATION. (Abstract #663)Josh Levitsky, Alison G. Freifeld, Kim Bargenquast, R.Brian Stevens, Andre C. Kalil. Omaha, NE.

P120 SEVEN-VALENT PNEUMOCOCCAL CONJUGATEVACCINE IN PEDIATRIC SOLID ORGANTRANSPLANT RECIPIENTS: INTERIM RESULTS.(Abstract #664)Upton Allen, Anne Dipchand, Diane Hébert, AnnieFecteau, Vicky Ng, David Grant, Lori West, Samia Wasfy.Toronto, ON, Canada.

P121 A SURVEY OF DENTAL CARE PROTOCOLSAMONG U.S. ORGAN TRANSPLANT CENTERS.(Abstract #665)Bijan Eghtesad, Debra Mayher, James Guggenheimer.Pittsburgh, PA.

P122 PREVALENCE OF BK VIRUS INFECTION INRECIPIENTS OF NON-RENAL SOLID ORGANTRANSPLANTS WITH CHRONIC RENALDYSFUNCTION. (Abstract #666)Todd D. Barton, Ajit P. Limaye, Alden Doyle, Vivek N.Ahya, James N. Ferrenberg, Emily A. Blumberg.Philadelphia, PA; Seattle, WA.

P123 † IMMUNOPHENOTYPIC CORRELATES OF GRAFTADAPTATION IN STEROID-FREE PEDIATRICLIVER-INTESTINAL TRANSPLANTATION WITHTHYMOGLOBULIN (rATG) PRECONDITIONING.(Abstract #667)Rakesh Sindhi, Adrianna Zeevi.

P124 INTESTINAL TRANSPLANTATION FOR ADULTPATIENTS WITH CAMPATH 1-H INDUCTION.(Abstract #668)Seigo Nishida, Juan I. Madariaga, David M. Levi, JangMoon, Tomoaki Kato, Gennaro Selvaggi, WervistonDeFaria, Sergio Santiago, Anthony Gyamfi, Phillip Ruiz,Debbie Weppler, Andreas G. Tzakis. Miami, FL.

P125 A NEW CROSSMATCH TECHNIQUE ELIMINATESINTERFERENCE BY HUMANIZED AND CHIMERICDRUGS. (Abstract #669)Benita K. Book, Christopher H. Bearden, AvinashAgarwal, Richard A. Sidner, Nancy Higgins, Mark D.Pescovitz. Indianapolis, IN.

P126 COMPLICATIONS OF RABBIT ANTITHYMOCYTEGLOBULIN (RATG) IN PEDIATRICCARDIOTHORACIC TRANSPLANT PATIENTS.(Abstract #670)Deborah A. Kahler, Brandon K. Knott, K. O.Schowengerdt, F. Jay Fricker, Gary A. Visner, AlbertFaro. Gainesville, Fl.

P127 A STUDY OF THE CHANGES IN ABSORPTIVESURFACE AREA OF TRANSPLANTED SMALLBOWEL. (Abstract #671)Suman Setty, Gregorio Chejfec, Eunice John, GuilianoTesta, Enrico Benedetti. Chicago, IL.

P128 CHARACTERIZATION OF HUMAN AND NON-HUMAN PRIMATE COMPOSITE TISSUEALLOGRAFT REJECTION. (Abstract #672)Linda C. Cendales, David Kleiner, Michael A. Eckhaus,Robert Kampen, Allan D. Kirk. Bethesda, MD.

P129 OUTCOMES AND SYSTEM ERRORS OF PATIENTSEXPERIENCING AN IN-HOSPITAL CRISIS AFTERORGAN TRANSPLANTATION. (Abstract #673)Eric L. Marderstein, Michael Devita, R. ScottBraithwaite, Richard L. Simmons, David A. Geller.Pittsburgh, PA.

P130 PHARMACODYNAMIC MONITORING OFMONOCLONAL ANTIBODY THERAPY ININTESTINAL TRANSPLANTATION. (Abstract #674)Andreas Pascher, Jochen Klupp, Hans-Dieter Volk, PeterNeuhaus. Berlin, Germany.

P131 THROMBOTIC MICROANGIOPATHY (TMA) INTHE SIROLIMUS ERA. (Abstract #675)Robin K. Avery, Jeffrey T. Chapman, Anna P. Koo,Ronald M. Sobecks, Carlos M. Isada, Steven M. Gordon,Stuart M. Flechner, Richard A. Fatica, Sherif B. Mossad,Elizabeth Kuczkowski, Alan J. Taege, Atul C. Mehta,Omar A. Minai, Jeff Gonzales, Marcus Haug, Brian J.Bolwell. Cleveland, OH.

P132 IMPACT OF HLA-MATCHING ANDPRESENSITIZATION ON THE INCIDENCE ANDSEVERITY OF ACUTE AND CHRONICINTESITNAL ALLOGRAFT REJECTION.(Abstract #676)Geoffrey J. Bond, Yehia A. Awadalla, Medhat Z. Askar,Dolly Martin, Khristine M. Ruppert, Adriana Zeevi,Noriko Murase, George Mazariegos, Jorge Reyes, Rene J.Duquesnoy, Thomas E. Starzl, Kareem M. Abu-Elmagd.Pittsburgh, PA.

98

P133 EFFECTS OF IMMUNIZATION ON HUMANALLOIMMUNE REPERTOIRES. (Abstract #677)Emilio Poggio, Meagan Roddy, Jocelyn Riley, MichaelClemente, Snehal Thakkar, Ronald Bukowski, ErnestBorden, Edwina Robinson, Peter S. Heeger. Cleveland,OH.

P134 CAREGIVER BURDEN AS A PREDICTOR OFTRANSPLANT CANDIDATES’ PSYCHOLOGICALDISTRESS. (Abstract #678)James R. Rodrigue, Gail L. Lisson, Maher A. Baz, JamesA. Hill, John R. Wingard, David R. Nelson. Gainesville,FL.

P135 LONG TERM SUPPRESSION OF HLAEXPRESSION IN HUMAN CELLS BY LENTIVIRUS-MEDIATED GENE TRANSFER OF siRNACASSETTES. (Abstract #679)James C. Cicciarelli, Christopher Logg, Kazuo Mizutani,Noriyuki Kasahara, Yuichi Iwaki, David Cohen. LosAngeles, CA.

Kidney Immunosuppression: ComplicationsP136 INTERDEPENDENCE BETWEEN DRUG EXPOSURE,

LYMPHOCYTE PROLIFERATION, TGF-βββββ1EXPRESSION AND ENDOTHELIN-1 PRODUCTIONIN STABLE RENAL ALLOGRAFT RECIPIENTSTREATED WITH CYCLOSPORINE A ORTACROLIMUS. (Abstract #680)Johannes Waiser, Torsten Boehler, Michael Schneider,Hans-Hellmut Neumayer, Klemens Budde. Berlin, Berlin,Germany.

P137 DOSE AND COST REDUCTION WITH CD3GUIDED ANTI-THYMOCYTE GLOBULINTHERAPY IN KIDNEY AND LIVERTRANSPLANTATION. (Abstract #681)Maxine Lam, Gary Wong, Muhammad Zuberi, JenniferHarrison, Sarah Nia, Brenda Kisic, Bassem Hamandi,Florence Krakauer, Edward Cole, Gary Levy. Toronto,ON, Canada.

P138 MAINTENANCE IMMUNOSUPPRESSION INSENSITIZED RECIPIENTS OF FIRST AND SECONDKIDNEY TRANSPLANTS FROM DECEASEDDONORS. (Abstract #682)Wida S. Cherikh, Alan Ting, Adrian H. Cotterell, H. M.Kauffman. Richmond, VA.

P139 † SIROLIMUS-BASED THERAPY FOLLOWINGEARLY CYCLOSPORINE WITHDRAWALRESULTED IN SUPERIOR RENAL ALLOGRAFTSURVIVAL AT 48 MONTHS COMPARED WITHCONTINUOUS COMBINED SIROLIMUS ANDCYCLOSPORINE. (Abstract #683)Josep M. Campistol, Henri Kreis, Rainer Oberbauer,Alfredo Mota, Hany Riad, Jeremy Chapman, GiovanniStallone, Juan Carlos Ruiz, Giuseppe Nanni, James T.Burke, Martine Gioud-Paquet, the RapamuneMaintenance Regimen Study Group. Barcelona, Spain.

P140 † COMPARATIVE ANALYSIS OF RENAL FUNCTIONIN PATIENTS WITH CADAVERIC KIDNEYTRANSPLANTS TREATED WITH TACROLIMUS(TaC) OR CYCLOSPORIN (CsA). (Abstract #684)Miguel Gonzalez-Molina, Jose M. Morales, RobertoMarcen, Domingo Del Castillo, Jose M. Grinyo, SalvadorGil-Vernet, Federico Oppenheimer, Jose M. Campistol,Luis Capdevila, Ildefonso Lampreave, Francisco Valdes,Amado Andres, Fernando Anaya, Fernando Escuin,Manuel Arias, Luis Pallardo (Spanish Renal Forum).Malaga, Spain.

P141 † EFFECT OF IMMUNOSUPPRESSANTS ON TWOYEAR KIDNEY TRANSPLANT SURVIVAL IN THERECENT ERA. (Abstract #685)Barbara A. Bresnahan, Wida Cherikh, Yulin Cheng,Maureen A. McBride, Nauman Siddiqi, SundaramHariharan. Milwaukee, WI; Richmond, VA.

P142 † USE OF SIROLIMUS AS INITIAL THERAPY AFTERRENAL TRANSPLANTATION : PRELIMINARYRESULTS OF A RANDOMIZED PILOT STUDY INPATIENT RECEIVING MARGINAL KIDNEYS.(Abstract #686)Eric Thervet, Antoine Durrbach, Lionel Rostaing,Nacéra Ouali, Philippe Wolf, Claire Pouteil-Noble,Michele Kessler, Béatrice Viron. Paris, France; France.

P143 TACROLIMUS DOSE ADJUSTMENT AND POST-TRANSPLANT DIABETES MELLITUS IN US RENALTRANSPLANTATION. (Abstract #687)Mark A. Schnitzler, Karen L. Hardinger, Daniel C.Brennan. St. Louis, MO.

P144 POSTTRANSPLANT DIABETES MELLITUS INAFRICAN AMERICAN KIDNEY TRANSPLANTPATIENTS ON TACROLIMUS AND SIROLIMUS:EARLY ONSET AND RESISTANCE TO STEROIDWITHDRAWAL. (Abstract #688)Kenneth A. Bodziak, William Weiss, Joshua J. Augustine,Thomas C. Knauss, Donald E. Hricik. Cleveland, OH.

P145 † INCIDENCE AND RISK FACTORS FORPOSTTRANSPLANT DIABETES MELLITUS (PTDM)IN RENAL ALLOGRAFT RECIPIENTS IN SPAIN. APROSPECTIVE AND MULTICENTER STUDY.(Abstract #689)Roberto Marcen, Jose M. Morales, Domingo DelCastillo, Miguel Gonzalez-Molina, FedericoOppenheimer, Jose M. Campistol, Jose M. Grinyo,Salvador Gil-Vernet, Luis Capdevilla, IldefonsoLampreave, Francisco Valdes, Amado Andres, FernandoAnaya, Fernando Escuin, Manuel Arias, Luis Pallardo.Madrid, Spain.

P146 † ELEVATED URIC ACID LEVELS PRECEDEMEASURABLE CHANGES IN GFR OR BLOODPRESSURE IN RENAL TRANSPLANT PATIENTSTREATED WITH TACROLIMUS AS COMPAREDTO SIROLIMUS. (Abstract #690)A. S. Mahale, S. C. Textor, M. AbuAttieh, H. A.Khamash, S. J. Taler, N. L. Driscoll, J. E. Augustine, T. S.Larson, J. M. Gloor, M. D. Griffin, T. R. Schwab, F. G.Cosio, M. D. Stegall. Rochester, MN.

P147 LONG-TERM EXPERIENCE WITHTHYMOGLOBULIN INDUCTION: MALIGNANCYAND OPPORTUNITISTIC INFECTION.(Abstract #691)Agnes Lo, Nicole Walker, M. Francesca Egidi, Hosein-Shokouh Amiri, Santiago Vera, Nosratollah Nezakatgoo,A. Osama Gaber. Memphis, TN.

P148 CHARACTERIZATION OF THE HEMATOLOGICEFFECTS OF CAMPATH IN RENAL TRANSPLANTRECIPIENTS. (Abstract #692)James E. Hartle, Kamal Chater, Sayeed K. Malek, EvanR. Norfolk, Michael S. Schwartzman, Taher M. Yahya,Santosh Potdar. Danville, PA.

P149 SIDE EFFECTS AND DAILY LIFE FUNCTION INKIDNEY TRANSPLANT RECIPIENTS AT 1 TO 3YEARS POSTTRANSPLANT: A REPORT FROMTHE PATIENT OUTCOMES REGISTRY FORTRANSPLANT EFFECTS ON LIFE (PORTEL).(Abstract #693)Donna Hathaway, the PORTEL Study Group. Memphis,TN.

99

Mo

nd

ay, May 17

P150 OVER-IMMUNOSUPPRESSION AFTER HLA-IDENTICAL LIVING-RELATED KIDNEYTRANSPLANTATION. (Abstract #694)Nicole M. van Besouw, Jeroen H. Gerrits, Saskia M.Postma, Jacqueline Rischen, Jacqueline van de Wetering,Lenard M. B. Vaessen, Barbara J. van der Mast, WillemWeimar. Rotterdam, ZH, Netherlands.

P151 PROSPECTIVE STUDY ON LATECONSEQUENCES OF SUBCLINICAL NON-COMPLIANCE WITH IMMUNOSUPPRESSIVETHERAPY IN RENAL TRANSPLANT PATIENTS.(Abstract #695)Hans Vlaminck, Bart Maes, Yves Vanrenterghem.Leuven, Belgium.

Kidney Immunosuppression: New ChallengesP152 RISK FACTORS FOR GRAFT FAILURE IN

PATIENTS CONVERTED TO SIROLIMUS WITHCALCINEURIN INHIBITOR MINIMIZATION.(Abstract #696)David J. Taber, Jeffrey Rogers, Elizabeth E. Ashcraft, G.Mark Baillie, Angello Lin, Prabhakar K. Baliga, KennethD. Chavin, P. R. Rajagopalan. Charleston, SC.

P153 ERYTHROPOIESIS AFTER KIDNEYTRANSPLANTATION: COMPARISON OFSIROLIMUS TO MYCOPHENOLATE MOFETIL.(Abstract #697)Joshua J. Augustine, Thomas C. Knauss, Kenneth A.Bodziak, Christopher T. Siegel, James A. Schulak, DonaldE. Hricik. Cleveland, OH.

P154 CUTANEOUS ADVERSE EVENTS IN RENALTRANSPLANT RECIPIENTS ON SIROLIMUS BASETHERAPY. (Abstract #698)Emmanuel Mahe, Emmanuel Morelon, Sophie Lechaton,Rafik Mansouri, Marie-France Mamzer, Yves De Prost,Christine Bodemer, Henri Kreis. Paris, France.

P155 INDUCTION WITH BASILIXIMAB (SIMULECT) INELDERLY RECIPIENTS OF KIDNEY TRANSPLANTSALLOWS IMPROVED SAFETY, REDUCEDREJECTION, AND LOWER COST WHENCOMPARED TO ANTI-LYMPHOCYTE GLOBULIN(ATGAM) AND MUROMONAB (OKT-3).(Abstract #699)Michael Heifets, Mohammad I. Saeed, Michael J. Moritz,Debra Sierka, Susan Stabler, Mitten H. Parikh, Mysore S.Anil Kumar. Philadelphia, PA.

P156 ETHNIC VARIATIONS IN POLYMORPHISMSWITHIN GENES INVOLVED IN RESPONSE TOIMMUNOSUPPRESSIVE AGENTS. (Abstract #700)Faieza J. Qasim, Mohammed R. Bazrafshani, Kay V.Poulton. Manchester, United Kingdom.

P157 THREE YEAR RESULTS OF A RANDOMIZEDSTUDY COMPARING AS INDUCTION TREATMENTSIMULECT® AND THYMOGLOBULINE®.(Abstract #701)Matthias Buchler, Lilia Benfatma, Patrice Lepogamp,Franck Bridoux, Yann Lemeur, Olivier Toupance, SophieCaillard, Christiane Mousson, Bruno Hurault de Ligny,Jean F. Marliere, Yvon Lebranchu. Tours, France; Rouen,France; Rennes, France; Poitiers, France; Limoges,France; Reims, France; Dijon, France; Strasbourg, France;Caen, France.

P158 A SINGLE CENTER EXPERIENCE WITH STEROID-SPARING IMMUNOSUPPRESSION IN PANCREASAND RENAL TRANSPLANTATION:THYMOGLOBULIN® INDUCTION WITHDELAYED USE OF RAPAMUNE® AND PROGRAF®.(Abstract #702)R. Brian Stevens, Jean Botha, Wendy Grant, GeraldGroggel, James Lane, Lucile Wrenshall. Omaha, NE.

P159 † RENAL GRAFT SURVIVAL AND CALCINEURININHIBITOR. (Abstract #703)Robert S. Woodward, Andrea Kutinova, Mark A.Schnitzler, Daniel C. Brennan. Durham, NH; St Louis,MO.

P160 A NEW APPROACH TO DESENSITIZATION OFPOSITIVE T-AND B LYMPHOCYTE CROSSMATCH RECIPIENTS: KIDNEYTRANSPLANTATION ACROSS HLA BARRIERSFROM LIVING DONORS. (Abstract #704)Khalid Al Meshari, Khalid Al Shaibani, Ibrahim AlAhmadi, Ahmed Chaballot, Khaled Hamawi, AbdulghaniTabakhi, Samhar Al Akash, Hazem El Gamal, Syed Raza,Kesavamurthy Mohan, Ahmad Al Jedai, Arla Manser.Riyadh, Central Province, Saudi Arabia.

P161 BASILIXIMAB (SIMULECT) WITH CICLOSPORIN(NEORAL) AS A STRATEGY FOR STEROIDAVOIDANCE IN RENAL TRANSPLANTATION.(Abstract #705)Neil R. Parrott, Abdel Q. Hammad, Christopher J. E.Watson, Peter J. A. Lodge, Christopher Andrews.Manchester, United Kingdom; Liverpool, UnitedKingdom; Cambridge, Cambridgeshire, United Kingdom;Leeds, West Yorkshire, United Kingdom; Frimley, Surrey,United Kingdom.

P162 A PROSPECTIVE PILOT STUDY OF EARLYCORTICOSTEROID ELIMINATION UNDERMODERN IMMUNOSUPPRESSION IN PATIENTSAT HIGH IMMUNOLOGIC RISK: ONE-YEARRESULTS. (Abstract #706)R. R. Alloway, J. Trofe, R. E. Boardman, C. C. Rogers,M. Kidd, J. F. Buell, M. J. Hanaway, R. Munda, J. W.Alexander, M. J. Thomas, P. Roy-Chaudhury, M. A.Cardi, J. Austin, S. Goel, S. Safdar, S. Huang, E. S.Woodle. Cincinnati, OH.

P163 ANEMIA IN RENAL TRANSPLANT RECIPIENTS ONSIROLIMUS BASE THERAPY FOR CHRONICALLOGRAFT NEPHROPATHY. (Abstract #707)Olivier Thaunat, Emmanuel Morelon, Sophie Lechaton,Rafik Mansouri, Marie-France Mamzer, Marie-NoellePeraldi, Henri Kreis. Paris, France.

P164 LONG TERM RESULTS OF SINGLEPERIOPERATIVE HIGH DOSE OF ATG ASINDUCTION IN KIDNEY TRANSPLANTATION.(Abstract #708)R. Samsel, A. Chmura, G. Korczak-Kowalska, Z.Wlodarczyk, J. Pliszczynski, L. Adadynski, D. Wasiak,B. Lagiewska, M. Glyda, J. Wyzgal, T. Cieciura, M.Durlik, L. Paczek, W. Rowinski. Warsaw, Poland;Bydgoszcz, Poland; Poznan, Poland.

P165 COMPARISON OF RAPID STEROIDELIMINATION WITH BASILIXIMAB INDUCTIONVS STANDARD IMMUNOSUPPRESSION(MMF,TACROLIMUS AND STEROIDS) INRECIPIENTS OF LIVE-DONOR RENALALLOGRAFTS. (Abstract #709)Luis Campos, Anne M. Weiland, Benjamin Philosophe,Eugene J. Schweitzer, Clarence E. Foster, Stephen T.Bartlett. Baltimore, MD.

P166 EVALUATION OF BONE MINERAL DENSITYAFTER RENAL TRANSPLANTATION ON LOW-DOSE STEROID IMMUNOSUPPRESSION. (Abstract #710)Darrin Willingham, Martin L. Mai, Nasimul Ahsan,Peter Fitzpatrick, Thomas A. Gonwa. Jacksonville, FL.

P167 EFFECT OF STATINS AND BISPHOSPONATES ONPOST TRANSPLANT BONE DISEASE IN KIDNEYAND KIDNEY/PANCREAS TRANSPLANTRECIPIENTS. (Abstract #711)Elena Slavcheva, Charles McCuskey, Gregory Jaffers.Temple, TX.

100

P168 LUMBAR BONE MINERAL DENSITY (BMD)AFTER KIDNEY TRANSPLANTATION. APROSPECTIVE STUDY. (Abstract #712)Roberto Marcen, Julio Pascual, Carmen Caballero, JoseL. Teruel, Juan J. Villafruela, Javier Ocaña, Maria T.Tenorio, Cristina Galeano, Francisco J. Burgos, JoaquinOrtuño. Madrid, Spain.

P169 THE SIGNIFICANCE OF PROTOCOL BIOPSIESIN THE MODERN IMMUNOSUPPRESSIVE ERA;WHAT FOR? (Abstract #713)Mark R. Laftavi, Rabie N. Stephan, Barbara K. Stefanick,Romesh Kohli, Andrea Rubino, Mary Applegate, HayleyGuzowski, Fadi Y. Dagher, Oleh G. Pankewycz. Buffalo,NY.

P170 † PARTICIPATION IN CLINICAL STUDIES DOESNOT ALTER OUTCOMES AFTER LIVING DONORKIDNEY TRANSPLANTATION. (Abstract #714)Todd V. Brennan, Catherine K. Chang, Stephen J.Tomlanovich, Alan Bostrom, JoAnn K. Zlatunich,Flavio Vincenti, Sandy Feng. San Francisco, CA.

P171 † IMPACT OF DACLIZUMAB AND LOW DOSECYCLOSPORINE IN COMBINATION WITHMYCOPHENOLATE MOFETIL AND STEROIDS ONRENAL FUNCTION AFTER KIDNEYTRANSPLANTATION. (Abstract #715)Josef Fangmann, Wolfgang Arns, Hans Marti, KlemensBudde, Hans Neumayer, Tobias Beckurts, Juergen Floege,Raimund Margreiter, Johann Hauss. Leipzig, Germany;Koeln-Merheim, Germany; Bern, Switzerland; Berlin,Germany; Koeln, Germany; Aachen, Germany;Innsbruck, Austria.

P172 † ELDERLY GRAFT RECIPIENTS DO NOT SHOWSIGNS OF “RELATIVE IMMUNODEFICIENCY”.(Abstract #716)G. Bold, P. Nickel, F. Presber, D. Bitti, J. Juergensen, Ch.Rosenberger, N. Eibl, U. Frei, H.-D. Volk, P. Reinke.Berlin, Germany.

P173 USE OF LOW-DOSE TACROLIMUS,DACLIZUMAB, MYCOPHENOLATE MOFETILAND STEROIDS IN NON HEART BEATING RENALTRANSPLANTS. (Abstract #717)María Marques, Ana Sanchez-Fructuoso, Dolores Prats,Jose Conesa, Natalia Ridao, Julia Blanco, AlbertoBarrientos. Madrid, Spain.

P174 † CARDIOVASCULAR RISK FACTOR PROFILE INWOMEN RECIPIENTS OF RENAL TRANSPLANT:DIFFERENCES BETWEEN TACROLIMUS (TAC)AND CYCLOSPORIN A (CSA). (Abstract #718)Jonathan C. Prather, Murali S. Golconda, Ali J. Olyaei,Ann M. Rivinus, Gautham Mogilishetty, John M. Barry,Douglas J. Norman, Angelo M. de Mattos. Portland, OR.

P175 † MMF DOSE MODIFICATION FOLLOWING GICOMPLICATIONS IN RENALTRANSPLANTATION. (Abstract #719)Mark A. Schnitzler, Karen L. Hardinger, Daniel C.Brennan. St. Louis, MO.

P176 † LONG-TERM FUNCTION OF RENAL ALLOGRAFTWITH THE USE OF RAPAMUNE ANDTACROLIMUS COMBINATION. (Abstract #720)Rafik A. El-Sabrout, Veronica A. Delaney, Linda A.Bonini, Kerri E. Buch, Patricia A. Hanson, Khalid M. H.Butt. Valhalla, NY.

P177 EFFECT OF STEROID AVOIDANCE ON EARLYGRAFT FUNCTION AFTER KIDNEYTRANSPLANTATION. (Abstract #721)Hootan C. Roozrokh, Linda Chen, John D. Scandling,Anne Momsen, Jane Tan, Stephan Busque. Stanford, CA.

Liver Transplantation: Disease RecurrenceP178 MAINTENANCE OF EXCELLENT PATIENT

SURVIVAL AFTER LIVER TRANSPLANTATIONFOR CHRONIC HEPATITIS C IN A SINGLECENTER DURING THREE ERAS OFIMMUNOSUPPRESSION CHARACTERIZED BYWIDE VARIATION IN USE OF OKT3.(Abstract #722)Lisa M. Forman, Igal Kam, Gregory T. Everson. Denver,CO.

P179 Abstract #173 has been WithdrawnP180 LIVING DONOR LIVER TRANSPLANTATION

(LDLT) IS SAFE AND EFFECTIVE FOR HEPATITIS CRECIPIENTS. (Abstract #724)A. Fahmy, C. A. O’Mahony, H. Kaul, G. R. Morgan, D.John, T. Diflo, L. Teperman. New York, NY.

P181 IMPACT OF HLA COMPATIBILITIES ONOUTCOME IN HCV POSITIVE PATIENTS AFTERORTHOTOPIC LIVER TRANSPLANTATION.(Abstract #725)Ulf P. Neumann, Marcus Bahra, Jan M. Langrehr, PeterNeuhaus. Berlin, Germany.

P182 AN ANALYSIS OF HEPATITIS C VIRUSREINFECTION IN LIVER TRANSPLANTSPERFORMED USING EXTENDED CRITERIADONOR ALLOGRAFTS. (Abstract #726)M. Gupta, M. J. Hanaway, T. D. Merchen, J. F. Buell, M.Alonzo, M. J. Thomas, E. S. Woodle, S. M. Rudich.Cincinnati, OH.

P183 RELAVANCE OF RIBAVIRIN CONCENTRATION INPLASMA/BLOOD IN POST LIVER TRANSPLANTPATIENTS INFECTED WITH HEPATITIS CVIRUS(HCV). (Abstract #727)Ashok Jain, Raman Venkataramanan, Bijan Eghtesad,Shakil Obaid, Randeep Kashyap, Amadeo Marcos, JohnFung. Rochester, NY; Pittsburgh, PA.

P184 HEPATITIS C RECURRENCE (HCVR) IN LIVERTRANSPLANT RECIPIENTS (OLT) UNDERMYCOPHENOLATE MOFETIL (MMF)IMMUNOSUPPRESSION (IS): A LONG-TERMFOLLOW UP. (Abstract #728)Carlos G. Fasola, George J. Netto, Edmund Q. Sanchez,Shrinath Chinnakotla, Marlon F. Levy, Robert M.Goldstein, Goran B. Klintmalm. Dallas, TX.

P185 HCV ASSOCIATED CHOLESTASIS RELATED TOBILIARY COMPLICATIONS FOLLOWINGDECEASED AND LIVING DONOR LIVERTRANSPLANTATION: POOR OUTCOMESDESPITE THERAPY. (Abstract #729)Paul J. Gaglio, Elizabeth C. Verna, Alex Novogrudsky,Jay Lefkowitch, Milan Kinkhabwala, Jean C. Emond,Robert S. Brown. New York, NY.

P186 EFFICACY AND SAFETY OF INDUCTIONTHERAPY WITH ANTITHYMOCYTE GLOBULINS(ATG) IN HEPATITIS C VIRUS POSITIVE LIVERTRANSPLANT PATIENTS: COMPARISON WITHANTI-CD25 INDUCTION THERAPY.(Abstract #730)Nassim Kamar, Karine Sandres-Saune, Bertrand Suc,David Ribes, Jean Sebastien Borde, Olivier Cointault,Karl Barange, Dominique Durand, Janik Selves, LionelRostaing. Toulouse, France.

P187 STEROID-FREE IMMUNOSUPRESSION RESULTSIN DECREASED HCV RECURRENCE IN LIVERTRANSPLANT RECIPIENTS. (Abstract #731)Nahel Elias, Martin Hertl, Tatsuo Kawai, Dicken S. C.Ko, Michael Thiim, Raymond T. Chung, A. BenedictCosimi. Boston, MA.

101

Mo

nd

ay, May 17

P188 ACUTE REJECTION OR RECURRENT HEPATITISC: CAN LIVER BIOPSY MAKE THE DIAGNOSIS?(Abstract #732)Ryan McTaggart, Linda Ferrell, Charles Lassman, AlanBostrom, Peter Bacchetti, Norah Terrault, John Roberts,Sandy Feng. San Francisco, CA; Los Angeles, CA.

P189 HISTOLOGIC EVALUATION OF HEPATITIS CRECURRENCE AND ACUTE CELLULARREJECTION FOLLOWING OLTX: APRELIMINARY REPORT ON THE HEPATITIS CTHREE TRIAL. (Abstract #733)George J. Netto, the Hepatitis C Three Trial Group.Dallas, TX.

P190 HYPOGAMMAGLOBULINEMIA IN LIVERTRANSPLANT PATIENTS: INCIDENCE, TIMING,RISK FACTORS, AND OUTCOMES.(Abstract #734)Shira Doron, Robin Ruthazer, Arthur Rabson, Barbara G.Werner, David R. Snydman. Boston, MA; Jamaica Plain,MA.

P191 VALGANCICLOVIR FOR CMV PROPHYLAXIS INLIVER TRANSPLANT RECIPIENTS: AN INITIALEXPERIENCE. (Abstract #735)Suzanne C. Berkman, Elizabeth Ashcraft, G. MarkBaillie, David Taber, Angello Lin, Jeffrey Rogers, P.Baliga, Kenneth D. Chavin. Charleston, SC.

P192 PROPHYLAXIS OF CMV INFECTION IN ADULTLIVER TRANSPLANT PATIENTS USINGVALGANCICLOVIR (VALCYTE). (Abstract #736)Michael R. Marvin, Maureen B. Burke-Davis, Marcelo E.Facciuto, Leona Kim-Schluger, David C. Wolf, PatriciaA. Sheiner. Valhalla, NY.

P193 VANCOMYCIN-RESISTANT ENTEROCOCCUS INLIVER TRANSPLANT RECIPIENTS: A DRAMATICIMPROVEMENT IN OUTCOMES WITH NEW ANTI-VRE ANTIBIOTICS. (Abstract #737)Jordana L. Soule, Ali J. Olyaei, Ann M. H. Busch,Jonathan M. Schwartz, Hugo R. Rosen, John M. Ham,Susan L. Orloff. Portland, OR.

P194 RETROSPECTIVE EVALUATION OF SURGICALPROPHYLAXIS AND BACTERIALCOMPLICATIONS AFTER LIVERTRANSPLANTATION. (Abstract #738)E. Clark Drake, Benjamin T. Duhart, Jr., A. OsamaGaber, Naseem Amarshi, M. Hosein Shokouh-Amiri,Timothy H. Self, John M. Norwood. Memphis, TN.

P195 SURGICAL / NON SURGICAL,IMMUNOLOGICAL / NON IMMUNOLOGICAL,EARLY AND LATE COMPLICATIONS AFTERPRIMARY LIVER TRANSPLANTATION AND ITSIMPACT ON GRAFT AND PATIENT SURVIVAL INADULTS AND CHILDREN. AN ANALYSIS OF 1000CONSECUTIVE PATIENTS WITH 9-12 YEARSFOLLOW-UP. (Abstract #739)Ashok Jain, Reyes Jorge, Randeep Kashyap, MarcosAmadeo, Mazariegos Gorge, Eghtesad Bijon, FontePaulo, Cacciarelli Tom, Marsh Wallis, Devera Mike,Fung John. Pittsburgh, PA; Rochester, NY.

P196 A SURVEY OF PROPHYLACTIC IMMUNICATIONPRACTICES AT LIVER TRANSPLANT CENTERS INNORTH AMERICA AND EUROPE - A WEB-BASEDSTUDY. (Abstract #740)Nadeem Anwar, Michael Ellis, Savant Mehta, JenniferDaly. Worcester, MA.

P197 REFRACTORY ASCITES AFTER LIVERTRANSPLANTATION. (Abstract #741)Seigo Nishida, Noboru Nakamura, Juan Madariaga, DavidLevi, Jang Moon, Tomoaki Kato, Gennaro Selvaggi,Debbie Weppler, Phillip Ruiz, Guy Neff, Andreas Tzakis.Miami, FL.

P198 NO RECURRENCE IN PATIENTS TRANSPLANTEDFOR YMDD GENOTYPIC MUTATIONS USINGPRE-EMPTIVE LAMIVUDINE FOLLOWED BYCOMBINATION PROPHYLAXIS. (Abstract #742)Lucio Caccamo, Raffaella Romeo, Luca S. Belli, MarcelloVangeli, Giorgio Rossi, Alberto B. Alberti,Giovambattista Pinzello, Massimo Colombo, Luigi R.Fassati. Milano, MI, Italy.

P199 HEPATITIS C RECURRENCE FOLLOWING LIVERTRANSPLANTATION: DOES HISTOLOGICSEVERITY OF INFLAMMATION IN THE EXPLANTCOORELATE WITH RECURRENCE?(Abstract #743)Paul J. Gaglio, Simona Jakab, Alex Novogrudsky, Jean C.Emond, Robert S. Brown. NY, NY.

P200 IMPACT OF RENAL TRANSPLANTATION ONHEPATIC FIBROSIS PROGRESSION OFCHRONIC HEPATITIS C VIRUS (HCV)INFECTION IN PATIENTS WITH END-STAGERENAL DISEASE (ESRD). (Abstract #744)Richard K. Sterling, Kevin H. Peacock, R. Todd Stravitz,Anne L. King, Velimir A. Luketic, Arun J. Sanyal,Melissa J. Contos, A. Scott Mills, Mitchell L. Shiffman.Richmond, VA.

Liver Transplantation: Management ofImmunosuppressionP201 † CLINICAL USEFULNESS OF THE MLR ASSAY

USING THE CFSE-LABELING TECHNIQUE TOMONITOR THE IMMUNOSUPPRESSIVE STATEAFTER LIVING-DONOR LIVERTRANSPLANTATION. (Abstract #745)Yuka Tanaka, Hideki Ohdan, Toshimasa Asahara.Hiroshima, Japan.

P202 † MONITORING OF CIRCULATING DC AND TCELL SUBSETS IN PATIENTS RECEIVINGTHYMOGLOBULIN INDUCTION IN LIVERTRANSPLANT. (Abstract #746)Mario Arpinati, Michele Masetti, Alessandra Zagnoli,Damiano Rondelli, Antonio D. Pinna. Bologna, Italy;Modena, Italy; Chicago, IL.

P203 C2 MONITORING USING 4-HOUR INTRAVENOUS

INFUSIONS OF CYCLOSPORINE IN DE NOVOLIVER TRANSPLANT RECIPENTS. (Abstract #747)R. Lück, J. Böger, E. Kuse, J. Klempnauer, B. Nashan.Hannover, Germany; Halifax, NS, Canada.

P204 † CHRONIC REJECTION AND ITS RISK FACTORSFOLLOWING LIVER TRANSPLANTATION.(Abstract #748)Tom P. Theruvath, Ulf P. Neumann, Volker Schmitz,Ruth Neuhaus, Stefan G. Tullius, Jan M. Langrehr, PeterNeuhaus. Berlin, Germany.

P205 † INCREASING ADHERENCE TO THERAPY FORRECURRENT HEPATITIS C AFTER LIVERTRANSPLANTATION BY STARTING AT LOWERDRUG DOSES AND ADDING GROWTHFACTORS. (Abstract #749)Nazir A. Rahim, Katherine Suggett, ChristophTroppmann, Colette Chambers, John P. McVicar, RajenRamsamooj, Michael O’Brien, Christopher L. Bowlus,Lorenzo Rossaro. Sacramento, CA; Boston, MA.

102

P206 † DECREASED CELLULAR IMMUNE RESPONSE INHEPATITIS C PATIENTS AWAITING LIVERTRANSPLANTATION. (Abstract #750)James Huang, Mayra Lopez-Cepero, James Mayes, AngelAlsina, David Bruce, John Leone, Victor Bowers. Tampa,FL.

P207 † ASPECTS OF SPONTANEOUSMICROCHIMERISM AFTER ORTHOTOPIC LIVERTRANSPLANTATION. (Abstract #751)G. Junge, T. Härtl, M. Nagy, U. Neumann, R. Neuhaus, P.Neuhaus. Berlin, Berlin, Germany.

P208 CALCINEURIN (CNI) WITHDRAWAL IN LIVERTRANSPLANT (LTx) RECIPIENTS WITH LATERENAL DYSFUNCTION—A VIABLE ANDWORTHWHILE OPTION. (Abstract #752)Abhinav Humar, Kristin Horn, Ann Kalis, BrookeGlessing, Angelika Gruessner, Rainer Gruessner, RajaKandaswamy, William D. Payne, John R. Lake.Minneapolis, MN.

P209 FOURTY EIGHT HOUR DELAY INIMMUNOSUPPRESSIVE THERAPY FOLLOWINGLIVER TRANSPLANTATION: IMPLICATIONS FORACTIVATION-ASSOCIATED TOLERANCE.(Abstract #753)A. Agarwal, J. A. Fridell, D. A. Rouch, W. C. Goggins, P.Y. Kwo, N. P. Chalasani, L. Lumeng, M. L. Milgrom, M.D. Pescovitz, A. J. Tector. Indianapolis, IN.

P210 COMPARATIVE ANALYSIS OF DELAYEDTACROLIMUS IMMUNOSUPPRESSION, +/-ANTIBODY INDUCTION, IN ORTHOTOPIC LIVERTRANSPLANT PATIENTS WITH PRE-OPERATIVERENAL DYSFUNCTION. (Abstract #754)Mark Johnson, Jane Salm, Paula McIver, Robert Dupuis,Ruthann Conoley, Roshan Shrestha, Steven Zacks, DavidGerber, Jeffrey Fair, Kenneth Andreoni. Chapel Hill, NC.

P211 A PROSPECTIVE RANDOMIZED TRIALCOMPARING STEROID-FREEIMMUNOSUPPRESSION INDUCTION WITHTACROLIMUS AND MMF VERSUS TACROLIMUSAND STEROIDS IN PATIENTS WITH HCV.(Abstract #755)Martina T. Mogl, Ulf P. Neumann, Jan M. Langrehr,Peter Neuhaus. Berlin, Germany.

P212 36 MONTH RESULTS WITH EVEROLIMUS (E) INLIVER TRANSPLANTATION. (Abstract #756)G. Levy, V. M. Moeller, J. Jaffe, J. Punch, P. Neuhaus, D.Mayer. Toronto, ON, Canada; East Hanover, NJ; AnnArbor, MI; Berlin, Germany; Edgbaston, Birmingham,United Kingdom.

P213 SWITCH FROM CALCINEURIN INHIBITORS TOMYCOPHENOLATE MOFETIL IN LIVERTRANSPLANT PATIENTS WITH LONG TERM SIDEEFFECTS OF IMMUNOSUPPRESSION.(Abstract #757)Giuseppe Tisone, Andrea Cardillo, Alessandro Anselmo,Tommaso M. Manzia, Claudia Ciceroni, Linda De Luca,Nicola De Liguori Carino, Carlo U. Casciani. Rome,Italy.

P214 IMPROVEMENT IN RENAL FUNCTIONFOLLOWING INTRODUCTION OF SIROLIMUSIN LIVER TRANSPLANT RECIPIENTS.(Abstract #758)Moreno Luna Laura, Gregory J. Gores, Walter K.Kremers, Russell H. Wiesner, David J. Brandhagen, K. V.Narayanan Menon. Rochester, MN.

P215 MYCOPHENOLATE MOFETIL IN LIVERTRANSPLANT PATIENTS WITH CALCINEURININHIBITOR WITHDRAWL. (Abstract #759)Maria Lucia Zanotelli, Ana Luiza Gleisner, Alfeu Fleck,Jr., Eduardo Schlindwein, Alvaro Cassal, Ian Leipnitz,Tomaz De Jesus Grezzana, Mario Henrique Meine, LisiaHope, Ajacio de Mello Brandão, Claudio AugustoMarroni, Guido Pio Cracco Cantisani. Porto Alegre, RS,Brazil.

P216 POPULATION PHARMACOKINETIC STUDY OFTACROLIMUS (FK506) IN ADULT LIVERTRANSPLANT RECIPIENTS. (Abstract #760)Hamim Zahir, Ameeta Nelson, Margaret Gleeson,Geoffry McCaughan, Andrew J. McLachlan, FatemehAkhlaghi. Kingston, RI; Sydney, NSW, Australia.

P217 COMBINATION OF CYTOCHROME P-450 3A4,3A5, AND P-GLYCOPROTEIN ASPHARMACOGENOMIC PREDICTORS OFTACROLIMUS PHARMACOKINETICS ANDCLINICAL OUTCOMES IN LIVER TRANSPLANTRECIPIENTS. (Abstract #761)Christine M. Formea, Tuan Luu, Hossein Yarandi,Taimour Langaee, Valerie Greene, Shiro Fujita, Willemvan der Werf, Alan Hemming, Richard Howard, AlanReed, Janet L. Karlix. Gainesville, FL.

P218 PHARMACOKINETICS OF MYCOPHENOLICACID AND CLINICAL OUTCOMES IN LIVERTRANSPLANT RECIPIENTS WITH HEPATITIS C(HCV). (Abstract #762)Theodore M. Sievers, Curtis D. Holt, R. Mark Ghobrial,Lucy Artinian, Sue V. McDiarmid, Ronald W. Busuttil.Los Angeles, CA.

P219 PHARMACOKINETICS OF NEORAL® INPATIENTS RECEIVING MARGINAL LIVER GRAFT.(Abstract #763)Francesco Lupo, Chiara Stratta, Guido Liddo, Gian PaoloZara, Roberto Passera, Federico Casale, DonatellaMoscato, Roberto Mosso, Alessandro Ricchiuti, AndreaBrunati, Stefano Skurzak, Stefano Mirabella, ElisabettaCerutti, Mario Eandi, Mauro Salizzoni. Turin, Italy.

P220 BASILIXIMAB INDUCTION ALLOWS THE DELAYOF TACROLIMUS FOLLOWING LIVERTRANSPLANTATION IN PATIENTS WITH RENALINSUFFICIENCY. (Abstract #764)Benjamin Philosophe, Sharon L. Wilson. Baltimore,MD.

P221 IMPROVED RENAL FUNCTION IN ADULT LIVING-DONOR LIVER TRANSPLANTATION (LDLT)RECIPIENTS USING POLYCLONALANTILYMPHOCYTE INDUCTION THERAPY.(Abstract #765)M. S. Cattral, I. McGilvray, L. Adcock, L. Lilly, N.Girgrah, G. A. Levy, M. Walsh, R. Kim, S. Sakamoto, C.Moulton, P. D. Greig, D. R. Grant. Toronto, ON, Canada.

P222 THYMOGLOBULIN INDUCTION THERAPYALLOWS DELAY OF CALCINEURIN INHIBITORSIN LIVER TRANSPLANT RECIPIENTS WITHRENAL INSUFFICIENCY. (Abstract #766)Iman E. Bajjoka, Rozelle H. Dingle, Atsi Yoshida, KimDean, John Jerius, Kate O’Dell, Marwan S. Abouljoud.Detroit, MI.

103

Mo

nd

ay, May 17

P223 INTERLEUKIN-2 RECEPTOR ALPHA SUB-UNITANTIBODY (IL-2Rααααα-Ab) THERAPY ALLOWSDELAYED INTRODUCTION OF CALCINEURIN-INHIBITOR (CI) BASED IMMUNOSUPPRESSIONIN LIVER TRANSPLANT PATIENTS WITHPERIOPERATIVE RENAL IMPAIRMENT (RD).(Abstract #767)Barry Rosser, Martin Mai, David Kramer, Hani Grewal,Raj Satyanarayana, Andrew Keaveny, Rolland Dickson,Denise Harnois, Winston Hewitt, Justin Nguyen,Christopher Hughes, Thomas Gonwa, Jeffrey Steers.Jacksonville, FL.

P224 THYMOGLOBULIN INDUCTION IN LIVERTRANSPLANTATION AND RECURRENCE OFHEPATITIS C. (Abstract #768)Antonio D. Pinna, Nicola De Ruvo, AlessandroCucchetti, Augusto Lauro. Bologna, Italy.

P225 POOR PREDICTION OF THE GLOMERULARFILTRATION RATE USING CURRENT FORMULASIN THE NOVO LIVER TRANSPLANT PATIENTS.(Abstract #769)M. Cantarovich, E. Yoshida, P. Marotta, P. Greig, N.Kneteman, D. Marleau, K. Peltekian, G. Facciponte, B.Simpson, R. Balshaw, J. Barkun. Montréal, QC, Canada;Vancouver, BC, Canada; London, ON, Canada; Toronto,On, Canada; Edmonton, AB, Canada; Halifax, NS,Canada; Mississauga, ON, Canada.

P226 EFFECT OF CYCLOSPORINE ONHEPATOCELLULAR CARCINOMA RECURRENCEAFTER LIVER TRANSPLANTATION. (Abstract #770)Marco Vivarelli, Alessandro Cucchetti, Giuliano LaBarba, Antonino Cavallari, Antonio D. Pinna. Bologna,Italy.

P227 POSITIVE T-CELL FLOW CYTOMETRYCROSSMATCH IN THE LIVER TRANSPLANTPOPULATION: IS IT CLINICALLY SIGNIFICANT?(Abstract #771)T. D. Merchen, B. Susskind, M. Gupta, J. F. Buell, E. S.Woodle, S. M. Rudich. Cincinnati, OH.

P228 LIVER TRANSPLANTATION RECIPIENTSWITHOUT HEPATITIS C RECEIVING SIROLIMUSAS PRIMARY IMMUNOSUPPRESSION HAVEMILD ELEVATIONS IN ALT. (Abstract #772)Steven R. Kaptik, Julie C. Osborne, James F. Trotter.Denver, CO.

P229 PRELIMINARY RESULTS OF ANTI-IL-2RECEPTOR ANTIBODY (BASILIXIMAB) IN ADULTLIVING DONOR LIVER TRANSPLANTATION.(Abstract #773)Chih-Che Lin, Feng-Rong Chuang, Chih-Chi Wang, Yaw-Sen Chen, Chih Hsiung Lee, Yueh-Wei Liu, Yu-FanCheng, Chao-Long Chen. Kaohsiung, Taiwan.

Living Donor Kidney TransplantationP230 ASSESSMENT OF THE QUALITY OF LIVING

DONOR KIDNEYS. (Abstract #774)Jesse D. Schold, Shiro Fujita, Michael Bucci, Pamela R.Patton, Bruce Kaplan, Herwig-Ulf Meier-Kriesche.Gainesville, FL.

P231 † CONVALESCENCE AFTER LAPAROSCOPIC LIVEDONOR NEPHRECTOMY. (Abstract #775)S. Bergman, L. S. Feldman, F. Carli, M. Anidjar, P. P.Metrakos, J. I. Tchervenkov, S. Paraskevas, D. Klassen,M. C. Vassiliou, C. G. Andrew, D. D. Stanbridge, G. M.Fried. Montreal, QC, Canada.

P232 IMPLANT BIOPSIES AND DONOR OUTCOMEFOLLOWING LIVING DONOR NEPHRECTOMY.(Abstract #776)Yook M. Woo, William Gourlay, Gerald Da Roza,Alexander Magil, Janet Holden, Gary Nussbaumer, JohnS. Gill, David Landsberg. Vancouver, BC, Canada.

P233 SERUM CYSTATIN C DOES NOT PROVIDE ANADVANTAGE OVER CONVENTIONAL TESTING INEVALUATION OF POTENTIAL LIVING KIDNEYDONORS. (Abstract #777)Sita Gourishankar, Gian S. Jhangri, Philip F. Halloran.Edmonton, AB, Canada.

P234 FATAL AND NON-FATAL HEMORRHAGICCOMPLICATIONS OF LIVING KIDNEYDONATION. (Abstract #778)Amy L. Friedman, Lloyd E. Ratner, Thomas G. Peters.New Haven, CT; Philadelphia, PA; Jacksonville, FL.

P235 CONVENTIONAL AND UNCONVENTIONALPAIRED KIDNEY EXCHANGES. (Abstract #779)Matthew Cooper, Janet M. Hiller, Jennifer Rickard,Hamid Rabb, Andrea A. Zachary, Julie Graziani, RobertA. Montgomery. Baltimore, MD.

P236 WHEN DOES THE GENDER DISPARITY DEVELOPIN THE KIDNEY DONOR EVALUATIONPROCESS? (Abstract #780)Kathryn A. Tuohy, Scott Johnson, Khalid Khwaja,Martha Pavlakis. Boston, MA.

P237 HEMODYNAMIC ADAPTATION AFTER LIVINGDONOR NEPHRECTOMY. (Abstract #781)Sandra J. Taler, Nancy Driscoll, Mary Tibor, GenieSprau, Jo Ellen Augustine, Timothy S. Larson, Mark D.Stegall, Stephen C. Textor. Rochester, MN.

P238 ATTITUDINAL AND PSYCHOLOGICALDIFFERENCES BETWEEN ALTRUISTICSTRANGERS AND THE GENERAL PUBLIC.(Abstract #782)L. Ebony Boulware, Misty U. Troll, Lloyd E. Ratner,Andrew S. Klein, Neil R. Powe. Baltimore, MD;Philadelphia, PA.

P239 COMPLICATION RATES OF OPEN VS.LAPROSCOPIC DONATION NEPHRECTOMY ASREPORTED BY DONORS TO THE LIVING ORGANDONOR NETWORK (LODN) REGISTRY.(Abstract #783)Thomas R. McCune, Thomas A. Armata, John W.Blanton, Leroy R. Thacker. Norfolk, VA; Richmond, VA.

P240 LESSONS LEARNED IN 100 ROBOTIC-ASSISTEDDONOR NEPHRECTOMIES FOR KIDNEYTRANSPLANTATION. (Abstract #784)Santiago Horgan, Garth Jacobsen, Antonio Manzelli,Piero Fisichella, Jason Harris, Diego Bogetti, RobertBerger, Howard N. Sankary, Giuliano Testa, EnricoBenedetti. Chicago, IL.

P241 LONG-TERM OUTCOME OF RENALTRANSPLANTION USING HLA MISMATCHED A2DONOR KIDNEYS. (Abstract #785)Patrick P. W. Luke, Vaishali Karnik, MahmsMohammed, Andrew A. House, Norman Muirhead, DavidHollomby, Vivian C. McAlister, Anthony M. Jevnikar.London, ON, Canada; London, ON, Central AfricanRepublic.

P242 COST-EFFECTIVENESS OF THE USE OF HTK(HISTIDINE-TRYPTOPHAN-KETOGLUTARATE) ASAN ALTERNATIVE PRESERVATION SOLUTION INLIVE DONOR RENAL TRANSPLANTATION.(Abstract #786)Meelie A. DebRoy, Mark Gravel, Richard Chenault,Robert M. Merion, Jeffrey D. Punch, John C. Magee,Juan D. Arenas. Ann Arbor, MI.

104

P243 PROSPECTIVE PSYCHOSOCIAL EVALUATIONAND OBJECTIVE ASSESSMENT OF MOTIVATIONIN LIVE RENAL DONATION. (Abstract #787)Mukut Minz, Navalkishor Udgiri, Munish K. Heer,Randeep Kashyap, Ritu Nehra, Vinay Sakhuja.Chandigarh, U.T., India.

P244 WHATEVER IT TAKES: RULED OUT KIDNEYDONORS’ WILLINGNESS TO PARTICIPATE INDONOR SWAPPING. (Abstract #788)Amy D. Waterman, Daniel C. Brennan, Barry Hong,Emily Schenk, Tonie Covelli, Tracye Davis, AnneBarrett, Sarah Stanley, Mark A. Schnitzler. Saint Louis,MO.

P245 IMAGE ANALYSIS OF STRUCTURALINTERSTITIAL REMODELING, TOTAL MATRIXAREA AND GLOMERULOSCLEROSIS ARECLOSELY CORRELATED IN POTENTIAL DONORBIOPSIES. (Abstract #789)Paul C. Grimm, David C. Rayner, Adam L. Merry, PhilipF. Halloran, Anette Melk. La Jolla, CA; Edmonton, AB,Canada; Calgary, AB, Canada; Heidelberg, Germany.

P246 A PROSPECTIVE SURVEY OF CONCERNS INKIDNEY TRANSPLANTATION: DONOR ANDRECIPIENT PERSPECTIVES. (Abstract #790)Prabhakar Baliga, Gilbert Smalls, Greg Gilbert, LillessShilling, Margaret Martin, Michele Norman, JenniferMilton, Laura Hildebrand, Kenneth Chavin. Charleston,SC.

P247 THE SPECTRUM OF CHRONIC HISTOLOGICABNORMALITIES IN LIVING DONOR KIDNEYTRANSPLANTS AT THE TIME OF IMPLANTATION:CORRELATION WITH DONOR AND RECIPIENTCLINICAL DATA. (Abstract #791)Montserrat M. Diaz Encarnacion, Matthew D. Griffin,Stephen C. Textor, Fernando C. Cosio, James R.Gregoire, Thomas R. Schwab, James M. Gloor, Sandra J.Taler, Timothy S. Larson, Mark D. Stegall, Joseph P.Grande. Rochester, MN.

P248 NONDIRECTED DONATION (NDD) - CONTINUEDOBSERVATIONS AND PROGRAM EVOLUTION.(Abstract #792)Catherine Garvey, Cheryl Jacobs, Deborah Roman,Arthur Matas. Minneapolis, MN.

P249 PERCEPTIONS OF FINANCIAL INCENTIVES,PRESUMED CONSENT, AND FAMILY VETOAMONG NEXT-OF-KIN WHO REFUSED VS.CONSENTED TO ORGAN DONATION.(Abstract #793)James R. Rodrigue, Danielle L. Cornell, Richard J.Howard. Gainesville, FL.

P250 THE LIVING ORGAN DONOR NETWORK: THREEYEARS EXPERIENCE WITH A MODEL REGISTRYTO PROSPECTIVLY FOLLOW THE HEALTH ANDWELL-BEING OF KIDNEY DONORS.(Abstract #794)Thomas R. McCune, Leroy R. Thacker, Thomas A.Armata, John W. Blanton. Norfolk, VA; Richmond, VA.

Pancreas and Islet TransplantationP251 † TYPE 1 DIABETES FOLLOWING PANCREAS

TRANSPLANTATION: DO AUTO-ANTIBODIESMARK RECURRENCE OF AUTO-IMMUNITY?(Abstract #795)George W. Burke, Gaetano Ciancio, Joshua Miller, GloriaAllende, Alberto Pugliese. Miami, FL.

P252 † A MULTICENTER ANALYSIS ON THESIGNIFICANCE OF HLA MATCHING ONOUTCOMES FOLLOWING KIDNEY-PANCREASTRANSPLANTATION. (Abstract #796)Robert J. Stratta, Rita R. Alloway, Agnes Lo, ErnestHodge. Winston-Salem, NC; Cincinnati, OH; Memphis,TN; Nutley, NJ.

P253 † IMPROVED HUMAN ISLET ISOLATIONOUTCOME BY ADDITION OF VITAMIN E ANDNICOTINAMIDE TO THE ISLET PROCESSINGMEDIUM. (Abstract #797)Hirohito Ichii, Ismail Al-Abdullah, Joel Szust, JorgeMontelongo, Itzia Iglesias, Day Longsomboom, AishaKhan, Yoshikazu Kuroda, Rodolfo Alejandro, CamilloRicordi. Miami, FL; Kobe, Japan.

P254 FACTORS CORRELATED WITH SUCCESSFULPANCREATIC ISLET ISOLATION. (Abstract #798)Adam M. Frank, Shaoping Deng, Ergun Veledeoglu, NirajM. Desai, Xialun Huang, Mohammed M. Mohiuddin,Moh Moh Lian, Thavachenthan Thambi-Pillai, YongSuk Bae, Chengyang Liu, Clyde F. Barker, Ali Naji, JamesF. Markmann. Philadelphia, PA.

P255 EFFICACY OF HUMAN ISLET ISOLATION FROMTAIL PART OF PANCREAS FOR THE POSSIBLELIVING DONOR ISLET TRANSPLANTAION.(Abstract #799)Shinichi Matsumoto, Teru Okitsu, Yasuhiro Iwanaga,Hirofumi Noguchi, Yukihide Yonekawa, D. MichaelStrong, Jo Anna Reems, Koichi Tanaka. Kyoto, Kyoto,Japan; Seattle, WA.

P256 THE EFFECT OF DONOR AND ISOLATIONFACTORS ON HUMAN ISLET IN-VIVOFUNCTION. (Abstract #800)Omaima Sabek, Patricia Cowan, Daniel Fraga, MalakKotb, Osama Gaber. Memphis, TN.

P257 NUMBER OF ISLET βββββ CELLS BETTER PREDICTSSUSTAINED INSULIN-INDEPENDENCE THANNUMBER OF ISLET EQUIVALENTS (IE)TRANSPLANTED IN TYPE 1 DIABETIC PATIENTS.(Abstract #801)Hui-Jian Zhang, Jeffrey Ansite, Sung-Hee Ihm, JeremyOberbroeckling, Andrew Friberg, Bernhard J. Hering.Minneapolis, MN.

P258 POTENTIAL ROLE OF TELOMERASE ANDTELOMERES IN HUMAN ISLETS. (Abstract #802)Annie T. L. Young, Douglas Wu, Ronald B. Moore,Jonathan R. T. Lakey. Edmonton, AB, Canada.

P259 † ISLET TRANSPLANTATION ALONE IN TYPE 1DIABETES: SINGLE CENTER EXPERIENCE.(Abstract #803)Paola Maffi, Federico Bertuzzi, Francesca De Taddeo,Rita Nano, Massimo Venturini, Alessandro Del Maschio,Antonio Secchi. Milan, Italy.

P260 † COLLABORATIVE ISLET TRANSPLANTREGISTRY (CITR). (Abstract #804)Bernhard J. Hering, Nicole C. Close, Ravinder Anand,Thomas L. Eggerman. Minneapolis, MN; Rockville, MD;Bethesda, MD.

P261 SIROLIMUS AND TACROLIMUS INPREPARATION FOR ISLET CELLTRANSPLANTATION IN TYPE 1 DIABETICPATIENTS RECIPIENT OF RENAL ALLOGRAFTS.(Abstract #805)Enrico Cagliero, Anil K. Chandraker, Arthur Dea, SusanFritz, Kadir Omer, Martha Pavlakis, Gordon C. Weir,Hugh Auchincloss, Jr., David M. Nathan. Boston, MA.

105

Mo

nd

ay, May 17

P262 INSULIN INDEPENDENCE IN ISLET AFTER KIDNEY(IAK) TRANSPLANT RECIPIENTS USING ASIROLIMUS/TACROLIMUS-BASED STEROID-FREE IMMUNOSUPPRESSIVE REGIMEN.(Abstract #806)Thierry Berney, Axel Andres, Domenico Bosco, RetoBaertschiger, Pascal Bucher, Christian Toso, Leo H.Bühler, Philippe Morel. Geneva, Switzerland.

P263 IMPARED RENAL FUNCTION AFTER ISLETTRANSPLANT ALONE (ITA) OR ISLET-AFTER-KIDNEY (IAK) TRANSPLANTATION USING ASIROLIMUS-TACROLIMUS-BASED REGIMEN.(Abstract #807)Axel Andres, Christian Toso, Philippe Morel, SandrineDemuylder-Mischler, Domenico Bosco, Pascal Bucher,Zoltan Mathe, Reto Baertschiger, Leo H. Buhler,Thierry Berney. Geneva, Geneva, Switzerland.

P264 † PANCREAS TRANSPLANTATION PROVIDESEXCELLENT LONG TERM INSULIN-FREEOUTCOMES FOR PATIENTS WITH TYPE 2DIABETES MELLITUS (DM). (Abstract #808)D. Nath, A. Gruessner, R. Kandaswamy, R. Gruessner, D.Sutherland, A. Humar. Minneapolis., MN.

P265 PERSISTENT HYPERGLYCEMIA FOLLOWINGPANCREAS TRANSPLANTATION. (Abstract #809)Patrick G. Dean, Yogish C. Kudva, Timothy S. Larson,David J. Rea, Mark D. Stegall. Rochester, MN.

P266 SAFETY AND EFFICACY OF PANCREASTRANSPLANTATION ALONE IN TYPE 1 DIABETICPATIENTS: EFFECTS ON METABOLICPARAMETERS AND LATE DIABETESCOMPLICATIONS. (Abstract #810)Ugo Boggi, Fabio Vistoli, Alberto Coppelli, RosaGiannarelli, Tiziana Vanadia Bartolo, Michele Aragona,Chiara Croce, Marco Del Chiaro, Alberto Piaggesi,Stefano Del Prato, Franco Mosca, Piero Marchetti. Pisa,Italy.

P267 RESULTS WITH PANCREAS TRANSPLANT INRECIPIENTS WITH A HISTORY OF MAJORLOWER EXTREMITY AMPUTATIONS. (Abstract #811)Abhinav Humar, Raja Kandaswamy, James Harmon,Joseph Melancon, Miguel Tan, Ty Dunn, Rainer W. G.Gruessner, David E. R. Sutherland, Angelika C. Gruessner.Minneapolis, MN.

P268 MULTIVARIATE ANALYSIS OF THE INFLUENCEOF DONOR AND RECIPIENT CMV SERO-PAIRING ON OUTCOMES IN SIMULTANEOUSKIDNEY-PANCREAS TRANSPLANTATION: THESOUTH-EASTERN ORGAN PROCUREMENTFOUNDATION EXPERIENCE. (Abstract #812)Robert J. Stratta, Leroy R. Thacker, Aimee K. Sundberg.Winston-Salem, NC; Richmond, VA.

P269 GANCICLOVIR VS. VALGANCICLOVIR FORCMV PROPHYLAXIS IN SOLITARY PANCREASTRANSPLANT RECIPIENTS. (Abstract #813)David J. Rea, Yogish C. Kudva, Timothy S. Larson, MarkD. Stegall. Rochester, MN.

P270 MODE OF DIALYSIS DOES NOT INFLUENCEPOST-OPERATIVE INTRA-ABDOMINALINFECTION RATES IN SIMULTANEOUSPANCREAS-KIDNEY TRANSPLANTATION.(Abstract #814)Robin D. Kim, Kenneth Qiu, Lesley Adcock, IanMcGilvray, David Grant, Paul Greig, Mark S. Cattral.Toronto, ON, Canada.

P271 OUTCOMES FOR AFRICAN-AMERICANS (AA)UNDERGOING SIMULTANEOUS KIDNEYPANCREAS TRANSPLANTATION (SPK) ISEQUIVALENT TO CAUCASIANS (C) WITHTHYMOGLOBULIN (THY) INDUCTION.(Abstract #815)Carlton J. Young, Clifton Kew, Sharon Hudson, MichaelGallichio, Arun Chandrakantan, Bruce Julian, MarkDeierhoi, Robert Gaston. Birmingham, AL.

P272 IMPAIRED RENAL VASODILATORY RESERVEAND KIDNEY HIGH ENERGY PHOSPHATES(HEPs) METABOLISM IN TYPE 1 DIABETIC (T1DM)UREMIC PATIENTS AFTER KIDNEY-ALONE (K)BUT NOT KIDNEY-PANCREASTRANSPLANTATION (KP). (Abstract #816)Paolo Fiorina, Gianluca Perseghin, Francesco De Cobelli,Marta Bruno Ventre, Gabriella Mazzolari, ChiaraGremizzi, Giorgio Torri, Valerio Di Carlo, Alessandro DelMaschio, Antonio Secchi. Milan, Italy.

P273 LATE ANASTOMOTIC LEAKS IN PANCREASTRANSPLANT (PTx) RECIPIENTS—CLINICALCHARACTERISTICS AND PREDISPOSINGFACTORS . (Abstract #817)D. Nath, A. Gruessner, R. Kandaswamy, R. Gruessner, D.Sutherland, A. Humar. Minneapolis, MN.

P274 DELAYED PANCREAS GRAFT FUNCTION IN SPKRECIPIENTS – ITS IMPACT ON KIDNEY GRAFTFUNCTION. (Abstract #818)Abhinav Humar, James V. Harmon, Ty Dunn, J. KeithMelancon, Miguel Tan, Raja Kandaswamy, Rainer W. G.Gruessner, Arthur Matas, David E. R. Sutherland,Angelika C. Gruessner. Minneapolis, MN.

P275 IMPACT OF PANCREAS AFTER KIDNEYTRANSPLANTATION ON KIDNEY ALLOGRAFTSURVIVAL. (Abstract #819)Ajay K. Israni, Kevin C. Mange, Kathleen Propert, MaryLeonard, Harold I. Feldman. Philadelphia, PA.

Pediatric Liver Transplant: Advances in Technique andImmunosuppressionP276 † LONG-TERM NEUROLOGIC OUTCOMES AND

COMPLICATIONS IN PEDIATRIC PATIENTSTRANSPLANTED FOR FULMINANT HEPATICFAILURE (FHF). (Abstract #820)Abhinav Humar, Brooke Glessing, Marci Knaak, BrendaDurand, Elizabeth Larson, William D. Payne, KhalidKhan, Sarah-Jane Schwarzenberg, Harvey Sharp.Minneapolis, MN.

P277 ORTHOTOPIC LIVER TRANSPLANTATION ININFANTS UNDER 5 KILOGRAMS. (Abstract #821)Greg M. Tiao, Maria Alonso, John Bucuvalas, JorgeBezerra, Nada Yazigi, James Heubi, William Balistreri,Frederick Ryckman. Cincinnati, OH.

P278 THE PRESENCE OF MULTIPLE BILE DUCTS INTHE LIVER GRAFT INCREASES THE INCIDENCEOF BILIARY COMPLICATIONS IN PEDIATRICLIVER TRANSPLANTATION. (Abstract #822)Paolo Salvalaggio, Kishore Iyer, Peter Whitington,Estella Alonso, Riccardo Superina. Chicago, IL.

P279 BILIARY RECONSTRUCTIONS IN ISOLATEDLIVER TRANSPLANT (ILTx) FOR INTESTINALFAILURE ASSOCIATED LIVER DISEASE (IFALD).(Abstract #823)Khalid Sharif, Susan V. Beath, Patrick J. McKiernan,Darius F. Mirza, Anthony David Mayer, Carla Lloyd,Deirdre A. Kelly, Jean de Ville de Goyet. Birmingham,United Kingdom.

106

P280 SPLIT LIVER TRANSPLANTATION: LOCALSHARING BETWEEN PEDIATRIC AND ADULTTRANSPLANT CENTERS. (Abstract #824)Patrick J. Healey, Adam E. Levy, James D. Perkins.Seattle, WA.

P281 IMPACT OF GRAFT SIZE MISMATCHING ONOUTCOME IN PEDIATRIC SPLIT LIVERTRANSPLANTATION. (Abstract #825)Marco Spada, Alessandro Aluffi, Matteo Cescon, MichelaGuizzetti, Alessandro Lucianetti, Domenico Pinelli,Giuliano Torre, Bruno Gridelli, Michele Colledan.Bergamo, Italy; Palermo, Italy.

P282 A SINGLE CENTER’S 34 YEARS OF EXPERIENCEWITH PEDIATRIC LIVER TRANSPLANTATION(LTx) FOR ALPHA-1-ANTITRYPSIN DEFICIENCY(AATD). (Abstract #826)J. Keith Melancon, Harvey Sharp, Angelika C. Gruessner,Lakshmi Kanth, A. Humar, William D. Payne, Rainer W.Gruessner. Minneapolis, MN.

P283 INCREASED PREVALENCE OF AUTOANTIBODIESAFTER PEDIATRIC LIVER TRANSPLANTATIONAND ITS CLINICAL IMPACT. (Abstract #827)Yaron Avitzur, Annie Fecteau, Vicky Lee Ng. Toronto,ON, Canada.

P284 SUCCESSFUL ABO INCOMPATIBLE PEDIATRICLIVER TRANSPLANTATION UTILIZINGSELECTIVE PLASMAPHERESIS. (Abstract #828)Thomas G. Heffron, David Welch, Todd Pillen, GregoryA. Smallwood, Renee Romero. Atlanta, GA.

P285 LONG TERM RENAL FUNCTION IN CHILDRENAFTER LIVER TRANSPLANTATION (OLT) WITHCALCINEURIN INHIBITOR (CNI) BASEDIMMUNOSUPPRESSION. (Abstract #829)Silke Wiesmayr, Helmut Ellemunter, Johannes Eder,Alfred Königsrainer, Wolfgang Steurer, RaimundMargraiter, Lothar Bernd Zimmerhackl. Innsbruck,Austria.

P286 † LONG-TERM OUTCOMES WITH ANTI-CD20MONOCLONAL ANTIBODY IN THEMANAGEMENT OF POST-TRANSPLANTLYMPHOPROLIFERATIVE DISEASE IN PEDIATRICLIVER TRANSPLANT RECIPIENTS. (Abstract #830)I-Fen Chang, Ruben E. Quiros-Tejeira, Saul J. Karpen,Lisa J. Bristow, Jaymee D. Scott, John A. Goss. Houston,TX.

P287 SIGNIFICANCE OF SERIAL MONITORING OFREAL-TIME EBV PCR IN PEDIATRIC LIVINGDONOR LIVER TRANSPLANTAITON.(Abstract #831)Hiroyuki Furukawa, Tsuyoshi Shimamura, Maeng BongJin, Tomomi Suzuki, Masahiko Taniguchi, MasahiroHattori, Toshiya Kamiyama, Michiaki Matsushita,Satoru Todo. Sapporo, Japan.

P288 IMMUNOSPRESSION FOR LIVER TRANSPLANT(LTx) IN INFANTS WITH SHORT BOWELSYNDROME (SBS). (Abstract #832)Dominic Dell-Olio, Khalid Sharif, Carla Lloyd, SaraClarke, Patrick J. McKiernan, Indra V. van Mourik,Deirdre A. Kelly, Susan V. Beath. Birmingham, UnitedKingdom.

P289 BONE MINERAL STATUS IN CHILDREN AGEDOVER 3 YEARS UNDERGOING LIVERTRANSPLANTATION. (Abstract #833)Helen M. Evans, Sharon M. Bant, Nicola J. Crabtree,William D. Fraser, Deirdre A. Kelly, Patrick J.McKiernan, Nicholas J. Shaw. Birmingham, WestMidlands, United Kingdom; Liverpool, Merseyside,United Kingdom; Brimingham, West Midlands, UnitedKingdom.

P290 GLUCOSE INTOLERANCE IN LONG-TERMPEDIATRIC LIVER TRANSPLANT SURVIVORS.(Abstract #834)Nada Yazigi, Fredrick Ryckman, Maria Alonso, GregoryTiao, William Balistreri, John Bucuvalas. Cincinnati,OH.

P291 THE IMACT OF PRE-TRANSPLANT NUTRITIONON GROWTH AND DEVELOPMENT IN CHILDRENWITH BILIARY ATRESIA AWAITING LIVERTRANSPLANT. (Abstract #835)Kathleen P. Falkenstein. Wilmington, DE.

P292 THE USE OF RAPAMYCIN AND AZATHIOPRINEIN PEDIATRIC LIVER TRANSPLANT RECIPIENTS.(Abstract #836)Nanda Kerkar, Christina Dugan, Carolina Rumbo, NancyKrieger, Gabriel Gondolesi, Benjamin Shneider, SukruEmre. New York, NY.

P293 PEDIATRIC LIVER TRANSPLANTATION WITHOUTTHE USE OF MICROSURGICAL TECHNIQUES.(Abstract #837)Thomas G. Heffron, David Welch, Todd Pillen, GregoryA. Smallwood, Rene Romero. Atlanta, GA.

Tissue Injury IIP294 † INITIAL SELECTIN BLOCKADE OF T CELL

ACTIVATION AND SIGNALLING COMBINEDWITH LOW-DOSE SIROLIMUS/CsAIMMUNOSUPPRESSION PREVENTS CHRONICREJECTION OF KIDNEY ALLOGRAFTS.(Abstract #838)Martin Gasser, Miriam S. Lenhard, Michael Grimm,Martin Grimm, Gray D. Shaw, Wayne W. Hancock,Arnulf Thiede, Nicholas L. Tilney, Ana Maria Waaga-Gasser. Wuerzburg, Bavaria, Germany; Cambridge, MA;Philadelphia, PA; Boston, MA.

P295 † THE EFFECT OF HEPATIC ISCHEMIA/REPERFUSION INJURY ON EXPRESSION OFRAE-1 AND H60 GENES IN MICE LIVER.(Abstract #839)Feng Cheng, You-ping Li, Jing-qiu Cheng, Li Feng, YingHe, Zi-zhen Yie. Chengdu, Sichuan, China.

P296 † NEW INSIGHTS INTO A ROLE FOR VEGF ANDITS RECEPTORS IN LIVER ISCHEMIA-REPERFUSION INJURY. (Abstract #840)Yoshikazu Tsurui, Masayuki Sho, Yukiyasu Kuzumoto,Satoru Akashi, Hisanori Kashizuka, Naoya Ikeda, MizunoTakashi, Daniel J. Hicklin, David M. Briscoe, YoshiyukiNakajima. Kashihara, Nara, Japan; New York, NY;Boston, MA.

P297 † OBJECTIVE AND RAPID ASSESSMENT OFPANCREAS GRAFT VIABILITY USING 31P-NUCLEAR MAGNETIC RESONANCESPECTROSCOPY COMBINED WITH TWO-LAYER COLD STORAGE METHOD.(Abstract #841)Takuro Yoshikawa, Yasuyuki Suzuki, Masaru Kanashiro,Shiri Li, Tadahiro Goto, Tomohiro Tanaka, KeitaroKakinoki, Tetsuya Sakai, Yasuki Tanioka, YasuhiroFujino, Yoshikazu Kuroda. Kobe, Hyogo, Japan; Suita,Osaka, Japan.

P298 † LOCAL NITRIC OXIDE DELIVERY SYSTEMS:IMPLICATIONS FOR TRANSPLANTPRESERVATION. (Abstract #842)P. Roy-Chaudhury, M. Frost, H. Zhang, M. Batchelor, E.Chang, M. Meyerhoff, S. Rudich. Cincinnati, OH; AnnArbor, MI.

107

Mo

nd

ay, May 17

P299 † VERY EARLY T CELL INFILTRATION ANDACTIVATION IN ISCHEMIA-REPERFUSEDKIDNEYS IN THE ABSENCE OF ALLOANTIGEN.(Abstract #843)Chu-chun Chien, Manchang Liu, Hamid Rabb. Taoyuan,Taiwan; Baltimore, MD.

P300 † THE SYNERGISTIC EFFECT OF CARBONMONOXIDE AND BILIVERDIN FOR KIDNEY ANDCARDIAC ISCHEMIA/REPERFUSION INJURY.(Abstract #844)Atsunori Nakao, Joao Seda Neto, Shinichi Kanno, KeiKimizuka, Robert J. Bailey, Augustine M. K. Choi, FritzH. Bach, Leo E. Otterbein, Noriko Murase. Pittsburgh,PA; Boston, MA.

P301 CYCLOSPORINE-INDUCED RENAL INJURY ISASSOCIATED WITH INCREASEDIMMUNOGENICITY. (Abstract #845)Chul Woo Yang, Can Li, Sun Woo Lim, Bo Kyung Sun,Bum Soon Choi, Yong Soo Kim, Byung Kee Bang. Seoul,Republic of Korea.

P302 NON-SELECTIVE BLOCKADE OFCYCLOOXYGENASES-1 AND –2 AMELIORATESTHE HYPOXIC EFFECTS ON ENDOTHELIALCELLS. (Abstract #846)Maria A. Da Gloria, Marcos A. Cendeze, AlvaroPacheco-Silva, Niels O. S. Camara. Sao Paulo, Brazil.

P303 GENE EXPRESSION PROFILING AFTERPROLONGED COLD ISCHEMIA IN RAT KIDNEYTRANSPLANTS FOLLOWING INDUCTION OFHO-1. (Abstract #847)Katja Kotsch, Paulo N. A. Martins, Annelie Dernier,Uwe Janssen, Bernhard Gerstmayer, Birgit Sawitzki,Stefan G. Tullius, Hans-Dieter Volk. Berlin, Germany;Cologne, Germany.

P304 THE DYSREGULATION OF PI3-KINASE/AKTPATHWAY CONTRIBUTES TO THE ISCHEMIA/REPERFUSION INJURY DURING GRAFTPRESERVATION BY UW SOLUTION.(Abstract #848)Xian-Liang Li, Kwan Man, Kevin Tak-Pan Ng, ChrisKin-Wai Sun, Chung-Mau Lo, Sheung-Tat Fan. HongKong, China.

P305 PROTECTIVE EFFECT OF YM AGAINST WARMISCHEMIA REPERFUSION INJURY IN MURINEKIDNEY. (Abstract #849)Li Feng, Youping Li, Feng Cheng, Shengfu Li, Li Zhang,Zizhen Ye. Chengdu, Sichuan, China.

P306 δδδδδ-OPIOID AGONISTS, AS HIBERNATIONINDUCTION TRIGGERS, ATTENUATE THEMACROPHAGE RESPONSE TOLIPOPOLYSACCHARIDE STIMULATION.(Abstract #850)Thomas L. Husted, Alex B. Lentsch, Steven M. Rudich.Cincinnati, OH.

P307 SINGLET OXYGEN ENERGY (SOE)ILLUMINATION DURING COLD ISCHEMIAIMPROVES THE PRESERVATIVE EFFECT OF THEUW SOLUTION ON HIGH ENERGY PHOSPHATESIN ISCHEMIC RAT HEARTS. (Abstract #851)Daniel J. Lukes, Ulrika Skogsberg, Anna Nilsson, AndreasLundgren, Ann Lindgård, Olivier Rakotonorainy, BassamSoussi, Michael Olausson. Goteborg, 413 45 VastraGotaland, Sweden.

P308 RINGER’S ETHYL PYRUVATE SOLUTIONIMPROVES LIVER ISCHEMIA-REPERFUSIONINJURY IN RATS. (Abstract #852)Allan Tsung, Takashi Kaizu, Atsunori Nakao, BrainBucher, Mitchell P. Fink, Noriko Murase, David A.Geller. Pittsburgh, PA.

P309 IDENTIFICATION OF DIFFERENTIALLYEXPRESSED GENES IN KIDNEYS FROM BRAINDEAD DONORS USING OLIGONUCLEOTIDEARRAYS. (Abstract #853)Theo A. Schuurs, Frans Gerbens, Joost A. B. van derHoeven, Petra Ottens, Krista A. Kooi, Henri G. D.Leuvenink, Robert M. W. Hofstra, Rutger J. Ploeg.Groningen, Netherlands.

P310 EFFECT OF BRAIN DEATH AND NON-HEART-BEATING KIDNEY DONATION ON RENALFUNCTION AND INJURY. (Abstract #854)Mark M. E. D. van den Eijnden, Henri G. D. Leuvenink,Petra J. Ottens, Nils A. ‘t Hart, Wim van Oeveren,Aurora M. Morariu, Harry van Goor, Rutger J. Ploeg.Groningen, Netherlands.

P311 PROLONGED COLD ISCHEMIA IN RATCARDIAC ALLOGRAFTS PROMOTES ISCHEMIAREPERFUSION INJURY AND THE DEVELOPMENTOF GRAFT CORONARY ARTERY DISEASE IN ALINEAR FASHION. (Abstract #855)Masashi Tanaka, Raya D. Terry, Golnaz K. Mokhtari,Grant Hoyt, David T. Cooke, Anthony D. Caffarelli,Theo Kofidis, Robert C. Robbins. Stanford, CA.

P312 GERANYLGERANYLACETONE INCREASESRENAL EXPRESSION OF HEAY SHOCK PROTEIN70 AND PROTECTS KIDNEY FROM ISCHEMIA/REPERFUSION INJURY. (Abstract #856)Masayoshi Miura, Keita Minami, Ken Morita, YoshihikoWatarai, Katsuya Nonomura. Sapporo, Hokkaido, Japan.

P313 CONTRASTING EFFECT OF TGF-BETA,CYCLOSPORINE, TACROLIMUS, ANDSIROLIMUS ON EXPRESSION OF PRO-FIBROGENIC GENES AND iNOS IN RENALCELLS. (Abstract #857)Ashwani K. Khanna, Matthew S. Plummer, Galen M.Pieper. Milwaukee, WI; Milwaukee.

P314 IMORTANCE OF TUMOR NECROSIS FACTORCLEAVAGE PROCESS IN REIMPLANTATIONLUNG INJURY. (Abstract #858)Taichiro Goto, Akitoshi Ishizaka, Mitsutomo Kohno,Makoto Sawafuji, Kohichi Kobayashi. Tokyo, Japan.

P315 STAT3 CONFERS RESISTANCE AGAINSTHYPOXIA/REOXYGENATION-INDUCEDOXIDATIVE INJURY IN HEPATOCYTES VIA Mn-SOD. (Abstract #859)Keita Terui, Sanae Haga, Shin Enosawa, Naomi Onuma,Michitaka Ozaki. Setagaya, Tokyo, Japan; Chuo-ku,Chiba, Japan; Shikata, Okayama, Japan.

P316 WHICH COLLOID IS PREFERRED IN A NEWPRESERVATION SOLUTION FOR MACHINEPERFUSION OF THE LIVER? (Abstract #860)Maud Bessems, Benedict M. Doorschodt, OlgaHooijschuur, Arlene K. van Vliet, Thomas M. van Gulik.Amsterdam, Netherlands.

P317 COLD ISCHEMIA-REPERFUSION CONTRIBUTESTO THE DEVELOPMENT OF CHRONICREJECTION VIA LOSS OF MITOCHONDRIA INCARDIAC ALLOGRAFTS. (Abstract #861)Stefan Schneeberger, Oliver Renz, Peter Obrist, JuliaHeizinger, Hugo Meusburger, Gerald Brandacher, WalterMark, Raimund Margreiter, Andrey V. Kuznetsov.Innsbruck, Austria; Innsbruck, Austria.

P318 NITRIC OXIDE MODULATES RENAL VASCULARFUNCTION IN THE BRAIN DEATH DONOR.(Abstract #862)Terezia B. Andrasi, Anna Blazovics, Pal Soos, JorgGastmeier, Gabor Szabo, Hans-Detlev Saeger. Dresden,Germany; Budapest, Hungary; Heidelberg, Germany.

108

Mini-Oral: Antigen Presentation andAlloimmunity12:45 - 1:45 PM

Room 306Chairs: Eugenia Fedoseyeva and Gregg A. Hadley

12:45 PM MONOCYTES ENGULF ENDOTHELIALMEMBRANES VIA A SCAVENGER RECEPTOR,AND SCAVENGER RECEPTOR BLOCKADEPREVENTS MONOCYTE ACTIVATION.(Abstract #863)He Xu, Xiao-Jie Zhang, Allan D. Kirk. Bethesda, MD.

12:52 PM INDUCTION OF “INFECTIOUS TOLERANCE” BYDENDRITIC CELLS DERIVED FROM TOLERANTALLO-CARDIAC TRANSPLANT RECIPIENTS.(Abstract #864)Dameng Lian, Mu Li, Thomas E. Ichim, Bertha Garcia,Robert Zhong, Wei-Ping Min. London, ON, Canada.

12:59 PM PAR-1 AND PAR-2 ACTIVATION DIFFERENTIALLYMODULATE TH-RESPONSE INDUCED BYDENDRITIC CELLS (DC). (Abstract #865)P. Pontrelli, G. Grandaliano, M. Ursi, A. Blasi, V.Petruzzelli, L. Roca, E. Ranieri, L. Gesualdo, F. P.Schena. Italy.

1:06 PM FREQUENCIES OF ALLOREACTIVE BLYMPHOCYTES IN RENAL TRANSPLANTPATIENTS WITH HISTORIC AND CURRENTSENSITIZATION TO HLA ANTIGENS.(Abstract #866)Mary S. Leffell, Dessislava Kopchaliiska, Robert A.Montgomery, Andrea A. Zachary. Baltimore, MD.

1:13 PM INTERACTIONS BETWEEN INDIRECT MHAGREACTIVE CD4+ T CELLS AND DIRECT CLASS IALLOREACTIVE CD8+ T CELLS IN A MODEL OFCHRONIC GRAFT REJECTION. (Abstract #867)David M. Richards, Stacy L. Dalheimer, Marshall I.Hertz, Daniel L. Mueller. Minneapolis, MN.

1:20 PM OVEREXPRESSION OF ELAFIN, A SERINEELASTASE –SPECIFIC INHIBITOR, PREVENTSACUTE CARDIAC ALLOGRAFT REJECTION.(Abstract #868)Monika Zwierzchoniewska, Robert C. Robbins, MarleneRabinovitch, Eugenia V. Fedoseyeva. Stanford, CA.

1:27 PM POTENTIAL ROLE OF CD103 IN PROMOTINGPANCREATIC ISLET DESTRUCTION DURINGPROGRESSION TO TYPE I DIABETES.(Abstract #869)Adam W. Bingaman, Donghua Wang, Gregg A. Hadley.Baltimore, MD.

Mini-Oral: Donation, Preservation, and Outcome12:45 - 1:45 PM

Ballroom AChairs: Donald C. Dafoe and Martin Mozes

12:45 PM CASPASE-3 INHIBITOR PROTECTS ISOLATEDHUMAN ISLET CELLS FROM APOPTOSISRESULTING IN IMPROVEMENT OF ISLET GRAFTFUNCTIONS. (Abstract #870)Masahiko Nakano, Ippei Matsumoto, Toshiya Sawada,Jeff Ansite, Jeremy Oberbroeckling, Hui J. Zhang, NicoleKirchhof, Jeff Shearer, David E. R. Sutherland, BernhardJ. Hering. Minneapolis, MN.

12:52 PM PERSISTENCE OF COLD ISCHEMIA TIME ANDOF ITS NEGATIVE CONSEQUENCES ON RENALALLOGRAFTS. (Abstract #871)Abdulla K. Salahudeen, Warren May. Jackson, MS.

12:59 PM THE USE OF PERFUSION PARAMETERS INPREDICTING OUTCOMES OF MACHINEPRESERVED KIDNEYS. (Abstract #872)Martin F. Mozes, Ron B. Skolek, Brian C. Korf, theKidney Subcommittee. Elmhurst, IL.

1:06 PM DELAYED GRAFT FUNCTION AND PRIMARYNONFUNCTION IN EXPANDED-CRITERIA-DONOR KIDNEY TRANSPLANTATION.(Abstract #873)Thomas D. Johnston, Leroy R. Thacker, Hoonbae Jeon,Bruce A. Lucas, Dinesh Ranjan. Lexington, KY;Richmond, VA.

1:13 PM TRANSPLANTATION OF RENAL ALLOGRAFTSFROM HEPATITIS C SEROPOSITIVE DECEASEDDONORS INTO ELDERLY HEPATITIS CSERONEGATIVE RECIPIENTS. (Abstract #874)Aloke K. Mandal, Nicholas Drew, Mara Tableman, JodiA. Lapidus. Portland, OR.

1:20 PM DONOR ASSESSMENT: IS A POLICY CHANGEWARRANTED? (Abstract #875)J. F. Buell, T. M. Beebe, T. G. Gross, M. J. Hanaway, R.R. Alloway, J. Trofe, E. S. Woodle. Cincinnati, OH.

1:27 PM TRENDS OVER A DECADE OF PEDIATRIC LIVERTRANSPLANTATION IN THE UNITED STATES.(Abstract #876)Ming-Sing Si, Philip Rosenthal, Maureen A. McBride,Sarah E. Taranto, Christine Mudge, Susan Stritzel, JohnP. Roberts, Sandy Feng. San Francisco, CA; Richmond,VA.

Mini-Oral: Ischemia-Reperfusion Injury12:45 - 1:45 PM

Room 309Chairs: Milagros Samaniego-Picota and Barbara A. Wasowska

12:45 PM IMPROVED PERFUSION IN HYPOTHERMICMACHINE PRESERVATION OF THE LIVER.(Abstract #877)Nils A. ‘t Hart, Arjan van der PLaats, Henri G. D.Leuvenink, Harry van Goor, Janneke Wiersema-Buist,Bart J. Verkerke, Gerhard Rakhorst, Rutger J. Ploeg.Groningen, Netherlands.

12:52 PM PRESERVING THE MUCOSAL BARRIER VIANUTRIENT &&&&& ANTIOXIDANT TREATMENT DURINGSMALL BOWEL STORAGE. (Abstract #878)Payam Salehi, Christopher Samuel, Thomas A. Churchill.Edmonton, AB, Canada.

12:59 PM CD39/ECTO-NUCLEOSIDE TRIPHOSPHATEDIPHOSPHOHYDROLASE-1 MAINTAINSVASCULAR INTEGRITY IN INTESTINALISCHEMIA-REPERFUSION INJURY.(Abstract #879)Olaf Guckelberger, Xiofeng Sun, Jean Sévigny, MasatoImai, Elzbieta Kaczmarek, Keiichi Enjyoji, Simon C.Robson. Berlin, Germany; Boston, MA.

1:06 PM CARBON MONOXIDE SIGNIFICANTLY REDUCESTHE APOPTOTIC EVENTS ASSOCIATED WITHISCHEMIA-REPERFUSION INJURY:OBSERVATIONS IN A RENAL PIG-TO-PRIMATEMODEL. (Abstract #880)E. Cozzi, M. Seveso, F. Calabrese, G. De Benedictis, N.Baldan, M. Boldrin, M. Castagnaro, L. Ravarotto, P.Carraro, R. Busetto, L. E. Otterbein, M. Lavitrano, D.Bernardini, G. Thiene, F. H. Bach, E. Ancona. Padua,Italy; Padua, Italy; Legnaro, Italy; Pittsburgh, PA;Monza, Italy; Boston, MA.

109

Mo

nd

ay, May 17

1:13 PM NITRIC OXIDE (NO) CAN PROMOTE SURVIVALOF TUBULAR EPITHELIAL CELLS (TEC) ANDINCREASE SURVIVAL OF RENAL ALLOGRAFTS.(Abstract #881)C. Du, J. Jiang, Q. Guan, Z. Yin, R. Zhong, A. M.Jevnikar. London, ON, Canada; London, ON.

1:20 PM A SINGLE SHORT-TERM DONOR TREATMENTFOR THE INDUCTION OF CO REDUCES GRAFTIMMUNOGENICITY AND IMPROVESALLOGRAFT LONG-TERM FUNCTION.(Abstract #882)Paulo N. A. Martins, Anke Jurisch, Anja Reutzel-Selke,Andreas Pascher, Sven Jonas, Johann Pratschke, PeterNeuhaus, Hans-Dieter Volk, Stefan G. Tullius. Berlin,Germany.

1:27 PM BENEFICIAL EFFECT OF CARBON MONOXIDE-INHALATION AGAINST ISCHEMIA/REPERFUSION INJURY AFTER RAT LIVERTRANSPLANTATION: POSSIBLE MECHANISM OFiNOS/NO PATHWAY BLOCKADE. (Abstract #883)Takashi Kaizu, Eric L. Marderstein, Lee L. Sonis, LifangShao, Brian T. Bucher, Atsunori Nakao, Leo E.Otterbein, David A. Geller, Noriko Murase. Pittsburgh,PA.

Mini-Oral: Liver Transplantation: Controversies12:45 - 1:45 PM

Ballroom BChairs: Devin Eckhoff and Rafik M. Ghobrial

12:45 PM DECLINING NUMBER OF POTENTIAL LIVINGDONOR CANDIDATES FOR ADULT LDLT.(Abstract #884)Dianne LaPointe Rudow, Milan Kinkhabwala, SilviaHafliger, Douglas Marratta, Janet Lee, Jean C. Emond,Robert S. Brown, Jr. New York, NY.

12:52 PM THE SEVERITY OF RECURRENT HEPATITIS C(HCV) IN LIVING DONOR ADULT LIVERTRANSPLANT (LDALT) RECIPIENT IS THE SAMEAS CADAVER (CAD) RECIPIENTS. (Abstract #885)Fredric D. Gordon, Elizabeth A. Pomfret, James J.Pomposelli, Andrew Keaveny, Mary Ann Simpson,David Lewis, Denise Morin, Urmila Khettry, Roger L.Jenkins. Burlington, MA.

12:59 PM IMMUNOMONITORING OF LIVER RECIPIENTSTREATED WITH TOLERANCE-ENHANCINGREGIMEN OF IMMUNOSUPPRESSION.(Abstract #886)Noriko Murase, Diana Metes, Adriana Zeevi, CarolBentlejewski, David Guaspari, Camila Macedo, AngieFarren, Pam McGregor, Bijan Eghtesad, Paulo Fontes,Amadeo Marcos, Jennifer Woodward, Anthony J.Demetris, John J. Fung, Thomas E. Starzl. Pittsburgh,PA.

1:06 PM REGIONAL VARIATIONS IN MELD EXCEPTIONSFOR NON-STANDARD DIAGNOSES.(Abstract #887)Hector Rodriguez-Luna, Hugo E. Vargas, Adyr Moss,Kunam S. Reddy, Richard B. Freeman, Ann M. Harper,Erick B. Edwards, David C. Mulligan. Phoenix, AZ;Boston, MA; Richmond, VA.

1:13 PM HIGHER PELD SCORES AT LISTING ARE NOTASSOCIATED WITH WORSE POST-TRANSPLANTOUTCOME IN PEDIATRIC LIVERTRANSPLANTATION (LT): A RETROSPECTIVESTUDY IN 100 RECIPIENTS. (Abstract #888)Raymond Reding, Christophe Bourdeaux, Tran ThanhTri, Jeremie Gras. Brussels, Belgium.

1:20 PM TOLERANCE OF LIVER TRANSPLANTRECIPIENTS TO STRENUOUS PHYSICALACTIVITY IN HIGH ALTITUDE. (Abstract #889)J. Pirenne, F. Van Gelder, C. Verslype, W. Peetermans, F.Nevens. Leuven, Belgium.

1:27 PM COMBINED LUNG (HEART) AND LIVERTRANSPLANTATION: INDICATION ANDOUTCOME. (Abstract #890)Gerrit Grannas, Martin Strueber, Rainer Lueck, ThomasBecker, Michael Neipp, Juergen Klempnauer, BjoernNashan. Hannover, Germany.

Concurrent Session 21: ABO-IncompatibleKidney Transplantation2:00 - 3:30 PM

Ballroom AChairs: James M. Gloor and Mahendra V. Govani

2:00 PM ACCOMMODATION IN ABO INCOMPATIBLELIVING-DONOR KIDNEY TRANSPLANTATION.(Abstract #891)Atsushi Aikawa, Tomomi Hadano, Takehiro Ohara,Kenji Arai, Takeshi Kawamura, Masaki Muramatsu,Tosihiro Itabashi, Ken Sakai, Sonoo Mizuiri, AkiraHasegawa, Tetsuo Kanai, Noriko Kawada. Tokyo,Tokyo, Japan.

2:10 PM ABO-INCOMPATIBLE KIDNEYTRANSPLANTATION WITHOUT SPLENECTOMYUSING ANTIGEN-SPECIFICIMMUNOADSORPTION AND RITUXIMAB.(Abstract #892)Gunnar Tydén, Gunilla Kumlien, Ingela Fehrman.Stockholm, Sweden.

2:20 PM THREE-YEAR OUTCOME OF ABO-INCOMPATIBLE KIDNEY TRANSPLANTATIONUNDER PRETRANSPLANT ONE-WEEKIMMUNOSUPPRESSION WITH TACROLIMUS,MYCOPHENOLATE MOFETIL, AND STEROID.(Abstract #893)Kazunari Tanabe, Tadahiko Tokumoto, Hideki Ishida,Nobuo Ishikawa, Naoshi Miyamoto, Tsunenori Kondo,Hiroaki Shimmura, Kiyoshi Setoguchi, Hiroshi Toma.Shinkuku, Tokyo, Japan.

2:30 PM EXCELLENT LONG-TERM OUTCOME OF ABO-INCOMPATIBLE RENAL TRANSPLANTATION. ASINGLE-CENTER EXPERIENCE. (Abstract #894)Hiroshi Toma, Kazunari Tanabe, Tadahiko Tokumoto,Hideki Ishida, Nobuo Ishikawa, Naoshi Miyamoto,Hiroaki Shimmura, Ichiro Nakajima, Shouhei Fuchinoue,Satoshi Teraoka. Tokyo, Japan.

2:40 PM OUTCOMES OF ABO-INCOMPATIBLE KIDNEYTRANSPLANTATION RECIPIENTS WITH POSITIVEPRA. (Abstract #895)Hiroaki Shimmura, Kazunari Tanabe, TadahikoTokumoto, Hideki Ishida, Nobuo Ishikawa, NaoshiMiyamoto, Kiyoshi Setoguchi, Hiroshi Toma. Shinjuku,Tokyo, Japan.

2:50 PM EFFECT OF ANTI-CD20 ANTIBODY ON SPLENICAND PERIPHERAL BLOOD B LYMPHOCYTES INPOSITIVE CROSSMATCH KIDNEY TRANSPLANTRECIPIENTS RECEIVING PLASMAPHERESIS ANDINTRAVENOUS IMMUNOGLOBULIN.(Abstract #896)James M. Gloor, Joseph P. Grande, William R. Macon,Mark D. Stegall. Rochester, MN.

110

3:00 PM IMMUNOGLOBULIN G-A-M REMOVAL DURINGPLASMAPHERESIS TREATMENT FOR POSITIVECROSSMATCH AND ABO INCOMPATIBLEKIDNEY TRANSPLANTATION. (Abstract #897)Lloyd Ratner, Mark Chaballa, Beth Colombe, NancyEdger-Hall, Liise Kayler, Donald Dafoe. Philadelphia,PA.

3:10 PM REJECTION EPISODES IN PATIENTSFOLLOWING POSITIVE CROSSMATCH ANDABO INCOMPATIBLE LIVE DONOR RENALTRANSPLANTATION UNDER THEPLASMAPHERESIS/IVIg PROTOCOL.(Abstract #898)Liise K. Kayler, Donald C. Dafoe, Beth Colombe,Deborah LaCava, James A. Rothschild, George C.Francos, James F. Burke, Jr., John J. Friedewald, John L.Farber, Lloyd E. Ratner. Philadelphia, PA.

3:20 PM SUCCESSFUL PRIMARY DECEASED DONORTRANSPLANTATION IN THE PRESENCE OFDONOR-SPECIFIC HLA CLASS I ANTIBODYWITHOUT IVIG OR PLASMAPHERESISTHERAPY. (Abstract #899)Christopher F. Bryan, Scott B. McDonald, Alan M.Luger, Franz T. Winklhofer, A. Michael Borkon, CharlesF. Shield, Bradley A. Warady, Mark I. Aeder. Westwood,KS.

Concurrent Session 22: Campath2:00 - 3:30 PM

Veterans BallroomChairs: Thomas D. Batiuk and Allan S. MacDonald

2:00 PM CAMPATH 1H (ALEMTUZUMAB) IN RENALTRANSPLANTATION: 5-YEAR COMPARATIVEFOLLOW UP. (Abstract #900)Christopher J. Watson, John Firth, John Bradley,Kenneth G. Smith, Neville V. Jamieson, Peter J. Friend,Geoff Hale, Herman Waldmann, Andrew J. Bradley, SirRoy Y. Calne. Cambridge, United Kingdom; Oxford,United Kingdom.

2:10 PM CAMPATH-1H IN PATIENTS WITH DELAYEDGRAFT FUNCTION: REDUCED REJECTION ANDIMPROVED GRAFT SURVIVAL. (Abstract #901)Stuart J. Knechtle, John D. Pirsch, Barbara J. Voss, GlenE. Leverson, Bryan N. Becker, Luis A. Fernandez, L.Thomas Chin, Yolanda T. Becker, Jon S. Odorico,Anthony M. D’Alessandro, Hans W. Sollinger. Madison,WI.

2:20 PM THE USE OF CAMPATH-1H AS INDUCTIONTHERAPY IN RENAL TRANSPLANTATION:PRELIMINARY RESULTS. (Abstract #902)Gaetano Ciancio, George W. Burke, Jeff J. Gaynor, AdelaD. Mattiazzi, Anne Rosen, Ramir Roohipour, DavidRoth, Warren Kupin, Delvis Jorge, Joshua Miller. Miami,FL.

2:30 PM MONOCYTES ARE DOMINANT INFLAMMATORYCELLS FOR ACUTE RENAL REJECTION AFTERCOMBINED TREATMENT WITH PREOPERATIVECampath-H AND POSTOPERATIVEIMMUNOSUPPRESSION. (Abstract #903)Ping L. Zhang, Sayeed K. Malek, Jeffery W. Prichard,Fan Lin, Taher M. Yahya, Michael S. Schwartzman, RuthP. Latsha, Evan R. Norfolk, Robert E. Brown, James E.Hartle, Santosh Potdar. Danville, PA.

2:40 PM CELLULAR PHENOTYPES AFFECTED BYINDUCTION THERAPY WITH CAMPATH-1H VSTHYMOGLOBULIN VS ZENAPAX IN KIDNEYALLOGRAFT RECIPIENTS. (Abstract #904)Manuel R. Carreno, Gaetano Ciancio, George W. Burke,Anne Rosen, Camillo Ricordi, Andreas Tzakis, JoshuaMiller, Violet Esquenazi. Miami, FL.

2:50 PM IMMUNOPHENOTYPIC ANALYSIS OFCELLULAR INFILTRATE OF RENAL ALLOGRAFTBIOPSIES IN PATIENTS WITH ACUTE REJECTIONAFTER INDUCTION WITH CAMPATH 1H.(Abstract #905)Lorenzo G. Gallon, Marina Noris, Elena Gagliardini, W.James Chon, Joseph R. Leventhal, Dixon B. Kaufman,Giuseppe Remuzzi. Chicago, IL; Bergamo, Italy; Chicago.

3:00 PM CAMPATH 1-H PRECONDITIONING ANDTACROLIMUS MONOTHERAPY WITHSUBSEQUENT WEANING IN RENAL TRANSPLANTRECIPIENTS. (Abstract #906)Ron Shapiro, Henkie P. Tan, Amit Basu, Akhtar Khan,Edward A. Gray, Parmjeet S. Randhawa, Noriko Murase,Adriana Zeevi, Anthony J. Demetris, JenniferWoodward, Mark L. Jordan, Kristine M. Ruppert,Amadeo Marcos, John J. Fung, Thomas E. Starzl.Pittsburgh, PA.

3:10 PM INTRAOPERATIVE CAMPATH-1H INDUCTIONWITH TACROLIMUS OR MYCOPHENOLATEMOFETIL(MMF) BASED MAINTENANCEIMMUNOSUPPRESSION - IN ADULT CADAVERICKIDNEY TRANSPLANTATION. (Abstract #907)Santosh Potdar, Sayeed Khan Malek, Patricia Seneko,Ping L. Zhang, Fan Ling, Jeffery W. Prichard, MichealSchwartzman, Evan Norfolk, Taher Yahya, James E.Hartle. Danville, PA.

3:20 PM CAMPASIA: A PILOT RANDOMISEDCONTROLLED TRIAL OF THE EFFECTIVENESSOF CAMPATH-1H (MABCAMPATH®) AS ANINDUCTION AGENT FOR PREVENTION OFGRAFT REJECTION AND PRESERVATION OFRENAL FUNCTION IN PATIENTS RECEIVINGKIDNEY TRANSPLANTS. (Abstract #908)Anantharaman Vathsala, Enrique T. Ona, Si-Yen Tan,Shirley Suresh, Yiong-Huak Chan, Huei-Xin Lou,Concesca B. Cabanayan Casasola, Jorgen Seldrup, RoyCalne. Singapore; Quezon City, Philippines; KualaLumpur, Malaysia.

Concurrent Session 23: ExperimentalImmunosuppression: New Insights I2:00 - 3:30 PM

Room 310Chairs: Markus H. Frank and Douglas A. Hale

2:00 PM IMMATURE DENDRITIC CELLS PLUSSUBDOSING SIROLIMUS ACHIEVE LONG-TERMALLOGRAFT SURVIVE. A MECHANISTICINSIGHT. (Abstract #909)Ran Tao, Lina Lu, Shi-He Wang, Richard Demarco,Michael T. Lotze, John J. Fung, Shiguang Qian.Pittsburgh, PA.

2:10 PM RAPAMYCIN INHIBITS EPSTEIN BARR VIRUS + BCELL LYMPHOMA PROLIFERATION THROUGHMODULATION OF CELL CYCLE PROTEINEXPRESSION. (Abstract #910)Maria Vaysberg, Cynthia E. Balatoni, Ronald R.Nepomuceno, Sheri M. Krams, Olivia M. Martinez.Stanford, CA.

111

Mo

nd

ay, May 17

2:20 PM RAPAMYCIN BLOCKS TUMOR PROGRESSIONINDUCED BY CYCLOSPORINE IN A MOUSETUMOR-TRANSPLANT MODEL. (Abstract #911)Joachim Andrassy, Gudrun E. Koehl, Markus Guba,Alexander Kroemer, Marcus N. Scherer, Christian Graeb,Karl-Walter Jauch, Edward K. Geissler. Madison, WI;Regensburg, Germany.

2:30 PM THE EFFECT OF RAPAMYCIN (RAPA) ANDMYCOPHENOLIC ACID (MMF) ON VASCULARENDOTHELIAL GROWTH FACTOR (VEGF)FUNCTION IN VITRO. (Abstract #912)Stefan G. Kiessling, Christopher Geehan, David M.Briscoe. Boston, MA.

2:40 PM DEOXYSPERGUALIN (DSG) DISRUPTS THEMYD88 INNATE IMMUNE PATHWAY ANDPROMOTES DENDRITIC CELL APOPTOSIS: ARATIONAL BASIS FOR USE OF DSG INTOLERANCE. (Abstract #913)Jianguo Wu, Jin He, Clement Asiedeu, Frank T. Thomas,Anne Hutchings, Stephanie Le Bas-Bernardet, Judith M.Thomas. Birmingham, AL.

2:50 PM FTY720 INDUCES PROLONGED ALLOGRAFTSURVIVAL IN THE PRESENCE OF MEMORY CD4T CELLS. (Abstract #914)Anna Valujskikh, Alla Gomer, Peter S. Heeger. Cleveland,OH.

3:00 PM THE SPHINGOSINE-1-PHOSPHATE RECEPTORAGONIST FTY720 REGULATES DENDRITIC CELLTRAFFICKING BY MODULATION OF ADHESIONMOLECULE EXPRESSION. (Abstract #915)Yuk Yuen Lan, An De Creus, P. Toby Coates, Angus W.Thomson. Pittsburgh, PA.

3:10 PM NIBR713: A NEW, MORE SELECTIVE FTY720ANALOGUE WITH SIMILAR EFFICACY BUTLONGER DURATION OF ACTION IN ANIMALTRANSPLANT MODELS. (Abstract #916)Klaus Hinterding, Carsten Spanka, Charles Pally, BarbaraNuesslein-Hildesheim, Volker Brinkmann, Marc Bigaud,Klaus Menninger, Gisbert Weckbecker, Christian Beerli,Danilo Guerini, Karl Welzenbach, Gabriele Weitz,Christian Bruns. Basel, Switzerland.

3:20 PM THE NOVEL IMMUNOMODULATOR FTY720DESENSITIZES AND DISRUPTS ENDOGENEOUSS1P RECEPTOR SIGNALING PATHWAYS INVITRO. (Abstract #917)Danilo Guerini, Rao Movva, Thi-Thanh-Thao Tran,Christoph Hangartner. Basel, Switzerland.

Concurrent Session 24: Liver Transplantation:Hepatitis C2:00 - 3:30 PM

Ballroom BChairs: Michael R. Charlton and Federico G. Villamil

2:00 PM LIVER TRANSPLANTATION FOR HCVCIRRHOSIS: RESULTS ARE NOT GETTINGWORSE IN RECENT YEARS. (Abstract #918)Luca S. Belli, Dimitrios N. Samonakis, Alberto B.Alberti, George V. Papatheodiridis, Marcello Vangeli,David W. Patch, Aldo Airoldi, Alberto Quaglia, KeithRolles, Luciano de Carlis, Andrew K. Burroughs,Giovambattista Pinzello. Milan, Italy; London, UnitedKingdom.

2:10 PM RECONSTITUTION OF HEPATITIS C VIRUS-SPECIFIC T CELL-MEDIATED IMMUNITYFOLLOWING LIVER TRANSPLANTATION.(Abstract #919)Scott Weston, Rachel Leistikow, Rajendar Reddy, MariaTorres, Michael Davey, Anne M. Wertheimer, HugoRosen. Portland, OR; Philadephia, PA; Miami, FL.

2:20 PM SUSTAINED RESPONSE TO HCV TREATMENTFOLLOWING TRANSPLANTATION LEADS TOLOWER HCV ACTIVITY AND FIBROSIS ANDGREATER GRAFT SURVIVAL. (Abstract #920)Stephen C. Rayhill, Patricia Kirby, Michael Voigt,Douglas Labrecque, Daniel Katz, Rachael Miller, AlanStolpen, Frank Mitros, You Min Wu, Warren Schmidt.

2:30 PM INFLUENCE OF CLASS II HUMAN LEUKOCYTEANTIGENS ON RECURRENT HEPATITIS C ANDGRAFT SURVIVAL IN LIVER TRANSPLANTRECIPIENTS. (Abstract #921)Richard T. Stravitz, Pamela Kimball, Velimir A. Luketic,Richard K. Sterling, Arun J. Sanyal, Robert A. Fisher,Adrian H. Cotterell, Daniel Maluf, Marc P. Posner, ScottA. Mills, Melissa Contos, Mitchell L. Shiffman.Richmond, VA.

2:40 PM HCV CORE PROTEIN IMPAIRS T CELLACTIVATION AND ENHANCES RESPONSE TOCYCLOSPORINE. (Abstract #922)Pam M. Kimball, Scott Verbeke, Mitchell Shiffman.Richmond, VA.

2:50 PM MULTICENTER RANDOMIZED HEPATITIS C (HCV)THREE TRIAL POST LIVER TRANSPLANTATION(OLT): A PRELIMINARY REPORT. (Abstract #923)Carlos G. Fasola, Goran B. Klintmalm, C. HepatitisThree Study Group. Dallas, TX.

3:00 PM THE IMPACT OF CALCINEURIN INHIBITORS(CNIs) ON RECURRENT HEPATITIS C INFECTION.(Abstract #924)Gary A. Levy, Leslie B. Lilly, David R. Grant, Nigel T.Girgrah, Atul Humar, Paul D. Greig, Mark S. Cattral.Toronto, ON, Canada.

3:10 PM PRIMARY HEPATOCYTES DERIVED FROM THEDONOR LIVER EXHIBIT A SIMILAR PATTERN OFHEPATITIS C QUASISPECIES SELECTIVITY ASTHE LIVER ALLOGRAFT. (Abstract #925)Tae W. Chong, Robert L. Smith, Michael G. Hughes,Christine K. Rudy, Robert G. Sawyer, Timothy L. Pruett.Charlottesville, VA.

3:20 PM INTRAHEPATIC TISSUE HEPATITIS C PCRTESTING TO HELP DETERMINE SUSTAINEDVIROLOGICAL RESPONSE IN LIVERTRANSPLANT RECIPIENTS FOLLOWINGSUCCESSFUL COMPLETION OF HCVANTIVIRAL THERAPY. (Abstract #926)Guy W. Neff, Christopher B. O’Brien, Robert Cirocco,Kamran Safdar, Marzia Montalbano, Jose A. Gascon,Eugene Schiff. Miami, FL.

Concurrent Session 25: Mechanisms of AcuteGraft Injury2:00 - 3:30 PM

Room 309Chairs: Sheri M. Krams and Didier A. Mandelbrot

2:00 PM DIRECT AND INDIRECT ALLORECOGNITION:VISUALIZATION OF DENDRITIC CELLINTERACTIONS IN GRAFT REJECTION. (Abstract #927)Jordi C. Ochando, Jaime Llodra, Gwendalyn J. Randolph,Alexander Y. Rudensky, Jonathan S. Bromberg, Nancy R.Krieger. New York, NY; Seattle, WA.

112

2:10 PM ACUTE REJECTION OF HEART ALLOGRAFTSWITH A SINGLE MHC II DISPARITY IS MEDIATEDBY BLOCKING CD25+ REGULATORY CELLS BUTNOT BY DONOR-SPECIFIC DENDRITIC CELLPRIMING. (Abstract #928)Soren Schenk, Danielle D. Kish, Anton V. Gorbachev,Kiyotaka Fukamachi, Peter S. Heeger, Robert L.Fairchild. Cleveland, OH.

2:20 PM SYNERGISTIC INFECTIOUS TOLERANCE BYADOPTIVE TRANSFER OF TOLEROGENICDENDRITIC CELLS AND T REGULATORY TCELLS. (Abstract #929)Wei-Ping Min, Dameng Lian, Mu Li, Thomas E. Ichim,Bertha Garcia, Robert Zhong. London, ON, Canada.

2:30 PM NKT CELLS PARTICIPATE IN REJECTION OFISLET ALLOGRAFTS IN THE LIVER OF MICE.(Abstract #930)Atsushi Toyofuku, Yohichi Yasunami, KentarohNabeyama, Masahiko Nakano, Masayuki Satoh,Nobuhide Matsuoka, Junko Ono, Toshinori Nakayama,Masaru Taniguchi, Masao Tanaka, Seiyo Ikeda. Fukuoka,Japan; Chiba, Japan; Yokohama, Japan.

2:40 PM IN VIVO REGULATION OF TH1 RESPONSES ANDMURINE CARDIAC ALLOGRAFT REJECTION BYMUTIDRUG RESISTANCE P-GLYCOPROTEIN.(Abstract #931)Atsushi Izawa, Natasha Y. Frank, Shona S. Pendse,Armen Margaryan, Masayuki Sho, Mohamed H. Sayegh,Markus H. Frank. Boston, MA.

2:50 PM IMPAIRED REJECTION IN THE ABSENCE OFLIGHT: A COMPARISON OF CD8 AND CD4 TCELLS. (Abstract #932)Zhong Guo, Ying Dong, Jun Wang, Marvin Newton-West, Yang-Xin Fu, Kenneth A. Newell. Atlanta, GA;Chicago, IL.

3:00 PM DISTINCT REQUIRMENTS FOR HOST CD80/CD86COSTIMULATORY MOLECULES IN CARDIACVERSUS ISLET REJECTION. (Abstract #933)Zachary Johnson, Joshua Beilke, Biagio Pietra, BrianKelly, Ronald G. Gill. Denver, CO.

3:10 PM EARLY ALLOGRAFT REJECTION IS MEDIATEDBY CD3+CD4+CD45RA-CD62L- MEMORY CELLSFOLLOWING ALEMTUZUMAB DEPLETION.(Abstract #934)Steven C. Hoffmann, Jonathan P. Pearl, Douglas A.Hale, Roslyn B. Mannon, S. J. Swanson, Allan D. Kirk.Bethesda, MD; Washington, DC.

3:20 PM PRO-INFLAMMATORY EFFECTS OF NON-COMPLEMENT ACTIVATING ANTIBODIES ONENDOTHELIAL CELLS AND MACROPHAGES.(Abstract #935)Barbara A. Wasowska, Zhiping Qian, Morteza Loghmani,Salma Rahimi, Karen Fox-Talbot, William M. BaldwinIII. Baltimore, MD.

Concurrent Session 26: Organ Allocation andPublic Policy2:00 - 3:30 PM

Ballroom CChairs: Herwig-Ulf Meier-Kriesche and James J. Wynn

2:00 PM PROPOSED LUNG ALLOCATION SYSTEM BASEDON MEDICAL URGENCY AND TRANSPLANTBENEFIT. (Abstract #936)Robert M. Merion, Tempie E. Hulbert-Shearon, Rami T.Bustami, Edward R. Garrity, Thomas M. Egan, FriedrichK. Port, Robert A. Wolfe, Susan Murray. Ann Arbor, MI;Maywood, IL; Chapel Hill, NC.

2:10 PM USE OF DONOR HEARTS WITH LEFTVENTRICULAR EJECTION FRACTION ≤≤≤≤≤50% FORTRANSPLANTATION. (Abstract #937)Fotios A. Mitropoulos, Hillel Laks, Reza Kermani,Daniel Marelli, Abbas Ardehali, Mark Plunkett, FardadEsmailian, Jonah Odim, Jamie Moriguchi, LindaHamilton, Jignesh Patel, Jon Kobashigawa. Los Angeles,CA; Kansas City, KS.

2:20 PM NATIONAL EXPERIENCE WITH LIVE DONORRENAL TRANSPLANTATION OF A

2/A

2B INTO B

AND O PATIENTS. (Abstract #938)Christopher F. Bryan, Wida S. Cherikh, Jude Maghirang,Mark I. Aeder, James Gloor, Paul W. Nelson, Douglas J.Norman, Charles F. Shield, John B. Sorensen, Mark D.Stegall, Francis H. Wright, Jr. Westwood, KS; Richmond,VA; Rochester, MN; Portland, OR; Salt Lake City, UT;San Antonio, TX.

2:30 PM ELIMINATING POINTS FOR HLA-B SIMILARITYINCREASED KIDNEY ALLOCATION TOMINORITY, PEDIATRIC, SENSITIZED, AND ZEROMM CANDIDATES. (Abstract #939)Friedrich K. Port, Valarie B. Ashby, Alan B. Leichtman,Maureen A. McBride, James J. Wynn, Winfred W.Williams, John P. Roberts, Sarah H. Rush, Robert A.Wolfe. Ann Arbor, MI; Richmond, VA; Augusta, GA;Boston, MA; San Francisco, CA.

2:40 PM THE EFFECT OF CREG MATCHING ON GRAFTSURVIVAL AND HLA SENSITIZATION IN RENALRECIPIENTS. (Abstract #940)Deborah O. Crowe, William A. Nylander, HaroldHelderman, Anthony J. Langone, Tarik Kizilisik, DavidShaffer. Nashville, TN.

2:50 PM ASSIGNMENT OF ACCEPTABLE MISMATCHEDHLA ANTIGENS ACCURATELY PREDICTSRESULTS OF CYTOTOXICITY AND FLOWCROSSMATCHES. (Abstract #941)Karen A. Nelson, Danny Youngs, William H. Marks,Connie Davis, Ruth McDonald, Robert L. Wilburn.Seattle, WA.

3:00 PM ORGAN DONATION INCREASES AT LEVEL 1TRAUMA CENTERS AFTER IN-HOUSECOORDINATORS IMPLEMENTED: COMPARISONOF HOUSTON TO NEW YORK CITY AND LOSANGELES. (Abstract #942)Teresa J. Shafer, Charles T. VanBuren, Ronald N. Ehrle,Kimberly D. Davis, Roger E. Durand, Samuel M.Holtzman, Nicholas J. Crafts, Phillip J. Decker. Houston,TX; Clear Lake, TX.

3:10 PM THE IMPACT OF A NATIONAL MINORITYCOMMUNITY BASED TRANSPLANT EDUCATIONPROGRAM: A NATIONAL COMPARATIVEANALYSIS. (Abstract #943)Clive O. Callender, Patrice V. Miles, Gwendolyn D.Maddox. Washington, DC.

3:20 PM INCREASING THE KIDNEY DONOR POOL BYMORE EFFICIENT USE OF KIDNEYS RECOVEREDFROM DECEASED DONORS. (Abstract #944)Michael Cecka, Bernard Cohen, Mike Smith, JohnRosendale. Los Angeles, CA; Leiden, Netherlands;Richmond, VA.

113

Mo

nd

ay, May 17

Concurrent Session 27: Pediatric CardiacTransplantation and Post-TransplantComplications2:00 - 3:30 PM

Room 306Chairs: Gregory M. Hirsch and Jon A. Kobashigawa

2:00 PM INFANTS BECOME SENSITIZED TO DONOR HLAANTIGENS BUT NOT TOLERISED TOINCOMPATIBLE DONOR ABO ANTIGENSFOLLOWING IMPLANTATION OF TISSUEALLOGRAFTS WITH THE NORWOODPROCEDURE FOR SINGLE VENTRICLEPALLIATION. (Abstract #945)Natalia E. Lobach, Lisa Hornberger, Jeffrey F.Smallhorn, Anne I. Dipchand, Neal denHollander, GlenVanArsdell, Stacey M. Pollock-BarZiv, Lori J. West.Toronto, ON, Canada.

2:10 PM LATE ACUTE CARDIAC REJECTIONS INPEDIATRIC HEART TRANSPLANTATION:INCIDENCE AND IMPACT ON LONG-TERMOUTCOME. (Abstract #946)Michael Dandel, Dagmar Kemper, Hans B. Lehmkuhl,Rudolf Meyer, Christoph Knosalla, Onnen Grauhan,Manfred Hummel, Roland Hetzer. Berlin, Germany.

2:20 PM INFLUENCE OF PRE- AND POST-TRANSPLANTELISA-DETECTED ANTI-HLA ANTIBODIES ONPEDIATRIC TRANSPLANT OUTCOME.(Abstract #947)Sylvie Di Filippo, Steven A. Webber, Alin Girnita,Sabrina Tsao, Gerard J. Boyle, Susan A. Miller, Sanjiv K.Gandhi, Adriana Zeevi. Pittsburgh, PA.

2:30 PM GROWTH FACTOR GENE POLYMORPHISMSAND RENAL FUNCTION IN PEDIATRIC HEARTTRANSPLANTATION. (Abstract #948)Sylvie Di Filippo, Adriana Zeevi, Anat Tambur, RobertFerrel, Gil Burkart, Kevin McDade, Gerard J. Boyle,Susan A. Miller, Sanjiv K. Gandhi, Steven A. Webber.Pittsburgh, PA; Chicago, IL; Los Angeles, CA.

2:40 PM NEGATIVE IMMUNIZATION PRIOR TO INFANTHEART TRANSPLANTATION: RBC TRANSFUSIONUNDER CYCLOSPORINE COVER. (Abstract #949)Mark M. Bouck, Biagio A. Pietra, Erin Kunz, ChristineMashburn, D. Dunbar Ivy, Max B. Mitchell, David N.Campbell. Denver, CO.

2:50 PM SIROLIMUS CAUSES TESTOSTERONEDEFICIENCY IN MALE HEART TRANSPLANTRECIPIENTS. (Abstract #950)Ingo Kaczmarek, Ioannis Adamidis, Bruno Meiser, PeterLandwehr, Jan Groetzner, Markus Mueller, PeterUeberfuhr, Bruno Reichart. Munich, Germany.

3:00 PM SUBCLINICAL INFLAMMATION ANDPROTHROMBOTIC STATE IN STABLE LONG-TERM HEART TRANSPLANT RECIPIENTS WITHTREATED BUT PERSISTENT MILD DYSLIPIDEMIA.(Abstract #951)Michel White, Haissam Haddad, Jacques Genest, MarieHelene LeBlanc, Normand Racine, Peter Pflugfelder,Nadia Giannetti, Ross Davies, Eduardo Azevedo, DebraIsaac, Jeffrey Burton, Ralph Ferguson, Heather Ross.Montreal, QC, Canada; Halifax, NS, Canada; Ste Foy,QC, Canada; London, ON, Canada; Ottawa, ON, Canada;Winnipeg, MB, Canada; Calgary, AB, Canada;Edmonton, AB, Canada; Toronto, ON, Canada.

3:10 PM ACTIVATION OF PURINE NUCLEOTIDE SALVAGEPATHWAY IN MONONUCLEAR CELLS OFCARDIAC TRANSPLANT RECIPIENTS TREATEDWITH MYCOPHENOLATE MOFETIL. (Abstract #952)Elena Devyatko, Andreas Zuckermann, Daniela Dunkler,Ernst Wolner, Michael Grimm, Guenter Weigel. Vienna,Austria.

3:20 PM BK VIRAL REACTIVATION IN CARDIACTRANSPLANT PATIENTS: A DOUBLE-HITHYPOTHESIS? (Abstract #953)Shona S. Pendse, Eric Knight, Emilio Ramos, Tania T.Von Visger, Anil K. Chandraker. Boston, MA; Baltimore,MD.

Concurrent Session 28: Pediatric Liver andIntestinal Transplantation2:00 - 3:30 PM

Room 312Chairs: John Bucuvalas and Doug Farmer

2:00 PM BILIARY ATRESIA: CURRENT PRACTICES ANDOUTCOMES. (Abstract #954)John C. Magee, Tempie E. Hulbert-Shearon, M. JamesLopez, Friedrich K. Port, Robert M. Merion. Ann Arbor,MI.

2:10 PM RENAL FUNCTION IN PEDIATRIC LIVERTRANSPLANT SURVIVORS – A REPORT FROMTHE SPLIT DATABASE. (Abstract #955)Kathleen M. Campbell, John C. Bucuvalas, RavinderAnand, Lan Zeng, The SPLIT Research Group.Cincinnati, OH; Rockville, MD.

2:20 PM LAPAROSCOPIC LIVING DONOR LEFT LATERALSECTIONECTOMY FOR PEDIATRIC LIVERTRANSPLANTATION. (Abstract #956)Daniel Cherqui, Olivier Soubrane, Christophe Chardot,Gauthier Frederic, Fagniez Pierre-Louis, Houssin Didier.Paris, France.

2:30 PM OUTCOME OF ABO INCOMPATIBLE LIVERGRAFTS IN CHILDREN. (Abstract #957)Sue V. McDiarmid, Ravinder Anand, SPLIT ResearchGroup. Los Angeles, CA; Rockville, MD.

2:40 PM SIMULATION MODELING OF REGIONALSHARING IN PEDIATRIC DONOR LIVERALLOCATION. (Abstract #958)Nathan P. Goodrich, Keith P. McCullough, SueMcDiarmid, Ruth A. McDonald, Ann M. Rodgers,William E. Harmon, John C. Magee, Robert M. Merion.Ann Arbor, MI; Los Angeles, CA; Seattle, WA; Boston,MA.

2:50 PM SOURCES OF DISPARITY IN PEDIATRIC ACCESSTO TRANSPLANTATION. (Abstract #959)Susan E. Thomas, Valarie B. Ashby, Alan B. Leichtman,William E. Harmon, Robert M. Merion, Friedrich K.Port, Robert A. Wolfe, John C. Magee. Ann Arbor, MI;Boston, MA.

3:00 PM SAFETY AND EFFICACY OF LIVE VIRALVACCINES IN POST LIVER TRANSPLANTRECIPIENTS ON MONOTHERPAYIMMUNOSUPPRESSION. (Abstract #960)Patricia Harren, Robert S. Brown, Jean C. Emond, StevenJ. Lobritto. New York, NY.

3:10 PM INTESTINAL TRANSPLANTATION FORCHILDREN– SINGLE CENTER EXPERIENCE OFOVER 100 CASES. (Abstract #961)Tomoaki Kato, Naveen Mittal, Gennaro Selvaggi,Monica Gonzalez, Barbara Miller, Juan Madariaga, JangMoon, Seigo Nishida, David Levi, John Thompson,Andreas Tzakis. Miami, FL.

114

3:20 PM NEURODEVELOPMENTAL AND PSYCHOSOCIALOUTCOMES WITH LONGITUDINAL FOLLOW-UPOF PEDIATRIC INTESTINAL TRANSPLANTRECIPIENTS. (Abstract #962)Beverly K. Park, Sunny Z. Hussain, Mary B. Ehmann,Mary B. Hickey, John Campo, George V. Mazariegos,Jorge Reyes. Pittsburgh, PA; Washington, DC.

Concurrent Session 29: T-Regulatory CellFunction in Tolerance2:00 - 3:30 PM

Room 311Chairs: Gilles Benichou and Nader Najafian

2:00 PM LOW AVIDITY HA-1 SPECIFIC CD8+ T CELLSWITH REGULATORY PHENOTYPE (TGF-βββββ OR IL-10) MAY BE INFLUENCED BY HA-1MICROCHIMERISM IN THE DENDRITIC CELLSUBSET. (Abstract #963)Richard Derks, Junchao Cai, Junglim Lee, EwaJankowska-Gan, Jos Pool, Tuna Mutis, Els Goulmy,William Burlingham. Madison, WI; Leiden, Netherlands.

2:10 PM RAPID PRESENCE OF CD4+/CD45RC-REGULATORY CELLS IN TOLERATED GRAFTS:EVIDENCE FOR A PROTECTIVE ROLE IN THETOLERATED TISSUES. (Abstract #964)M. Kawai, H. Kitade, C. Mathieu, M. Waer, J. Pirenne.Leuven, Vlaams-Brabant, Belgium.

2:20 PM ANTI-CD28 INDUCED REGULATORY CELLS ANDA DEVIATED ANTIBODY RESPONSE TO KIDNEYALLOGRAFTS IN THE RAT. (Abstract #965)Fabienne Haspot, Celine Seveno, Flora Coulon, MarcelloHill, Karine Renaudin, Claire Usual, Jean Paul Soulillou,Bernard Vanhove. Nantes, France.

2:30 PM DIRECT EVIDENCE OF ALLOREACTIVE CD8+ TCELL INHIBITION BY CD4+ T REGULATORYCELLS IN THE MAINTENANCE OFTRANSPLANTATION TOLERANCE. (Abstract #966)Yuan Zhai, Lingzhong Meng, Ronald W. Busuttil, JerzyW. Kupiec-Weglinski. Los Angeles, CA.

2:40 PM LINK BETWEEN PROTOCOLS WHICH INDUCEALLOGRAFT TOLERANCE AND EARLY ANDSELECTIVE HIGH INTRAGRAFT FOXP3EXPRESSION. (Abstract #967)Iris Lee, Liqing Wang, Engin Ozkaynak, Wayne W.Hancock. Philadelphia, PA; Cambridge, MA.

2:50 PM CARDIAC ALLOGRAFT TOLERANCEESTABLISHED BY INTRATHYMIC MODULATIONIN A RAT MODEL DISPARATE IN A SINGLECLASS I MOLECULE IS MEDIATED BY CD4+CD25+

TREG THAT EXPRESS FOXP3. (Abstract #968)Sadi Koksoy, Esma S. Yolcu, Haval Shirwan. Louisville,KY.

3:00 PM METASTABLE TOLERANCE IN THE KIDNEYALLOGRAFT— PERITUBULAR TGFΒΒΒΒΒ(LATENT)+GRAFT INFILTRATING CELLS INCLUDE BOTHCD4+ T AND NON-T REGULATORY CELLS ANDINHIBIT THE LOCAL DTH RESPONSE.(Abstract #969)Jose Torrealba, William J. Burlingham, John H. Fechner,Ewa Jankowska-Gan, Krista Haanstra, JacquelineWubben, Margreet Jonker, Stuart J. Knechtle. Madison,WI; Rijswijk, Netherlands.

3:10 PM DIRECT VISUALISATION OF INDIRECTSPECIFICITY OF CD4+CD25+ REGULATORY TCELLS FOR ALLOPEPTIDES IN VITRO AND INVIVO. (Abstract #970)Shuiping Jiang, Dela Golshayan, David S. Game, Robert I.Lechler. London, United Kingdom.

3:20 PM A ROLE FOR NATURALLY OCCURINGCD4+CD25+ REGULATORY T CELLS INSPONTANEOUS ALLOGRAFT ACCEPTANCE.(Abstract #971)Laurence A. Turka, Elise Chiffoleau, Chuangqi Chen,Zihao Wu, Sigrid Sandner, Mohamed H. Sayegh.Philadelphia; Boston.

Concurrent Session 30: Viral Infections2:00 - 3:30 PM

Room 302/204Chairs: Emily A. Blumberg and Marian G. Michaels

2:00 PM A SEROPREVALENCE STUDY OF WEST NILEVIRUS IN SOLID ORGAN TRANSPLANTRECIPIENTS. (Abstract #972)Deepali Kumar, Michael Drebot, Susan Wong, GillianLim, Harvey Artsob, Peter Buck, Victoria Edge, AtulHumar. Toronto, ON, Canada; Winnipeg, MB, Canada;New York, NY; Ottawa, ON, Canada.

2:10 PM WEST NILE ENCEPHALITIS IN RECIPIENTS OFORGAN TRANSPLANTS. (Abstract #973)Kadiyala V. Ravindra, Alison G. Freifeld, Andre C. Kalil,David F. Mercer, Wendy J. Grant, Jean F. Botha, LucileE. Wrenshall, R. Brian Stevens. Omaha, NE.

2:20 PM COMMUNITY-ACQUIRED WEST NILE VIRUSENCEPHALOMYELITIS IN SOLID ORGAN ANDBONE MARROW TRANSPLANT RECIPIENTS:CLINICAL, DIAGNOSTIC, ANDNEUROPATHOLOGICAL FEATURES.(Abstract #974)Gregory T. Everson, Brad Marder, Marilyn Levi, StephenP. Laird, Trevor McNutt, W. John Pape, Lisa Forman, B.K. Kleinschmidt-DeMasters, Kenneth Tyler. Denver,CO.

2:30 PM SEVERE ACUTE RESPIRATORY SYNDROME(SARS) IN TRANSPLANTATION: CLINICAL ANDVIROLOGIC FINDINGS AND IMPLEMENTATIONOF A SARS SCREENING TOOL. (Abstract #975)Deepali Kumar, Gabriella Farcas, Karl Uy, Kevin Kain,Gary Levy, Atul Humar. Toronto, ON, Canada.

2:40 PM AN ASSESSMENT OF HERPESVIRUS CO-INFECTIONS IN PATIENTS WITH CMV DISEASE:CORRELATION WITH CLINICAL ANDVIROLOGIC OUTCOMES. (Abstract #976)Atul Humar, Deepali Kumar, David Safronetz, GrahamTipples. Toronto, ON, Canada; Winnipeg, MB, Canada.

2:50 PM AN ASSESSMENT OF ADENOVIRUS INFECTIONIN A LARGE COHORT OF SOLID ORGANTRANSPLANT RECIPIENTS. (Abstract #977)Atul Humar, George Moussa, Tony Mazzulli, RaymundRazonable, Carlos Paya, Emma Covington, EmmaAlecock, the PV 16000 Study Group. Toronto, ON,Canada; Rochester, MN; Welwyn Garden City, UnitedKingdom.

3:00 PM DETERMINANTS OF TRANSPLANT SURGEONS’WILLINGNESS TO PROVIDE ORGANS FORPATIENTS INFECTED WITH THE HEPATITIS B,HEPATITIS C, AND HUMAN IMMUNODEFICIENCYVIRUSES. (Abstract #978)Scott D. Halpern, David A. Asch, Peter Stock, AbrahamShaked, Emily Blumberg. Philadelphia, PA; SanFrancisco, CA.

115

Mo

nd

ay, May 17

3:10 PM USE OF CIDOFOVIR AS A RESCUE AGENT FORGANCYCLOVIR RESISTANT CMV INFECTIONAND DISEASE AND PAPILLOMA VIRUSASSOCIATED SKIN LESIONS IN TRANSPLANTRECIPIENTS. (Abstract #979)Hugo Bonatti, Stefan Schneeberger, Claudia Boesmueller,Wolfgang Steurer, Raimund Margreiter, Ferguel Cakar,Paul Hengster. Innsbruck, Tirol, Austria.

3:20 PM GENERATION OF ANTIGEN-SPECIFIC TLYMPHOCYTES FOR ADOPTIVEIMMUNTHERAPY IN TRANSPLANT PATIENTS.(Abstract #980)M. H. Hammer, G. Brestrich, H.-D. Volk, P. Reinke.Berlin, Germany.

Concurrent Session 31: Early Post-Transplantand Donor Issues4:00 - 5:30 PM

Ballroom AChairs: Jeffrey Lowell and Marty Sellers

4:00 PM FACTORS PREDICTING THE FUNCTIONALOUTCOME OF LAPAROSCOPIC DONORNEPHRECTOMY: AN ANALYSIS. (Abstract #981)Mahesh C. Goel, Charles S. Modlin, Ithaar H. Derweesh,J. Feng, Stuart M. Flechner, David A. Goldfarb, InderbirGill, Andrew C. Novick. Cleveland, OH.

4:10 PM STEROID FREE IMMUNOSUPPRESSION INKIDNEY RECIPIENTS WITH DELAYED GRAFTFUNCTION(DGF) MONITORED BY PROTOCOLBIOPSIES: A CONTROLLED STUDY TOEVALUATE THE OUTCOME OF ACUTEREJECTION(AR), GRAFT FUNCTION(GF),SUBCLINICAL ACUTE REJECTION(SCAR),CHRONIC ALLOGRAFT NEPHROPATHY(CAN)AND ONE YEAR SURVIVAL. (Abstract #982)Mysore S. Anil Kumar, Michael Heifets, Billie Fyfe,Miten H. Parikh, Muhammed I. Saeed, Sheng G. Xiao,Susan Stabler, Michael J. Moritz, Debra Sierka, AparnaKumar. Philadelphia, PA.

4:20 PM KIDNEY TRANSPLANTATION IN THE ELDERLY:VARIATIONS OF THE “MATCH” GAME.(Abstract #983)Robert J. Stratta, Aimee K. Sundberg, Julie A. Roskopf,Michael S. Rohr, Alan C. Farney, Erica L. Hartmann,Greg Armstrong, Gloria Hairston, David F. Kiger, TeresaK. Anderson, Patricia L. Adams. Winston-Salem, NC.

4:30 PM DOES THE TERMINAL CREATININE VALUE IN AYOUNG DECEASED DONOR INFLUENCE THELONG-TERM GRAFT SURVIVAL FOLLOWINGKIDNEY TRANSPLANTATION ? (Abstract #984)Kunam S. Reddy, Darcy Davies, Adyr Moss, MarekMazur, Raymond Heilman, David C. Mulligan. Phoenix,AZ; Richmond, VA.

4:40 PM RESOURCE UTILIZATION IN CADAVER RENALTRANSPLANTION. (Abstract #985)Prabhakar Baliga, Sylvia Odom, Greg Gilbert, KathyTurissi, Angello Lin, Fuad Afzal, Osemwegie Emmovon,Jeffrey Rogers, P. R. Rajagopalan, Kenneth Chavin.Charleston, SC.

4:50 PM INCREASED RISK OF PERI-OPERATIVE CARDIACEVENTS IN KIDNEY TRANSPLANT RECIPIENTSWITH DELAYED GRAFT FUNCTION.(Abstract #986)John S. Gill, Craig Solid, Brian J. G. Pereira, Allan J.Collins. Vancouver, BC, Canada; Boston, MA;Minneapolis, MN.

5:00 PM SEVERE DYSBALANCE OF ANTIOXIDATIVECAPACITY IN OLDER RECIPENTS ISASSOCIATED WITH POORER OUTCOME INKIDNEY TRANSPLANTATION. (Abstract #987)Susanne Kolodziej, Michael Marzinzig, AlexanderSchneider, Jens M. Mayer. Ulm, Germany.

5:10 PM RESOLUTION OF NATIVE KIDNEY PROTEINURIAIN THE IMMEDIATE POST RENAL TRANSPLANTPERIOD. (Abstract #988)Prakas T. D’Cunha, Ravi Parasuraman, K. K. Venkat.Detroit, MI.

5:20 PM MATHEMATICAL MODELS DO NOT PREDICTEARLY RENAL ALLOGRAFT DYSFUNCTIONPOST LIVING DONATION. (Abstract #989)Vajreshwari Shivaprakash, Kenneth E. Kokko. Atlanta,GA.

Concurrent Session 32: ExperimentalImmunosuppression: New Insights II4:00 - 5:30 PM

Room 311Chairs: Richard N. Mitchell and Thalachallour Mohanakumar

4:00 PM ASSESSMENT OF REGULATORY T CELLFUNCTIONS IN KIDNEY TRANSPLANT PATIENTSON MMF BASED IMMUNOSUPPRESSION.(Abstract #990)Igor Tsaur, Martin Gasser, Andrea Trumpfheller, KaiLopau, Michael Clarkson, Joana E. Kist-van Holthe,Andreas Opitz, Marco Bueter, Ana Maria Waaga-Gasser.Wuerzburg, Bavaria, Germany; Boston, MA.

4:10 PM Abstract #991 has been withdrawn.4:20 PM CD4+CD25+ T CELLS INHIBIT INNATE IMMUNE

RESPONSES OF MURINE ISLETS. (Abstract #992)Nan Zhang, Shuang Fu, Dongmei Chen, Haojiang Zhang,Yaozhong Ding, Jonathan S. Bromberg. New York, NY.

4:30 PM B LYMPHOCYTE DIRECTED INDUCTIONIMMUNOTHERAPY INDUCES LONG-TERM ISLETALLOGRAFT SURVIVAL IN NON-HUMANPRIMATES. (Abstract #993)Chengyang Liu, Ergun Velidedeoglu, Trayn Green, LesRolf, Susan Y. Rostami, Brigitte Koeberlein, HoomanNoorchashm, Clyde F. Barker, Ali Naji. Philadelphia, PA.

4:40 PM SHORT TERM ANTI-CD4 PLUS ANTI-TNF-αααααRECEPTOR TREATMENT IN ALLOGENEIC SMALLBOWEL TRANSPLANTATION RESULTS IN LONGTERM ALLOGRAFT SURVIVAL. (Abstract #994)Jan M. Langrehr, Markus H. Hammer, Kathrin Gube,Andreas Pascher, Dietrich Polenz, Manfred Lehmann,Petra Reinke. Berlin, Berlin, Germany.

4:50 PM LONG-TERM CARDIAC ALLOGRAFT SURVIVALAFTER DUAL THERAPY WITH ANTI-CD40L ANDANTI-LFA-1 ANTIBODIES. (Abstract #995)Biagio A. Pietra, Robert J. Plenter, Susan O. Cushing, AnDoan, Ronald G. Gill. Denver, CO.

5:00 PM SANGLIFEHRIN A, A NEW SELECTIVE IN VIVOINHIBITOR OF BIOACTIVE IL-12 PRODUCTION.(Abstract #996)Holger Hackstein, Christoph Steinschulte, TimucinTaner, Angus W. Thomson, Gregor Bein. Giessen,Germany; Pittsburgh, PA.

5:10 PM MULTIPLE MECHANISMS OF B CELL ANDPLASMA CELL APOPTOSIS INDUCED BYPOLYCLONAL RABBIT ANTI-THYMOCYTEGLOBULIN (rATG). (Abstract #997)Martin S. Zand, Thuong Vo, Jennifer Huggins, TinaPellegrin. Rochester, NY.

116

5:20 PM CORTICOSTEROID AVOIDANCE AMELIORATESLYMPHOCELE FORMATION AND WOUNDHEALING COMPLICATIONS ASSOCIATED WITHSIROLIMUS THERAPY: 2 YEAR FOLLOW-UP IN109 PATIENTS. (Abstract #1007)C. C. Rogers, J. W. Alexander, R. R. Alloway, T. J.Metze, R. E. Boardman, J. Trofe, M. Gupta, T. Merchen,M. J. Hanaway, J. F. Buell, M. Cardi, P. Roy-Chaudhury,E. S. Woodle. Cincinnati, OH.

Concurrent Session 34: Innate and AdaptiveImmunity and Cytokines in Ischemia-Reperfusion4:00 - 5:30 PM

Room 306Chairs: Robert L. Fairchild and Milagros D. Samaniego-Picota

4:00 PM T AND B CELLS INTERACT TO MODULATEKIDNEY ISCHEMIA REPERFUSION INJURY.(Abstract #1008)Melissa J. Burne-Taney, Naoko Yokota, Hamid Rabb.Baltimore, MD; Yokohama, Japan.

4:10 PM THE TLR4 SIGNALING PATHWAY LINKS INNATEAND ADAPTIVE IMMUNITY IN LIVER ISCHEMIA/REPERFUSION INJURY. (Abstract #1009)Yuan Zhai, Xiu-Da Shen, Feng Gao, Ryan O’Connell,Ronald W. Busuttil, Genhong Cheng, Jerzy W. Kupiec-Weglinski. Los Angeles, CA.

4:20 PM HO-1 CYTOPROTECTIVE AND ANTI-INFLAMMATORY EFFECTS IN HEPATICISCHEMIA/REPERFUSION INJURY ARE TOLL-LIKE RECEPTOR-4 INDEPENDENT.(Abstract #1010)Sei-ichiro Tsuchihashi, Constantino Fondevila, JeffreyMa, Bibo Ke, Yuan Zhai, Ronald W. Busuttil, Jerzy W.Kupiec-Weglinski. Los Angeles, CA.

4:30 PM A NEW MOUSE MODEL OF PROLONGEDHEPATIC COLD ISCHEMIA FOLLOWED BYORTHOTOPIC LIVER TRANSPLANTATION (OLT).(Abstract #1011)Xiu-Da Shen, Feng Gao, Bibo Ke, Yuan Zhai, Sei-IchiroTsuchihashi, Charles R. Lassman, Douglas G. Farmer,Ronald W. Busuttil, Jerzy W. Kupiec-Weglinski. LosAngeles, CA.

4:40 PM SIGNIFICANCE AND THERAPEUTIC POTENTIALOF PROSTAGLANDIN E2 RECEPTORS IN LIVERISCHEMIA REPERFUSION INJURY.(Abstract #1012)Yukiyasu Kuzumoto, Masayuki Sho, Naoya Ikeda, KaoruHamada, Takashi Mizuno, Satoru Akashi, YoshikazuTsurui, Hisanori Kashizuka, Yoshiyuki Nakajima.Kashihara, Japan.

4:50 PM CD40Ig GENE TRANSFER DOWNREGULATES THEEXPRESSION OF VASCULAR ENDOTHELIALGROWTH FACTOR (VEGF) AND PROTECTS RATLIVERS FROM ISCHEMIA/REPERFUSIONINJURY. (Abstract #1013)Bibo Ke, Xiu-Da Shen, Feng Gao, Douglas G. Farmer,Ronald W. Busuttil, David M. Briscoe, Jerzy W. Kupiec-Weglinski. Los Angeles, CA; Boston, MA.

5:00 PM 17βββββ-ESTRADIOL DIFERENTIALLY ACTIVATES THEMITOGEN-ACTIVATED PROTEIN-KINASES ANDIMPROVES SURVIVAL FOLLOWINGREPERFUSION INJURY OF REDUCED-SIZELIVER. (Abstract #1014)Mario Vilatoba, Guadalupe Bilbao, Christopher Eckstein,Irshad H. Chaudry, Devin E. Eckhoff, Juan L. Contreras.Birmingham, AL.

5:20 PM TRANSIENT SHORT COURSE OF POLYCLONALANTI-T CELL ANTIBODY FOR CURE OF FULLBLOWN DIABETES. (Abstract #998)Takashi Maki, Norihiko Ogawa, James F. List, Joel F.Habener. Boston, MA.

Concurrent Session 33: ImmunosuppressionComplications and Medical Complications4:00 - 5:30 PM

Ballroom CChairs: Michelle A. Josephson and George E. Loss, Jr.

4:00 PM TRANSPLANT CENTER MONITORING USING ACONTINUOUSLY UPDATABLE, RISK-ADJUSTEDTECHNIQUE (CUSUM). (Abstract #999)David A. Axelrod, Mary K. Guidinger, Robert A.Metzger, Russell H. Wiesner, Randall L. Webb, Robert M.Merion. Chicago, IL; Ann Arbor, MI; Orlando, FL;Rochester, MN.

4:10 PM FTY720 WITH REDUCED DOSE NEORAL (RDN)MAY OFFER A SAFETY/TOLERABILITY PROFILEADVANTAGE OVER CONVENTIONALIMMUNOSUPPRESSIVE THERAPIES.(Abstract #1000)G. Russ, R. M. Ferguson, S. Mulgaonkar, H. Tedesco-Silva, F. Oppenheimer, R. Walker, A. Knoflach, U.Kunzendorf, Y. Patel, R. Preiss. Woodville, SA,Australia; Columbus, OH; Livingston, NJ; Sao Paulo, SP,Brazil; Barcelona, Spain; Parkville, VIC, Australia;Zuerich, Switzerland; Kiel, Germany; East Hanover, NJ;Basle, Switzerland.

4:20 PM CALCIUM CHANNEL BLOCKADE ANDPREVENTION OF RENAL GRAFT FUNCTIONDETERIORATION IN CYCLOSPORINE-TREATEDRECIPIENTS: A MULTI-CENTRE PROSPECTIVE,RANDOMIZED, PLACEBO-CONTROLLED, 2-YEAR STUDY. (Abstract #1001)Dirk R. J. Kuypers, Hans H. Neumayer, Lutz Fritsche,Klemens Budde, Yves Vanrenterghem. Leuven, Belgium;Berlin, Germany.

4:30 PM PREGNANCIES FATHERED BY MALE KIDNEYTRANSPLANT RECIPIENTS ON NEWERIMMUNOSUPPRESSIVE MEDICATIONS.(Abstract #1002)Scott W. Cowan, Antonella Lavelanet, Lisa A. Coscia,Michael J. Moritz, Vincent T. Armenti. Philadelphia, PA.

4:40 PM IMMUNOSUPPRESSIVE CHANGES BEFORE ORDURING PREGNANCY: DO THEY AFFECTNEWBORN AND GRAFT OUTCOMES?(Abstract #1003)William J. Gaughan, Lisa A. Coscia, Stephen R. Dunn,Michael J. Moritz, Vincent T. Armenti. Philadelphia, PA.

4:50 PM NEPHROTIC-RANGE PROTEINURIA AND OTHERSEVERE ADVERSE EVENTS AFTER CONVERSIONTO SIROLIMUS IN RENAL TRANSPLANTATION:IS HIGH EXPOSURE TO SIROLIMUSRESPONSIBLE? (Abstract #1004)Karine Hadaya, Martin Wissing, Nylufer Broeders,Daniel Abramowicz. Brussels, Belgium.

5:00 PM DE NOVO ANORECTAL CANCERS IN RENALTRANSPLANT RECIPIENTS. (Abstract #1005)S. M. Rudich, J. F. Buell, T. M. Beebe, T. G. Gross, M. J.Hanaway, R. R. Alloway, J. Trofe, E. S. Woodle.Cincinnati, OH.

5:10 PM SKIN MALIGNANCY IN TRANSPLANTRECIPIENTS. (Abstract #1006)J. F. Buell, T. M. Beebe, T. G. Gross, M. J. Hanaway, J.Trofe, R. R. Alloway, E. S. Woodle. Cincinnati, OH.

117

Mo

nd

ay, May 17

5:10 PM CYCLIC RGD PEPTIDES WITH HIGH AFFINITYFOR ααααα5βββββ1 INTEGRIN PROTECT GENETICALLYFAT ZUCKER RAT LIVERS FROM COLDISCHEMIA/REPERFUSION INJURY.(Abstract #1015)Constantino Fondevila, Xiu-Da Shen, Carolina Moore,Judy Melinek, Ronald W. Busuttil, Ana J. Coito. LosAngeles, CA.

5:20 PM IL-13 PROTECTS MOUSE INTESTINES FROMISCHEMIA AND REPERFUSION INJURY BYACTIVATION OF STAT6 PATHWAY.(Abstract #1016)Bibo Ke, Xiu-Da Shen, Ian C. Carmody, Feng Gao,Ronald W. Busuttil, Jerzy W. Kupiec-Weglinski, DouglasG. Farmer. Los Angeles, CA.

Concurrent Session 35: Liver Transplantation:Public Policy and Economics4:00 - 5:30 PM

Ballroom BChairs: Robert S. Brown, Jr. and Robert M. Merion

4:00 PM LIVER TRANSPLANTATION WITH NEOADJUVANTCHEMORADIOTHERAPY FOR HILARCHOLANGIOCARCINOMA. (Abstract #1017)Charles B. Rosen, Julie K. Heimbach, Michael G.Haddock, Steven R. Alberts, Scott L. Nyberg, Michael B.Ishitani, Gregory J. Gores. Rochester, MN.

4:10 PM ARE TOO MANY PEDIATRIC LIVER RECIPIENTSTRANSPLANTED AT STATUS 1? (Abstract #1018)Sue V. McDiarmid, Ann M. Harper. Los Angeles, CA;Richmond, VA.

4:20 PM HAS THE PELD SYSTEM IMPROVED ORGANALLOCATION FOR PEDIATRIC LIVERTRANSPLANT RECIPIENTS WITH CHRONICLIVER DISEASE? (Abstract #1019)Paolo Salvalaggio, Katie Neighbors, Susan Kelly, KaranM. Emerick, Kishore Iyer, Riccardo A. Superina, Peter F.Whitington, Estella M. Alonso. Chicago, IL.

4:30 PM REGIONAL REVIEW BOARDS DO NOTINCREASE MORTALITY BY DENYINGACCELERATED LISTING TO PATIENTS.(Abstract #1020)Michael D. Voigt, Bridget Zimmerman, Daniel A. Katz,Stephen C. Rayhill. Iowa City, IA.

4:40 PM SPLIT LIVER TRANSPLANTATION: STATEWIDEUSAGE OF THE RIGHT TRISEGMENTAL GRAFT.(Abstract #1021)Kenneth Washburn, Glenn Halff, Pat Wood, Luis Mieles,Robert Goldstein, John Goss. San Antonio, TX; Houston,TX; Dallas, TX.

4:50 PM ADDITION OF SERUM SODIUM INTO THE MELDSCORE PREDICTS WAITING LIST MORTALITYBETTER THAN MELD ALONE. A SINGLE-CENTEREXPERIENCE. (Abstract #1022)Andres E. Ruf, Silvina E. Yantorno, Valeria I. Descalzi,Oscar C. Andriani, Luis G. Podesta, Federico G. Villamil.Buenos Aires, Argentina.

5:00 PM IMPACT OF LIVER TRANSPLANTATION OFPATIENTS WITH HIGH DISEASE SEVERITY ONHEALTH CARE RESOURCES: UNIVERSITYHEALTHSYSTEM CONSORTIUM (UHC)BENCHMARKING PROJECT. (Abstract #1023)Rafik M. Ghobrial, C. Wright Pinson, Jeffrey D. Punch,Jackie Dostal, Danielle Carrier. Los Angeles, CA;Nashville, TN; Ann Arbor, MI; Chicago, IL.

5:10 PM EASTERN CO-OPERATIVE ONCOLOGY GROUP(ECOG) PERFORMANCE STATUS IS ASSOCIATEDWITH POST LIVER TRANSPLANTATIONMORTALITY. ON BEHALF OF THE UK &&&&& IRELANDLIVER TRANSPLANT AUDIT. (Abstract #1024)Mathew Jacob, Lynn P. Copley, James D. Lewsey, Giles J.Toogood, Mohamed Rela, Alex Gimson, Jan van derMeulen. London, United Kingdom; Leeds, UnitedKingdom; Cambridge, United Kingdom.

5:20 PM ARE ROUTINE CHEST COMPUTEDTOMOGRAPHY AND BONE SCAN REQUIRED INPATIENTS WITH HEPATOMA AND CIRRHOSISUNDERGOING LIVER TRANSPLANTEVALUATION? A COOPERATIVE STUDY BY THEHEPATOMA AND LIVER TRANSPLANTATION(HALT). (Abstract #1025)B. Koneru, L. Teperman, C. Manzarbeitia, M. Facciuto,K. Cho, D. Reich, D. Campbell, P. Scheiner, A. Fisher,M. Korogodsky, K. Noto. Newark, NJ; New York, NY;Philadelphia, PA; Valhalla, NY.

Concurrent Session 36: Lymphocyte Activation:Costimulatory Molecules and CostimulatoryBlockade4:00 - 5:30 PM

Room 309Chairs: Reza Abdi and William J. Burlingham

4:00 PM PROLONGED IMMUNOLOGICAL SYNAPSEFORMATION IS CRITICAL FOR B7COSTIMULATORY ACTIVITY. (Abstract #1026)Robert S. Liwski, Jennifer Chase, Geoff Rowden,Kenneth A. West. Halifax, NS, Canada.

4:10 PM TARGETING CD40 VERSUS CD40 LIGAND YIELDSDIFFERENTIAL OUTCOMES FOLLOWINGCARDIAC TRANSPLANTION. (Abstract #1027)Theodore Welling, Sherri Chan Wood, Keri Csencsits,Guanyi Lu, D. Keith Bishop. Ann Arbor, MI.

4:20 PM IN VIVO FUNCTIONS OF ALLOREACTIVEMEMORY CD4 T CELLS REMAIN INTACT DESPITEDONOR SPECIFIC TRANSFUSION AND ANTI-CD154 THERAPY. (Abstract #1028)Anna Valujskikh, Yifa Chen, Peter S. Heeger. Cleveland,OH.

4:30 PM BLOCKING CD134 COSTIMULATION ISREQUIRED TO PREVENT CD8+ MEDIATEDREJECTION. (Abstract #1029)Minh Diem Vu, Terry B. Strom, Mohamed H. Sayegh,Xian C. Li. Boston, MA.

4:40 PM THE B7 HOMOLOG, B7-H3, PROMOTES ACUTEAND CHRONIC ALLOGRAFT REJECTION.(Abstract #1030)Liqing Wang, Christopher C. Fraser, Andrew D. Wells,Anthony J. Coyle, Lieping Chen, Wayne W. Hancock.Philadelphia, PA; Cambridge, MA; Rochester, MN.

4:50 PM THE CD134/CD134L PATHWAY IS CRITICAL INCD8-MEDIATED COSTIMULATION BLOCKADERESISTANT REJECTION. (Abstract #1031)Andrew B. Adams, Thomas R. Jones, Erik A. Heiss,Nozomu Shirasugi, Phyllis A. Rees, Hideo Yagita,Thomas C. Pearson, Christian P. Larsen. Atlanta, GA;Tokyo, Japan.

5:00 PM TARGETING THE NOVEL CD28 HOMOLOG,BTLA, PROLONGS ALLOGRAFT SURVIVAL.(Abstract #1032)Ran Tao, Qunrui Ye, Theresa L. Murphy, Kenneth M.Murphy, Wayne W. Hancock. Philadelphia, PA; St.Louis, MO.

118

5:10 PM SYNERGISTIC EFFECT OF ICOS/B7RP-1 ANDCD40/CD40L COSTIMULATION BLOCKADE INTHE INDUCTION OF TOLERANCE IN A RATHEART TRANSPLANTATION MODEL.(Abstract #1033)Carole Guillonneau, Venceslas Aubry, Karine Renaudin,Katsunari Tezuka, Ignacio Anegon. Nantes, France;Osaka, Japan.

5:20 PM EFFECT OF INFLAMMATION ONCOSTIMULATION BLOCKADE RESISTANTALLOGRAFT REJECTION. (Abstract #1034)Katsuyoshi Habiro, Motoko Kotani, Kazuya Omoto,Kazunari Tanabe, Hiroaki Shimmura, Hiroshi Toma, RyoAbe. Noda City, Chiba, Japan; Tokyo, Japan.

Concurrent Session 37: New Agents inImmunosuppression4:00 - 5:30 PM

Veterans BallroomChairs: Richard M. Lewis and Wojciech A. Rowinski

4:00 PM CO-STIMULATION BLOCKADE WITH LEA29Y INRENAL TRANSPLANT: IMPROVED RENALFUNCTION AND CV/METABOLIC PROFILE AT 6MONTHS COMPARED WITH CYCLOSPORINE.(Abstract #1035)B. Nashan, J. Grinyo, F. Vincenti, P. Halloran, D.Hagerty, W. Zhou, B. Charpentier, LEA29Y StudyGroup. Germany; Spain; Canada; France.

4:10 PM TREATMENT OF KIDNEY TRANSPLANT PATIENTSWITH THE NOVEL CO-STIMULATORY BLOCKERLEA29Y (BMS-224818) AND ANTI-IL2 RECEPTORANTIBODY DOES NOT IMPEDE THEDEVELOPMENT OF REGULATORY T CELLS.(Abstract #1036)Kenzo Hirose, Andrew M. Posselt, Peter G. Stock,Ryutaro Hirose, Flavio Vincenti. San Francisco, CA.

4:20 PM CO-STIMULATION BLOCKADE WITH LEA29Y INA CALCINEURIN INHIBITOR FREEMAINTENANCE REGIMEN IN RENALTRANSPLANT: 6-MONTH EFFICACY AND SAFETY.(Abstract #1037)F. Vincenti, F. Muehlbacher, B. Nashan, C. Larsen, E.Atillasoy, K. Natarajan, B. Charpentier, LEA29Y StudyGroup. Austria; Germany; France.

4:30 PM SYNGERGY OF IMMUNOSUPPRESSION BYPG490-88 AND FK506 IS THROUGHDOWNREGULATION OF NF-kB AND IL-2.(Abstract #1038)Hongtao Sun, Gang Chen, Ximo Wang, Iram Siddiqui,Weihua Liu, Kouichi R. Tamura, Yuji Sudo, RobertZhong, Bertha Garcia. London, ON, Canada; Osaka,Japan.

4:40 PM NEW IMMUNOSUPPRESSANT FK778 SHOWSEFFICACY IN RENAL TRANSPLANTATION.(Abstract #1039)Johannes P. van Hooff, Yves Vanrenterghem, MarianKlinger, Zbigniew Wlodarczyk, Jean-Paul Squifflet, theEuropean FK778 Kidney Transplant Study Group.Maastricht, Netherlands; Leuven, Belgium; Wroclaw,Poland; Bydgoszcz, Poland; Bruxelles, Belgium.

4:50 PM FTY720, A SPHINGOSINE 1-PHOSPHATERECEPTOR AGONIST, DOES NOT ELICITADVERSE EFFECTS ON CARDIAC RHYTHM INRENAL TRANSPLANT PATIENTS ONMAINTENANCE THERAPY. (Abstract #1040)A. Jardine, J. M. Grinyo, S. Mulgaonkar, R. M. Ferguson,M. Cremer, R. Preiss. Glasgow, United Kingdom;Barcelona, Spain; Livingston, NJ; Columbus, OH; Basle,Switzerland.

5:00 PM CYCLOSPORIN A (CSA) MAY BE USEDINTERCHANGEABLY WITH TACROLIMUS (TAC)IN MAINTENANCE MINIMIZATION PROTOCOLSFOLLOWING ALEMITUZUMAB (CAMPATH-1H)INDUCTION IN RENAL TRANSPLANTRECIPIENTS. (Abstract #1041)Richard Lewis, Tracy Van Ness, Lisa Etter, DavidBekofsky, Michael Ko, Carla Stark, Wayne Waltzer.Stony Brook, NY.

5:10 PM CONTROLLED STUDY TO REDUCE THEIMMUNOSUPPRESSIVE LOAD AFTER KIDNEYTRANSPLANTATION GUIDED BY DONORSPECIFIC CTLp MONITORING. (Abstract #1042)Jacqueline van de Wetering, Barbara J. van der Mast,Petronella de Kuiper, Nicolle M. van Besouw, JacquelineRichen-Vos, Jan N. M. IJzermans, Willem Weimar.Rotterdam, Netherlands.

5:20 PM ASSOCIATION OF AREA UNDER THE CURVE OFMYCOPHENOLATE MOFETIL AND SUBCLINICALALLOGRAFT REJECTION EPISODES.(Abstract #1043)Charles F. Shield III, Joan S. Kramer, John L. Smith.Wichita, KS.

Concurrent Session 38: Translational Researchin Liver Transplantation4:00 - 5:30 PM

Room 312Chairs: Abhi Humar and Jorge Reyes

4:00 PM GENE EXPRESSION PATTERNS IN CIRRHOSISAND HEPATOCELLULAR CARCINOMA (HCC) INHCV-INFECTED PATIENTS AWAITING LIVERTRANSPLANTATION. (Abstract #1044)Valeria R. Mas, Daniel G. Maluf, Richard K. Sterling,Bradly Clark, Cheryl Rodgers, Andrea Ferriera-Gonzalez,Robert A. Fisher. Richmond, VA.

4:10 PM ELUCIDATING THE PATHOGENESIS OF HEPATICISCHEMIA/REPERFUSION INJURY IN CLINICALLIVER TRANSPLANTATION USINGMICROARRAY. (Abstract #1045)Ian D. McGilvray, Limin Chen, Ivan Borozan, Jing Sun,Maha Guindi, Mark S. Cattral, Paul Greig, Aled M.Edwards, David R. Grant. Toronto, ON, Canada.

4:20 PM EVIDENCE THAT TH1/TH2 IMMUNE DEVIATIONIMPACTS ON EARLY GRAFT ACCEPTANCEAFTER PEDIATRIC LIVER TRANSPLANTATION:RESULTS OF IMMUNOLOGICAL MONITORINGIN 40 CHILDREN. (Abstract #1046)Jérémie Gras, Anne Cornet, Dominique Latinne,Raymond Reding. Brussels, Belgium.

4:30 PM T-SUPPRESSORS MAY EXPLAIN REDUCEDIMMUNOSUPPRESSION IN PEDIATRIC LIVER-INTESTINE (LTx-SBTx) RECIPIENTS RECEIVINGSTEROID-FREE, THYMOGLOBULIN (rATG)PRETREATMENT. (Abstract #1047)Rakesh Sindhi, Sanil Manavalan, Amy Magill, JorgeReyes, Adrianna Zeevi. Pittsburgh, PA; New York, NY.

119

Mo

nd

ay, May 17

4:50 PM ALLOGENIC CELL THERAPY FOR TREATMENTOF LIVER FAILURE. (Abstract #1049)John W. Ludlow, Andrew T. Bruce, Michael J. Kulik,Darell W. McCoy, Sonya O. Meheux, Thomas M.Asfeldt. Durham, NC.

5:00 PM DEVELOPMENT OF AN OBJECTIVE METHODFOR THE ESTIMATION OF LIVER STEATOSIS.(Abstract #1050)Ryan N. Fiorini, Jeremy Kirtz, Basker Periyasamy,Zachary Evans, David Lewin, Michael Schmidt, KennethChavin. Charleston, SC.

5:10 PM HEPATIC OXIDATION OF ORALLY DELIVEREDAMINO ACIDS REMAINS IMPAIRED FOR WEEKSAFTER LIVING LIVER DONATION.(Abstract #1051)Richard B. Freeman, Michelle Dixon, Beth Horth, MaryBeth Palladino, Ann Marie Melanson, Jeffery T. Cooper,Richard J. Rohrer, Anil Modak. Boston, MA; Andover,MA.

5:20 PM PHARMACODYNAMIC (PD) CORRELATES OFREJECTION WITH THYMOGLOBULIN (rATG)AND TACROLIMUS MONOTHERAPY (TAC) INPEDIATRIC LIVER RECIPIENTS. (Abstract #1052)Rakesh Sindhi, Raman Venkataramanan, Amy Magill,Jorge Reyes, Adrianna Zeevi, Art Wetzel, SilvesterCzanner. Pittsburgh, PA.

Concurrent Session 39: Transplant RelatedMalignancies4:00 - 5:30 PM

Room 302/304Chairs: Joseph F. Buell and Michael Green

4:00 PM A MULTI-CENTER RANDOMIZED TRIAL OFGANCICLOVIR VS. GANCICLOVIR PLUSIMMUNE GLOBULIN FOR PROPHYLAXISAGAINST EBV RELATED PTLD IN HIGH RISKSOLID ORGAN TRANSPLANT RECIPIENTS: ONE-YEAR RESULTS. (Abstract #1053)Atul Humar, Diane Hebert, Dele Davies, Abhi Humar,Derek Stephens, Brenda O’Doherty, Upton Allen.Toronto, ON, Canada; Calgary, AB, Canada;Minneapolis, MN.

4:10 PM ANTIVIRAL USE AND ITS ASSOCIATION WITHPOST-TRANSPLANT LYMPHOPROLIFERATIVEDISORDER (PTLD) IN RENAL TRANSPLANTPATIENTS. (Abstract #1054)Mark D. Pescovitz, Donnie P. Funch, Gary Schneider,Alexander M. Walker. Indianapolis, IN; Auburndale, MA.

4:20 PM QUANTITATIVE EBV TITERS ANDIMMUNOSUPPRESSIVE ALTERATIONS TODECREASE THE INCIDENCE OF PTLD INPEDIATRIC LIVER TRANSPLANTION.(Abstract #1055)T. C. Lee, N. R. Barshes, B. Savoldo, C. M. Rooney, H.E. Heslop, L. Nguyen, L. J. Bristow, J. D. Scott, S. J.Karpen, R. E. Quiroz-Tejeira, J. A. Goss. Houston, TX.

4:40 PM DIFFERENCES IN SURVIVAL PATTERNS BETWEENTRANSPLANT RECIPIENTS AND GENERALPOPULATION PATIENTS DEVELOPING DE NOVOCOLORECTAL CANCER. (Abstract #1058)J. F. Buell, H. T. Papaconstantinou, B. Sklow, T. M.Beebe, T. G. Gross, M. J. Hanaway, R. R. Alloway, J.Trofe, E. S. Woodle. Cincinnati, OH.

4:50 PM DONOR TRANSMITTED RENAL CELLCARCINOMA - WHAT TREATMENTS AREEFFECTIVE. (Abstract #1059)T. Merchen, M. Gupta, R. Boardman, T. G. Gross, T.Beebe, J. Trofe, R. R. Alloway, M. J. Hanaway, E. S.Woodle, J. F. Buell. Cincinnati, OH.

5:00 PM IL-2 RECEPTOR ANTIBODIES ANDMALIGNANCY: AN ANALYSIS OF EARLYPEDIATRIC RENAL TRANSPLANT REGISTRYDATA. (Abstract #1060)Vikas R. Dharnidharka, Donald M. Stablein. Gainesville,FL; Rockville, MD.

5:20 PM DE NOVO BREAST CANCER POST SOLIDORGAN TRANSPLANTATION. (Abstract #1061)R. E. Boardman, E. S. Woodle, T. G. Gross, M. J.Hanaway, R. R. Alloway, J. Trofe, M. R. First, T. Beebe,J. F. Buell. Cincinnati, OH.

Concurrent Session 40: Xenotransplantation4:00 - 5:30 PM

Room 310Chairs: Anita S.F. Chong and Richard N. Pierson

4:00 PM ADOPTIVE TRANSFER OF SPECIFIC SUBSETS OFDENDRITIC CELLS CHANGES THE XENOGRAFTSURVIVAL AND PATTERN OF REJECTION IN ARAT-TO-MOUSE CARDIAC TRANSPLANTATIONMODEL. (Abstract #1062)Hao Wang, Jacqueline Arp, Nobuyuki Kanai, XuyanHuang, Bertha Garcia, Weiping Min, Robert Zhong.London, ON, Canada.

4:10 PM PORCINE CTLA4-Ig AS A SPECIES-SPECIFICREAGENT TO PREVENT DIRECT PATHWAYXENOSPECIFIC T CELL SENSITIZATION. (Abstract #1063)Vincenzo Mirenda, Joseph Read, Ivan Berton, AnthonyWarrens, Robert Lechler. London, United Kingdom.

4:20 PM COMPLETE INHIBITION OF ACUTE HUMORALXENOGRAFT REJECTION BY REGULATEDENDOTHELIAL CELL EXPRESSION OF NOVELANTICOAGULANT FUSION PROTEINS.(Abstract #1064)Anthony Dorling, Daxin Chen, Robert I. Lechler.London, United Kingdom.

4:40 PM ANALYSIS OF PERIPHERAL BLOODMONONUCLEAR CELLS IN OPERATIONALTOLERANCE AFTER LIVING-DONOR LIVERTRANSPLANTATION (LDLT). (Abstract #1048)Ying Li, Takaaki Koshiba, Atsushi Yoshizawa, AtsushiIto, Hiroto Egawa, Shimon Sakaguchi, Nagahiro Minato,Kathryn J. Wood, Koichi Tanaka. Kyoto, Japan;Headington, Oxford, United Kingdom.Kaushik Mukherjee, and the UCLA Heart TransplantTeam. Los Angeles, CA.

5:10 PM IFN-γγγγγ GENOTYPE AND TGF-βββββ INTERACTIONSCONTRIBUTE TO EBV-ASSOCIATEDLYMPHOPROLIFERATIVE DISORDER (EBV-LPD)DEVELOPMENT. (Abstract #1056)Anne M. VanBuskirk, Tyler C. Hoppes, Amy K.Ferketich, Sameek Rowchowdhury, Robert Baiocchi.Columbus, OH.

4:30 PM PROGRESSION OF CANCER CELLS CARRIEDFROM THE GRAFTED LIVER. (Abstract #1057)Takashi Murakami, Mitsunobu Matsumoto, EijiKobayashi. Kawachi-gun, Tochigi, Japan.

120

4:50 PM PIG-TO-BABOON LIFE-SUPPORTING KIDNEYPLUS THYMUS TRANSPLANTATION USINGGALT-KO DONORS. (Abstract #1067)K. Yamada, K. Yazawa, A. Shimizu, M. Nuhn, S. Moran,T. Iwanaga, P. O’Malley, P. A. Vagefi, J. Fishman, D. K.C. Cooper, C. Patience, R. Hawley, J. Greenstein, H.-J.Schuurman, M. Awwad, M. Sykes, D. H. Sachs. Boston,MA; Cambridge, MA.

5:00 PM TRANSPLANTATION (Tx) OF HEARTS FROM ααααα1,3-GALACTOSYL-TRANSFERASE GENE-KNOCKOUT(GalT-KO) PIGS INTO BABOONS.(Abstract #1068)Yau-Lin Tseng, Kenji Kuwaki, Frank J. M. F. Dor, AkiraShimizu, Stuart L. Houser, Todd M. Sanderson, CourtneyJ. Lancos, Derek D. Prabharasuth, Kazuhiko Yamada,Robert Hawley, Clive Patience, Michel Awwad, Jay A.Fishman, Simon C. Robson, David H. Sachs, Henk-JanSchuurman, David K. C. Cooper. Boston, MA;Cambridge, MA.

5:10 PM THROMBOTIC MICROANGIOPATHY IN HDAFAND GalT-KNOCKOUT PIG HEARTSFOLLOWING TRANSPLANTATION INTOBABOONS. (Abstract #1069)Stuart L. Houser, Akira Shimizu, Kenji Kuwaki, Frank J.Dor, Yau-Lin Tseng, Christoph Knosalla, Jane Cheng,

4:30 PM POTENTIAL VALUE OF CLONED PIGSEXPRESSING ENDO-βββββ-GALACTOSIDASE C FORXENOTRANSPLANTATION. (Abstract #1065)Takaaki Kobayashi, Akira Onishi, Masaki Iwamoto,Daiichiro Fuchimoto, Shunichi Suzuki, Satoshi Watanabe,Satoko Arikawa, Yuko Miwa, Takaharu Nagasaka, DaGeLiu, Kenji Kadomatsu, Takashi Muramatsu, KunioMorozumi, Kazuharu Uchida, Akimasa Nakao. Tsukuba,Japan; Nagoya, Japan.

4:40 PM USE OF GALT-KO DONORS AVOIDS BOTHHYPERACUTE AND ACCELERATED HUMORALXENOGRAFT REJECTION FOLLOWINGMINIATURE SWINE-TO-BABOON RENALTRANSPLANTATION. (Abstract #1066)K. Yazawa, T. Iwanaga, A. Shimizu, M. Nuhn, S. Moran,S. Nobori, P. A. Vagefi, D. K. C. Cooper, R. Hawley, H.-J.Schuurman, J. Greenstein, D. H. Sachs, K. Yamada.Boston, MA; Cambridge, MA.

Henk-Jan Schuurman, David H. Sachs, David K. C.Cooper. Boston, MA; Cambridge, MA.

5:20 PM XENOANTIBODY RESPONSE TO ααααα-Gal KNOCK-OUT PIG ENDOTHELIAL CELLS FROM LIVERFAILURE PATIENTS EXPOSED TO PIGHEPATOCYTES FOLLOWING BIOARTIFICIALLIVER TREATMENT. (Abstract #1070)Angeles Baquerizo, Veneta Kirilova, Ian Williamson, OvaOakley, Henk-Jan Schuurman, Clive Patience, AchillesA. Demetriou, Ronald W. Busuttil, ChristopherShackleton. Los Angeles, CA; Cambridge, MA.

121

Tuesd

ay, May 18

AMERICAN TRANSPLANT CONGRESSDay-at-a-Glance, Tuesday, May 18, 2004

7:00 – 8:15 AM Concurrent Sunrise SymposiaPage 123 Sunrise Symposium I: Stem Cells and

Tissue RegenerationBallroom A

Sunrise Symposium II: Special Concernsof the Female Transplant RecipientBallroom B

7:00 – 8:15 AM Early Morning WorkshopsPage 123

8:30 – 10:00 AM Concurrent SymposiaPage 123 Basic Symposium: Regulatory T Cells in

Their Role in the Control of Counter-adaptive ImmunityBallroom B

Clinical Symposium: CampathVeterans Auditorium

10:15 AM – 12:30 PM Joint SessionVeterans Auditorium

10:15 AM AST Presidential AddressMichael R. Lucey

10:45 AM ASTS Presidential AddressAbraham Shaked

11:15 AM ASTS Awards

11:45 AM ASTS and AST Special Awards

12:00 PM History of First TransplantNicholas Tilney

12:20 PM 50th Anniversary of First SuccessfulOrgan TransplantPresentation of 50th Anniversary Award to the1954 Transplant Team and Donor

12:30 – 2:00 PM Poster Session IIIPresenters in AttendanceExhibits OpenExhibit Hall C

Page 124 Cardiac Transplantation: AllograftVasculopathy and Acute Rejection

Page 125 Chronic Injury: Antibody, Complement,and Fibrosis

Page 126 Inflammation and ExperimentalTransplantation

Page 127 Islet Cell and Stem Cell

Page 128 Kidney Transplant Outcomes andPredictors

Page 129 Kidney: Cardiovascular Risks, ChronicAllograft Nephropathy and Donor Issues

Page 131 Kidney: Complications,Immunosuppression and CMV

Page 134 Lymphocyte Activation: Basic Science

Page 135 Public Policy/Economics: All Organs

Page 136 Transplant Related Malignancies

12:45 – 1:45 PM Mini-Oral SessionsPage 137 Chronic Graft Injury: Novel Mechanisms

Room 309

Page 137 Experimental ImmunosuppressionRoom 306

Page 138 Liver Transplantation:ImmunosuppressionBallroom B

Page 138 Outcome in Pediatric Kidney TransplantBallroom A

2:00 – 3:30 PM Concurrent SessionsPage 139 Concurrent Session 41: Adult Living

Donor and Split Liver Transplant:Outcomes and InnovationsRoom 312

Page 139 Concurrent Session 42: CMV and Non-Organ Specific ImmunousuppressionRoom 302/304

Page 140 Concurrent Session 43: Cytokines andAlloreactivityRoom 306

Page 140 Concurrent Session 44: LiverTransplantation: Cancer and OtherConcernsBallroom B

Page 141 Concurrent Session 45: LymphocyteActivation: Generation of EffectorFunctionRoom 309

Page 141 Concurrent Session 46: MetabolicComplications and Hypertension AfterKidney TransplantationVeterans Ballroom

Page 142 Concurrent Session 47: Outcomes andComplications after CardiacTransplantationRoom 311

Page 142 Concurrent Session 48: PositiveCrossmatch Kidney Transplantation andSub-Clinical RejectionBallroom A

Page 143 Concurrent Session 49: Recent Progressin IsletBallroom C

Page 144 Concurrent Session 50: Strategies toAmeliorate Experimental RejectionRoom 310

Page 132 Liver Transplantation: Complicationsand Disease Recurrence

Page 134 Liver, Heart, Lung and Pancreas/Islets:Donation, Preservation, and Outcomes

122

AMERICAN TRANSPLANT CONGRESSDay-at-a-Glance, Tuesday, May 18, 2004

4:00 – 5:30 PM Concurrent SessionsPage 144 Concurrent Session 51: Apoptosis and

Potential Therapies in Ischemia-ReperfusionRoom 306

Page 145 Concurrent Session 52: Chemokines andAdhesion MoleculesRoom 310

Page 145 Concurrent Session 53: FactorsDetermining Outcomes in PancreasBallroom C

Page 146 Concurrent Session 54:Immunosuppression: Drug Interationsand Non-Immune EffectsRoom 302/304

Page 146 Concurrent Session 55: Kidney: Non-Immunological ComplicationsBallroom A

Page 147 Concurrent Session 56: LiverTransplantation: Complications andDisease Recurrence (Non-HCV)Room 312

Page 147 Concurrent Session 57: LiverTransplantation: Donors, Preservation,and OutcomesBallroom B

Page 148 Concurrent Session 58: Pediatric KidneyRoom 311

Page 148 Concurrent Session 59: Steroid andImmunosuppression Reduction/WithdrawalVeterans Ballroom

Page 149 Concurrent Session 60: TransplantTolerance IIRoom 309

123

Tuesd

ay, May 18

Tuesday, May 18, 2004

Concurrent Sunrise Symposia7:00 – 8:15 AM

Sunrise Symposium I: Stem Cells and TissueRegenerationBallroom AChair:Nicholas Zavazava

7:00 AM Nuclear transplantation and it’s potential for celltherapy

Rudolf Jaenisch7:25 AM Generation of pancreatic islet lineages from

embryonic stem cellsJon Odorico

7:50 AM Kidney regenerationMarc Hammerman

Sunrise Symposium II: Special Concerns of the FemaleTransplant Recipient

Ballroom BChair: Sheri Krams and Michelle Josephson

7:00 AM The ethical concerns of parenthood for transplantrecipients

Lainie Ross7:25 AM Cardiovascular disease and women transplant

patientsMark Sarnak

7:50 AM Bone disease post-transplantMaria Coco

Early Morning Workshops7:00 – 8:15 AM

Room locations will be printed in the onsite mini program and onthe tickets.

1. Regulatory T cellsRobert Lechler and Herman Waldman

2. Dendritic cell traffickingElizabeth Ingulli and Gwen Randolph

3. T cell activationDavid Rothstein and Maria-Luisa Alegre

4. Complement in acute and chronic rejectionWilliam Baldwin and Jeffrey L. Platt

5. The immunoregulatory role if IVIGStanley Jordan and Robert Montgomery

6. Management of recurrent HCV in the liver graftHugo Rosen and Fredric D. Gordon

7. Management of hepatitis B, use of core antibody +donors in liver and no-liver recipients

Geoffrey McCaugan and Angelo DeMattos8. The living kidney donor- Expanding criteria, donor risks

and follow up issuesStephen Textor and Connie Davis

9. Diagnosis and management of polyoma virus infectionEmilio Ramos and Anil Chandraker

10. Treatment of cardiac allograft vasculopathyHoward Eisen and Frances Johnson

11. Extending criteria for living donor liver transplantationfor hepatocellular carcinoma and cholangiocarcinoma

Myron Schwartz and Josep Llovet

13. Video workshop: New techniques of living donor livertransplantation

Amadeo Marcosn and Igal Kam14. Infectious Disease Guidelines for Transplant

Michael Green and Jutta Preiksaitis15. Special Early Morning Workshop - Open to all

Attendees, Organ Donation BreakthroughCollaborative Workshop

James Burdick, Virginia McBride and Kevin O’Connor

Concurrent Symposia8:30 – 10:00 AM

Basic Symposium: Regulatory T Cells in Their Role in theControl of Counter-adaptive Immunity

Ballroom BChairs: Stan Stepkowski and Karl Womer

8:30 AM Regulatory T cells in autoimmunityMatthias von Herrath

8:50 AM Transcriptional regulation and signaling pathwaysin regulatory T cells

Kathryn Wood9:10 AM Harnessing naturally occurring regulatory cells to

achieve transplantation toleranceRobert Lechler

9:30 AM Mechanisms underlying regulatory T-cellsHerman Waldman

Clinical Symposium: Campath

Veterans AuditoriumChairs: Dixon Kaufman and Stuart Knechtle

8:30 AM Development of Campath 1HHerman Waldman

8:50 AM The CD52 antigenGeoff Hale

9:10 AM Immunologic monitoring of the transplantrecipient receiving Campath 1H

Doug Hale9:30 AM Campath 1H in solid organ transplantation

Stuart Knechtle10:00 AM Break

Joint Session10:15 AM – 12:30 PMVeterans Auditorium

10:15 AM AST Presidential AddressMichael Lucey

10:45 AM ASTS Presidential AddressAbraham Shaked

11:15 AM ASTS Awards

11:45 AM ASTS and AST Special Awards

12:00 PM Keynote Address: History of TransplantationNicholas Tilney

12:20 PM Celebration of 50th Anniversary of the FirstSuccessful Transplant: History of the FirstTransplant

Presentation of the 50th Anniversary AwardHonoring the First Transplant Team and Donor

12. Video workshop: New techniques of living donor kidneytransplantation

Mikel Prieto and Lloyd E. Ratner

124

P2 INFLUENCE OF DONOR GENDER ONALLOGRAFT CORONARY VASCULOPATHY:EVIDENCE FROM INTRAVASCULARULTRASOUND. (Abstract #1072)Sabri K. Erinc, Mohamad H. Yamani, Randall C. Starling,James B. Young, Tim Crowe, Daniel J. Cook, RobertHobbs, Corinne Bott-Silverman, Gustavo Rincon, PatrickM. McCarthy, E. Murat Tuzcu. Cleveland, OH.

P3 SIMPLE NON-INVASIVE SCREENING TO SELECTPATIENTS FOR LATE FOLLOW-UP INVASIVEEXAMINATIONS AFTER HEARTTRANSPLANTATION. (Abstract #1073)Michael Dandel, Hans Lehmkuhl, Manfred Hummel,Roland Hetzer. Berlin, Berlin, Germany.

P4 NONINVASIVE ASSESSMENT OF CORONARYFLOW RESERVE IN HEART TRANSPLANTATIONRECIPIENTS PREDICTS CARDIAC ALLOGRAFTVASCULOPATHY. (Abstract #1074)Francesco Tona, Alida L. P. Caforio, Roberta Montisci,Antonio Gambino, Giuseppe Feltrin, Giuseppe Toscano,Cristiano Sarais, Riccardo Carta, Annalisa Vinci, AnnalisaAngelini, Gino Gerosa, Sabino Iliceto. Padova, Italy.

P5 THE DEVELOPMENT OF LEFT VENTRICULARHYPERTROPHY AFTER HEARTTRANSPLANTATION: IS THIS A MARKER FORPOOR OUTCOME? (Abstract #1075)Jignesh K. Patel, Angela Marquez, Eric Sue, ErinKobashigawa, Hillel Laks, Jon A. Kobashigawa. LosAngeles, CA.

P6 HEART TRANSPLANTATION FOR PATIENTSGREATER THAN 65 YEARS: ARE WE EXPECTINGTOO MUCH? (Abstract #1076)Jignesh K. Patel, Sheryllene Go, Gregg Fonarow, BrandyT. Oeser, Hillel Laks, Jon A. Kobashigawa. Los Angeles,CA.

P7 AMIODARONE UTILIZATION PRIOR TOCARDIAC TRANSPLANTATION DOES NOTINCREASE RISK OF RE-TRANSPLANTATION: ANANALYSIS OF THE UNITED NETWORK FORORGAN SHARING THORACIC REGISTRY.(Abstract #1077)Rajan Krishnamani, Andrew D. Feingold, Wenjun Li,Richard D. Patten, David DeNofrio. Boston, MA.

Diez, Polly Matzinger, Maria Gerbase-DeLima. SaoPaulo, SP, Brazil; Bethesda, MD.

P13 LEUKOCYTE GENE EXPRESSION SIGNATURE OFCMV VIREMIA IN CARDIAC ALLOGRAFTRECIPIENTS IS DISTINCT FROM THAT SEENDURING ALLOGRAFT REJECTION.(Abstract #1083)Mario C. Deng, Mandeep Mehra, Sharon Hunt, HannahValantine, Richard Miner, Julie Phillips, Jay G.Wohlgemuth, David Chernoff, Eleanor Woodward,Howard J. Eisen. New York, NY; New Orleans, LA;Stanford, CA; San Francisco, CA; South San Francisco,CA; Philadelphia, PA.

P14 POOR OUTCOME OF EARLY DEVELOPMENT OFCARDIAC ALLOGRAFT VASCULOPATHY AFTERCARDIAC TRANSPLANTATION. (Abstract #1084)Jignesh K. Patel, Jonathan Nakashima, Jaime D.Moriguchi, Brandy T. Oeser, Angela Marquez, HillelLaks, Jon A. Kobashigawa. Los Angeles, CA.

P15 HEMODYNAMIC MEASURES ARE AN ESSENTIALCOMPONENT OF THE ENDOMYOCARDIALBIOPSY PROCEDURE. (Abstract #1085)Frank W. Smart, Rajko Radovancevic, Igor D. Gregoric,Branislav Radovancevic, O. H. Frazier. Houston, TX.

P16 IS BNP A RELIABLE PREDICTOR FOR ACUTEREJECTION AFTER HEART TRANSPLANTATION?(Abstract #1086)Peter Landwehr, Ingo Kaczmarek, Ioannis Adamidis,Markus Mueller, Jan Groetzner, Peter Ueberfuhr, BrunoMeiser, Bruno Reichart. Munich, Germany.

P17 † VENTRICULAR-VASCULAR UNCOUPLING ANDEXPRESSION OF B-TYPE NATRIURETIC PEPTIDEIN HEART TRANSPLANTATION. (Abstract #1087)Mandeep R. Mehra, Richard V. Milani, Moriah Richie,Patricia A. Uber, Myung H. Park, Robert L. Scott,Hector O. Ventura. New Orleans, LA.

Poster Sesson III12:30 - 2:00 PM

Poster Viewing: 8:00 AM - 5:30 PMPresenters in Attendance: 12:30 - 2:00 PMExhibit Hall C

† Those posters identified as an ATC Poster of Distinction, bythis symbol have received review scores that place them inthe top 10% of their category. The Planning Committeeencourages you to make them a priority when you visit theposter session.

Cardiac Transplantation: Allograft Vasculopathy andAcute RejectionP1 † LEFT VENTRICULAR ASSIST DEVICES IN THE

DEVELOPMENT OF POST TRANSPLANTVASCULOPATHY. (Abstract #1071)Gonzalo V. Gonzalez-Stawinski, Patrick M. McCarthy,Daniel J. Cook, Fernando Atik, Patrick E. Parrino,Katheryn Hoercher, David O. Taylor, Randall A.Starling, Mohamed H. Yamani, James B. Young.Cleveland, OH.

P10 † INFLUENCE OF GROWTH FACTORS GENEPOLYMORPHISMS ON ACUTE AND CHRONICREJECTION AFTER PEDIATRIC HEARTTRANSPLANTATION. (Abstract #1080)Sylvie Di Filippo, Steven A. Webber, Anat Tambur,Robert Ferrel, Kevin McDade, Gerard J. Boyle, Susan A.Miller, Adriana Zeevi. Pittsburgh, PA; Chicago, IL.

P11 ROUTINE INVASIVE MONITORING MIGHT NOTBE NEEDED AFTER HEART TRANSPLANTATION INCHILDREN. (Abstract #1081)Sylvie Di Filippo, Pascale Boissonnat, Francois Sassolas,Jean Ninet, Gerard Champsaur, Andre Bozio. Lyon,France.

P12 † USING GENE CHIPS TO DISCRIMINATE AMONGREJECTION, NON-REJECTION AND CHAGAS’DISEASE REACTIVATION IN HEARTTRANSPLANTS. (Abstract #1082)Andrey Morgun, Natalia Shulzhenko, Ainhoa Perez-

P8 ASYMPTOMATIC CYTOMEGALOVIRUSACTIVATION LEADS TO ACUTE REJECTION INHEART TRANSPLANT RECIPIENTS DESPITE ANTI-VIRAL PROPHYLAXIS. (Abstract #1078)Luciano Potena, Cecile Holweg, Helen I. Luikart, EdwardS. Mocarski, John P. Cooke, David B. Lewis, Hannah A.Valantine. Stanford, CA.

P9 † IS THIRD-TIME RETRANSPLANTATIONJUSTIFIABLE? (Abstract #1079)Jonah Odim, Hillel Laks, Simin Bahrami, Ana Banerji,Kaushik Mukherjee, and the UCLA Heart TransplantTeam. Los Angeles, CA.

125

Tuesd

ay, May 18

P18 † IMPACT OF LATE ACUTE REJECTIONS ONLONG-TERM CARDIAC ALLOGRAFT FUNCTION.(Abstract #1088)Michael Dandel, Manfred Hummel, Hans B. Lehmkuhl,Rudolf Meyer, Christoph Knosalla, Onnen Grauhan,Roland Hetzer. Berlin, Germany.

P19 MOLECULAR ADAPTATIONS OF ENDOTHELIALCELLS TO ISCHEMIA/ REPERFUSION INJURYAFTER HEART TRANSPLANTATION.(Abstract #1089)Gaurang Shah, Frank Middleton, Maria Azizian, DaivdBruch, Dilip Kittur. Syracuse, NY.

Chronic Injury: Antibody, Complement, and FibrosisP20 ROLE OF COMPLEMENT IN ALLOGRAFT

REJECTION AND INDUCTIVE ANTIBODYTHERAPY. (Abstract #1090)Keri Csencsits, Sherri Chan Wood, Guanyi Lu, Gregory L.Stahl, D. Keith Bishop. Ann Arbor, MI; Boston, MA.

P21 † MEMORY ALLOANTIBODY RESPONSE ANDCOMPLEMENT-DEPENDENT CARDIAC GRAFTINJURY IN PREGNANCY-SENSITIZEDRECIPIENTS. (Abstract #1091)Zhiping Qian, Jinhuan Liu, Karen Fox-Talbot, Barbara A.Wasowska, William M. Baldwin III. Baltimore, MD.

P22 COMPLEMENT C1Q DEFICIENCY PROLONGSVASCULARIZED SOLID ORGAN GRAFTSURVIVAL. (Abstract #1092)Kenneth Christopher, Yurong Liang, Rachel DeFina,Thomas F. Mueller, David L. Perkins. Boston, MA.

P23 ROLE OF ALLOANTIBODY IN CD4+ T CELLDEPENDENT IMMUNE DAMAGE OFHEPATOCYTES. (Abstract #1093)Keri E. Lunsford, Phillip H. Horne, Yue Wang,Donghong Gao, Anna M. Eiring, Ginny L. Bumgardner.Columbus, OH.

P24 INJURY OF KIDNEY XENOGRAFTS FROM ααααα1,3-GALACTOSYL-TRANSFERASE GENE-KNOCKOUT(GalT-KO) PIGS INTO BABOONS ISCHARACTERIZED BY GLOMERULARTHROMBOTIC MICROANGIOPATHY.(Abstract #1094)A. Shimizu, K. Yamada, K. Yazawa, J. Cheng, S. C.Robson, H. J. Schuurman, D. H. Sachs, R. B. Colvin.Boston, MA; Cambridge, MA.

P25 DOES DONOR ANTIGEN-SPECIFICHYPOREACTIVITY PREDICT CHRONICREJECTION-FREE SURVIVAL IN SOLID ORGANRECIPIENTS? - A DECADE OF FOLLOW UP.(Abstract #1095)Nancy Reinsmoen, Angela Burnette, Karen Mohler, KaySavik, Lois McHugh, Arthur Matas. Durham, NC;Minneapolis, MN.

P26 REDUCTION OF CD4 ATTACHMENT ANDINFILTRATION INTO THE PERIVASCULAR SPACEOF ARTERIES AND THE MYOCARDIUM LEADSTO A SIGNIFICANT REDUCTION OFTRANSPLANT VASCULOPATHY AFTER CARDIACTRANSPLANTATION IN RATS. (Abstract #1096)Markus Richter, Markus Barten, Hartmut Bittner,Thomas Walther, Jan Gummert, Friedrich Mohr. Leipzig,Germany.

P27 INVOLVEMENT OF EPITHELIAL-TO-MESENCHYMAL TRANSITION (EMT) INCHRONIC RENAL ALLOGRAFT DYSFUNCTION.(Abstract #1097)Michael Zeisberg, Anil Chandraker, Mohamed H. Sayegh,Raghu Kalluri. Boston, MA.

P28 POSSIBLE CONTRIBUTION OF ENDOTHELIAL-MESENCHYMAL-TRANSITION (EMT) TOCARDIAC FIBROSIS IN HEART FAILURE ANDCHRONIC ALLOGRAFT REJECTION.(Abstract #1098)Elisabeth Höcht, Oleg Tarnavski, Michael Zeisberg, SeigoIzumo, Anil Chandraker, Xueli Yuan, Mohamed H.Sayegh, Raghu Kalluri. Boston, MA.

P29 PREVENTION OF EPITHELIAL TOMESENCHYMAL TRANSDIFFERENTIATION BYVITAMIN D. (Abstract #1099)Debra A. Hullett, Tina M. Stern, Arjang Djamali, HansW. Sollinger, Bryan N. Becker. Madison, WI.

P30 † GENOMIC ANALYSES OF PROTEINURICCONSOMIC RATS: POTENTIAL SURROGATEMARKERS OF CHRONIC ALLOGRAFTNEPHROPATHY. (Abstract #1100)Asher D. Schachter, Isaac S. Kohane. Boston, MA.

P31 MMF SIGNIFICANTLY REDUCES THETRANSENDOTHELIAL MIGRATION OF GRAFTINFILTRATING LEUCOCYTES. A COMPARATIVESTUDY WITH CSA AND FK506 AFTEREXPERIMENTAL CARDIAC TRANSPLANTATION.(Abstract #1101)Markus Richter, Hartmut Bittner, Thomas Walther,Volkmar Falk, Gummert Jan, Mohr Friedrich. Leipzig,Germany.

P32 † MYCOPHENPLATE MOFETIL INHIBITS INTIMALHYPERPLASIA AND ATTENUATES THEEXPRESSION OF GENES FAVOURING SMOOTHMUSCLE CELL PROLIFERATION ANDMIGRATION. (Abstract #1102)Julian R. Waller, Nicholas R. Brook, Michael L.Nicholson. Leicester, United Kingdom.

P33 BILIRUBIN SUPPRESSES NEOINTIMAFORMATION BY INHIBITION OF VASCULARSMOOTH MUSCLE CELL PROLIFERATION.(Abstract #1103)Robert Öllinger, Martin Bilban, Alberto Froio, JamesMcDaid, Anna Erat, Eva Csizmadia, Angela Liloia,Miguel P. Soares, Anny Usheva, Kenichiro Yamashita,Fritz H. Bach. Boston, MA; Innsbruck, Tyrol, Austria.

P34 COMBINED TREATMENT WITH εεεεεPKC ACTIVATORAND δδδδδPKC INHIBITOR REDUCES ISCHEMIAREPERFUSION INJURY AND GRAFT CORONARYARTERY DISEASE CAUSED BY PROLONGEDISCHEMIA IN RAT CARDIAC ALLOGRAFTS.(Abstract #1104)Masashi Tanaka, Feny Gunawan, Anthony D. Caffarelli,Koichi Inagaki, Theo Kofidis, Daria Mochly-Rosen,Robert C. Robbins. Stanford, CA.

P35 LOW DOSE INHALATION OF CARBONMONOXIDE PREVENTS THE DEVELOPMENT OFCHRONIC ALLOGRAFT NEPHROPATHY IN RATRENAL ALLOGRAFTS. (Abstract #1105)Joao Seda Neto, Hideyoshi Toyokawa, Anna Romanosky,Kei Kimizuka, Donna Stolz, Atsunori Nakao, NorikoMurase. Pittsburgh, PA.

P36 CARBON MONOXIDE INHALATION PROTECTSHEART ALLOGRAFT FROM CHRONICREJECTION. (Abstract #1106)Atsunori Nakao, Hideyoshi Toyokawa, Kei Kimizuka,Tetsuma Kiyomoto, Robert J. Bailey, Michael A.Nalesnik, Noriko Murase. Pittsburgh, PA.

P37 VASCULAR ENDOTHELIAL GROWTH FACTOREXPRESSION IN RENAL ALLOGRAFT REJECTIONAND CYCLOSPORINE TOXICITY.(Abstract #1107)B. Handan Ozdemir, A. Nihan Haberal, BeyhanDemirhan, Remzi Emiroglu, Aydin Dalgic, MehmetHaberal. Ankara, Turkey.

126

P38 ROLE OF MATRIX METALLOPROTEINASES 2 AND9 IN SKIN AND CARDIAC ALLOGRAFTREJECTION. (Abstract #1108)Hiroyuki Amano, Shoji Koga, Satoshi Hirohato,Masayoshi Miura, Suneel Apte, Robert Senior, HiroshiToma, Andrew C. Novick, Robert L. Fairchild.Cleveland, OH; Tokyo, Tokyo, Japan; St. Louis, MO.

P39 THE NOVEL AGENT PIRFENIDONE ATTENUATESTHE PRO-FIBROTIC MOLECULARENVIRONMENT GENERATED BY CALCINEURIN-INHIBITORS IN THE RAT SALT-DEPLETIONMODEL. (Abstract #1109)Nicholas R. Brook, Julian R. Waller, Gareth R. Bicknell,Michael L. Nicholson. Leicester, United Kingdom.

Inflammation and Experimental TransplantationP40 † POST-TRANSPLANT LYMHPOPROLIFERATIVE

DISEASE AFTER ALLOGENEIC SPLEENTRANSPLANTATION IN MINIATURE SWINE.(Abstract #1110)Frank J. M. F. Dor, Karen E. Doucette, Nicolas J.Mueller, Robert A. Wilkinson, Junaid A. Bajwa, Isabel M.McMorrow, Yau-Lin Tseng, Kenji Kuwaki, Stuart L.Houser, David H. Sachs, Jay A. Fishman, Christene A.Huang, David K. C. Cooper. Boston, MA.

P41 † TELOMERE SHORTENING IN RENAL TUBULAREPITHELIAL CELLS IN RESPONSE TOCYCLOSPORINE A IN VITRO – A PARAMETEROF REDUCED KIDNEY TRANSPLANT SURVIVALIN VIVO? (Abstract #1111)Gabriele Schratzberger, Christian Koppelstaetter, PaulJennings, Anna Maria Wolf, Walter Pfaller, Gert Mayer.Innsbruck, Austria; Insbruck, Austria.

P42 PREVALENCE OF HCV VIREMIA IN THEABSENCE OF ANTI-HCV ANTIBODIES AMONGSOLID ORGAN DONORS IN A LARGEMETROPOLITAN TRANSPLANT CENTER.(Abstract #1112)Marek Nowicki, Sali Aswad, Claudia Chinchilla, LivierCorado, Nasreen Khan, Hamid Shidban, Rafael G.Mendez, Robert Mendez. Los Angeles, CA.

P43 FK778, A SYNTHETIC MALONONITRILAMIDE, ISA POTENT ANTI-CYTOMEGALOVIRAL AGENTWITH A UNIQUE MECHAMISM OF ACTION THATIS REVERSIBLE WITH ADDITION OF URIDINE.(Abstract #1113)Kenneth A. Andreoni, David L. Evers, Xin Wang, Shu-Mei Huong, Eng-Shang Huang. Chapel Hill, NC.

P44 TELOMERE LENGTH AS A NOVEL PREDICTOROF DONOR ORGAN SURVIVAL IN RENALTRANSPLANTATION. (Abstract #1114)Gabriele Schratzberger, Christian Koppelstaetter, RainerOberbauer, Bernd Mayer, Heinz Regele, Gert Mayer.Innsbruck, Austria; Austria; Vienna, Austria.

P45 PORCINE VON WILLEBRAND FACTOR ANTIGENDEFICIENCY WITH PULMONARYINTRAVASCULAR MACROPHAGE DEPLETIONABROGATES HYPERACUTE PULMONARYXENOGRAFT DYSFUNCTION. (Abstract #1115)Edward Cantu, Sarah Gibson, Aaron Wyse, Christine Lau,Jeffery Gaca, Gonzalo V. Gonzalez-Stawinski1, KamranBaig, Timothy Nichols, William Parker, R. Duane Davis.Durham, NC; Chapel Hill, NC.

P46 DIFFERENTIAL GENE EXPRESSION PATTERNS INHUMAN KIDNEYS WITH AGE: A POTENTIALTOOL FOR EVALUATING MARGINAL DONORS?(Abstract #1116)Anette Melk, Elaine Mansfield, Philip F. Halloran,Minnie Sarwal. Edmonton, AB, Canada; Heidelberg,Germany; Palo Alto, CA.

P47 EXPRESSION OF FORKHEAD ACTIVIN SIGNALTRANSDUCER-1 (FAST-1) IN ACTIVATEDINFILTRATING MACROPHAGES IN ARTERIESFROM PATIENTS WITH CARDIAC ALLOGRAFTVASCULOPATHY. (Abstract #1117)Sheri E. Kelemen, Howard J. Eisen, Michael V. Autieri.Philadelphia, PA.

P48 RIBAVIRIN COUPLED TO HEMOGLOBINPROTECTS AGAINST EXPERIMENTAL VIRALHEPATITIS: THERAPY FOR HEPATITIS C VIRUSPOST-TRANSPLANT. (Abstract #1118)Gary A. Levy, Anand Ghanekar, Nancy F. Ng, AdamLevy, Laisum Fung, M. James Phillips, Pieter Biessels,Caroline Woods, Gord Adamson, David N. Bell. Toronto,ON, Canada; Mississauga, ON, Canada.

P49 THE SIGNIFICANCE OF HEPATIC ISCHEMIA-REPERFUSION INJURY ON LIVER TUMORDEVELOPMENT - ACTIVATION OF CELLINVASION AND MIGRATION PATHWAYS.(Abstract #1119)Kwan Man, Kevin T. P. Ng, Chung-Mau Lo, Joanna W.Y. Ho, Yi Zhao, Chris K. W. Sun, Terence K. W. Lee,Xian-Liang Li, Sheung-Tat Fan. Hong Kong, China.

P50 EPITHELIAL-MESENCHYMALTRANSDIFFERENTIATION DURING LATEDETERIORATION OF HUMAN KIDNEYTRANSPLANTS: POTENTIAL ROLE OF TUBULARCELLS IN FIBROGENESIS. (Abstract #1120)Attapong Vongwiwatana, Adis Tasanarong, David C.Rayner, Anette Melk, Philip F. Halloran. Edmonton,AB, Canada.

P51 ANALYSIS OF REGULATORY SIGNALS OF LIVERREGENERATION -SIGNALS REGULATINGHEPATOCELLULAR PROLIFERATION ANDGROWTH. (Abstract #1121)Sanae Haga, Shin Enosawa, Keita Terui, Wataru Ogawa,Hiroshi Inoue, Michitaka Ozaki. Segaya, Tokyo, Japan;Inohana, Chuo-ku, Japan; Shikata, Okayama, Japan;Chuo-ku, Kobe, Japan.

P52 HEMATOPOIETIC STEM CELLTRANSPLANTATION PREVENTS LYMPHOMA INAtm DEFICIENT MICE. (Abstract #1122)Jessamyn Bagley, John Iacomini. Boston, MA.

P53 BENEFICIAL EFFECTS OF PANCREASTRANSPLANTATION ON PROGRESSIVEDESTRUCTION OF PANCREATIC BETA-CELLS INSPONTANEOUSLY DIABETIC SDT RAT.(Abstract #1123)Gang Miao, Toshinori Ito, Fumihiro Uchikoshi, YusukeAkamaru, Tetsuma Kiyomoto, Hiroshi Komoda, JinghaiSong, Masumi Nozawa, Hikaru Matsuda. Osaka, Japan.

P54 GENE EXPRESSION PROFILING OF LIVERREGENERATION IN A MOUSE HEPATECTOMYMODEL. (Abstract #1124)Christopher T. Barry, Ryan McTaggart, John P. Roberts,Sandy Feng. San Francisco, CA.

P55 TRANSLATIONAL ENHANCEMENT IMPROVESGLUCOSE-DEPENDENT HEPATIC INSULINEXPRESSION AND REDUCES HYPERGLYCEMIAIN STZ-INDUCED DIABETIC RATS.(Abstract #1125)Philipp C. Nett, Hans W. Sollinger, Tausif Alam.Madison, WI.

P56 LIVER-SPECIFIC INSULIN PRODUCTION IN STZ-INDUCED DIABETIC MICE AFTER SYSTEMICPLASMID DNA GENE DELIVERY. (Abstract #1126)Philipp C. Nett, Hans W. Sollinger, Tausif Alam.Madison, WI.

127

Tuesd

ay, May 18

P57 EMERGENCE OF A CD4+CD28- GRANZYME B+,CMV-SPECIFIC T CELL SUBSET AFTERRECOVERY OF PRIMARY CMV-INFECTION.(Abstract #1127)Ester M. M. van Leeuwen, Ester B. M. Remmerswaal,Rene A. W. van Lier, Ineke J. M. ten Berge. Amsterdam,Netherlands.

P58 INNATE IMMUNE RESPONSE IS ACTIVATED VIATLR4 SIGNALING IN BAL FLUIDS OF HUMANLUNG TRANSPLANT RECIPIENTS.(Abstract #1128)Sabarinathan Ramachandran, Kalpaj R. Parekh, G. A.Patterson, T. Mohanakumar. St Louis, MO.

P59 LONG-TERM CYCLOSPORINE TREATMENTIMPAIRS URINE CONCENTRATING MECHANISMBY INHIBITING AQUAPORINS AND UREATRANSPORTERS. (Abstract #1129)Chul Woo Yang, Can Li, Bum Soon Choi, Sun Woo Lim,Bo Kyoung Sun, Yong Soo Kim, Jin Kim, Byung KeeBang. Seoul, Republic of Korea.

P60 DOWN REGULATION OF GENE EXPRESSION INTHE GRAFT LIMB BY RNA INTERFERENCE.(Abstract #1130)Yuki Sato, Takashi Ajiki, Yoji Hakamata, TakashiMurakami, Eiji Kobayashi. Minamikawachi, Kawachi,Tochigi, Japan.

Islet Cell and Stem CellP61 † MARKED PROLONGATION OF ISLET

ALLOGRAFT SURVIVAL IN NOD MICE WITHHIGH DOSE RAPAMYCIN AND CD154 PLUSICOSL BLOCKADE. (Abstract #1131)Mohammed Javeed I. Ansari, Arezou Khosroshahi, IndiraGuleria, Hideo Yagita, Hugh Auchincloss, Jr., MohamedH. Sayegh. Boston, MA; Tokyo, Japan.

P62 † IN VIVO QUANTITATIVE NONINVASIVEBIOLUMINESCENCE IMAGING OFINTRAPORTAL TRANSPLANTED ISLETS.(Abstract #1132)Juan L. Contreras, Tandra R. Chaudhuri, Amanda S.Starget, Hongju Wu, Cheryl A. Smyth, Guadalupe Bilbao,David T. Curiel, Devin Eckhoff, Kurt R. Zinn.Birmingham, AL.

P63 DONOR T-CELL CHIMERISM IS ASSOCIATEDWITH ABROGATION OF RECURRENTAUTOIMMUNITY IN ISLET GRAFTED NOD MICE.(Abstract #1133)Donghua Wang, Qixin Shi, Gregg A. Hadley, Donna L.Farber, Stephen T. Bartlett. Baltimore, MD.

P64 ISLET-KIDNEY TRANSPLANTATION:DETERMINING THE MINIMUM NUMBER OF ISLETEQUIVALENTS NEEDED TO CURE DIABETES ININBRED MINIATURE SWINE. (Abstract #1134)Matthew Nuhn, Emma Samelson-Jones, ChisakoKamano, Vaja Tchipashvili, Koji Yazawa, Shuji Nobori,Parsia A. Vagefi, David H. Sachs, Kazuhiko Yamada.Boston, MA.

P65 A LOW DONOR ISLET MASS IS SUFFICIENT TORESTORE NORMOGLYCEMIA IN DIABETIC NODMICE AFTER PRETRANSPLANT INDUCTION OF ASUBSTANTIAL LEVEL OF DONOR CHIMERISM.(Abstract #1135)Zhiguang Guo, Hannes Kalscheuer, Yisheng Pan, BinLuo, Haken Sozen, David E. R. Sutherland, Bernhard J.Hering. Minneapolis, MN.

P66 ANTI-INFLAMMATORY ANDIMMUNOSUPPRESSIVE EFFECTS OF THEGLUCOCORTICOID-INDUCED LEUCINE-ZIPPERPROTEIN GILZ ON ISOLATED PANCREATICISLETS (PI). (Abstract #1136)Juan L. Contreras, Hongju Wu, Guadalupe Bilbao,Christopher Eckstein, Carlton Young, Carlo Riccardi,David Curiel, Judith Thomas, Devin Eckhoff.Birmingham, AL; Perugia, Italy.

P67 A NOVEL APPROACH TOXENOTRANSPLANTATION COMBININGSURFACE ENGINEERING AND GENETICMODIFICATION OF ISOLATED ADULT PORCINEISLETS (PI). (Abstract #1137)Devin E. Eckhoff, Dong Xie, Cheryl A. Smyth,Cristopher Eckstein, Guadalupe Bilbao, Carlton J. Young,Anthony Thompson, Firoz Rahemtulla, David L. Curiel,Juan L. Contreras. Birmingham, AL.

P68 FUNCTIONAL BENEFITS AFTERTRANSPLANTATION OF HEMATOPOIETIC STEMCELL ENRICHED BONE MARROW INTOISCHEMIC MYOCARDIUM ARE NOT DUE TOTRANSDIFFERENTIATION. (Abstract #1138)Leora B. Balsam, Amy J. Wagers, Theo Kofidis, IrvingL. Weissman, Robert C. Robbins. Stanford, CA.

P69 AN ESSENTIAL ROLE OF IFN-γγγγγ IN PRIMARYNON-FUNCTION OF ISLET GRAFTS IN THE LIVEROF MICE. (Abstract #1139)Masayuki Sato, Yohichi Yasunami, YoshiichirohNakamura, Masahiko Nakano, Kentaroh Nabeyama,Atsushi Toyofuku, Nobuhide Matsuoka, Junko Ono,Masaru Taniguchi, Seiyo Ikeda. Fukuoka, Fukuoka,Japan; Yokohama, Kanagawa, Japan.

P70 PROTEIN BIOMARKERS OF METABOLIC STRESSIN ISLET TRANSPLANTATION. (Abstract #1140)Mark R. Nicolls, Michelle M. Kerklo, Nanette Gomez,Joshua Beilke, Mark W. Duncan, Ronald G. Gill. Denver,CO.

P71 MESENCHYMAL STEM CELLS CAN REDUCECONDITIONING REQUIREMENTS FORALLOGENEIC ENGRAFTMENT. (Abstract #1141)Phyllis E. Napoles, David Polchert, Ada Moadsiri,Edmund Ho, Julius Turian, Zheng Yu, Pamela Witte,Amelia M. Bartholomew. Chicago, IL; Maywood, IL.

P72 TRANSDUCTION OF HUMAN PANCREATICISLETS USING A BICISTRONIC FELINEIMMUNODEFICIENCY VIRAL VECTOR;IMPLICATIONS FOR ISLET TRANSPLANTATION.(Abstract #1142)Elizabeth S. Fenjves, Maria S. Ochoa, Carlota Gay-Rabinstein, Camillo Ricordi, Michael A. Curran. Miami,FL; Stanford, CA.

P73 A NEW TREATMENT FOR TYPE 1 DIABETES:SYSTEMIC TGF-BETA1 GENE THERAPYRESTORES SELF-TOLERANCE AND FACILITATESISLET REGENERATION. (Abstract #1143)X.-R. Luo, H. Yang, F. Sainte-Hilaire, D. Thomas, I.-S.Kim, B. De, W. W. Hancock, R. G. Crystal, M.Suthanthiran. New York, NY; PA.

P74 THE ROLE OF NEUTRAL PROTEASE DURINGISLET ISOLATION EVALUATED WITH A NEWENZYME PREPARATION. (Abstract #1144)Pascal Bucher, Domenico Bosco, Philippe Morel, ZoltanMathe, Manfred Kurfuest, Leo Buhler, Thierry Berney.Geneva, Switzerland; Uetersen, Germany.

P75 EARLY MOLECULAR MECHANISMS INAPOPTOSIS OF ISOLATED ISLETS (ANOIKIS).(Abstract #1145)Francis T. Thomas, Jianguo Wu, Jin He, Stacie Jenkins,Clement Asiedu, Juan L. Contreras, Anne Hutchings,Judith M. Thomas. Birmingham, AL.

128

P76 SYSTEMIC TGF-BETA 1 GENE THERAPY ELICITS T-

REGULATORY CELLS, INDUCES FOXP3EXPRESSION AND RETARDS THE DEVELOPMENTOF TYPE 1 DIABETES. (Abstract #1146)H. Yang, F. Saint Hilaire, X.-R. Luo, D. Thomas, B. De,R. Ding, T. Muthukumar, V. K. Sharma, M. He, W. W.Hancock, R. G. Crystal, M. Suthanthiran. New York, NY;PA.

P77 CD8+ TCR- FACILITATING CELLS HAVE A DIRECTEFFECT TO ENHANCE HEMATOPOIETIC STEMCELL FUNCTION IN VIVO AND IN VITRO : ANOVEL IN VITRO ASSAY FOR FACILITATINGCELLS. (Abstract #1147)Francine Rezzoug, Yiming Huang, Michael K. Tanner,Isabelle J. Fugier-Vivier, Suzanne T. Ildstad. Louisville,KY.

P78 PRESERVATION OF PANCREAS INPERFLUROCARBON INHIBITS APOPTOSIS INISOLATED HUMAN ISLETS. (Abstract #1148)S. Ramachandran, K. Narayanan, N. Benshoff, N.Steward, B. Olack, N. Desai, T. Mohanakumar. St Louis,MO.

P79 LOSS OF DONOR ISLET GRAFTS IN DIABETICNOD MICE WITH A LOW LEVEL OF DONORCHIMERISM IS MEDIATED BY AUTOIMMUNITY.(Abstract #1149)Baolin Liu, Yisheng Pan, Neal Heuss, David E. R.Sutherland, Bernhard J. Hering, Zhiguang Guo.Minneapolis, MN.

P80 RECENT PRECLINICAL STUDIES FOR“PROSPECTIVE PHASE I/II SAFETY STUDY OFENCAPSULATED ISOLATED PRIMARY HUMANPANCREATIC ISLET TRANSPLANTATION WITHLOW DOSE SHORT TERM IMMUNESUPPRESSION IN PATIENTS WITH TYPE IDIABETES MELLITUS”. (Abstract #1150)Wen-Ghih Tsang, Carolyn C. Huntenburg, Tianli Zheng,Andrew Schaeffer, Yan Ping Wang, Kermit Lim. SantaMonica, CA.

Kidney Transplant Outcomes and PredictorsP81 † SERUM CREATININE IN THE FIRST YEAR POST-

TRANSPLANT AS A PREDICTOR OF LONG-TERMRENAL TRANSPLANT OUTCOME IN THE UK.(Abstract #1151)Rachel J. Johnson, Christopher J. Rudge, David Collett,John L. R. Forsythe. Bristol, United Kingdom.

P82 † THE IMPACT OF DELAYED GRAFT FUNCTION ONLONG TERM GRAFT SURVIVAL. (Abstract #1152)Herwig-Ulf Meier-Kriesche, Carl J. Cardella, Jesse D.Schold, Alan I. Reed, Ayesha Kaleem, Richard J. Howard,Bruce Kaplan. Gainesville, FL; Toronto, ON, Canada.

P83 † IS EPITOPE MATCHING (EPI M) A BETTERPREDICTOR OF SHORT-TERM RENALALLOGRAFT OUTCOME THAN HLA MATCHING(HLA M)? (Abstract #1153)A. Haririan, S. Gruber, H. Daneshvar, K. Morawski, J.ElAmm, D. Granger, M. West, D. Sillix, O. Fagoaga, S.Nehlsen-Cannarella. Detroit, MI.

P84 † POST TRANSPLANT CHANGE IN GFR BETWEEN 6AND 12 MONTHS (∆∆∆∆∆GFR6-12) CORRELATES WITHLONG-TERM GRAFT FAILURE. (Abstract #1154)Nauman Siddiqi, John S. Gill, Nathan Johnson, SundaramHariharan. Milwaukee, WI; Vancouver, BC, Canada.

P85 LONG-TERM RESULTS OF ELDERLY DONORKIDNEY TRANSPLANTS. A SINGLE-CENTEREXPERIENCE. (Abstract #1155)Kazunari Tanabe, Tadahiko Tokumoto, Hideki Ishida,Nobuo Ishikawa, Naoshi Miyamoto, Tsunenori Kondo,Hiroaki Shimmura, Kiyoshi Setoguchi, Ichiro Nakajima,Shouhei Fuchinoue, Satoshi Teraoka, Hiroshi Toma.Shinjuku, Tokyo, Japan.

P86 KIDNEY TRANSPLANT OUTCOME IN A LARGESINGLE CENTER HISPANIC POPULATION.(Abstract #1156)Alger Aquino, Sali Aswad, Akshay Mehta, Rafael G.Mendez, Robert Mendez. Los Angeles, CA.

P87 PREVIOUS TRANSPLANT CHARACTERISTICSPREDICT ALLOGRAFT AND RECIPIENTSURVIVAL. (Abstract #1157)Alex S. Goldfarb-Rumyantzev, Gregory Stoddard, BradleyBaird, Sukil Kim, Lev Barenbaum, Sergei Krikov, AlfredK. Cheung. Salt Lake City, UT.

P88 OUTCOME OF RENAL TRANSPLANTATION INELDERLY RECIPIENTS. (Abstract #1158)Jeffrey Rogers, Sylvia Odom, Muriel Labonte, GregGilbert, Angello Lin, Kenneth Chavin, Prabhakar Baliga,Osemwegie Emovon, Fuad Afzal, Elizabeth Ashcraft, G.Mark Baillie, David Taber, Ruy Marques, P. R.Rajagopalan. Charleston, SC.

P89 ARE PRE-TRANSPLANT SENSITISED KIDNEYRECIPIENTS AT HIGHER RISK OF TRANSPLANTFAILURE? (Abstract #1159)Iren Szeki, Susanne Mills, Faieza Qasim, Phil Dyer.Manchester, United Kingdom.

P90 FACTORS RESPONSIBLE FOR IMPROVEMENT INGRAFT FUNCTION SEEN IN THE 1990S, ANALYSISOF OPTN DATA. (Abstract #1160)Douglas S. Keith, Angelo deMattos, MuralikrishnaGolconda, Jonathan Prather, Douglas Norman. Portland,OR.

P91 DETERMINANTS OF KIDNEY GRAFT FUNCTIONDURING THE FIRST TWO YEARS POST-TRANSPLANT. (Abstract #1161)Fernando G. Cosio, Matthew D. Griffin, Thomas R.Schwab, James M. Gloor, Jorge A. Velosa, StephenTextor, Mark S. Stegall, Timothy S. Larson. Rochester,MN.

P92 FUNCTIONAL CAPACITY CORRELATES WITHQUALITY OF LIFE IN RECENT AND LONG-TERMTRANSPLANT RECIPIENTS. (Abstract #1162)Patricia A. Cowan, Donna K. Hathaway, Ann K.Cashion, Gayle Gower, A. Osama Gaber. Memphis, TN.

P93 RENAL ALLOGRAFT OUTCOME FORMAGHREBIAN VERSUS CAUCASIANRECIPIENTS. (Abstract #1163)Marc Hazzan, Maxime Hoffmann, Francois Provot,Francois Glowacki, Francois-Rene Pruvot, ChristianNoel. Lille, France.

P94 Abstract #1164 has been withdrawn.P95 THE LIVING DONOR ADVANTAGE: BETTER

GLOMERULAR FILTRATION RATE BUT NOTBETTER LONG TERM STABILITY (SLOPE).(Abstract #1165)Sita Gourishankar, Lawrence G. Hunsicker, Philip F.Halloran. Edmonton, AB, Canada; Iowa City, IA.

P96 † CHARACTERISTICS OF RENAL TRANSPLANTRECIPIENTS WITH GOOD LONGTERM RENALFUNCTION. (Abstract #1166)Jeremy Chapman, Andreas Bock, Bertrand Dussol, LutzFritsche, John Jeffery, Volker Kliem, Yvon Lebranchu,Federico Oppenheimer, Erich Pohanka, MaurizioSalvadori, Gunnar Tufveson. Westmead, NSW 2145,Australia.

129

Tuesd

ay, May 18

P97 † LIMITATIONS OF CREATININE CLEARANCEEQUATIONS IN RENAL TRANSPLANT PATIENTS.(Abstract #1167)Ahmed Shoker, Dharmapaul L. Raju, Vaneeta K. Grover.Saskatoon, SK, Canada.

P98 RECURRENCE OF IgA NEPHROPATHY ANDHENOCH –SCHÖNLEIN PURPURA NEPHRITISAFTER KIDNEY TRANSPLANTATION: MAIN RISKFACTORS. (Abstract #1168)Mª Josep Soler, Josep Mª Puig, Marisa Mir, M. AntoniaOrfila, Eva Rodriguez, Mª Asuncion Munne, SusanaVazquez, Josep Lloveras. Barcelona, Spain.

P99 OUTCOME OF RENAL TRANSPLANTATION INPATIENTS WITH AN ILEAL CONDUIT.(Abstract #1169)Molly M. P. Eng, Richard E. Power, Saad Al-Dousari,David P. Hickey, Denis M. Murphy, Dilly M. Little.Dublin, Dublin, Ireland.

P100 PERFORMANCE OF TWO SERUM CREATININEBASED FORMULAS AND 24 HOUR CREATININECLEARANCE IN KIDNEY TRANSPLANTRECIPIENTS WITH EXCELLENT GRAFTFUNCTION. (Abstract #1170)Hassan Ibrahim, Ziad Zoghby, Furqan Raja, RichardSpong, Will Thomas, Arthur Matas, Michael Mauer.Minneapolis, MN.

P101 CALCIUM LEVELS AS A RISK FACTOR FORDELAYED GRAFT FUNCTION. (Abstract #1171)Henk Boom, Marko J. K. Mallat, Johan W. de Fijter, JanA. Bruyn, Leendert A. van Es, Leendert C. Paul. Leiden,Netherlands.

P102 SEQUENTIAL LIVING DONOR KIDNEY ANDAUTOLOGOUS STEM CELL TRANSPLANTATIONFOR AL (“PRIMARY”) AMYLOIDOSIS WITHPREDOMINANT RENAL INVOLVEMENT.(Abstract #1172)Matthew D. Griffin, Nelson Leung, Angela Dispenzieri,James M. Gloor, Thomas R. Schwab, Stephen C. Textor,Martha Q. Lacy, Mark R. Litzow, Timothy S. Larson,Morie A. Gertz, Mark D. Stegall. Rochester, MN.

P103 URINARY TRANSFORMING GROWTH FACTOR-BETA1 (TGF- βββββ

1) EXCRETION IS NORMAL IN

RENAL TRANSPLANT RECIPIENTS WITH STABLEALLOGRAFT FUNCTION. (Abstract #1173)Geeta G. Gyamlani, Catherine E. Gray, Mark D. Stegall,Joseph P. Grande, Timothy S. Larson. Rochester, MN.

P104 MARKERS OF INFLAMMATION BEFORE ANDAFTER RENAL TRANSPLANTATION.(Abstract #1174)Alfonso Cueto-Manzano, Luis E. Morales-Buenrostro,Liliana Gonzalez, Norma Gonzalez-Tableros, Isela Valera,Ricardo Correa-Rotter, Josefina Alberu. Guadalajara, Jal.,Mexico; Mexico City, Mexico.

P105 RENAL ALLOGRAFT AND PATIENT SURVIVAL INPATIENTS WITH AND WITHOUT A GENETICHYPERCOAGULABLE STATE WHO UNDERGOREPEAT RENAL TRANSPLANTATION AFTER ANINITIAL PRIMARY RENAL ALLOGRAFTTHROMBOSIS. (Abstract #1175)Ashley B. Irish, Fiona R. Green, Derek W. R. Gray.Perth, WA, Australia; Oxford, United Kingdom.

P106 HIGH-RISK FACTORS (HRF) IN RENALTRANSPLANTATION HAVE CHANGED WITH THEADVENT OF NEW IMMUNOSUPPRESSIVEAGENTS. (Abstract #1176)Carlton J. Young, Clifton Kew, Sharon Hudson, ArunChandrakantan, Michael Gallichio, Bruce Julian, MarkDeierhoi, Robert Gaston. Birmingham, AL.

P107 MISMATCHES IN AFRICAN-AMERICAN VERSUSNON-AFRICAN AMERICAN RECIPIENTS OFCADAVERIC RENAL TRANSPLANTS BASED ONLOW RESOLUTION (LR) DNA TYPING ANDAMINO-ACID SEQUENCE AT HLA LOCI. (Abstract #1177)Ajay K. Israni, Christina Gaughan, Tracey Hoy, MarshallM. Joffe, Kevin C. Mange, Malek Kamoun, MelissaNewman, Jane Kearns, Noah Goodman, David Feldman,Sylvia E. Rosas, Rene J. Duquesnoy, Harold I. Feldman.Philadelphia, PA; Pittsburg, PA.

P108 AFRICAN AMERICANS HAVE A LOWER RATE OFCONVERSION FROM TRANSPLANTEVALUATION TO PLACEMENT ON THE ACTIVEWAITING LIST. (Abstract #1178)Erica L. Hartmann, Aimee K. Sundberg, Julie A.Roskopf, Alan C. Farney, Michael S. Rohr, Patricia L.Adams, Robert J. Stratta. Winston-Salem, NC.

P109 IMPROVEMENT IN DISEASE ACTIVITY ANDMORTALITY FOLLOWING RENAL TRANSPLANTFOR SYSTEMIC SCLEROSIS. (Abstract #1179)Eric M. Gibney, Alkesh Jani, Michael J. Fischer, ChiragR. Parikh, David Collier, Alex C. Wiseman. Denver, CO.

Kidney: Cardiovascular Risks, Chronic AllograftNephropathy and Donor IssuesP110 ASSESSING RISK FOR POSTOPERATIVE

MYOCARDIAL INFARCTION AFTER RENALTRANSPLANTATION. (Abstract #1180)Anup Manoharan, Anita Patel. Detroit, MI.

P111 PURE LAPAROSCOPIC RIGHT DONORNEPHRECTOMY: EQUIVALENT DONOR ANDRECIPIENT OUTCOMES AS COMPARED WITHLAPAROSCOPIC LEFT DONOR NEPHRECTOMY.(Abstract #1181)Harish D. Mahanty, Jonathan T. Carter, Sang-Mo Kang,John P. Roberts, Chris E. Freise, Andrew M. Posselt. SanFrancisco, CA.

P112 NORMAL DIPYRIDAMOLE-STRESSTECHNETIUM-TETROFOSMIN SPECT STUDIESPREDICT LOW RISK OF CARDIAC MORTALITYFOLLOWING KIDNEY TRANSPLANTATION.(Abstract #1182)Pary Sivaraman, Kheng-Thye Ho. Singapore.

P113 RESULTS USING A RISK-WEIGHTEDALGORITHM FOR CARDIAC SCREENING INRENAL TRANSPLANT CANDIDATES.(Abstract #1183)Ayman Iskander, Beth Bouthot, Edward Walshe,Christopher Ying, Samir Kassissieh, Hannah Gilligan,Marti Hoar, Mary Ann Simpson, Arsalan Shahzad, KanFang, Richard W. Nesto. Burlington, MA.

P114 INFLAMMATION, ENDOTHELIAL DYSFUNCTIONAND INHERITANCE PREDICT PREVALENT ANDINCIDENT CARDIOVASCULAR DISEASE INRENAL TRANSPLANT RECIPIENTS: RESULTS OFTHE OxSPIRes COHORT. (Oxford Study ofProcoagulant factors In Renal TransplantRecipients). (Abstract #1184)Ashley B. Irish, Fiona R. Green, Derek W. R. Gray.Perth, WA, Australia; Oxford, United Kingdom; Oxford,United Kingdom.

P115 ANGIOTENSIN GENE POLYMORPHISM ISASSOCIATED WITH DEVELOPMENT OF POSTRENAL TRANSPLANT HYPERTENSION.(Abstract #1185)Kamal Sud, Madhu Khullar, Deepak Sharma, VinaySakhuja. Chandigarh, UT, India.

130

P116 QUALITY ASSURANCE OF HYPERTENSION ANDLIPID TARGETS IN RENAL TRANSPLANTRECIPIENTS. (Abstract #1186)Jeffrey S. Zaltzman, Sumeet Suneja, Michelle Nash, G. V.Ramesh Prasad. Toronto, ON, Canada.

P117 THE ROLE OF HOME BLOOD PRESSUREMONITORING (HBPM) IN THE CONTROL OFHYPERTENSION IN RENAL TRANSPLANTRECIPIENTS. (Abstract #1187)Bangi Awosika, Gail Makos, Susan Steigerwalt, MohamedEL-Ghoroury, Robert Provenzano. Detroit, MI.

P118 THE RENIN ALDOSTERONE AXIS IN STABLERENAL TRANSPLANT RECIPIENTS.(Abstract #1188)Hassan Ibrahim, Arthur Matas, Richard Spong, MichaelMauer. Minneapolis, MN.

P119 PATHOGENIC MECHANISMS OF POST-TRANSPLANT ERYTHROCYTOSIS. A NEW ROLEFOR CALCIUM. (Abstract #1189)Luisa Jimeno, Raquel Rodado, Alfredo Minguela, MatildeCampos, Francisco Nicolas, Luis Marin. Murcia, Spain.

P120 RECOVERY OF ANTI-RECOMBINANT-HUMAN-ERYTHROPOIETIN ASSOCIATED PURE RED CELLAPLSIA IN END STAGE RENAL DISEASE PATIENTSAFTER RENAL TRANSPLANTATION.(Abstract #1190)Kearkiat Praditpornsilpa, Yingyos Avihingsanon,Somphon Buranasot, Narudee Bhokaisuwan, TalerngsakKansanabuch, Somchai Eiam-Ong, Sauwaluck Chusil,Kriang Tungsanga. Thailand; Bangkok, Thailand.

P121 ANEMIA MANAGEMENT PRIOR TO KIDNEYTRANSPLANTATION AND THE RISK OF POST-TRANSPLANT BLOOD TRANSFUSION.(Abstract #1191)John S. Gill, Craig Solid, Brian J. G. Pereira, Allan J.Collins. Vancouver, BC, Canada; Boston, MA;Minneapolis, MN.

P122 † A RETROSPECTIVE ANALYSIS OF EZETIMIBE(ZETIA®) TREATMENT IN RENAL TRANSPLANTRECIPIENTS. (Abstract #1192)Christie L. Buchanan, Lonnie D. Smith, Jacke Corbett,Troy Somerville, John Holman, Fuad S. Shihab. Salt LakeCity, UT.

P123 TREATMENT OF SIROLIMUS INDUCED POST-TRANSPLANT HYPERLIPIDEMIA WITHATORVASTATIN AND SLOW RELEASE NIACINTHERAPY. (Abstract #1193)Martin S. Zand, Richard Demme, Jeremy Taylor.Rochester, NY.

P124 † ADIPONECTIN AND PROTECTION AGAINSTPOSTTRASPLANT DIABETES MELLITUS.(Abstract #1194)Beatriz Bayés, Ricardo Lauzurica, Marisa Granada,Asumpta Serra, Nestor Fontseré, Isabel Salinas, RamónRomero. Badalona, Barcelona, Spain.

P125 A PROSPECTIVE RANDOMISED TRIAL OFMYCOPHENOLATE MOFETIL ANDAZATHIOPRINE AFTER CALCINEURINREDUCTION IN RENAL ALLOGRAFTS WITHESTABLISHED CHRONIC ALLOGRAFTNEPHROPATHY. (Abstract #1195)Nicholas R. Brook, Matthew S. Metcalfe, Julian R.Waller, Sunjay Jain, Sarah A. Hosgood, Michael L.Nicholson. Leicester, United Kingdom.

P126 CORRELATION OF RENAL RESISTANCE INDEXAND BIOPSY PROVEN CHRONIC ALLOGRAFTNEPHROPATHY: A PART OF THE GENERALTRANSPLANT PHYSICAL EXAM. (Abstract #1196)Eric A. Elster, Douglas Hale, Linda B. Cendales, DavidKleiner, Micheal Ring, Beverly Niles, S. John Swanson,Roslyn B. Mannon, Allan D. Kirk. Bethesda, MD.

P127 HYPERPARATHYROIDISM AND BONETURNOVER IN THE FIRST YEAR FOLLOWINGKIDNEY TRANSPLANTATION: A PROSPECTIVESTUDY. (Abstract #1197)Martin Flamant, Magali Ciroldi, Dominique Prié, EricThervet, Frank Martinez, Gérard Friedlander, ChristopheLegendre. Paris, France.

P128 LAPAROSCOPIC PROCUREMENT OF DONORKIDNEYS WITH MULTIPLE RENAL ARTERIESDOES NOT COMPROMISE DONOR OUTCOMEBUT IS ASSOCIATED WITH INCREASEDURETERAL COMPLICATIONS IN THE RECIPIENT.(Abstract #1198)Jonathan T. Carter, Andrew M. Posselt, Ryan A.McTaggart, Harish D. Mahanty, Sang-Mo Kang, John P.Roberts, Chris Freise. San Francisco, CA.

P129 PRESERVATION OR SACRIFICE: DETECTION OFSMALL RENAL ARTERIES WITH 3-DIMENSIONALOR AXIAL COMPUTED TOMOGRAPHY FORDECISION MAKING. (Abstract #1199)Nobuyuki Fukuzawa, Masayoshi Miura, Hiroshi Harada,Hirokazu Shinojima, Toshimori Seki, Masaki Togashi,Tetsuo Hirano. Sapporo, Hokkaido, Japan.

P130 IMPACT OF KIDNEY WEIGHT-BODY WEIGHTRATIO ON ALLOGRAFT FUNCTION IN LIVINGRENAL TRANSPLANTATION. (Abstract #1200)Mukut Minz, Navalkishor Udgiri, Munish K. Heer, M. S.Reddy, Vivekanand Jha, Randeep Kashyap. Chandigarh,UT, India.

P131 IMPACT OF RENAL ALLOGRAFTIMMUNOGLOBULIN A DEPOSITS ATTRIBUTABLETO DONOR ON THE OUTCOME OF LIVING-RELATED RENAL TRANSPLANTATION.(Abstract #1201)Kanji Nagahama, Shingo Yamamoto, Noriyuki Ito,Hidehumi Kinoshita, Toshiyuki Kamoto, Hiroshi Okuno,Takahiko Ono, Osamu Ogawa. Kyoto, Japan.

P132 RENAL FUNCTION AND HORMONE OUTPUT. APROSPECITVE STUDY COMPARING OPEN,LAPAROSCOPIC ANDRETROPERITONEOSCOPIC LIVE DONORNEPHRECTOMY. (Abstract #1202)Pernilla Sundqvist, Ulla Feuk, Mikael Haggman, A. ErikG. Persson, Mats Stridsberg, Jonas Wadstrom. Uppsala,Sweden; Simrishamn, Sweden.

P133 HLA MATCHING AND OUTCOME OF LIVINGDONOR KIDNEY TRANSPLANTS IN THE UK.(Abstract #1203)Rachel J. Johnson, Rachel A. Hodge, Susan V. Fuggle,Christopher J. Rudge, John L. R. Forsythe. Bristol,United Kingdom.

P134 LAPAROSCOPIC RIGHT LIVE DONORNEPHRECTOMY: REFINING TECHNIQUE.(Abstract #1204)Alun R. Williams, Magdi Shehata. Nottingham, UnitedKingdom.

P135 LAPAROSCOPIC DONOR NEPHRECTOMYYIELDS KIDNEYS THAT ARE STRUCTURALLYAND FUNCTIONALLY EQUIVALENT TO THOSEPROCURED BY OPEN SURGERY - RESULTS OF ARANDOMISED TRIAL. (Abstract #1205)Nicholas R. Brook, Gareth R. R. Lewis, Julian R. Waller,Jennifer C. Bains, Peter S. Veitch, Michael L. Nicholson.Leicester, United Kingdom.

131

Tuesd

ay, May 18

Kidney: Complications, Immunosuppression and CMVP136 PROPHYLAXIS AGAINST

CYTOMEGALOVIRUS(CMV) USINGGANCICLOVIR(G) OR VALGANCICLOVIR(V) INKIDNEY(K) AND KIDNEY-PANCREAS(SPK)TRANSPLANTATION UNDER ANTIBODYPRECONDITIONING. (Abstract #1206)Amit Basu, Kenan Keven, Sunil Sharma, Henkie Tan,Akhtar Khan, Amadeo Marcos, John Fung, ThomasStarzl, Ron Shapiro. Pittsburgh, PA.

P137 ADVERSE IMPACT OF STEROIDS ON OUTCOMEIN THE ALERT STUDY. (Abstract #1207)Alan G. Jardine, Hallvard Holdaas, Bengt Fellstrom, onBehalf of the ALERT Investigators. Glasgow, UnitedKingdom; Oslo, Norway; Uppsala, Sweden.

P138 IS IT NECESSARY TO WITHHOLD NEORAL®(CSA) THERAPY DURING DELAYED GRAFTFUNCTION IN RENAL TRANSPLANT RECIPIENTS?(Abstract #1208)Flavio Vincenti, Jimmy Light, Thomas Pearson, YouMin Wu, John Curtis, Robert Mendez, Ralph Barbeito.San Francisco, CA; Washington, DC; Atlanta, GA; IowaCity, IA; Birmingham, AL; Los Angeles, CA; E Hanover,NJ.

P139 PRE-TRANSPLANT RISK FACTORS FOR UKRENAL TRANSPLANT PATIENT WITHCICLOSPORIN. (Abstract #1209)Xiang He, Atholl Johnston. London, England, UnitedKingdom.

P140 COMPARABLE RENAL FUNCTION IN LIVINGKIDNEY DONORS AND THEIR RECIPIENTS ONTACROLIMUS-BASED IMMUNOSUPPRESSION.(Abstract #1210)Elly M. van Duijnhoven, Henricus J. A. Dackus, MaartenH. L. Christiaans, Johannes P. van Hooff. Maastricht,Netherlands.

P141 SERUM SICKNESS DOES NOT SEEM TO BE DUETO ANTI-Gal IMMUNIZATION. (Abstract #1211)Joanna Ashton-Chess, Guillaume Meurette, JeanneNaulet, Maghed Ekklas, Jean-Paul Soulillou, GillesBlancho. Nantes, France.

P142 PHARMACOKINETICS ANDPHARMACODYNAMICS OF ISA247 A NEW-GENERATION CALCINEURIN INHIBITOR INSTABLE RENAL TRANSPLANT PATIENTS.(Abstract #1212)Patrick Mayo, Derrick Freitag, Bruno Boutouyrie-Dumont, Mahdi Farhan. Edmonton, AB, Canada; Basel,Switzerland; Welwyn Garden City, Herts, UnitedKingdom.

P143 COMBINED USE OF SIROLIMUS ANDVORICONAZOLE IN RENAL TRANSPLANTATION.(Abstract #1213)A. Scott Mathis, Nita K. Shah, Gary S. Friedman.Piscataway, NJ; Livingston, NJ; West Orange, NJ.

P144 ACCOMMODATION OF ABO INCOMPATIBLERENAL ALLOGRAFTS IS ASSOCIATED WITHPERSISTENT C4D STAINING. (Abstract #1214)Christopher E. Simpkins, Daniel S. Warren, ChristopherJ. Sonnenday, Matthew Cooper, Karen E. King, MarkHaas, Robert A. Montgomery. Baltimore, MD.

P145 SALAVAGE OF COMPROMISED RENAL VESSELSIN KIDNEY TRANSPLANTATION USING THIRD-PARTY CADAVERIC EXTENDERS: IMPACT ONPOST TRANSPLANT ANTI-HLA ANTIBODYFORMATION. (Abstract #1215)Mahesh C. Goel, Stuart M. Flechner, M. El-Jack, JohnVeniro, Charles Modlin, Lynne Klingman, Daniel J.Cook. Cleveland, OH.

P146 IMPACT OF HLA-IDENTITY ON RESULTS OFABO-INCOMPATIBLE LIVING KIDNEYTRANSPLANTATION. (Abstract #1216)Hiroaki Shimmura, Kazunari Tanabe, Hideki Ishida,Tadahiko Tokumoto, Nobuo Ishikawa, NaoshiMiyamoto, Kiyoshi Setoguchi, Hiroshi Toma. Shinjuku,Tokyo, Japan.

P147 COMBINED KIDNEY AND BONE MARROWTRANSPLANTATION FOR INDUCTION OF MIXEDCHIMERISM AND RENAL ALLOGRAFTTOLERANCE IN HLA MISMATCHEDTRANSPLANTATION. (Abstract #1217)Tatsuo Kawai, David H. Sachs, Thomas Spitzer, MeganSykes, Nina Tolkoff-Rubin, Francis Delmonico, SusanSaidman, Juanita Shaffer, Bimalangshu Dey, StevenMcAfee, Winfred Williams, Dicken Ko, Martin Hertl,Nelson Goes, Waichi Wong, Robert B. Colvin, A.Benedict Cosimi. Boston, MA; Charlestown, MA.

P148 † IMPACT OF PREDNISONE FREEIMMUNOSUPPRESSION ON BONE MINERALDENSITY IN KIDNEY TRANSPLANT RECIPIENTS.(Abstract #1218)Furqan Raja, Arthur Matas, Hassan Ibrahim.Minneapolis, MN.

P149 COLONIC PARACELLULAR PERMEABILITY ISINCREASED IN RENAL TRANSPLANT RECIPIENTSWITH CHRONIC DIARRHEA. (Abstract #1219)Wim Lemahieu, Bart Maes, Kirstin Verbeke, YvesVanrenterghem. Leuven, Belgium.

P150 VASCULAR COMPLICATIONS OF ALLOGRAFTNEPHRECTOMY. (Abstract #1220)Molly M. P. Eng, Dilly M. Little, Richard E. Power,John G. Calleary, David P. Hickey. Dublin, Ireland.

P151 PREDICTIVE MODEL FOR RENAL REPLACEMENTTHERAPY (RRT) FOLLOWING ORTHOTOPICLIVER TRANSPLANTATION (OLTX) BASED ONMELD, CREATININE, BUN, ICU LENGTH OF STAY.(Abstract #1221)Edmund Q. Sanchez, Thomas A. Gonwa, Adrian P.Martin, Takehisa Ueno, Nicholas Onaca, Henry B.Randal, Sherfield Dawson, Srinath Chinnakotla, MarlonF. Levi, Robert M. Goldstein, Martin L. Mai, Steven R.Hays, Larry B. Melton, Goran B. Klintmalm. Dallas, TX.

P152 TYPE OF ALLOGRAFT, REQUIREMENT FORREOPERATION AND NATURE OF INITIALIMMUNOSUPPRESSION ARE ALL ASSOCIATEDWITH WOUND COMPLICATIONS IN RENALRECIPIENTS. (Abstract #1222)Deborah Verran, Taras Kusyk, Jodi Fisher, PamelaDilworth, Graham Stewart, Steve Chadban, John Boulas,Josette Eris. Camperdown, Australia.

P153 RENAL TRANSPLANTATION IN THE MORBIDLYOBESE. (Abstract #1223)William M. Bennett, Kevin M. McEvoy, Karen R.Henell, Viken Douzdjian. Portland, OR.

P154 CHANGES IN WEIGHT DURING THE FIRST YEARPOST RENAL TRANSPLANT. (Abstract #1224)Ann K. Cashion, Patricia A. Cowan, Donna K.Hathaway, Agnes Lo, A. Osama Gaber. Memphis, TN.

P155 † VALACYCLOVIR FOR CYTOMEGALOVIRUSPROPHYLAXIS REDUCES THE RISK OF ACUTERENAL ALLOGRAFT REJECTION: ARANDOMIZED COMPARISON WITH ORALGANCICLOVIR AND DEFERRED THERAPY.(Abstract #1225)Tomas Reischig, Pavel Jindra, Jan Mares, Karel Opatrny,Jr., Vladislav Treska, Miloslav Cechura, MiroslavaSvecova. Pilsen, Czech Republic.

132

P156 SAFETY AND EFFICACY OF A LOW-DOSEVALGANCICLOVIR REGIMEN FOR CMVPROPHYLAXIS IN ADULT RENAL TRANSPLANTRECIPIENTS RECEIVING INDUCTION THERAPY.(Abstract #1226)Patricia K. Aggers, Lonnie D. Smith, Troy Somerville,Jacke Corbett, John Holman, Fuad S. Shihab. Salt LakeCity, UT.

P157 PREEMPTIVE MANAGEMENT OF CMV ISASSOCIATED WITH LOWER RATES OFLEUKOPENIA AND SIMILAR INCIDENCE OF CMVINFECTION AS COMPARED TO ROUTINEPROPHYLAXIS IN KIDNEY TRANSPLANTRECIPIENTS RECEIVING CAMPATH INDUCTION.(Abstract #1227)Paolo Salvalaggio, Dixon Kaufman, Lorenzo Gallon, LisaScholz, Patrice Al-Saden, Frank Stuart, Jr., MichaelAbecassis, W. James Chon, Alan Koffron, JonathanFryer, Talia Baker, Joseph Leventhal. Chicago, IL.

P158 PROPHYLAXIS FOR CYTOMEGALOVIRUSDISEASE IN A RANDOMIZED TRIAL OF THREEDIFFERENT IMMUNOSUPPRESSIVE REGIMENS INRENAL TRANSPLANTATION. (Abstract #1228)Gaetano Ciancio, George W. Burke, Adela D. Mattiazzi,Jeff J. Gaynor, Ramir Roohipour, Lorraine Dowdy, DavidRoth, Warren Kupin, Anne Rosen, Delvis Jorge, NancyJohnson, Joshua Miller. Miami, FL.

P159 RATIONALE USE OF VALGANCICLOVIR FORTHE PREVENTION OF CYTOMEGALOVIRUSDISEASE IN RENAL TRANSPLANT RECIPIENTS.(Abstract #1229)Steven Gabardi, Colm C. Magee, Steven A. Baroletti,John Powelson, Anil K. Chandraker. Boston, MA.

P160 6 MONTHS VALGANCICLOVIR PROPHYLAXISSIGNIFICANTLY DECREASESCYTOMEGALOVIRUS INFECTION INCIDENCE INTHYMOGLOBULIN TREATED TRANSPLANTPATIENTS. (Abstract #1230)Enver Akalin, Jonathan S. Bromberg, Vinita Sehgal, ScottAmes, Lisa Daly, Barbara Murphy. New York, NY.

P161 CYTOMEAGLOVIRUS REPLICATION AS RISKFACTOR OF CARDIOVASCULAR EVENTS IN THEFIRST YEAR AFTER RENAL TRANSPLANT.(Abstract #1231)E. Gómez, A. S. Laurés, S. Melón, J. Baltar, M. Oña, J.Alvarez. Oviedo, Spain.

P162 A NATIONWIDE SURVEY OFCYTOMEGALOVIRUS PROPHYLAXIS ANDTREATMENT IN THE TRANSPLANT COMMUNITY.(Abstract #1232)Rajendra S. Baliga, Pradeep V. Kadambi, Basit Javaid,Robert Harland, James W. Williams, J. R. Thistlethwaite,Michelle A. Josephson. Chicago, IL.

P163 PROLONGED COURSE OF PROPHYLACTICGANCICLOVIR RESULTS IN AN LOWER RISK OFDEVELOPING CMV DISEASE IN HIGH RISKPATIENTS. (Abstract #1233)Alden M. Doyle, Emily Blumberg, Simin Goral, Roy D.Bloom. Philadelphia, PA.

P164 † A PROSPECTIVE, CROSS-OVER TRIALCOMPARING CYCLOSPORIN A +ATORVASTATIN TO TACROLIMUS ALONE ANDTACROLIMUS + ATORVASTATIN INHYPERCHOLESTEROLEMIC RENALTRANSPLANT PATIENTS. (Abstract #1234)K. Martin Wissing, Isabelle Dupont, Philippe Unger,Nilufer Broeders, Yvon Carpentier, Daniel Abramowicz.Brussels, Belgium.

P165 IMPACT OF GRAFT MASS ON THE CLINICALOUTCOME OF KIDNEY TRANSPLANTS.(Abstract #1235)Magali Giral, Yohann Foucher, Georges Karam, JeanMichel Nguyen, Michèle Kessler, Bruno Hurault deLigny, Mattias Buchler, François Bayle, Carole Meyer,Marie Laure Martin, Pascal Daguin, Jean Paul Soulillou.France.

Liver Transplantation: Complications and DiseaseRecurrenceP166 † DURATION OF ABSTINENCE FROM ALCOHOL

BEFORE TRANSPLANTATION FAVORABLYAFFECTS POST TRANSPLANT ALCOHOLRELAPSE IN PATIENTS WITH ALCOHOLIC LIVERDISEASE. (Abstract #1236)Jennifer T. Wells, Adnan Said, Alexandru Musat, MunciKalayoglu, Stuart J. Knechtle, Thomas Chin, AnthonyM. D’Alessandro, John D. Pirsch, Michael R. Lucey.Madison, WI.

P167 † DONOR AGE AND PRIMARY TRANSPLANT FORHEPATITIS C: HOW OLD IS TOO OLD?(Abstract #1237)Sasan Roayaie, Gabriel E. Gondolesi, Nancy R. Krieger,Sukru H. Emre, Myron E. Schwartz. New York, NY.

P168 † ANALYSIS OF OUTCOME FOLLOWING LIVERRETRANSPLANTATION FOR HCV. (Abstract #1238)Ergun H. Velidedeoglu, Peter L. Abt, Adam M. Frank,Niraj M. Desai, Robert Stephenson, Mary Kaminski,Rajander R. Reddy, James F. Markmann. Philadelphia,PA.

P169 FACTORS DIFFERENTIALLY CORRELATED WITHTHE OUTCOME OF LIVER TRANSPLANTATION INHCV+ AND HCV - RECIPIENTS. (Abstract #1239)Ergun H. Velidedeoglu, Kevin C. Mange, Peter L. Abt,Adam M. Frank, Niraj M. Desai, Mary Kaminski,Rajander R. Reddy, James F. Markmann. Philadelphia,PA.

P170 ANTIVIRAL MAINTENANCE TREATMENT WITHINTERFERON AND RIBAVIRIN LIMITS FIBROTICGRAFT DAMAGE IN LIVER TRANSPLANTPATIENTS WITH RECURRENT HEPATITIS C.(Abstract #1240)Arno Kornberg, Andrea Tannapfel, Bernadett Küpper,Johannes Scheele. Jena, Germany; Leipzig, Germany.

P171 HEPATITIS C IS A RISK FACTOR FOR DEATHAFTER LIVER RETRANSPLANTATION.(Abstract #1241)Shawn J. Pelletier, Douglas E. Schaubel, Jeffrey D.Punch, Robert A. Wolfe, Friedrich K. Port, Robert M.Merion. Ann Arbor, MI.

P172 EFFECT OF TIMING OF INTERFERON THERAPYON FIBROSIS PROGRESSION IN RECURRENTHEPATITIS C INFECTION AFTER LIVERTRANSPLANTION. (Abstract #1242)Marwan S. Ghabril, Murli Krishna, Victor I. Machicao,Hugo Bonatti, Ronald F. Borlaza, Barry Rosser, RajSatyanarayana, Jaime Aranda-Michel, Bashar Aqel,Andrew Keaveny, Denise Harnois, Winston Hewitt, HaniGrewal, Justin Nguyen, Christopher Hughes, JefferySteers, Rolland C. Dickson. Jacksonville, FL.

P173 ACHIEVING EVR IN POST-LIVER TRANSPLANTPATIENTS WITH CHRONIC HEPATITIS C: IS IT AFAIR GOAL OF THERAPY? (Abstract #1243)Christy Kennedy, Mary McClure, Timothy Brackett,Bethanie Fernandes, Tracy Steinberg, Marcelo Kugelmas.Denver, CO.

133

Tuesd

ay, May 18

P174 DETECTABLE SERUM CRYOPRECIPITATE POSTTRANSPLANTATION IS ASSOCIATED WITHWORSE OUTCOME AFTER LIVERTRANSPLANTATION FOR HEPATITIS C. (Abstract #1244)Stephen C. Rayhill, Patricia Kirby, Michael Voigt,Douglas LaBrecque, Daniel Katz, Charles Lutz, AlanStolpen, Rachael Miller, Roberto Kalil, Dennis Heisey,Wu You Min, Warren Schmidt. Iowa City, IA.

P175 Abstract #1245 has been WithdrawnP176 RISK FACTORS FOR DEATH IN RECIPIENTS

WITH RECURRENT HEPATITIS C CIRRHOSIS.(Abstract #1246)Sammy Saab, Henry Niho, Scott Comulada, R. MarkGhobrial, Jonathan Hiatt, Fransico Durazo, Steven Han,Douglas G. Farmer, Curtis Holt, Hasan Yersiz, Leonard I.Goldstein, Ronald W. Busuttil. Los Angeles, CA.

P177 HEPATITIS C VIRAL QUASISPECIESSELECTIVITY OF ALLOGRAFT INFECTION AFTERLIVER TRANSPLANTATION. (Abstract #1247)Michael G. Hughes, Tae W. Chong, Robert L. Smith,Heather L. Evans, Robert G. Sawyer, Christine K. Rudy,Timothy L. Pruett. Charlottesville, VA.

P178 PREOPERATIVE ALPHA-FETOPROTEIN SLOPE ISPREDICTIVE OF HEPATOCELLULARCARCINOMA RECURRENCE AFTER LIVERTRANSPLANTATION. (Abstract #1248)Kathy Han, George Tzimas, Peter Metrakos, NirHilzenrat, Philip Wong, Marc Deschenes. Montreal, QC,Canada.

P179 OUTCOMES OF LIVER TRANSPLANTRECIPIENTS WITH HEPATITIS C RECEIVINGINTERFERON / RIBAVIRIN TREATMENT.(Abstract #1249)Gregory A. Smallwood, Renee Devine, JenniferLehneman, Kathlene Connor, Andrei C. Stieber, ThomasG. Heffron. Atlanta, GA.

P180 † LIVER TRANSPLANT OUTCOMES USINGEXTENDED CRITERIA DONOR ORGANS: ASINGLE CENTER EXPERIENCE. (Abstract #1250)M. Gupta, L. Trumbull, J. Martin, J. F. Buell, T. D.Merchen, M. J. Hanaway, E. S. Woodle, J. G. Drewett, S.M. Rudich. OH.

P181 † BILIARY COMPLICATIONS IN PEDIATRIC LIVERTRANSPLANTATION: SINGLE CENTEREXPERIENCE. (Abstract #1251)Manuel I. Rodriguez-Davalos, Rafael J. Maurette,Benjamin Shneider, Gabriel E. Gondolesi, Nancy Krieger,Sukru Emre. New York, NY.

P182 REJECTION IS A RISK FACTOR IN THEDEVELOPMENT OF PEDIATRIC POST-TRANSPLANT DE-NOVO AUTOIMMUNEHEPATITIS. (Abstract #1252)Robert S. Venick, Sue V. McDiarmid, Jeff Gornbein,Steven Wu, Susan J. Pacini-Edelstein, Mini Mehra,Martin G. Martin, Jorge H. Vargas, Ron W. Busutill,Marvin E. Ament. Los Angeles, CA.

P183 THE EFFECT OF DONOR AND RECIPIENT HLACOMPATIBILTY ON LIVER TRANSPLANTATIONOUTCOMES: AN ANALYSIS OF THE UNOSDATABASE. (Abstract #1253)Charles P. Katopes, Beth W. Colombe, C. Victor Spain,Steven K. Herrine, Victor J. Navarro. Philadelphia, PA.

P184 CARDIOVASCULAR DISEASE AFTER LIVERTRANSPLANTATION. (Abstract #1254)Arie P. van den Berg, Maarten Borg, Stephan Bakker,Wim J. Sluiter, Maarten J. H. Slooff, Els B. Haagsma.Groningen, Netherlands.

P185 AN EVALUATION OF THE LONG-TERM CLINICALOUTCOME AND SURVIVAL OF PATIENTSUNDERGOING LIVER TRANSPLANTATION ATAGE 65 YEARS OR OLDER. (Abstract #1255)Michael A. Heneghan, Paolo Muiesan, Raffaeli Girlanda,Mohammed Rela, Matthew Bowles, John G. O’Grady,Nigel D. Heaton. London, United Kingdom.

P186 TRANSPLANT VS RESECTION FORHEPATOCELLULAR CARCINOMA IN THECONTEXT OF HEPATITIS C:AN INTENTION TOTREAT ANALYSIS. (Abstract #1256)Sasan Roayaie, Gabriel E. Gondolesi, Nancy R. Krieger,Sukru H. Emre, Myron E. Schwartz. New York, NY.

P187 EFFICACY AND SAFETY OF LOW-DOSEVALGANCICLOVIR FOR THE PREVENTION OFCYTOMEGALOVIRUS DISEASE IN LIVERTRANSPLANT RECIPIENTS. (Abstract #1257)Jeong M. Park, Juan D. Arenas, Robert J. Fontana,Kathleen D. Lake. Ann Arbor, MI.

P188 EFFICACY OF CMV ANTIGEEMIA DIRECTEDPREEMPTIVE THERAPY WITH GANCICLOVIR ATONE YEAR IN LIVER TRANSPLANT RECIPIENTSPRETREATED WITH THYMOGLOBULIN ORALEMTUZUMAB. (Abstract #1258)Eun J. Kwak, Shahid Husain, David L. Paterson, PauloFontes, Thomas Cacciarelli, Amadeo Marcos, John Fung,Bijan Eghtesad. Pittsburgh, PA.

P189 LOW DROP-OUT RATE FROM LIVERTRANSPLANT WAITING LIST IN PATIENTS WITHHEPATOCELLULAR CARCINOMA (HCC)TREATED WITH INTRA-ARTERIAL CHEMO/EMBOLIZATION (TACE/TAE). (Abstract #1259)Giovanni B. Vizzini, Angelo Luca, Adele D’Antoni,Roberto Miraglia, Ugo Palazzo, Giada Pietrosi, LucioMandalà, Salvatore Gruttadauria, Tommaso Piazza,Bruno Gridelli. Palermo, Italy.

P190 LEVETIRACETAM (KEPRA) HAS SUPERIOREFFICACY AND IS ASSOCIATED WITH REDUCEDDOSES OF ANTI-REJECTION MEDICATIONSAFTER LIVER TRANSPLANTATION.(Abstract #1260)Abigail Mithoffer, Graham Glass, James Stankiewicz,Peter Bergethon, Jeffery Cooper, Richard J. Rohrer,Richard B. Freeman. Boston, MA.

P191 OUTCOME OF LIVER TRANSPLANTATIONFOLLOWING KIDNEY-ONLYTRANSPLANTATION. (Abstract #1261)John R. Lake, Sarah H. Rush, Robert M. Marion.Minneapolis, MN; Ann Arbor, MI.

P192 STEROID-FREE INDUCTION FOR LIVERTRANSPLANRT RECIPIENTS WITH HEPATITIS C -A PROSPECTIVE RANDOMIZED STUDY.(Abstract #1262)Tomoaki Kato, Hideo Yoshida, Olivia Hung, MarziaMontalvano, Guy Neff, Kamron Sadfar, Seigo Nishida,Jang Moon, Juan Madariaga, Genarro Selvaggi, JuanMadariaga, Phillip Ruiz, Andreas Tzakis. Miami, FL.

P193 ARTERY STENTING FOR HEPATIC ARTERYSTENOSIS IN LIVER TRANSPLANTATION.(Abstract #1263)Takehisa Ueno, Greg Jones, Adrian Martin, EdmundSanchez, Srinath Chinnakotla, Sherfield Dawson, HenryRandall, Nicolas Onaca, Robert Goldstein, Marlon Levy,Goran Klintmalm. Dallas, TX.

134

Liver, Heart, Lung and Pancreas/Islets: Donation,Preservation, and OutcomesP194 † IN VIVO VIABILITY ASSESSMENT OF ISLETS

ISOLATED FROM THE PANCREAS PRESERVEDBY THE TWO-LAYER METHOD. (Abstract #1264)Keitaro Kakinoki, Yasuhiro Fujino, Yasuyuki Suzuki,Takuro Yoshikawa, Tomohiro Tanaka, Shiri Li, NaohiroGoto, Yasuki Tanioka, Tetsuya Sakai, Yoshikazu Kuroda.Kobe, Hyogo, Japan.

P195 DOES DURATION OF DONOR BRAIN INJURYAFFECT OUTCOME AFTER ORTHOTOPICPEDIATRIC HEART TRANSPLANTATION?(Abstract #1265)Jonah Odim, Hillel Laks, Chris Vincent, Charles Murphy,Ana Banerji, Kaushik Mukherjee, David Gjertson, andthe UCLA Heart Transplant Team. Los Angeles, CA.

P196 † DOES TYPE OR CONSTITUENT OFPRESERVATION SOLUTIONS INFLUENCE EARLYGRAFT FAILURE AFTER CARDIACTRANSPLANTATION? A MULTI-INSTITUTIONALSTUDY. (Abstract #1266)N. Moazami, R. C. Bourge, R. N. Brown, L. E. Wagoner,J. P. Boehmer, G. Ewald, E. K. Kasper, J. O’Donnell, B.K. Rayburn, B. Czerska, P. Solon. Birmingham, AL.

P197 OUTCOMES IN ELDERLY PATIENTS RECEIVINGORTHOTOPIC HEART TRANSPLANTS.(Abstract #1267)G. V. Gonzalez-Stawinski, P. M. McCarthy, K. Hoercher,J. Feng, E. A. Beyer, E. McGee, P. E. Parrino, D. O.Taylor, R. C. Starling, J. B. Young. Cleveland, OH.

P198 † SHOULD THORACIC TRANSPLANT PATIENTS BEPRIORITIZED IN THE RENAL ALLOCATIONSCHEME? (Abstract #1268)Jacqueline M. Smits, Erwin de Vries, Mike Smith, GuidoG. Persijn, Gunther Laufer, Ulrich Frei. Leiden,Netherlands; Innsbruck, Austria; Berlin, Germany.

P199 PLATELET FUNCTION AND CORONARY FLOWRESERVE PROVIDE A POINT OF CAREASSESSMENT OF CORONARY ACTIVATIONAFTER BRAIN DEATH. (Abstract #1269)Robert S. Poston, Junyan Gu, Deyanira Prastein, JamesGammie, James Brown, Richard N. Pierson III, Bartley P.Griffith. Baltimore, MD.

P200 LIVER TRANSPLANTATION FROM CONTROLLEDNON-HEART BEATING DONORS: AN IMPORTANTNEW SOURCE OF GRAFTS. (Abstract #1270)Paolo Muiesan, Raffaele Girlanda, Heather Tollerton,Wayel Jassem, Michael Heneghan, Mohamed Rela, NigelDavid Heaton. London, United Kingdom.

P201 CAN LIVER DONORS AGE SEVENTY AND OLDERBE USED ROUTINELY FOR LIVERTRANSPLANTATION? (Abstract #1271)Glenn Halff, Ken Washburn, Robert Esterl, GregAbrahamian, Alejandro Mejia, Kermit V. Speeg,Francisco Cigarroa. San Antonio, TX.

P202 IS COLD ISCHEMIA TIME BECOMING LESSIMPORTANT IN LIVER TRANSPLANTATION?(Abstract #1272)Erick B. Edwards, Richard B. Freeman. Richmond, VA;Boston, MA.

P203 A COMPARISON OF MEDICAL OUTCOMES ANDQUALITY OF LIFE (QOL) SURVEYS IN RIGHTLOBE (RL) VS. LEFT LATERAL SEGMENT (LLS)LIVER DONORS. (Abstract #1273)Abhinav Humar, Elizabeth Larson, Brooke Glessing,John R. Lake, William D. Payne. Minneapolis, MN.

P204 TRANSIENT IMPAIRED FUNCTION OF SYNTHESISOF ELDERLY GRAFTS IN THE POSTOPERATIVEPERIOD AFTER LIVER TRANSPLANTATION.(Abstract #1274)Alfonso S. Serralta, Francisco C. Orbis, Fernando R.Sanjuan, Eugenia I. Pareja, Angel H. Moya, RafaelLopez-Andujar, Juan C. Vila, Manuel B. Juan, Jose P. Mir.Valencia, Spain.

P205 ISCHEMIC PRECONDITIONING IN CADAVERDONOR LIVER TRANSPLANTATION: APROSPECTIVE RANDOMIZED CLINICAL TRIALOF SAFETY AND EFFICACY. (Abstract #1275)B. Koneru, A. Fisher, J. Skurnick, K. Klein, Y. He, D.Wilson, A. De la Torre, R. Arora, A. Merchant, A.Samanta. Newark, NJ.

Lymphocyte Activation: Basic ScienceP206 † COMPOSITE TISSUE ALLOTRANSPLANTATION:

DEVELOPMENT OF A NON-HUMAN PRIMATEMODEL. (Abstract #1276)Linda C. Cendales, Xiaojie Zhang, He Xu, John Bacher,Allan D. Kirk. Bethesda, MD.

P207 γδγδγδγδγδ T CELLS INDUCE EPITHELIAL REGENERATIONAFTER INJURY OF THE LUNG. (Abstract #1277)Ruedi K. Braun, Robert F. Zink, Zhuzai Xiang, William J.Burlingham, Robert B. Love. Madison, WI.

P208 HEMATOPOIETIC STEM CELLTRANSPLANTATION RESTORES IMMUNE SYSTEMFUNCTION IN Atm DEFICIENT MICE.(Abstract #1278)Jessamyn Bagley, John Iacomini. Boston, MA.

P209 THE THYMUS IS INDISPENSIBLE FOR A BONEMARROW DERIVED CD8+ TCR- LYMPHOCYTESUBPOPULATION THAT FACILITATESALLOGENIC STEM CELL ENGRAFTMENT INMICE. (Abstract #1279)Nupur N. Gangopadhyay, Matthew J. Schuchert, James D.Luketich, Rodney Landreneau. Pittsburgh, PA.

P210 DONOR SPECIFIC SPLEEN CELL INJECTIONLEADS TO ANTIBODY UNRESPONSIVENESS TOA SINGLE TRANSGENIC MHC CLASS I (HLA-A2)DISCORDANCE. (Abstract #1280)Tetsu Sado, Raju Radha, Stanley C. Jordan, MiekoToyoda. Los Angeles, CA.

P211 CD28/CD154 SIGNALS RENDER CD4+ MEDIATEDREJECTION RESISTANT TO GROWTH FACTORBLOCKADE. (Abstract #1281)Minh Diem Vu, Gulcin Demirci, Xian C. Li. Boston, MA.

P212 EXOGENOUS IL-12 ENHANCES DONORREACTIVE IMMUNITY AND PRECIPITATESREJECTION OF MINOR ANTIGEN DISPARATEMALE HEART GRAFTS IN MICE. (Abstract #1282)Chunshui He, Anna Valujskikh, Peter S. Heeger.Cleveland, OH.

P213 RECIPROCAL ROLE OF CYCLINS AND CYCLININHIBITOR p21 IN ALLO-IMMUNE ACTIVATION,INFLAMMATION AND GRAFT SURVIVAL.(Abstract #1283)Ashwani K. Khanna. Milwaukee, WI.

P214 IMPACT OF IN VIVO BLOCKADE OF SLP-76/GADS INTERACTION. (Abstract #1284)Jonathan S. Maltzman, Martha S. Jordan, AmromObstfeld, Andrew L. Singer, Gary A. Koretzky.Philadelphia, PA.

P215 DIFFERENTIAL EXPRESSION AND FUNCTION OFPD-L1 AND PD-L2 ON HEPATIC AND SPLENICDENDRITIC CELLS. (Abstract #1285)Audrey H. Lau, An de Creus, Alison J. Logar, Angus W.Thomson. Pittsburgh, PA.

135

Tuesd

ay, May 18

P216 A ROLE FOR GRAFT SITE AND LYMPHATICS INTHE EFFECTIVENESS OF COSTIMULATIONBLOCKADE-BASED STRATEGIES IN MURINEMODELS OF TRANSPLANTATION.(Abstract #1286)Sulaiman A. Nanji, Colin C. Anderson, Bin Luo, WayneW. Hancock, Colleen D. Schur, Rena L. Pawlick, Lin FuZhu, Norman M. Kneteman, A. M. James Shapiro.Edmonton, AB, Canada; Philadelphia, PA.

P217 NK RECEPTOR, RAT NKP30, IS A POLYMORPHICGLYCOPROTEIN INVOLVED IN THE IMMUNERESPONSE DURING ALLOGENEIC LIVERTRANSPLANTATION. (Abstract #1287)Christine L. Hsieh, Yasuhiro Ogura, Hideaki Obara,Unzila Ali, Wei-wei Su, Guadalupe Rodriguez, RonaldNepomuceno, Olivia M. Martinez, Sheri M. Krams.Stanford, CA.

P218 EXPRESSION OF SECRETORY LEUKOCYTEPROTEASE INHIBITOR (slpi) IN EXPERIMENTALACUTE CARDIAC ALLOGRAFT REJECTION.(Abstract #1288)Sheri E. Kelemen, Michael V. Autieri, Anbin Mu, HowardJ. Eisen. Philadelphia, PA, American Samoa;Philadelphia, PA.

P219 EPSTEIN BARR VIRUS CAN PROTECT LATENTLYINFECTED B CELL LYMPHOMAS FROM FASL/TRAIL-INDUCED APOPTOSIS. (Abstract #1289)Andrew L. Snow, Sheri M. Krams, Olivia M. Martinez.Stanford, CA.

P220 DOWN-REGULATION OF DONOR-SPECIFICANTIBODY: A T CELL AFFAIR? (Abstract #1290)Andrea A. Zachary, Robert A. Montgomery, DessislavaKopchaliiska, Mary S. Leffell. Baltimore, MD.

P221 REDUCED NUMBER OF Vααααα24+Vβββββ11+ NKT CELLS INPERIPHERAL BLOOD OF LONG TERMREJECTION-FREE RECIPIENTS OF HUMANKIDNEY ALLOGRAFTS. (Abstract #1291)Nelson Z. Galante, Esper G. Kallás, Marcos A. Cenedeze,Reinaldo Salomão, Alvaro Pacheco-Silva, Niels O. S.Câmara. São Paulo, Brazil.

P222 IDENTIFICATION OF HEPATITIS B VIRUS (HBV) -SPECIFIC LYMPHOCYTES IN HUMAN LIVERALLOGRAFTS FROM HBV IMMUNE DONORS.(Abstract #1292)Ying Luo, Chung-Mau Lo, Cindy Ka-Yee Cheung, GeorgeKa-Kit Lau, Sheung-Tat Fan, John Wong. Hong Kong,China.

P223 ANTI-CD3 MONOCLONAL ANTIBODIES INDUCEMITOGENIC PROLIFERATION BUT PREVENTEXPANSION OF ALLOREACTIVE T CELLS.(Abstract #1293)Sicco H. Popma, Don Griswold, Lily Li. Malvern, PA.

P224 PROTEOMIC ANALYSIS OF THE ALLOGRAFTRESPONSE. (Abstract #1294)Basset El Essawy, Hassan H. Otu, Aviado Manuel, Yon SuKim, Towia Libermann, Terry Strom. Boston, MA.

P225 HLA-G MODIFIES THE LEVEL OFCOSTIMULATORY MOLECULES ON RATDENDRITIC CELLS. (Abstract #1295)Maurice A. Smith, Anatolij Horuzsko, Stephanie L.White, Oscar Grandas. Augusta, GA.

P226 † IMMUNE REGULATION WITHIN THE GRAFT ISMEDIATED BY FLIP AND FOXP3. (Abstract #1296)Carla C. Baan, Barbara J. van der Mast, Esme Dijke,Hester A. de Groot-Kruseman, Sander S. Korevaar, LexP. Maat, Aggie H. Balk, Willem Weimar. Rotterdam,Netherlands.

P227 FEEDBACK INHIBITION OF T CELL RESPONSESBY ACTIVATED HEPATIC STELLATE CELLS, APOSSIBLE MECHANISM OF HEPATICTOLERANCE. (Abstract #1297)Cheng-Hsu Chen, Ming-Chin Yu, Lianfu Wang, ShekharGandhi, John J. Fung, Lina Lu, Shiguang Qian. Pittsburgh,PA.

P228 ONLY RAPAMYCIN DOES NOT INTERFERE WITHFOXP3 EXPRESSION OF HUMAN ACTIVATEDPERIPHERAL BLOOD CELLS. (Abstract #1298)Carla C. Baan, Annemiek M. Peeters, Dennis A.Heselink, Wendy M. Mol, Barbara J. van der Mast,Willem Weimar. Rotterdam, Netherlands.

P229 TOWARDS THE DEVELOPMENT OF A DENDRITICCELL-BASED VACCINE FOR HEPATITIS B:INDUCTION OF TUMOR IMMUNITY ANDCYTOTOXIC T LYMPHOCYTE RESPONSESUSING DC TRANSFECTED BY AN ADENOVIRALVECTOR ENCODING HEPATITIS B SURFACEANTIGEN. (Abstract #1299)Shuangjian Qiu, Michael E. de Vera, Shiguang Qian, LinaLu, C. Andrew Bonham. Pittsburgh, PA.

P230 † HUMAN RENAL TUBULAR EPITHELIAL CELLSMODULATE T CELL RESPONSES VIA ICOS-LAND B7-H1. (Abstract #1300)Cees van Kooten, Simone de Haij, Andrea M. Woltman,Leendert A. Trouw, Astrid C. Bakker, Lieping Chen,Richard A. Krozcek, Mohamed R. Daha. Leiden,Netherlands; Rochester; Berlin, Germany.

P231 † HYPOXIA INDUCIBLE FACTOR-1ααααα REGULATESTCR SIGNAL TRANSDUCTION. (Abstract #1301)Aaron K. Neumann, Mangat P. Biju, Randall S. Johnson,Volker H. Haase, Laurence A. Turka. Philadelphia, PA;San Diego, CA.

Public Policy/Economics: All OrgansP232 † PRE-OPERATIVE DELTA-MELD SCORE DOES NOT

INDEPENDENTLY PREDICT MORTALITY AFTERLIVER TRANSPLANTATION. (Abstract #1302)Patrick G. Northup, Carl L. Berg. Charlottesville, VA.

P233 SPECIFIC LABORATORY METHODOLOGIESACHIEVE HIGHER MODEL FOR ENDSTAGELIVER DISEASE (MELD) SCORES FOR PATIENTSLISTED FOR LIVER TRANSPLANTATION.(Abstract #1303)Russ R. Arjal, James F. Trotter, Brad Brimhall. Denver,CO.

P234 REDUCTION IN PRIORITY POINTS FOR LIVERTRANSPLANT CANDIDATES WITHHEPATOCELLULAR CARCINOMA (HCC) DIDNOT INCREASE DROP OUT RATES FROM THEWAITING LIST. (Abstract #1304)Richard B. Freeman, Erick B. Edwards, Ann Harper.Boston, MA; Richmond, VA.

P235 DECEASED DONOR LIVER TRANSPLANTSURVIVAL RATES UNDER THE MELD/PELDSYSTEM. (Abstract #1305)Richard B. Freeman, Ann Harper, Erick Edwards.Boston, MA; Richmond, VA.

P236 IMPACT OF DIFFERENT THROMBLOPLASTINSON THE INTERNATIONAL NORMALIZED RATIOAND MELD SCORE IN PATIENTS WITHCIRRHOSIS LISTED FOR LIVERTRANSPLANTATION. (Abstract #1306)Andres E. Ruf, Marta E. Martinuzzo, Graciela S. Cerrato,Lila L. Chavez, Silvina E. Yantorno, Valeria I. Descalzi,Oscar C. Andriani, Luis G. Podesta, Federico G. Villamil.Buenos Aires, Argentina.

136

P237 MELD OR PELD: WHICH IS THE BETTERPREDICTOR OF PRE-TRANSPLANT MORTALITYIN PEDIATRIC CANDIDATES? (Abstract #1307)Erick B. Edwards, Ann M. Harper, Richard B. Freeman.Richmond, VA; Boston, MA.

P238 IMPROVEMENTS IN THE MODEL FOR END-STAGELIVER DISEASE (MELD) SEVERITY SCORE.(Abstract #1308)Dawn M. Dykstra, Russell H. Wiesner, Friedrich K. Port,Robert A. Wolfe, Robert M. Merion. Ann Arbor, MI;Rochester, MN.

P239 MODEL FOR END-STAGE LIVER DISEASESCORES DO NOT PREDICT LIVERTRANSPLANTATION WAITING LIST MORBIDITY.(Abstract #1309)Terianne Cowling, Linda W. Jennings, Takehisa Ueno,Patrick Martin, Edmund Q. Sanchez, SrinathChinnakotla, Henry Randall, Sherfield Dawson, RobertM. Goldstein, Goran B. Klintmalm, Marlon F. Levy.Dallas, TX; Fort Worth, TX.

P240 † WHICH PELD FACTORS HAVE THE STRONGESTASSOCIATION WITH PRE- AND POST-TRANSPLANT OUTCOMES? (Abstract #1310)Erick B. Edwards, Ann M. Harper, Richard B. Freeman.Richmond, VA; Boston, MA.

P241 SHORT- AND LONG-TERM OUTCOME OFORTHOTOPIC LIVER TRANSPLANTATION USINGHEPATITIS C VIRUS-INFECTED ALLOGRAFTS.(Abstract #1311)Fabio Vasta, John J. Fung, Bijan Eghtesad, DeAnnaBlisard, A. Jake Demetris, Thomas V. Cacciarelli.Palermo, Sicily, Italy; Pittsburgh, PA.

P242 IMPACT OF THE USE OF MARGINAL, HIGH-RISK, OR LIVING DONORS ON PATIENTSRECEIVING LIVER TRANSPLANTATION FORHILAR CHOLANGIOCARCINOMA.(Abstract #1312)Julie K. Heimbach, Gregory J. Gores, Scott L. Nyberg,Michael B. Ishitani, Steven R. Alberts, Michael G.Haddock, Charles B. Rosen. Rochester, MN.

P243 STATE OF RENAL TRANSPLANTATION IN OLDERAMERICANS: AN ANALYSIS OF THE UNOSDATABASE. (Abstract #1313)V. Ram Peddi, Steven Katznelson, Vish Halukurike,Timothy J. Baker, Maureen A. McBride. San Francisco,CA; Richmond, VA.

P244 FATE OF LIVERS NOBODY WANTS.(Abstract #1314)Nimmi Arora, Sarah Bellemare, Paul Gaglio, JeanEmond, Lorna Dove, Robert S. Brown, Jr., John Renz,Milan Kinkhabwala. New York, NY.

P245 SUCCESSFUL TRANSPLANTATION OF LIVERSFROM OLDER CADAVERIC DONORS.(Abstract #1315)Gerald R. Stephenson, Peter Abt, Adam Frank, MaryKaminsky, Abraham Shaked, James Markmann, Kim M.Olthoff. Philadelphia, PA.

P246 DISPARATE ACCESS TO THE LIVER TRANSPLANTWAITLIST BY AGE, GENDER, RACE, ANDGEOGRAPHY. (Abstract #1316)Alan B. Leichtman, Valarie B. Ashby, Friedrich K. Port,Robert M. Merion, Roger W. Evans, Robert A. Wolfe.Ann Arbor, MI; Rochester, MN.

P247 PREDICTORS FOR RETURNING TO WORKFOLLOWING ORTHOTOPIC LIVERTRANSPLANT BASED ON DATA FROM THE OPTNREGISTRY. (Abstract #1317)Vincent P. Casingal, Justin M. Burns, Brent D. Matthews,Daniel H. Hayes, Amy E. Lincort, Lon B. Eskind.Charlotte, NC.

P248 LIVING DONOR LIVER TRANSPLANTATION ISASSOCIATED WITH REDUCED COSTS.(Abstract #1318)Richard B. Freeman, Susan E. FitzMaurice, Jeffery T.Cooper, Richard J. Rohrer, Mark Epstien, Jan Smith,Daniel S. Pratt. Boston, MA.

P249 THE COST OF RECOVERING DECEASED DONORORGANS FOR TRANSPLANTATION.(Abstract #1319)Joshua J. McGowan, Akinlolu O. Ojo, Richard E.Pietroski, Friedrich K. Port, Philip J. Held. Ann Arbor,MI.

P250 TRANSPLANT STAFFING RESOURCES: ANEVIDENCED-BASED ASSESSMENT ANDPOTENTIAL DECISION SUPPORT TOOL FORTRANSPLANT CENTERS. (Abstract #1320)E. Y. Zavala, M. Strode, L. B. Edwards, S. Williams, F.Wright, C. W. Pinson. Nashville, TN; San Antonio, TX;Richmond, VA.

P251 COMPARATIVE FINANCIAL ANALYSIS OF LIVERTRANSPLANTATION IN THE PRE &&&&& POST M.E.L.D.ERA. (Abstract #1321)Dinesh Ranjan, Thomas D. Johnston, Hoonbae Jeon, R.Craig Rogers, Frank Blair. Lexington, KY.

P252 COST EFFECTIVENESS OF CYCLOSPORINE(CSA), RAPAMUNE(RAPA), AND TACROLIMUS(TAC)IN COMBINATION WITHMYCOPHENOLATE MOFETIL (MMF) INCADAVERIC RENAL TRANSPLANTS.(Abstract #1322)Nauman Siddiqi, Syed A. Hussain, Sundaram Hariharan.Milwaukee, WI.

P253 EDUCATIONAL PROGRAM TO REDUCENONCOMPLIANCE AFTER RENALTRANSPLANTATION. (Abstract #1323)Nathalie Breu Dejean, Lionel Rostaing, Maryse LapeyreMestre, Bernadette Roge, Dominique Durand. Toulouse,France.

Transplant Related MalignanciesP254 † IMMUNOMODULATION IMPACTS SURVIVAL OF

DONOR TRANSMITTED MALIGNANCIES.(Abstract #1324)C. C. Rogers, T. M. Beebe, M. J. Hanaway, M. J.Thomas, T. G. Gross, S. M. Rudich, M. R. First, R. R.Alloway, J. Trofe, E. S. Woodle, J. F. Buell. Cincinnati,OH.

P255 † SQUAMOUS CELL CARCINOMA OF THEPERINEUM AND RECTUM IN TRANSPLANTRECIPIENTS. (Abstract #1325)J. F. Buell, T. M. Beebe, H. T. Papaconstantinou, T. G.Gross, M. J. Hanaway, J. Trofe, R. R. Alloway, E. S.Woodle. Cincinnati, OH.

P256 † EFFECT OF SITES OF PRESENTATION OF PTLDMARKEDLY INFLUENCES SURVIVAL AFTERSOLID ORGAN TRANSPLANTATION.(Abstract #1326)Michael J. Hanaway, Joseph F. Buell, Thomas G. Gross,Jennifer Trofe, Thomas M. Beebe, Rita R. Alloway,Steven M. Rudich, E. Steve Woodle. Cincinnati, OH.

P257 REGULATORY T-CELLS IN ADOPTIVEIMMUNOTHERAPY. (Abstract #1327)M. H. Hammer, L. Ang´ani, H.-D. Volk, P. Reinke.Berlin, Germany.

P258 AGGRESSIVE SKIN CANCERS IN TRANSPLANTRECIPIENTS. (Abstract #1328)J. F. Buell, T. M. Beebe, C. Muthiah, T. G. Gross, M. R.First, M. J. Hanaway, J. Trofe, R. R. Alloway, E. S.Woodle. Cincinnati, OH.

137

Tuesd

ay, May 18

P259 MALIGNANCY TRANSMISSION FROM DONORSWITH MELANOMA. (Abstract #1329)J. F. Buell, T. M. Beebe, T. G. Gross, M. J. Hanaway, M.R. First, C. Muthiah, J. Trofe, R. R. Alloway, E. S.Woodle. Cincinnati, OH.

P260 THE INFLUENCE OF ANTIGEN PRESENTING CELL(APC) MICROENVIRONMENT ON EBV MEMORYRESPONSES: TGF-βββββ, BUT NOT IL-10, TREATMENTOF APC REDUCES IFN-γγγγγ PRODUCTION ANDINHIBITS EBV-REACTIVE MEMORY CTLRESTIMULATION. (Abstract #1330)Tyler C. Hoppes, Navneet Cheema, Anne M.VanBuskirk. Columbus, OH.

P261 SUCCESSFUL MINIMIZATION OFIMMUNOSUPPRESSION(IM) AND CONVERSIONTO SIROLIMUS(SLR) IN KIDNEY TRANSPLANTRECIPIENTS WITH POST TRANSPLANTLYMPHOPROLIFERATIVE DISEASE(PTLD) ANDDE NOVO NONSKIN MALIGNANCIES(DNSM).(Abstract #1331)Debra Sierka, Mysore S. Anil Kumar, Michael Heifets,Miten Parikh, Michael J. Moritz, Aparna Kumar.Philadelphia, PA.

P262 CONVERSION TO SIROLIMUS, A SUCCESSFULTREATMENT FOR POSTTRANSPLANTATIONKAPOSI’S SARCOMA. (Abstract #1332)Alex Gutierrez-Dalmau, Jose M. Campistol, AnaSanchez-Fructuoso, Aurelio Sanz-Guajardo, AuxiliadoraMazuecos, Jose V. Torregrosa, Federico Oppenheimer.Barcelona, Spain; Madrid, Spain; Cadiz, Spain.

P263 EBV-DNAEMIA AND PTLD IN LUNG TRANSPLANTRECIPIENTS WITH CYSTIC FIBROSIS.(Abstract #1333)Robin K. Avery, Lara Danziger-Isakov, Atul C. Mehta,Omar A. Minai, Jeffrey T. Chapman. Cleveland, OH.

Mini-Oral: Chronic Graft Injury: NovelMechanisms12:45 - 1:45 PM

Room 309Chairs: Paul C. Grimm and Anthony M. Jevnikar

12:45 PM ANTIBODY RESPONSE AGAINST GLOMERULARBASEMENT MEMBRANE AGRIN IN PATIENTSWITH TRANSPLANT GLOMERULOPATHY.(Abstract #1334)Cees van Kooten, Simone A. Joosten, Vanessa van Ham,Johan van der Vlag, Bert van den Heuvel, Yvo W. J.Sijpkens, Leendert C. Paul. Leiden, Netherlands;Nijmegen, Netherlands.

12:52 PM IDENTIFICATION OF A NOVEL SMOOTHMUSCLE PROTEIN INVOLVED IN THEPATHOGENESIS OF CHRONIC GRAFTREJECTION. (Abstract #1335)Majed M. Hamawy, Jose R. Torrealba, Matthew Colburn,Susan Golner, Zhen Davis, Tara Scheunaman, HuaizhongHu, Hyoung T. Kim, Tausif Alam, Turan Kanmaz, StuartJ. Knechtle. Madison, WI.

12:59 PM MODULATING CHRONIC GRAFT INJURY: ANEW ROLE FOR CONNECTIVE TISSUE GROWTHFACTOR (CTGF). (Abstract #1336)Orlena H. Cheng, Xiaojie Zhang, Gary Grottendorst,Roslyn B. Mannon. Bethesda, MD; Miami, FL.

1:06 PM CHRONIC ALLOGRAFT NEPHROPATHY ISASSOCIATED WITH EPITHELIAL TOMESENCHYMAL TRANSDIFFERENTIATION.(Abstract #1337)Arjang Djamali, Shannon Reese, Joseph Yracheta, LynnJacobson, Debra Hullett, Bryan Becker. Madison, WI.

1:13 PM EXTRA-CELLULAR MATRIX DEGRADATIONDURING APOPTOSIS OF ENDOTHELIAL CELLSACTIVATES NOVEL FIBROGENIC PATHWAYS.(Abstract #1338)Patrick Laplante, Gabrielle Gagnon, Marc-AndreRaymond, Anik Desormeaux, Normand Vigneault, Marie-Josee Hebert. Montreal, QC, Canada.

1:20 PM PROGRESSIVE ACTIVATION OFALLORESPONSE AND TISSUE-SPECIFICAUTOIMMUNITY IN A NOVEL MOUSE MODELOF SPONTANEOUS GRAFT CORONARY ARTERYDISEASE. (Abstract #1339)Masashi Tanaka, Monika Zwierzchoniewska, Golnaz K.Mokhtari, Theo Kofidis, Robert C. Robbins, Eugenia V.Fedoseyeva. Stanford, CA.

1:27 PM ADVENTITIAL GERMINAL CENTER-LIKESTRUCTURES IN A VASCULAR CHRONICREJECTION MODEL. (Abstract #1340)Olivier Thaunat, Anne-Christine Field, Patrick Bruneval,Antonino Nicoletti, Jean-Baptiste Michel, BlancheBellon. Paris, France.

Mini-Oral: Experimental Immunosuppression12:45 - 1:45 PM

Room 306Chairs: Wayne Flye and Kenneth Newell

12:45 PM THE TRIALS AND TRIBULATIONS OFTRANSLATING A MURINE TOLERANCE MODELTO THE NONHUMAN PRIMATE. (Abstract #1341)Edip Akpinar, Jodie M. Keary, Edwin Preston, He Xu,Roger Kurlander, Douglas A. Hale. Bethesda, MD.

12:52 PM THE G2677T BUT NOT THE C3435TPOLYMORPHISM OF THE MULTIDRUGRESISTANCE GENE 1 (MDR-1) AFFECTSCYCLOSPORIN DOSE REQUIREMENTS INSTABLE ADULT HEART TRANSPLANT PATIENTS.(Abstract #1342)Anne B. Taegtmeyer, Jane B. Breen, PanagiotisPantelidis, John D. Smith, Ken I. Welsh, Nicholas R.Banner, Magdi H. Yacoub, Paul J. R. Barton. Harefield,Middlesex, United Kingdom; United Kingdom.

12:59 PM RAPAMYCIN INHIBITS NK CELL FUNCTION.(Abstract #1343)Saori Takeda, Christine Hsieh, Hideaki Obara, Olivia M.Martinez, Sheri M. Krams. Stanford, CA.

1:06 PM MELATONIN ABROGATES ACUTE ANDACCELERATED CARDIAC REJECTION IN RATS.(Abstract #1344)Florian J. Jung, Lin Yang, Luc Haerter, Didier Schneiter,Didier Lardinois, Marius Keel, Walter Weder, StephanKorom. Zurich, Switzerland.

1:13 PM MCI-186 (FREE RADICAL SCAVENGER) INDUCEPROLONGED SURVIVAL OF FULLY-ALLOGENEIC CARDIAC GRAFTS.(Abstract #1345)Katsunori Tanaka, Nozomu Shirasugi, Fumihiko Inoue,Takurin Akiyoshi, Osamu Aramaki, Qi Zhang, KenjiMatsumoto, Masaki Kitajima, Masanori Niimi.Shinjuku-ku, Tokyo, Japan; Itabashi-ku, Tokyo, Japan.

138

1:20 PM THE EXPRESSION OF APOPTOSIS GENES ISMODULATED BY THE ANTIFIBROTIC MOLECULEPIRFENIDONE IN CHRONIC CYCLOSPORINENEPHROTOXICITY. (Abstract #1346)Fuad S. Shihab, William M. Bennett, Hong Yi, Takeshi F.Andoh. Salt Lake City, UT; Portland, OR.

1:27 PM MYCOPHENOLATE MOFETIL SYNERGIZED WITHCD28/CD154 BLOCKADE IN PREVENTION OFSKIN ALLOGRAFT REJECTION. (Abstract #1347)Minh Diem Vu, Yongsheng Li, Terry B. Strom, Xian C.Li. Boston, MA.

Mini-Oral: Liver Transplantation:Immunosuppression12:45 - 1:45 PM

Ballroom BChairs: Marwan Abouljoud and Christopher Marsh

12:45 PM THYMOGLOBULIN SIGNIFICANTLY REDUCESTHE RISK OF ACUTE REJECTION IN RIGHT LOBELIVING-DONOR LIVER TRANSPLANT (LDLT)RECIPIENTS. (Abstract #1348)M. S. Cattral, I. McGilvray, L. Adcock, L. Lilly, N.Girgrah, G. A. Levy, P. D. Greig, D. R. Grant. Toronto,ON, Canada.

12:52 PM USE OF A HUMANIZED MONOCLONALANTIBODY (BASILIXIMAB) FOR INDUCTIONTHERAPY REDUCES THE RATE OF ACUTEREJECTION BUT DOES IT ALSO INCREASE THERISK OF SERIOUS INFECTIONS POST LIVERTRANSPLANT IN CHILDREN? (Abstract #1349)Kathleen P. Falkenstein, Stephen P. Dunn, Adela Casas,Louise Flynn. Wilmington, DE; Phila, PA.

12:59 PM COMPARISON OF ACUTE REJECTION BETWEENWHOLE LIVER GRAFTS AND ADULT PARTIALLIVING DONOR GRAFTS AND CADAVERICSPLIT LIVER GRAFTS. (Abstract #1350)J. Keith Melancon, William D. Payne, Rainer W.Gruessner, Raja Kandaswamy, John R. Lake, Miguel Tan,Angelika C. Gruessner, Abhinav Humar. Minneapolis,MN.

1:06 PM SEQUENTIAL DETERMINATION OFPHARMACOKINETICS (PK) ANDPHARMACODYNAMICS (PD) OFMYCOPHENOLATE MOFETIL (MMF) IN LIVERTRANSPLANT (LT) PATIENTS. (Abstract #1351)Merce Brunet, Jaume Martorell, Elena Vidal, OlgaJimenez, Olga Millan, Isabel Rojo, Isabel Cirera, AntoniRimola. Barcelona, Spain.

1:13 PM ALTERATIONS IN CYTOCHROME P450 ACTIVITYWITH HERBALS: A NEW PARADIGM FOR THEMANAGEMENT OF IMMUNOSUPPRESSION.(Abstract #1352)Kenneth D. Chavin, G. Mark Baillie, Jennifer L.Donovan, C. Lindsay DeVane, Robin M. Taylor, YingRuan, Jun-Sheng Wang, John S. Markowitz. Charleston,SC.

1:20 PM THE ROLE OF BONE MARROW INFUSIONS INWITHDRAWAL OF IMMUNOSUPPRESSION INADULT LIVER ALLOTRANSPLANTATION.(Abstract #1353)Panagiotis Tryphonopoulos, Debbie Weppler, TomoakiKato, Juan R. Madariaga, David M. Levi, Seigo Nishida,Jang Moon, Gennaro Selvaggi, Arie Regev, PabloBejarano, Amr Khaled, Joshua Miller, Phillip Ruiz,Camillo Ricordi, Andreas G. Tzakis. Miami, FL.

1:27 PM ADJUSTING CYCLOSPORINE DOSE TOACHIEVE C

2 TARGET RANGE: EVIDENCE FROM A

PROSPECTIVE, MULTICENTER TRIAL IN LIVERTRANSPLANTATION. (Abstract #1354)Stephen Pollard, Federico Villamil. Leeds, UnitedKingdom; Buenos Aires, Argentina.

Mini-Oral: Outcome in PediatricKidney Transplant12:45 - 1:45 PM

Ballroom AChairs: Robert Ettenger and Kathy Jabs

12:45 PM MATHEMATICAL MODELING TO PREDICT RENALFUNCTION AND GRAFT SURVIVAL BASED ON 5YEAR DATA OF PEDIATRIC RENAL TRANSPLANTPATIENTS WITH MYCOPHENOLATE MOFETIL(MMF) VERSUS AZATHIOPRIN (AZA) BASEDIMMUNOSUPPRESSION. (Abstract #1355)Therese Christina Jungraithmayr, Burkhard Tönshoff,Lothar Bernd Zimmerhackl, for the German MMF StudyGroup. Innsbruck, Austria; Heidelberg, Germany.

12:52 PM SUCCESSFUL WITHDRAWAL OF STEROIDS INPEDIATRIC RENAL TRANSPLANT RECIPIENTS ONCYCLOSPORIN A AND MYCOPHENOLATEMOFETIL - 4-YEAR FOLLOW-UP. (Abstract #1356)Britta Höcker, Ulrike John, Christian Plank, Elke Wühl,Lutz T. Weber, Joachim Misselwitz, Wolfgang Rascher,Otto Mehls, Burkhard Tönshoff. Heidelberg, Germany;Jena, Germany; Erlangen, Germany.

12:59 PM RECURRENCE OF FOCAL SEGMENTALGLOMERULOSCLEROSIS (FSGS) FOLLOWINGPEDIATRIC KIDNEY TRANSPLANTATION IN THEMODERN IMMUNOSUPPRESSION ERA: AREPORT FROM THE NORTH AMERICANPEDIATRIC RENAL TRANSPLANT COOPERATIVESTUDY (NAPRTCS). (Abstract #1357)Sharon M. Bartosh, Donald M. Stablein, Richard N. Fine.Madison, WI; Rockville, MD; Stony Brook, NY.

1:06 PM CORRELATES OF NON-ADHERENCE FORADOLESCENTS ONE YEAR AFTER A KIDNEYTRANSPLANT. (Abstract #1358)Nataliya Zelikovsky, Aileen Walsh, Kevin Meyers.Philadelphia, PA.

1:13 PM LYMPHOPENIA AS A PREDICTOR OF RISK OFVIRAL DISEASE VERSUS SUBCLINICALINFECTION. (Abstract #1359)Jodi Smith, Carrie Gordon, Connie Davis, Patrick Healey,Ruth McDonald. Seattle, WA.

1:20 PM UNEXPECTEDLY HIGH PREVALENCE OF PRE-TRANSPLANT ABNORMAL GLUCOSETOLERANCE IN PEDIATRIC KIDNEYTRANSPLANT RECIPIENTS. (Abstract #1360)Seiichiro Shishido, Hiroyuki Satoh, Hiroshi Asanuma,Hiroshi Hataya, Kenji Ishikura, Masahiro Ikeda, AkiraHasegawa. Kiyose, Tokyo, Japan; Ohmori, Tokyo,Japan.

1:27 PM GRAFT THROMBOTIC RISK FACTORS INPEDIATRIC RENAL TRANSPLANT RECIPIENTS.(Abstract #1361)Laura Massella, Antonia Legato, Luca Dello Strologo,Erica De Candia, Raffaele Landolfi, Gianfranco Rizzoni.Rome, Italy.

139

Tuesd

ay, May 18

Concurrent Session 41: Adult Living Donor andSplit Liver Transplant: Outcomes andInnovations2:00 - 3:30 PM

Room 312Chairs: Jean C. Emond and Charles Miller

2:00 PM MELD SCORE AND PREOPERATIVE VARIABLESAS PREDICTORS OF THE OUTCOMES AFTERADULT-TO-ADULT LIVING DONOR LIVERTRANSPLANTATION. (Abstract #1362)Ichiro Tsunematsu, Yasuhiro Ogura, Koichi Kozaki,Kayoko Inoue, Akio Koizumi, Koichi Tanaka. Osaka,Japan; Kyoto, Japan.

2:10 PM ADULT LIVING DONOR VERSUS DECEASEDDONOR LIVER TRANSPLANTATION: A SIX YEARSINGLE CENTER EXPERIENCE. (Abstract #1363)Daniel G. Maluf, Adrian H. Cotterell, Marc P. Posner,Mitsuru Nakatsuka, Richard T. Stravitz, Martha K.Behnke, Mitchell L. Shiffman, Richard K. Sterling,Velimer A. Luketic, Robert A. Fisher. Richmond, VA.

2:20 PM POST-OPERATIVE LIVER DYSFUNCTIONFOLLOWING DONATION OF SEGMENTAL LIVERGRAFTS. (Abstract #1364)Mark S. Orloff, Adel Bozorgzadeh, Kerrie E. Lansing,Jackie Cullen, Charlotte Ryan, Ashok Jain, DavidWaldman. Rochester, NY.

2:30 PM IGF-1 AND GH IN LIVING-DONOR LIVERTRANSPLANTATION. (Abstract #1365)Martin Stockmann, Diana Hünerbein, Sabine Nolting,Klaus-Jürgen Gräf, Thomas Konrad, Thomas Steinmüller,Peter Neuhaus. Berlin, Germany; Frankfurt, Germany.

2:40 PM FEASIBILITY OF LEFT-LOBE LIVING DONORLIVER TRANSPLANTATIONS BETWEEN ADULTS:SINGLE CENTER EXPERIENCE OF 89 CASES.(Abstract #1366)Yuji Soejima, Mitsuo Shimada, Tomoharu Yoshizumi,Yoshihiko Maehara. Fukuoka, Japan.

2:50 PM LIVER TRANSPLANTATION USING CAVO-PORTAL TRANSPOSITION: AN EFFECTIVETREATMENT IN PATIENTS WITH COMPLETESPLANCHNIC VENOUS THROMBOSIS.(Abstract #1367)J. Pirenne, B. Ceulemans, R. Aerts, D. Monbaliu, W.Coosemans, C. Verslype, W. Van Steenbergen, P. Yap, J.Fevery, F. Nevens. Leuven, Belgium.

3:00 PM SPLIT LIVER TRANSPLANT (SLT) FOR 2 ADULTRECIPIENTS – EVOLUTION OF THE SURGICALPROCEDURE. (Abstract #1368)Abhinav Humar, Timothy D. Sielaff, John R. Lake,William D. Payne. Minneapolis, MN.

3:10 PM SPLIT LIVER TRANSPLANTATION: A UNOSANALYSIS. (Abstract #1369)Tse-Ling Fong, Yong W. Cho, John Donovan, HassanZaghla, Linda Sher, Yuichi Iwaki, Rick Selby. LosAngeles, CA.

3:20 PM SPLIT LIVER TRANSPLANTATION USING THELEFT LATERAL SEGMENT: A MULTI-CENTERSTATEWIDE EXPERIENCE. (Abstract #1370)T. C. Lee, N. R. Barshes, W. K. Washburn, G. A. Halff,B. A. Carter, L. J. Bristow, J. D. Scott, L. Nguyen, J. A.Goss. Houston, TX; San Antonio, TX.

Concurrent Session 42: CMV and Non-OrganSpecific Immunousuppression2:00 - 3:30 PM

Room 302/204Chairs: Ravi C. Chari and Atul Humar

2:00 PM AN ASSESSMENT OF THE CLINICAL UTILITY OFCMV SEROLOGY TESTING IN A LARGECOHORT OF HIGH RISK CMV D+/R-TRANSPLANT RECIPIENTS. (Abstract #1371)Atul Humar, George Moussa, Tony Mazzulli, RaymundRazonable, Carlos Paya, Emma Covington, EmmaAlecock, the PV 16000 Study Group. Toronto, ON,Canada; Rochester, MN; Welwyn Garden City, UnitedKingdom.

2:10 PM A CONTRAST IN THE INCIDENCE ANDPREVALENCE OF HUMAN HERPESVIRUS (HHV)-6 AND HHV-7 REACTIVATION INCYTOMEGALOVIRUS (CMV) D+/R- SOLIDORGAN TRANSPLANT (SOT) PATIENTSRECEIVING ORAL GANCICLOVIR ORVALGANCICLOVIR PROPHYLAXIS.(Abstract #1372)Raymund R. Razonable, Robert A. Brown, Atul Humar,Emma Covington, Emma Alecock, Carlos V. Paya, thePV16000 Study Group. Rochester, MN; Toronto, ON,Canada; Welwyn Garden City, United Kingdom.

2:20 PM KINETICS OF CMV LOAD REDUCTIONSFOLLOWING PRE-EMPTIVE THERAPY WITHVALGANCICLOVIR OR INTRAVENOUSGANCICLOVIR IN ADULT SOLID ORGANTRANSPLANT PATIENTS. (Abstract #1373)Frank M. Mattes, Emma G. Hainsworth, Aycan F.Hassan-Walker, Andrew K. Burroughs, Paul Sweny, PaulD. Griffiths, Vincent C. Emery. London, UK, UnitedKingdom.

2:30 PM RANDOMIZED TRIAL OF ORAL GANCICLOVIRPLUS CYTOMEGALOVIRUS (CMV) IMMUNEGLOBULIN (Ig) VERSUS ORAL GANCICLOVIRALONE FOR CMV PROPHYLAXIS IN LIVER ANDKIDNEY TRANSPLANT RECIPIENTS.(Abstract #1374)Mark Johnson, Steven Zacks, Paula McIver, Mark Russo,Robert Dupuis, Kenneth Andreoni, David Gerber, GregMalat, Jane Salm, Roshan Shrestha, Jeffrey Fair. ChapelHill, NC.

2:40 PM ABROGATION OF THE ALLOREACTIVERESPONSES OF CADAVER DONOR INTESTINALLYMPHOCYTES BY SHORT-TERM CAMPATH-1HEXPOSURE. (Abstract #1375)James M. Mathew, Werviston De Faria, Tomoaki Kato,Teresa Vallone, Silvia Alvarez, Manuel Carreno, BonnieBlomberg, Laphalle Fuller, Violet Esquenazi, JoshuaMiller, Andreas G. Tzakis. Miami, FL.

2:50 PM CALCINERUIN INHIBITOR (CI) AND STEROID-FREE IMMUNOSUPPRESSION (ImmSx) FORPANCREAS (Px) AND Px-KIDNEY (KD)RECIPIENTS USING CAMPATH FOR BOTHINDUCTION AND MAINTENANCE (maint.).(Abstract #1376)R. Kandaswamy, R. Gruessner, A. Gruessner, A. Humar,D. Sutherland. Minneapolis., MN.

3:00 PM RABBIT ANTI-THYMOCYTE (RATG)PRECONDITIONING AND INDUCTION FORPEDIATRIC INTESTINE TRANSPLANTATION.(Abstract #1377)Jorge Reyes, George V. Mazariegos, Geoffrey J. Bond,Rakesh Sindhi, Amy Smith, William McGhee, CamilaMacedo, John J. Fung, Kareem Abu-Elmagd. Pittsburgh,PA.

140

3:10 PM TYPE 1 PROGENITOR DENDRITIC CELL (pDC1)MAY CHARACTERIZE IMMUNOLOGICALEVENTS AFTER STEROID-FREE PEDIATRICABDOMINAL TRANSPLANTATION WITHTHYMOGLOBULIN (rATG). (Abstract #1378)Ali Abdullah, Joseph Seward, Amy Magill, Jorge Reyes,Adrianna Zeevi, Rakesh Sindhi. Pittsburgh, PA.

3:20 PM THE MANAGEMENT OF END STAGE RENALDISEASE IN THE RECIPIENTS OF EXTRARENALTRANSPLANTS. (Abstract #1379)Bradley H. Collins, Carlos E. Marroquin, Janet E. Tuttle-Newhall, Dev M. Desai, Stephen R. Smith, David W.Butterly, R. Randal Bollinger, Paul C. Kuo. Durham, NC.

Concurrent Session 43: Cytokines andAlloreactivity2:00 - 3:30 PM

Room 306Chairs: D. Keith Bishop and Olivia M. Martinez

2:00 PM T-BET DEFICIENT RECIPIENTS EXHIBIT A TH2PHENOTYPE, DEVELOP ACCELERATED ACUTEAND CHRONIC HUMORAL VASCULARIZEDALLOGRAFT REJECTION, AND ARE RESISTANTTO IMMUNOSUPPRESSION AND TOLERANCE.(Abstract #1380)Xueli Yuan, Micheal R. Clarkson, Isabela Schmitt, AlanD. Salama, Hugh Auchincloss, Jr., Laurie H. Glimcher,Mohamed H. Sayegh. Boston, MA.

2:10 PM ALLOANTIBODY PRODUCTION REQUIRESCOGNATE INTERACTIONS BETWEENINDIRECTLY PRIMED CD4 T CELLS AND PEPTIDE/MHC COMPLEXES EXPRESSED ON B CELLS.(Abstract #1381)Yifa Chen, Yilmaz Demir, Anna Valujskikh, Peter S.Heeger. Cleveland, OH.

2:20 PM TREATMENT OF PRE-DIABETIC NOD MICE WITHFLT3-LIGAND IN VIVO DELAYS THEDEVELOPMENT OF DIABETES AND RESTORESTHE GENERATION OF MYELOID DENDRITICCELLS. (Abstract #1382)Isabelle J. Fugier-Vivier, Paula M. Chilton, Leslie A.Weeter, Hong Xu, Yimimg Huang, Murkunda B. Ray,Francine Rezzoug, Suzanne T. Ildstad. Louisville, KY.

2:30 PM TNFR2 (P75) SIGNAL TRANSDUCTION ISREQUIRED FOR TRANSCRIPTIONALACTIVATION OF HCMV IE GENE EXPRESSION INALLOGENEIC TRANSPLANTATION.(Abstract #1383)Soo Jung Kim, Zheng J. Zhang, Thomas K. Varghese,Mary A. Hummel, Gail Thomas, Michael Abecassis.Chicago, IL.

2:40 PM STAT5a/b TRANSCRIPTION FACTORS AREIMPORTANT FOR T BUT NOT B CELLFUNCTIONS DURING ALLOGRAFT REJECTION.(Abstract #1384)Ye Zhang, Robert Kirken, Lucrezia Furian, SlawaJanczewska, Xiumei Qu, Mouer Wang, Ronald Kerman,Stanislaw M. Stepkowski. Houston, TX.

2:50 PM TOLL-LIKE RECEPTOR 4 (TLR4) EXPRESSIONAFTER IL-13 GENE TRANSFER IS STAT6-DEPENDENT. (Abstract #1385)Bibo Ke, Xiu-Da Shen, Feng Gao, Douglas G. Farmer,Ronald W. Busuttil, Jerzy W. Kupiec-Weglinski. LosAngeles, CA.

3:00 PM MONOCYTES ACT AS A BRIDGE BETWEEN TCELLS AND ALLOGENEIC ENDOTHELIAL CELLSVIA IFNγγγγγ-DEPENDENT PROCESSES.(Abstract #1386)He Xu, Kiran K. Dhanireddy, Allan D. Kirk. Bethesda,MD.

3:10 PM INTERFERON REGULATORY FACTOR 1(IRF-1)PLAYS A KEY ROLE IN LIVER ISCHEMIA/REPERFUSION INJURY. (Abstract #1387)Yuan Zhai, Feng Gao, Ryan O;Connell, Xiu-Da Shen, BoQiao, Genhong Cheng, Ronald W. Busuttil, Jerzy W.Kupiec-Weglinski. Los Angeles, CA.

3:20 PM ACTIVATION OF TLR4 IS CRITICAL IN THEMECHANISM OF EXTENDED COLD ISCHEMIA/REPERFUSION INJURY AFTER LIVERTRANSPLANTATION. (Abstract #1388)Xiu-Da Shen, Bibo Ke, Yuan Zhai, Feng Gao, Sei-IchiroTsuchihashi, Charles R. Lassman, Douglas G. Farmer,Ronald W. Busuttil, Jerzy W. Kupiec-Weglinski. LosAngeles, CA.

Concurrent Session 44: Liver Transplantation:Cancer and Other Concerns2:00 - 3:30 PM

Ballroom BChairs: Elizabeth A. Pomfret and Hugo R. Rosen

2:00 PM SHOULD HEPATOCELLULAR CARCINOMA BETREATED DURING THE WAITING LIST PERIOD?(Abstract #1389)Jean F. Botha, B. Daniel Campos, Wendy J. Grant, DebraL. Sudan, Byers W. Shaw, Jr., Fedja Rochling, Daniel F.Schafer, Alan N. Langnas. Omaha, NE.

2:10 PM RADIOFREQUENCY ABLATION OF LIVERTUMORS BEFORE LIVER TRANSPLANTATION-ACLINICAL AND HISTOLOGICAL EXAMINATION.(Abstract #1390)Adrian P. Martin, Robert M. Goldstein, George Netto,Nora Katabi, Takehisa Ueno, Nicholas Onaca, EdmundQ. Sanchez, Srinath Chinnakotla, Henry Randall,Sherfield Dawson, Marlon F. Levy, Goran B. Klintmalm.Dallas, TX.

2:20 PM ROLE FOR LIVING DONOR TRANSPLANTION INPATIENTS WITH HEPATIC MALIGNANCY.(Abstract #1391)David Axelrod, Alan Koffron, Laura Kulik, Elena Crisan,Patrice Al-Saden, Mary Mulcahy, Jonathan Fryer,Michael Abecassis. Chicago, IL.

2:30 PM LIVING DONOR LIVER TRANSPLANTATION FORHEPATOCELLULAR CARCINOMA IN A SINGLECENTER. (Abstract #1392)Mikiko Ueda, Yasutsugu Takada, Hironori Haga, KenjiUryuhara, Kohei Ogawa, Yasuhiro Fujimoto, MureoKasahara, Yasuhiro Ogura, Koichi Kozaki, Hiroto Egawa,Koichi Tanaka. Kyoto, Kyoto, Japan.

2:40 PM IMPACT OF MELD EXCEPTIONS ONTRANSPLANT AND DEATH RATES IN LIVERCANDIDATES. (Abstract #1393)Ann M. Harper, Erick B. Edwards, David C. Mulligan,Hugo E. Vargas, Hector Rodriguez-Luna, Kunam S.Reddy, Aydr A. Moss, Richard B. Freeman. Richmond,VA; Phoenix, AZ; Boston, MA.

2:50 PM DECREASED SURVIVAL IN LIVER TRANSPLANTPATIENTS REQUIRING CHRONIC DIALYSIS: ACANADIAN EXPERIENCE. (Abstract #1394)M. Cantarovich, F. Ivis, K. Badovinac. Montreal, QC,Canada; Toronto, ON, Canada.

141

Tuesd

ay, May 18

3:00 PM LIFE EXPECTANCY AFTER SUCCESSFUL LIVERTRANSPLANTATION. (Abstract #1395)Arie P. van den Berg, Wim J. Sluiter, Els B. Haagsma,Paul M. J. G. Peeters, Maarten J. H. Slooff. Groningen,Netherlands.

3:10 PM PARAMETERS FOR PATIERNT SELECTION FORLIVER RE-TRANSPLANTATION BASED ON MELDAND ALLOGRAFT CHARACTERISTICS.(Abstract #1396)Rafik M. Ghobrial, Yue Ming Huang, RandolphSteadman, Jeffrey A. Gornbein, Ronald W. Busuttil. LosAngeles, CA.

3:20 PM CONTRIBUTION OF TRANSJUGULAR LIVERBIOPSY (TJLB) IN PATIENTS WITH ACUTE LIVERFAILURE (ALF) CLINICAL PRESENTATION INDECIDING PATIENT SELECTION AND TIMINGFOR ORTHOTOPIC LIVER TRANSPLANTATION(OLT). (Abstract #1397)Angelo Luca, Marta Ida Minervini, Roberto Miraglia,Salvatore Gruttadauria, Giovanni Vizzini, AntonioArcadipane, Bruno Gridelli. Palermo, Italy.

Concurrent Session 45: Lymphocyte Activation:Generation of Effector Function2:00 - 3:30 PM

Room 309Chairs: Maria-Luisa Alegre and Majed M. Hamawy

2:00 PM LIVER NK CELLS EXPRESSING TNF-RELATEDAPOPTOSIS-INDUCING LIGAND HAVETOXICITY AGAINST TRANSPLANTEDAUTOLOGOUS HEPATOCYTES. (Abstract #1398)Hiroshi Mitsuta, Hideki Ohdan, Makoto Ochi, TakashiOnoe, Daisuke Tokita, Hidetaka Hara, Kohei Ishiyama,Wendy Zhou, Yuka Tanaka, Kentaro Ide, ToshimasaAsahara. Hiroshima, Hiroshima, Japan.

2:10 PM ADAPTOR PROTEINS AND HOSTALLORESPONSES: TARGETING THE SLAMFAMILY MEMBER, LY-108, PROLONGSALLOGRAFT SURVIVAL. (Abstract #1399)Qunrui Ye, Christopher C. Fraser, Ran Tao, Liqing Wang,Andrew D. Wells, Andre Veillette, Anthony J. Coyle,Wayne W. Hancock. Philadelphia, PA; Cambridge, MA;Montreal, QC, Canada.

2:20 PM THE INDUCIBLE NF-KB ACTIVATING KINASE,IKKΕΕΕΕΕ, PROMOTES T CELL ACTIVATION ANDPROLIFERATION IN VIVO DURINGALLORESPONSES. (Abstract #1400)Tao Wang, Sha-Mei Liao, Tom Maniatis, Anthony J.Coyle, Wayne W. Hancock. Philadelphia, PA;Cambridge, MA.

2:30 PM GENERATION OF POLYCLONAL ALLOSPECIFICMEMORY BY SORTING ALLOACTIVATED CD25+

T CELLS. (Abstract #1401)Adam W. Bingaman, David B. Leeser, Donna L. Farber.Baltimore, MD.

2:40 PM T CELL REPERTOIRE EXPANSION BY B CELLSAND IMMUNOGLOBULIN. (Abstract #1402)Marilia Cascalho, Cristina Joao, Brenda M. Ogle, JeffreyL. Platt. Rochester, MN.

2:50 PM ICOS AND OX40 MEDIATED COSTIMULATION ISREQUIRED FOR ALLOREACTIVE MEMORY CD8T CELL ACTIVATION. (Abstract #1403)Wei Gao, Yuan Zhai, Hideo Yagita, Ronald W. Busuttil,Mohammed H. Sayegh, Jerzy W. Kupiec-Weglinski. LosAngeles, CA; Boston, MA; Japan.

3:00 PM CONTRIBUTION OF CD4 AND CD8 T CELLS TOSKIN AND VASCULARIZED CARDIACALLOGRAFT REJECTION IN THE ABSENCE OFCD28. (Abstract #1404)Michael R. Clarkson, Xueli Yuan, Hideo Yagita, ReshmaKewalramani, Toshiro Ito, Hugh Auchincloss, Jr., NaderNajafian, Mohamed H. Sayegh. Boston, MA.

3:10 PM INEFFECTIVE ACTIVATION OF GRAFT-SPECIFICCD8 T CELLS AFTER HEART BUT NOT SKINTRANSPLANTATION. (Abstract #1405)Alexander Filatenkov, Elizabeth Ingulli. Minneapolis,MN.

3:20 PM TRANSITION, MAINTENANCE, AND RECALL OFALLOREACTIVE CD4 AND CD8 MEMORY TCELLS INDEPENDENT OF EACH OTHER AND OFSECONDARY LYMPHOID ORGANS.(Abstract #1406)Jagdeep S. Obhrai, Geetha Chalasani, Lonnette A. Smith-Diggs, Fadi G. Lakkis. New Haven, CT.

Concurrent Session 46: MetabolicComplications and Hypertension After KidneyTransplantation2:00 - 3:30 PM

Veterans BallroomChairs: David J. Cohen and Stefan Vitko

2:00 PM HMG-CoA REDUCTASE INHIBITORS (STATINS)REDUCE THE INCIDENCE OF POST-RENALTRANSPLANT DIABETES MELLITUS (PTDM).(Abstract #1407)G. V. Ramesh Prasad, S. J. Kim, M. Huang, M.Thenganatt, J. Park, M. M. Nash, J. S. Zaltzman, D. C.Cattran, S. S. A. Fenton, E. H. Cole, C. J. Cardella.Toronto; Toronto, ON, Canada.

2:10 PM THE USE OF SIROLIMUS ANDMYCOPHENOLATE MOFETIL IS ASSOCIATEDWITH IMPROVED RENAL FUNCTION, BUTSIMILAR METABOLIC PROFILES TO SIROLIMUSAND TACROLIMUS. (Abstract #1408)Agnes Lo, M. Francesca Egidi, Benjamin Gross, Hosein-Shokouh Amiri, Santiago Vera, Nosratollah Nezakatgoo,A. Osama Gaber. Memphis, TN.

2:20 PM USE OF EZETIMBE INHYPERCHOLESTEROLEMIC KIDNEYTRANSPLANT PATIENTS. (Abstract #1409)Jacob P. John, Joseph Lawen, Bryce A. Kiberd. Halifax,NS, Canada.

2:30 PM A PROSPECTIVE, CROSS-OVER TRIALCOMPARING FLOW-MEDIATED BRACHIALARTERY VASODILATION INHYPERCHOLESTEROLEMIC RENALTRANSPLANT PATIENTS TREATED WITHCYCLOSPORINE A + ATORVASTATIN,TACROLIMUS ALONE AND TACROLIMUS +ATORVASTATIN. (Abstract #1410)K. Martin Wissing, Philippe Unger, Guy Berkenboom,Isabelle Dupont, Nilufer Broeders, Daniel Abramowicz.Brussels, Belgium.

2:40 PM STEROIDS HAVE NO CALORIES: WEIGHT GAINPOST TRANSPLANTATION IS NOT PREVENTEDBY STEROID AVOIDANCE. (Abstract #1411)E. A. Elster, C. Chamberlain, C. Salaita, A. D. Kirk, D.Hale, Roslyn B. Mannon. Bethesda, MD.

142

2:50 PM PREDICTIVE DIFFERENCES ANDMISSCLASSIFICATION BETWEEN CLINIC(Dinamap), AMBULATORY (ABPM), ANDHYPERTENSION NURSE (RN) BLOOD PRESSUREMEASUREMENTS IN KIDNEY RECIPIENTS ONEYEAR AFTER TRANSPLANTATION.(Abstract #1412)Stephen C. Textor, Mouhammed AbuAttieh, AditMahale, Sandra J. Taler, Driscoll Nancy, Augustine JoEllen, Larson S. Timothy, Gloor M. James, Griffin D.Matthew, Schwab R. Thomas, Cosio G. Fernando, StegallD. Mark. Rochester, MN.

3:00 PM METABOLIC COMPLICATIONS PRE AND POSTRENAL TRANSPLANTATION. (Abstract #1413)Agnes Lo, Barbara Culbreath, M. Francesca Egidi, AnnCashion, A. Osama Gaber. Memphis, TN.

3:10 PM AMBULATORY MONITORING OF BLOODPRESSURE IN A KIDNEY TRANSPLANTPOPULATION. (Abstract #1414)Hélène Lord, Suzon Collette, Raymond Dandavino,Michel Morin, Anne Boucher. Montréal, QC, Canada.

3:20 PM HYPERTENSION AND SURVIVAL FOLLOWINGRENAL TRANSPLANTATION-POTENTIALCARDIOVASCULAR PROTECTION WITH BETABLOCKERS. (Abstract #1415)Patrick B. Mark, Viliami Tutone, Graeme Stewart, C. C.Tan, R. S. C. Rodger, Colin Geddes, Alan G. Jardine.Glasgow, Scotland, United Kingdom.

Concurrent Session 47: Outcomes andComplications after Cardiac Transplantation2:00 - 3:30 PM

Room 311Chairs: Abbas Ardehali and George Tellides

2:00 PM MORTALITY FOLLOWING CARDIACTRANSPLANTATION FOR STATUS 1 PATIENTSWITH AND WITHOUT MECHANICALVENTRICULAR ASSIST DEVICES: AN ANALYSISOF THE UNITED NETWORK FOR ORGANSHARING THORACIC REGISTRY.(Abstract #1416)Rajan Krishnamani, Kamal R. Khabbaz, Wenjun Li,Richard D. Patten, Marvin A. Konstam, DavidDeNofrio. Boston, MA.

2:10 PM STATINS AND SURVIVAL IN DE NOVO CARDIACTRANSPLANTATION: A META-ANALYSIS.(Abstract #1417)Nirav Y. Raval, Mandeep R. Mehra. New Orleans, LA.

2:20 PM THE RELEVANCE OF HLA ANTIBODY AND ADONOR SPECIFIC FLOW CYTOMETRYCROSSMATCH TO REJECTION AND GRAFTSURVIVAL IN CARDIAC ALLOGRAFTRECIPIENTS. (Abstract #1418)Peter Przybylowski, Branislav Radovancevic, O. H.Frazier, F. Smart, Noriel Acordia, Paula Juarez, L. A.Nemeth, Barry D. Kahan, Ronald H. Kerman. Houston,TX.

2:30 PM RISK FACTORS FOR ACUTE REJECTION ANDVASCULOPATHY AMONG 634 PATIENTS TREATEDWITH EVEROLIMUS OR AZATHIOPRINE.(Abstract #1419)R. C. Starling, J. Kobashigawa, H. Eisen, J. Jaffe, Y. Li.Cleveland, OH; Los Angeles, CA; Philadelphia, PA; E.Hanover, NJ.

2:40 PM ANTI-DONOR IMMUNITY IN CARDIACALLOGRAFT RECIPIENTS WITH AND WITHOUTTRANSPLANT VASCULOPATHY (TV).(Abstract #1420)Emilio Poggio, Meagan Roddy, Michael Clemente,Jocelyn Riley, Randall Starling, Patrick McCarthy, JamesYoung, Barbara Gus, Mohamad Yamani, Peter S. Heeger.Cleveland, OH.

2:50 PM FURTHER ANALYSIS OF THE INTRAVASCULARULTRASOUND DATA FROM THE RANDOMIZEDMYCOPHENOLATE MOFETIL (MMF) TRIAL INHEART TRANSPLANT RECIPIENTS.(Abstract #1421)Jon A. Kobashigawa, Jonathan Tobis, Robert M.Mentzer, Hannah A. Valantine, Robert C. Bourge, FrankW. Smart, Leslie W. Miller, Robert D. Gordon. LosAngeles, CA; Lexington, KY; Stanford, CA; Birmingham,AL; Houston, TX; Minneapolis, MN; Basel, Switzerland.

3:00 PM MULTI-CENTER INTRAVASCULAR ULTRASOUNDVALIDATION STUDY AMONG HEARTTRANSPLANT RECIPIENTS: OUTCOMES AFTER 5YEARS. (Abstract #1422)Jon A. Kobashigawa, Jonathan M. Tobis, Randall C.Starling, Murat E. Tuzcu, Mandeep R. Mehra, AlanYeung, Hannah Valantine, Andrew Smith, Hitoshi Anzai,Brandy T. Oeser, Kamal Abeywickrama, Jane Murphy,Nathalie Cretin. Los Angeles, CA; Cleveland, OH; NewOrleans, LA; Stanford, CA; Atlanta, GA; Basel,Switzerland.

3:10 PM DECREASED SURVIVAL IN HEART TRANSPLANTPATIENTS REQUIRING CHRONIC DIALYSIS: ACANADIAN EXPERIENCE. (Abstract #1423)M. Cantarovich, F. Ivis, K. Badovinac. Montreal, QC,Canada; Toronto, ON, Canada.

3:20 PM SEROPOSITIVITY FOR CYTOMEGALOVIRUSPREDISPOSES TO ALLOGRAFT VASCULOPATHYIN HEART TRANSPLANT RECIPIENTSREGARDLESS OF GANCICLOVIR-PROPHYLAXYS. (Abstract #1424)Ombretta Biadi, Luciano Potena, Cecile Holweg, Helen I.Luikart, Sharon A. Hunt, Hannah A. Valantine. Stanford,CA.

Concurrent Session 48: Positive CrossmatchKidney Transplantation and Sub-ClinicalRejection2:00 - 3:30 PM

Ballroom AChairs: Anthony J. Langone and Robert A. Montgomery

2:00 PM RENAL TRANSPLANTATION USING LIVINGDONORS WITH A POSITIVE CROSSMATCH:CAN WE PREDICT EFFICACY OFDESENSITIZATION WITH IVIG BY AN “IN VITRO”TEST? (Abstract #1425)Maria Cristina Ribeiro Castro, Nicolas Panajotopoulos,Liliam M. P. Araujo, Helcio Rodrigues, Renata Maciel,Carla Ronda, Carlos Sérgio Viggiani, Willian Nahas, EliasDavid-Neto, Luiz Estevam Ianhez, Jorge Kalil Filho,Denis Glotz. São Paulo, SP, Brazil; Paris, France.

2:10 PM IMPROVED RESULTS WITH SELECTIVE USE OFSPLENECTOMY AND ANTI-CD 20 FOR POSITIVECROSSMATCH TRANSPLANTS. (Abstract #1426)Christopher E. Simpkins, Andrea A. Zachary, MatthewCooper, Daniel S. Warren, Lloyd E. Ratner, Robert A.Montgomery. Baltimore, MD.

143

Tuesd

ay, May 18

2:20 PM HIGHLY SUCCESSFUL LIVING DONOR KIDNEYTRANSPLANTATION AFTER CONVERSION TONEGATIVE OF A PREVIOUSLY POSITIVE FLOW-CYTOMETRY CROSS-MATCH BY PRE-OPERTIVEPLASMAPHERESIS. (Abstract #1427)Howard N. Sankary, James Thielke, PhilipDeChristopher, Kerri Kraft, Diego Bogetti, JoseOberholzer, Giuliano Testa, Enrico Benedetti. Chicago,IL.

2:30 PM MODULATION OF ANTI-CLASS I, ANTI-CLASS IIAND ANTI-ENDOTHELIAL CELL ANTIBODIES BYINTRAVENOUS GAMMAGLOBULIN (IVIG)IMPROVES TRANSPLANT RATES AND REDUCESALLOGRAFT REJECTION IN HIGHLY-SENSITIZED PATIENTS. (Abstract #1428)Mieko Toyoda, Anna Petrosyan, Lara Hilo, Andy Pao,Gail Rodich, Matthew McIntosh, Stanley C. Jordan. LosAngeles, CA; Rockville, MD.

2:40 PM INTRAVENOUS IMMUNGLOBULIN (IVIG) ANDTHYMOGLOBULIN INDUCTION TREATMENTDOWNREGULATE PREFORMED DONOR-SPECIFIC ANTI-HLA ANTIBODIES (DSA), BUT DONOT PREVENT THE DEVELOPMENT OF DE NOVODSA. (Abstract #1429)Enver Akalin, Marilena Fotino, Rex Friedlander, BarbaraMurphy, Scott Ames, Vinita Sehgal, Lisa Daly, JonathanS. Bromberg. New York, NY.

2:50 PM SAFETY AND ADVERSE EVENT PROFILES OFINTRAVENOUS GAMMAGLOBULIN (IVIG)PRODUCTS USED FOR IMMUNOMODULATION:A SINGLE CENTER EXPERIENCE. (Abstract #1430)Ashley A. Vo, Marina Lukovsky, Mieko Toyoda, DechuPuliyanda, Vinh Cam, Suphamai Bunnapradist, Stanley C.Jordan. Los Angeles, CA.

3:00 PM INCIDENCE OF SUBCLINICAL REJECTION INPROTOCOL BIOPSIES PROCURED FROMRENAL TRANSPLANT RECIPIENTS ONTACROLIMUS-BASED IMMUNOSUPPRESSIVEREGIMEN. (Abstract #1431)Mark L. Lipman, Paula Lavery, Yanping Shi, YingnianShen, Ziba Aalamian, Rolf Loertscher. Montreal, QC,Canada.

3:10 PM A NOVEL DRUG TOXICITY PATHOLOGY SCOREIN PROTOCOL BIOPSIES CAN PREDICTCLINICAL GRAFT AND PATIENT OUTCOMES INPEDIATRIC RENAL TRANSPLANTATION.(Abstract #1432)Suja Nagarajan, Sheryl Shah, Megan Troxell, MinnieSarwal, Neeraja Kambham. CA.

3:20 PM LOW MANNOSE-BINDING LECTIN LEVELS AREASSOCIATED WITH IMPROVED OUTCOME INCADAVER RENAL TRANSPLANTATION.(Abstract #1433)Stefan P. Berger, Anja Roos, Marko J. K. Mallat, JohanW. de Fijter, Mohamed R. Daha. Leiden, Netherlands.

Concurrent Session 49: Recent Progress in Islet2:00 - 3:30 PM

Ballroom CChairs: Camillo Ricordi and James Shapiro

2:00 PM INTERNATIONAL MULTICENTER TRIAL OF ISLETTRANSPLANTATION USING THE EDMONTONPROTOCOL IN PATIENTS WITH TYPE 1DIABETES. (Abstract #1434)James Shapiro, Camillo Ricordi, Bernhard Hering,Barbara DiMercurio, Robert Lindblad, Enrico Cagliero,Mathias Brendel, Paul Robertson, Thierry Berney,Antonio Secchi, Daniel Brennan, Eleanor Ramos, LisaViviano, Edmond Ryan, Nicole Close, Jonathan Lakey.Edmonton, AB, Canada; Minneapolis, MN; Miami, FL;Bethesda, MD; Rockville, MD; Boston, MA; Giessen,Germany; Seattle, WA; Geneva, Switzerland; Milan,Italy; St Louis, MO; San Francisco, CA.

2:10 PM GRAFT SURVIVAL ANALYSIS IN 20 TYPE 1DIABETIC ISLET ALLOGRAFT RECIPIENTS.(Abstract #1435)Bernhard J. Hering, Raja Kandaswamy, Jamen Parkey,Kathryn Duderstadt, Jeffrey D. Ansite, Hui-Jian Zhang,Masahiko Nakano, Ippei Matsumoto, Toshiya Sawada,Baolin Liu, Andrea Bauer, Lukas Guenther, Robin Jevne,Angelika Gruessner, Jeffrey A. Bluestone, David E. R.Sutherland. Minneapolis, MN; San Francisco, CA.

2:20 PM COMPARISON OF WHOLE ORGAN PANCREASAND ISOLATED ISLET TRANSPLANTATION FORTYPE 1 DIABETES. (Abstract #1436)Adam M. Frank, Shaoping Deng, ThavachenthanThambi-Pillai, Ergun Velededeoglu, Niraj M. Desai,Xiaolun Huang, Moh Moh Lian, Muhammad M.Mohiuddin, Yong Suk Bae, Gerald R. Stephenson, PeterL. Abt, Marty T. Sellers, Clyde F. Barker, Ali Naji, JamesF. Markmann. Philadelphia, PA.

2:30 PM PROSPECTIVE COMPARISON OF CLINICALOUTCOMES WITH FRESH VS CULTURED ISLETSAT A SINGLE INSTITUTION. (Abstract #1437)James Shapiro, Edmond Ryan, Deborah McGhee-Wilson,Peter Senior, Breay Paty, Parastoo Dinyari, TaraMcCready, Huey Chong, Norman Kneteman, DavidBigam, Jonathan Lakey. Edmonton, AB, Canada.

2:40 PM INSULIN INDEPENDENCE FOLLOWINGTRANSPLANTATION OF CULTURED HUMANISLETS IN PATIENTS WITH TYPE 1 DIABETES: THEMIAMI EXPERIENCE. (Abstract #1438)Rodolfo Alejandro, Jacqueline V. Ferreira, Tatiana Froud,David A. Baidal, Muhammad Hafiz, Norma S. Kenyon,Camillo Ricordi. Miami, FL.

2:50 PM CO-TRANSPLANTATION OF PORCINE ISLETSWITH SERTOLI CELLS IN TYPE 1 DIABETICPATIENTS PRODUCES ATYPICAL HUMORALIMMUNE RESPONSES AS ASSED BY ELICITEDANTI-PIG ANTIBODIES. (Abstract #1439)R. A. Valdes-Gonzalez, L. M. Dorantes, G. N. Garibay, E.Bracho, L. Teran, L. Silva, P. Valencia, L. Copeman, D.J. G. White. Mexico City, Mexico; London, ON, Canada.

3:00 PM SUCCESFSUL HUMAN ISLET TRANSPLANTATIONFOLLOWING DISCONTINUOUS GRADIENTRESCUE PURIFICARTION. (Abstract #1440)Hirohito Ichii, Antonello Pileggi, R. Damaris Molano,Aisha Khan, Ismail Al-Abdullah, Yoshikazu Kuroda, LucaInverardi, Rodolfo Alejandro, Camillo Ricordi. Miami,FL; Kobe, Japan.

144

3:10 PM INSULIN RESISTANCE AND PROCESSING,APOPTOTIC AND IMMUNOLOGICAL PROCESSIN THE COURSE OF ISLET GRAFT FAILURE INISLET TRANSPLANTED PATIENTS. (Abstract #1441)Paolo Fiorina, Alberto M. Davalli, Federico Bertuzzi,Paola Maffi, Chiara Gremizzi, Marta Bruno Ventre,Lucilla Monti, Ezio Bonifacio, Emanuele Bosi, AntonioSecchi. Milan, Italy.

3:20 PM AN INITIAL EXPERIENCE WITHLAPAROSCOPIC(LAP) DONOR DISTALPANCREATECTOMY FOR LIVING DONORPANCREAS TRANSPLANTATION. (Abstract #1442)Miguel Tan, Raja Kandaswamy, Rainer W. Gruessner.Minneapolis, MN.

Concurrent Session 50: Strategies to AmeliorateExperimental Rejection2:00 - 3:30 PM

Room 310Chairs: Karl L. Womer

2:00 PM OVEREXPRESSION OF HUMAN COPPER/ZINC-SUPEROXIDE DISMUTASE (SOD1) SUPPRESSESISCHEMIA REPERFUSION INJURY ANDSUBSEQUENT DEVELOPMENT OF GRAFTCORONARY ARTERY DISEASE IN MURINECARDIAC GRAFTS. (Abstract #1443)Masashi Tanaka, Feny Gunawan, Raya D. Terry, GolnazK. Mokhtari, Anthony D. Caffarelli, David T. Cooke,Theo Kofidis, Robert C. Robbins. Stanford, CA.

2:10 PM OVEREXPRESSION OF HUMAN BCL-2 BYADENOVIRAL GENE TRANSFER IN DONORCORONARY ARTERY SMOOTH MUSCLE CELLSREDUCES DONOR GRAFT APOPTOSIS ANDLEADS TO AN EARLY TH2 CYTOKINE PROFILEIN RAT CARDIAC ALLOGRAFTS. (Abstract #1444)David Tom Cooke, Jeremy I. Pearl, Masashi Tanaka, E.Grant Hoyt, Robert C. Robbins. Stanford, CA.

2:20 PM OVEREXPRESSION OF Bcl-2 REDUCES GRAFTCORONARY ARTERY DISEASE BYSUPPRESSING ISCHEMIA REPERFUSION INJURYAND IMMUNE RESPONSE DURING ACUTE ANDCHRONIC PHASE IN MURINE CARDIACALLOGRAFTS. (Abstract #1445)Masashi Tanaka, Susumu Nakae, Raya D. Terry, TheoKofidis, Robert C. Robbins. Stanford, CA.

2:30 PM IMMUNOSUPPRESSANT PROPERTIES OF ααααα-TOCOPHERYL (PEG-1000) SUCCINATE THATSYNERGIZES WITH LOW-DOSECYCLOSPORINE IN CARDIAC ALLOGRAFTREJECTION. (Abstract #1446)Galen M. Pieper, Thanh K. Nguyen, Vani Nilakantan,Christopher P. Johnson, Allan M. Roza, Mark B. Adams,Christopher C. Felix, Ashwani K. Khanna. Milwaukee,WI.

2:40 PM INDUCED HEME OXYGENASE-1 PLUS DONORSPECIFIC TRANSFUSION YIELDS ANTIGENSPECIFIC TOLERANCE MEDIATED BYREGULATORY CD4+CD25+ T CELLS.(Abstract #1447)Kenichiro Yamashita, James McDaid, Robert Öllinger,Hongjun Wang, Eva Csizmadia, R. Neal Smith, Miguel P.Soares, Fritz H. Bach. Boston, MA.

2:50 PM PROTEIN KINASE C EPSILON DEFICIENCY INKIDNEY TRANSPLANTS IMPROVES ALLOGENICTRANSPLANT SURVIVAL. (Abstract #1448)Song Rong, Joon-Keun Park, When Zen, Anke Schwarz,Michael Leitges, Hermann Haller, Faikah Gueler.Hannover, Germany.

3:00 PM ROLE OF INTERFERON-GAMMA IN THEREDUCTION OF HUMAN ARTERIAL INJURY INTHE SCID HUMAN TRANSPLANT MODEL VIASYNERGY OF SIROLIMUS & CYCLOSPORINE.(Abstract #1449)Tai Yi, Lisa Geiselhart, George Tellides, Jordan Pober,Marc Lorber. New Haven, CT.

3:10 PM THERAPEUTIC EFFICACY OF TARGETINGANGIOGENESIS IN ALLOIMMUNITY.(Abstract #1450)Masayuki Sho, Naoya Ikeda, Yukiyasu Kuzumoto, SatoruAkashi, Yoshikazu Tsurui, Hisanori Kashizuka, TakashiMizuno, Hiromichi Kanehiro, Marlies Reinders, Daniel J.Hicklin, Yoshiyuki Nakajima, David M. Briscoe. Nara,Japan; New York, NY; Boston, MA.

3:20 PM INTRAGRAFT EXPRESSION OF SDF-1 IS A NOVELPREDICTIVE MARKER OF POOR GRAFTOUTCOMES FOLLOWING ACUTE RENALTRANSPLANT REJECTION. (Abstract #1451)Sheryl Shah, Elaine Mansfield, Neeraja Kambham, Szu-Chuan Hsieh, Rosa Liu, Minnie Sarwal. Stanford, CA.

4:00 PM Break

Concurrent Session 51: Apoptosis and PotentialTherapies in Ischemia-Reperfusion4:00 - 5:30 PM

Room 306Chairs: John R. Renz and Daniel Shoskes

4:00 PM GENE TRANSFER OF HUMAN BCL-2 IN DONORRAT LUNG ALLOGRAFTS LIMITS ISCHEMIA/REPERFUSION MEDIATED INFLAMMATORYRESPONSE AND APOPTOSIS AND IMPROVESPOST-TRANSPLANT LUNG FUNCTION.(Abstract #1452)David Tom Cooke, Jeremy I. Pearl, Masashi Tanaka,Justin Cole, E. Grant Hoyt, Robert C. Robbins. Stanford,CA.

4:10 PM ISCHEMIA-REPERFUSION (I-R) INDUCESGLOMERULAR AND TUBULAR ACTIVATION OFPRO-INFLAMMATORY AND ANTI-APOPTOTICPATHWAYS: DIFFERENTIAL MODULATION OFRAPAMYCIN (RM). (Abstract #1453)A. Loverre, C. Capobianco, P. Ditonno, M. Battaglia, S.Palazzo, A. Crovace, G. Stallone, B. Infante, A. Schena,S. Di Paolo, F. P. Selvaggi, E. Ranieri, L. Gesualdo, F. P.Schena, G. Grandaliano. Italy.

4:20 PM CASPASE-3 AND -8 BLOCKADE REDUCESISCHEMIA/REPERFUSION DIRECTEDAPOPTOSIS AND INFLAMMATORY CHEMOKINEAND CYTOKINE PRODUCTION IN DONOR RATLUNG ALLOGRAFTS. (Abstract #1454)David Tom Cooke, E. Grant Hoyt, Robert C. Robbins.Stanford, CA.

4:30 PM CASPASE 8 SMALL INTERFERING RNADECREASES ISCHEMIA-REPERFUSION INJURYTO THE LIVER IN MICE. (Abstract #1455)Mario Vilatoba, Guadalupe Bilbao, Christopher Eckstein,Anthony Thompson, Devin E. Eckhoff, Juan L.Contreras. Birmingham, AL.

4:40 PM LYSOSOMAL RELEASE OF CATHEPSIN BPOTENTIATIES LIVER DAMAGE OF STEATOTICLIVERS AFTER COLD ISCHEMIA AND WARMREPERFUSION INJURY. (Abstract #1456)E. Baskin-Bey, A. Canbay, S. Bronk, N. Werneburg, S.Nyberg, G. Gores. Rochester, MN.

145

Tuesd

ay, May 18

4:50 PM DONOR PRE-TREATMENT WITH ATORVASTATINUP-REGULATES HEME-OXYGENASE 1 IN RENALTISSUE AND PREVENTS COLD PRESERVATIONINJURY IN ISOGENEIC TRANSPLANTATION INRATS. (Abstract #1457)Uwe Goettmann, Paul Brinkkoetter, Christian Karle,Benito Yard, Fokko J. van der Woude, Claude Braun.Mannheim, Germany.

5:00 PM LECTIN-LIKE OXIDIZED LDL RECEPTOR (LOX-1)MEDIATED PATHWAY AND VASCULAROXIDATIVE INJURY IN RAT RENALTRANSPLANTS WITH OLDER AGE.(Abstract #1458)Duska Dragun, Jan H. Braesen, Melina Nieminen-Kelhae,Denise Markmann, Wolfgang Schneider, Hans H.Neumayer, Klemens Budde, Friedrich C. Luft. Berlin,Germany.

5:10 PM EFFECT OF A NOVEL INDUCIBLE NITRIC OXIDESYNTHASE INHIBITOR IN PREVENTION OFRENAL ISCHEMIA/REPERFUSION INJURY INVERVET MONKEYS. (Abstract #1459)Shijie Qi, Dasheng Xu, Anlun Ma, Xiaochun Zhang, YangWang, Huijuan Gao, Noboru Chida, Yuji Sudo, KouichiTamura, Pierre Daloze, Huifang Chen. Montreal, QC,Canada; Osaka, Japan.

5:20 PM ATORVASTATIN (Ator) DECREASES LOSS OFHUMAN PANCREATIC ISLET (PI) MASS RELATEDTO INSTANT BLOOD-MEDIATEDINFLAMMATORY REACTION (IBMIR) BY DOWN-REGULATION OF TISSUE FACTOR (TF) ANDMACROPHAGE CHEMOATTRACTANT PROTEIN(MCP-1) EXPRESSION. (Abstract #1460)Juan L. Contreras, Cheryl A. Smyth, ChristopherEckstein, Carlton Young, Guadalupe Bilbao, AnthonyThompson, Devin Eckhoff. Birmingham, AL.

Concurrent Session 52: Chemokines andAdhesion Molecules4:00 - 5:30 PM

Room 310Chairs: Jonathan S. Bromberg and Robert L. Fairchild

4:00 PM ROLE OF CXCR2 IN RENAL ISCHEMIA/REPERFUSION INJURY. (Abstract #1461)Motoo Araki, Masayoshi Miura, Hiromi Kumon, JohnBelperio, Robert Strieter, Andrew Novick, RobertFairchild. Cleveland, OH; Okayama, Okayama, Japan;Los Angeles, CA.

4:10 PM EXPLOITING TISSUE-SPECIFIC HOMING TOTHERAPEUTIC EFFECT: TARGETING THE TECK/CCR9 PATHWAY PROLONGS SMALL BOWELALLOGRAFT SURVIVAL. (Abstract #1462)Ran Tao, Qunrui Ye, Rongxiang Han, Paul E. Love,Wayne W. Hancock. Philadelphia, PA; Bethesda, MD.

4:20 PM VASCULAR ENDOTHELIAL GROWTH FACTOR(VEGF) INDUCES THE EXPRESSION OF THECHEMOKINE IP-10 THROUGH THE PI-3 KINASESIGNALING PATHWAY IN ENDOTHELIAL CELLS.(Abstract #1463)Gwenola Boulday, Marlies E. J. Reinders, Soumitro Pal,David M. Briscoe. Boston, MA.

4:30 PM ORGAN SPECIFIC DIFFERENCES IN THEFUNCTION OF CHEMOKINES DURINGALLOGRAFT REJECTION. (Abstract #1464)Zdenka Haskova, Atsushi Izawa, Stuart W. Robertson,Jocelyn Corradi, David M. Briscoe. Boston, MA.

4:40 PM BLOCKADE OF FIBRONECTIN-ααααα4βββββ1 ADHESIVEINTERACTION SPECIFICALLY DOWN-REGULATES METALLOPROTEINASE-9 ANDPROLONGS RECIPIENT SURVIVAL IN A 24HOUR MODEL OF COLD HEPATIC I/R INJURY.(Abstract #1465)Carolina Moore, Xiu-Da Shen, Michael Witkosky, FengGao, Jerzi W. Kupiec-Weglinski, Ana J. Coito. LosAngeles, CA.

4:50 PM THE INTERACTION BETWEEN VASCULARENDOTHELIAL GROWTH FACTOR (VEGF) ANDCHEMOKINE EXPRESSION AND FUNCTION INACUTE ALLOGRAFT REJECTION.(Abstract #1466)Atsushi Izawa, Stuart W. Robertson, Zdenka Haskova,Masayuki Sho, Mohamed H. Sayegh, David M. Briscoe.Boston, MA.

5:00 PM CD103 PROMOTES RETENTION OF HOST-SPECIFIC CD8 EFFECTORS IN EPITHELIALCOMPARTMENTS DURING GRAFT-VERSUS-HOST DISEASE. (Abstract #1467)Riham El-Asady, Cinthia B. Drachenberg, Gregg A.Hadley. Baltimore, MD.

5:10 PM A LOW MOLECULAR WEIGHT CCR5CHEMOKINE RECEPTOR ANTAGONIST INCOMBINATION WITH CSA PROLONGS GRAFTSURVIVAL IN A LIFE-SUPPORTING KIDNEY TXMODEL IN CYNOMOLGUS MONKEYS.(Abstract #1468)Hans-Guenter Zerwes, Markus B. Streiff, Christian Buns,Marc Bigaud, Klaus Menninger, Adrien Kunkler, SabineRiesen, Grazyna Wieczorek, Nigel Cooke, Rainer Albert,Marcel Luyten, Christian Beerli, Randall E. Morris,Gebhard Thoma. Basel, Switzerland.

5:20 PM ADHESION MOLECULE EXPRESSION PROFILESOF REJECTING SKIN ALLOGRAFTS.(Abstract #1469)Thomas R. Jones, Andrew B. Adams, Rose Hendrix,Thomas C. Pearson, Christian P. Larsen. Atlanta, GA.

Concurrent Session 53: Factors DeterminingOutcomes in Pancreas4:00 - 5:30 PM

Ballroom CChairs: Paul F. Gores and Lucille E. Wrenshall

4:00 PM CHANGING PATTERN IN THE HISTOLOGICALFINDINGS IN PANCREAS TRANSPLANT NEEDLEALLOGRAFT BIOPSIES (PBx). (Abstract #1470)Cinthia B. Drachenberg, John C. Papadimitriou, EmilioRamos, David K. Klassen, Stephen T. Bartlett.Baltimore, MD.

4:10 PM CONVERSION TO A CALCINEURIN INHIBITOR(CI) AND STEROID FREE REGIMEN AFTERPANCREAS (Px) TRANSPLANTATION (Tx).(Abstract #1471)R. Gruessner, A. Humar, R. Kandaswamy, A. Gruessner,D. Sutherland. Minneapolis, MN.

4:20 PM STEROID AVOIDANCE VERSUS STEROIDWITHDRAWAL AFTER SIMULTANEOUSPANCREAS-KIDNEY TRANSPLANTATION: APROSPECTIVE AND RANDOMISED STUDY.(Abstract #1472)Diego Cantarovich, Georges Karam, Magali Giral,Maryvonne Hourmant, Jaques Dantal, Gilles Blancho,Jean-Paul Soulillou. Nantes, France.

146

4:30 PM CAN ACUTE REJECTION BE PREVENTED IN SPKTRANSPLANTATION? A RANDOMIZED,PROSPECTIVE STUDY WITH THYMOGLOBULIN/ZENAPAX INDUCTION, TACROLIMUS ANDSTEROID MAINTENANCE: COMPARINGRAPAMYCIN WITH MYCOPHENOLATE MOFETIL.(Abstract #1473)George W. Burke, Gaetano Ciancio, Adela Mattiazzi,Carmen Gomez, Anne Rosen, Joshua Miller. Miami, FL.

4:40 PM STEROID WITHDRAWAL IMPROVES ONE-YEAROUTCOMES IN SOLITARY PANCREASTRANSPLANTATION. (Abstract #1474)Anne M. Wiland, Benjamin Philosophe, Matthew R.Weir. Baltimore, MD.

4:50 PM REDUCTION OF CMV DISEASE WITH STEROID-FREE IMMUNOSUPPRESSION IN SPKTRANSPLANT RECIPIENTS. (Abstract #1475)Dixon B. Kaufman, Joseph R. Leventhal, Lorenzo G.Gallon, Michele A. Parker. Chicago, IL; Durham, NC.

5:00 PM INFLUENCE OF A PANCREAS TRANSPLANT ONRENAL FUNCTION IN PATIENTS WITH APREVIOUS KIDNEY TRANSPLANT.(Abstract #1476)Joshua J. Augustine, Christopher T. Siegel, James A.Schulak, Donald E. Hricik. Cleveland, OH.

5:10 PM GRAFT PANCREATITIS: SIGNIFICANT IMPACT OFDONOR FACTORS AND TYPE OFIMMUNOSUPPRESSION ON OUTCOME. A UNOSANALYSIS. (Abstract #1477)Christoph Troppmann, R. Perez, A. Gruessner, D.Sutherland, R. Gruessner. Sacramento, CA; Minneapolis,MN.

5:20 PM EFFECT OF CENTER VOLUME ON PANCREASTRANSPLANT OUTCOMES. (Abstract #1478)Aloke K. Mandal, Nicholas Drew, Jodi A. Lapidus.Portland, OR.

Concurrent Session 54: Immunosuppression:Drug Interactions and Non-Immune Effects4:00 - 5:30 PM

Room 302/304Chairs: Margaret J. Bia and Ross Isaacs

4:00 PM PREDICTORS OF ADHERENCE TOIMMUNOSUPPRESSION DRUG REGIMENSDURING THE FIRST YEAR AFTER CADAVERICRENAL TRANSPLANTATION (CRT).(Abstract #1479)Ajay K. Israni, Christina Gaughan, Tracey Hoy, MarshallJoffe, Kevin C. Mange, Sylvia Rosas, Kenneth Brayman,Harold I. Feldman. Philadelphia, PA; Gordansville, VA.

4:10 PM DIARRHEA DIFFERENTIALLY AFFECTSINTESTINAL PGP ACTIVITY IN PATIENTS ONMAINTENANCE IMMUNOSUPPRESSION WITHTACROLIMUS VERSUS CICLOSPORIN A.(Abstract #1480)Wim Lemahieu, Bart Maes, Kristin Verbeke, YvesVanrenterghem. Leuven, Belgium.

4:20 PM IMPACT OF ANTACIDS AND STATINS ONOVERALL CYP, CYP3A4 AND PGP ACTIVITY INVIVO. (Abstract #1481)Wim Lemahieu, Bart Maes, Kristin Verbeke, YvesVanrenterghem. Leuven, Belgium.

4:30 PM EARLY STEROID WITHDRAWAL DOES NOTINCREASE RISK FOR RECURRENT FOCALSEGMENTAL GLOMERULOSCLEROSIS.(Abstract #1482)R. E. Boardman, J. Trofe, R. R. Alloway, C. Rogers, P.Roy-Chaudhury, M. R. Cardi, S. Safdar, B. Groene, J. F.Buell, M. J. Hanaway, M. Thomas, W. J. Alexander, R.Munda, E. S. Woodle. Cincinnati, OH.

4:40 PM IMMUNOSUPPRESSIVE PROPERTIES OFMYCOPHENOLATE MOFETIL ANDVALGANCICLOVIR USED IN COMBINATION INRENAL TRANSPLANT PATIENTS. (Abstract #1483)Christopher M. Bearden, Benita K. Book, Richard A.Sidner, Mark D. Pescovitz. Indianapolis, IN.

4:50 PM CELL SURFACE AND INTRACELLULAR CTLA4AND CD40L EXPRESSION ON CD4+ T CELLS INKIDNEY ALLOGRAFT RECIPIENTS - A POSSIBLELINK TO FAVOURABLE OUTCOME ANDREJECTION. (Abstract #1484)Maria Magott-Procelewska, Agata Kosmaczewska, IrenaFrydecka, Lidia Ciszak, Dariusz Patrzalek, Piotr Szyber,Marian Klinger. Wroclaw, Lower Silesia, Poland.

5:00 PM WEAKER AND WEAKER STILL: STEROIDAVOIDANCE DOES NOT PREVENT BONE LOSSFOLLOWING KIDNEY TRANSPLANTATION.(Abstract #1485)Christine E. Chamberlain, Eric Elster, Douglas Hale,Allan D. Kirk, Charles E. Daniels, Roslyn B. Mannon.Bethesda, MD.

5:10 PM SIROLIMUS-BASED THERAPY AFTER EARLYCYCLOSPORINE WITHDRAWAL RESULTS INSIGNIFICANTLY BETTER RENAL HISTOLOGYAND FUNCTION AT 3 YEARS FOLLOWINGKIDNEY TRANSPLANTATION. (Abstract #1486)Alfredo Mota, Manuel Arias, Eero I. Taskinen, TimoPaavonen, Christophe Legendre, Kerstin Claesson, JosepM. Campistol, Brian Hutchison, James T. Burke, PekkaHayry, John F. Neylan, the Rapamune MaintenanceRegimen Study Group. Coimbra, Portugal.

5:20 PM RAPAMYCIN-ASSOCIATED POSTTRANSPLANTGLOMERULONEPHRITIS AND REMISSIONAFTER REINTRODUCTION OF CALCINEURIN-INHIBITORS. (Abstract #1487)Elisabeth Dittrich, Sabine Schmaldienst, AfschinSoleiman, Walter H. Hoerl, Erich Pohanka. Vienna,Austria.

Concurrent Session 55: Kidney: Non-Immunological Complications4:00 - 5:30 PM

Ballroom AChairs: Simin Goral and Emilio Ramos

4:00 PM HISTOLOGIC FINDINGS ON SURVEILLANCEPROTOCOL BIOPSIES AFTER RENALTRANSPLANATION. (Abstract #1488)David J. Rea, Mark D. Stegall, Fernando G. Cosio, JosephP. Grande, James M. Gloor, Timothy S. Larson.Rochester, MN.

4:10 PM LONG TERM SURVIVAL DISPARITIES AFTERCADAVERIC VS LIVING DONOR RENALTRANSPLANTATION IN PREVIOUS LIVERTRANSPLANT RECIPIENTS. (Abstract #1489)John C. Magee, Sarah H. Rush, John R. Lake, FriedrichK. Port, Akinlolu O. Ojo. Ann Arbor, MI; Minneapolis,MN.

147

Tuesd

ay, May 18

4:20 PM LONG TERM OUTCOME AFTER RENALTRANSPLANTATION (RTx) IN PATIENTS WITHSYSTEMIC LUPUS ERYTHEMATOSUS (SLE).(Abstract #1490)Rajendra S. Baliga, Pradeep V. Kadambi, AmandeepKhurana, Kristen Kasza, Michelle A. Josephson, BasitJavaid. Chicago, IL.

4:30 PM THE SIGNIFICANCE OF POST-TRANSPLANTMICROSCOPIC HEMATURIA IN RENALTRANSPLANT PATIENT. (Abstract #1491)Soon I. Kim, Jong H. Lee, Kyu H. Huh, Kyu H. Choi, YuS. Kim, Seung C. Yang, Hyun J. Jeong, Kiil Park. Seoul,Republic of Korea.

4:40 PM URINE CONCENTRATING CAPACITY ANDSODIUM EXCRETION FOLLOWING RENALTRANSPLANTATION. (Abstract #1492)Shilpanjali Prasad, Jen Van Tromp, Rawya Charif, SeemaSingh, Tom Cairns, Megan Griffith, Nadey Hakim, AdamMcLean, Andrew Palmer, Vassilios Papalois, DavidTaube. London, United Kingdom.

4:50 PM CALCIFICATION OF RENAL ALLOGRAFTSEARLY AFTER TRANSPLANTATION IS ANIMPORTANT FACTOR FOR GRAFT OUTCOME.(Abstract #1493)Wilfried Gwinner, Michael Mengel, Sylvia Suppa, HansH. Kreipe, Hermann Haller. Hannover, Germany.

5:00 PM CALCIUM OXALATE DEPOSITION IN KIDNEYALLOGRAFTS STRONGLY CORRELATES WITHPOOR LONG-TERM GRAFT SURVIVAL.(Abstract #1494)Helady S. Pinheiro, Niels O. S. Camara, Kikumi S. Ozaki,Luiz A. Moura, Alvaro Pacheco-Silva. Juiz de Fora,Minas Gerais, Brazil; Sao Paulo, Brazil.

5:10 PM SUBURETERIC COLLAGEN INJECTIONTREATMENT FOR VESICOURETERAL REFLUX INRENAL TRANSPLANTATION. (Abstract #1495)Piyush N. Joshi, Amalanshu Jha. Johnson City, TN.

5:20 PM MOLECULAR MECHANISMS OF TRANSPLANTRENAL ARTERY STENOSIS FROM EARLY USE OFERYTHROPOIETIN. (Abstract #1496)S. Nagarajan, J. Vidhun, E. Mansfield, S. Hsieh, R. Liu, O.Salvatierra, M. Sarwal. CA.

Concurrent Session 56: Liver Transplantation:Complications and Disease Recurrence(Non-HCV)4:00 - 5:30 PM

Room 312Chairs: James Neuberger and John P. Roberts

4:00 PM SUCCESSFUL LIVER TRANSPLANTATION OFCHRONIC HEPATITIS B RECIPIENTS IN THESETTING OF HIV COINFECTION ANDLAMIVUDINE RESISTANCE. (Abstract #1497)Jonathan Carter, Norah Terrault, Laurie Carlson,Michelle Roland, Gerald Lipshultz, Chris Freise, JohnRoberts, Nancy Ascher, Peter Stock. San Francisco, CA.

4:10 PM SIGNIFICANCE OF HEPATITIS B VIRUSGENOTYPE IN LIVER TRANSPLANTATION FORCHRONIC HEPATITIS B. (Abstract #1498)Chung-Mau Lo, Cindy Cheung, George K. K. Lau, Man-Fung Yuen, Chi-Leung Liu, Sheung-Tat Fan, John Wong.Hong Kong, China.

4:20 PM VALGAN (GANCICLOVIR HYDROCHLORIDE)PROVIDES INEFFECTIVE PROPHYLAXISAGAINST CYTOMEGALOVIRAL (CMV)INFECTION IN LIVER TRANSPLANT RECIPIENTS.(Abstract #1499)Ashok Jain, Mark Orloff, Kerrie Lansing, RandeepKashyap, Mark Kelley, Robert Betts, Marilyn Menegus,Bozorgzadeh Adel. Rochester, NY.

4:30 PM HEREDITARY CCR5-DELTA–32-POLYMORPHISM- A NEW RISK FAKTOR FOR ISCHEMIC TYPEBILIARY LESIONS AFTER ORTHOTOPIC LIVERTRANSPLANTATION. (Abstract #1500)Christian Moench, Anja Uhrig, Gerd Otto. Mainz,Germany.

4:40 PM RAPID RECOVERY OF BILE SALT SECRETION ISASSOCIATED WITH TRANSIENT BILE DUCTINJURY AFTER HUMAN LIVERTRANSPLANTATION. (Abstract #1501)E. Geuken, D. Visser, F. Kuipers, H. G. D. Leuvenink, K.P. de Jong, P. M. J. G. Peeters, P. L. M. Jansen, M. J. H.Slooff, R. J. Porte. Groningen, Netherlands.

4:50 PM LIVER TRANSPLANTATION FOR DRUG INDUCEDLIVER INJURY IN THE UNITED STATES.(Abstract #1502)Mark W. Russo, Roshan Shrestha, Michael W. Fried, PaulWatkins. Chapel Hill, NC.

5:00 PM RENAL FUNCTION IN LIVER TRANSPLANT (LT)RECIPIENTS: RESULTS FROM MOST, ANINTERNATIONAL OBSERVATIONAL STUDY.(Abstract #1503)Patrizia Burra, Juan Figueras, Robert Jones, FedericoVillamil. Padova, Italy.

5:10 PM TREATMENT OF CHOLESTATIC AND NON-CHOLESTATIC RECURRENT HEPATITIS C AFTERLIVER TRANSPLANTATION. (Abstract #1504)Jun-ichiro Sageshima, Seigo Nishida, Debbie Weppler,Guy Neff, Tomoaki Kato, Juan Madariaga, David Levi,Jang Moon, Gennaro Selvaggi, Phillip Ruiz, AnthonyGyamfi, Andreas Tzakis. Miami, FL.

5:20 PM ACCELERATED LIVER TRANSPLANTATION FORPATIENTS WITH HEPATOCELLULARCARCINOMA (HCC) RESULTS IN INCREASEDTUMOR RECURRENCE. (Abstract #1505)Laura Kulik, David Axelrod, Alan Koffron, Patrice Al-Saden, Mary Mulcahy, Elena Crisan, Jonathan Fryer,Lori Clark, Michael Abecassis. Chicago, IL.

Concurrent Session 57: Liver Transplantation:Donors, Preservation, and Outcomes4:00 - 5:30 PM

Ballroom BChairs: Christopher R. Shackleton

4:00 PM NORMOTHERMIC PRESERVATION WITH ANOVEL MACHINE PERFUSATE REDUCESISCHEMIA/REPERFUSION INJURY IN A PORCINELIVER MODEL. (Abstract #1506)James V. Guarrera, Maximillian Polyak, Ben O’MarArrington, Jean C. Emond, William T. Stubenbord, MilanKinkhabwala. New York, NY.

4:10 PM CELSIOR VERSUS UNIVERSITY OF WISCONSINPRESERVING SOLUTIONS IN LIVERTRANSPLANTATION: A PROSPECTIVERANDOMISED CONTROLLED STUDY.(Abstract #1507)Agustín García-Gil, Juan I. Arenas, Antonio Güemes,Esteban Esteban, Eloy Tejero, Felix Lamata, ElenaBarrao, Trinidad Serrano, Jesús Larraga, Juan J. Araiz,Alfredo Jiménez, Ramón Sousa. Zaragoza, Zaragoza,Spain.

148

4:20 PM SIGNIFICANT REDUCTION OFPROINFLAMMATORY CYTOKINES BYTREATMENT OF THE HUMAN BRAIN DEADDONOR. (Abstract #1508)Johann Pratschke, Onur Kuecuek, Lara Mantouvalou,Ronald Krueger, Roman Klemz, Sascha Weiss, DietmarHorch, Katia Kotsch, Sven Jonas, Claus Wesslau, Hans-Dieter Volk, Peter Neuhaus, Stefan Tullius. Berlin,Germany.

4:30 PM LIVER TRANSPLANTATION FROM NON-HEART-BEATING DONORS: A UNOS ANALYSIS.(Abstract #1509)Yong W. Cho, Rick Selby, Tse-Ling Fong. Los Angeles,CA.

4:40 PM UTILIZATION OF LIVERS FROM CONTROLLEDNON-HEARTBEATING DONORS (NHBD)- ASINGLE CENTER EXPERIENCE ON 55 LIVERTRANSPLANTS OVER A 10-YEAR PERIOD.(Abstract #1510)Bijan Eghtesad, Kusum Patel, Michael DeVera, NogcThai, Deanna Blisard, Kyle Soltys, Paulo Fontes,Thomas Cacciareli, Timothy Gayowski, Wallis Marsh,Anthony Demetris, Amadeo Marcos, John Fung.Pittsburgh, PA.

4:50 PM SHORT AND LONG TERM OUTCOME OF LIVERTRANSPLANTS FROM DONORS AFTERCARDIAC DEATH (DCD). (Abstract #1511)Mona D. Doshi, John D. Rosendale, Lawrence G.Hunsicker. Iowa City, IA; Richmond, VA.

5:00 PM LONG-TERM SUCCESS FOLLOWING LIVERTRANSPLANTATION USING OLDERCONTROLLED NON-HEART-BEATING DONORS:THE LARGEST REPORTED EXPERIENCE.(Abstract #1512)David J. Reich, Jorge A. Ortiz, Abdaal Khan, KhristianNoto, Victor A. Araya, Kenneth D. Rothstein, SantiagoJ. Munoz, Cosme Manzarbeitia. Philadelphia, PA.

5:10 PM OBESE DONORS FOR LDLT DO NOT HAVE ANINCREASED RATE OF SERIOUS POSTOPERATIVECOMPLICATIONS. (Abstract #1513)Jennifer L. G. Moss, Dianne Lapointe-Rudow, Jean C.Emond, Milan Kinkhabwala, Doug Marotta, Robert S.Brown, Jr. New York, NY.

5:20 PM ASSESMENT OF LIVER FUNCTION DURINGEXTRACORPOREAL MEMBRANE OXYGENATION(ECMO) IN THE NON-HEART BEATING DONOR(NHBD) SWINE. (Abstract #1514)Alvaro Rojas, Ling Chen, Robert H. Bartlett, Juan D.Arenas. Ann Arbor, MI; Baltimore, MD.

Concurrent Session 58: Pediatric Kidney4:00 - 5:30 PM

Room 311Chairs: Elias David-Neto and Oscar Salvatierra

4:00 PM LAPAROSCOPIC (LAP) LIVE DONORNEPHRECTOMY (DN) IS A SIGNIFICANT RISKFACTOR FOR DELAYED GRAFT FUNCTION (DGF)AND ACUTE REJECTION IN PEDIATRIC RENALTRANSPLANTATION (PedKtx): A UNOSANALYSIS. (Abstract #1515)Christoph Troppmann, M. A. McBride, T. Baker, R. V.Perez. Sacramento, CA; Richmond, VA.

4:10 PM LAPAROSCOPIC VS OPEN DONORNEPHRECTOMY (ODN) IN PEDIATRIC (peds)KIDNEY (KD) TRANPLANTS (Txs). (Abstract #1516)Raja Kandaswamy, Miguel Tan, Abhinav Humar, RainerW. G. Gruessner, David E. R. Sutherland, Arthur J. Matas.Minneapolis, MN.

4:20 PM A STUDY ABOUT THE SAFETY ANDTOLERABILITY OF THE CONVERSION TOENTERIC-COATED MYCOPHENOLATE SODIUMFROM MYCOPHENOLATE MOFETIL IN STABLEPEDIATRIC RENAL TRANSPLANT RECIPIENTS.(Abstract #1517)E. David-Neto, A. Turconi, F. Giron, M. Adragna, A.Otero, M. L. Pereira. Sao Paulo, Brazil; BA, Argentina;Bogota, Colombia; Argentina.

4:30 PM EVEROLIMUS IN DE NOVO PEDIATRIC RENALTRANSPLANTATION: RESULTS AT 24 MONTHS.(Abstract #1518)R. Ettenger, V. M. Moeller, P. F. Hoyer, J. Lemire, J.Mahan, N. Webb, P. Niaudet, J. Jaffe. Los Angeles, CA;East Hanover, NJ; Essen, Germany; San Diego, CA;Columbus, OH; Pendlebury, Manchester, UnitedKingdom; Paris, Cedex 15, France.

4:40 PM CAMPATH-1H USE IN PEDIATRIC RENALTRANSPLANTATION. (Abstract #1519)Sharon M. Bartosh, Hans W. Sollinger. Madison, WI.

4:50 PM DRUG MONITORING OF MYCOPHENOLIC ACID(MPA) IN THE LONG TERM FOLLOW UP OFPEDIATRIC TRANSPLANT RECIPIENTS: TROUGHLEVELS ARE NO GOOD INDICATOR FOR LONGTERM GRAFT FUNCTION. (Abstract #1520)Lars Pape, Jochen H. H. Ehrich, Juergen Strehlau, GiselaOffner. Hannover, Germany.

5:00 PM INFECTIOUS COMPLICATIONS IN ABO-INCOMPATIBLE KIDNEY TRANSPLANTATION INCHILDREN. (Abstract #1521)Seiichiro Shishido, Hiroyuki Satoh, Hiroshi Asanuma,Hiroshi Hataya, Masahiro Ikeda, Akira Hasegawa.Kiyose, Tokyo, Japan; Ohmori, Tokyo, Japan.

5:10 PM HERPESVIRUS DNA IN RENAL ALLOGRAFTS ISASSOCIATED WITH CHRONIC ALLOGRAFTNEPHROPATHY. (Abstract #1522)Jodi Smith, Connie Davis, Patrick Healey, Meei-LiHuang, Lawrence Corey, Ruth McDonald. Seattle, WA.

5:20 PM THE WAXING AND WANING OF CHRONICALLOGRAFT NEPHROPATHY GRADES INPEDIATRIC PROTOCOL BIOPSIES.(Abstract #1523)Patricia E. Birk, Tom D. Blydt-Hansen, Malcolm R.Ogborn, John G. Gartner, Ian W. Gibson. Winnipeg, MB,Canada.

Concurrent Session 59: Steroid andImmunosuppression Reduction/Withdrawal4:00 - 5:30 PM

Veterans BallroomChairs: Kenneth A. Bodziak and Sandy Feng

4:00 PM LONG-TERM EFFICACY AND SAFETY OFSTEROID-WITHDRAWAL IN TACROLIMUS-TREATED RENAL TRANSPLANT RECIPIENTS:RESULTS OF A 3-YEAR FOLLOW-UP.(Abstract #1524)Julio Pascual, Johannes P. van Hooff, Kaija Salmela,Budde Klemens, Rigotti Paolo, Lang Philippe. Madrid,Spain; Maastricht, Netherlands; Helsinki, Finland; Berlin,Germany; Padua, Italy; Paris, France.

4:10 PM PREDNISONE (P)-FREE MAINTENANCEIMMUNOSUPPRESSION (IS) AFTER KIDNEYTRANSPLANTATION: 92% GRAFT SURVIVAL AT 4YEARS. (Abstract #1525)Abhinav Humar, Raja Kandaswamy, James Harmon, J.Keith Melancon, David L. Dunn, Miguel Tan, Arthur J.Matas. Minneapolis, MN.

149

Tuesd

ay, May 18

4:50 PM STEROID WITHDRAWAL AT THREE DAYS AFTERRENAL TRANSPLANTATION WITH ANTI IL-2RECEPTOR THERAPY: A PROSPECTIVERANDOMIZED MULTICENTER TRIAL.(Abstract #1529)Teun van Gelder, Cornelis G. ter Meulen, Ronald J. Hene,Maarten H. L. Christiaans, George F. Borm, Iza C. vanRiemsdijk, Luuk B. Hilbrands, Willem Weimar, Andries J.Hoitsma. Rotterdam, Netherlands; Nijmegen,Netherlands; Utrecht, Netherlands; Maastricht,Netherlands.

5:00 PM COMPARISON OF EFFICACY AND SAFETY OFSIROLIMUS(SLR) AND MYCOPHENOLATEMOFETIL(MMF) AS ADJUNCT TO CALCINEURININHIBITOR(CNI) BASED STEROID FREEIMMUNOSUPPRESSION IN KIDNEYTRANSPLANTATION. (Abstract #1530)Mysore S. Anil Kumar, Billie Fyfe, Debra Sierka, MichaelHeifets, Muhammed I. Saeed, Miten H. Parikh.Philadelphia, PA.

5:10 PM OUTCOME OF PREDNISONE (P) MINIMIZATIONIN AN IMMUNOLOGICALLY HIGHER RISKCOHORT - WHO HAS ACUTE REJECTION (AR)?(Abstract #1531)J. Keith Melancon, James V. Harmon, Ty B. Dunn,Massimo Asolati, Abhinav Humar, Arthur J. Matas.Minneapolis, MN.

5:20 PM THE CLINICAL BENEFITS OF EARLY STEROIDWITHDRAWAL (7 DAYS) AND UTILITY OFPROTOCOL BIOPSIES AT 1, 6 AND 12 MONTHSIN GUIDING STEROID-FREEIMMUNOSUPPRESSIVE THERAPY AFTER RENALTRANSPLANTATION. (Abstract #1532)Oleh G. Pankewycz, Rabie Stephan, Barbara Stefanick,Fadi Dagher, Mary Applegate, Romesh Kohli, Mark R.Laftavi. Buffalo, NY.

4:40 PM PRE-PLASMACYTOID DENDRITIC CELLSPROPAGATED FROM BONE MARROW INDUCEALLOGENEIC T CELL HYPORESPONSIVENESSIN VIVO. (Abstract #1537)Masanori Abe, Zhiliang Wang, F. Jason Duncan, AngusW. Thomson. Pittsburgh, PA.

4:50 PM COMPARATIVE ANALYSIS OF TOLERANCEINDUCTION IN NOD AND NOR MICE REVEALS AROLE FOR APC FUNCTION IN ANTI-CD45RBINDUCED TOLERANCE. (Abstract #1538)Daniel Moore, Xiaolun Huang, Muhammad M.Mohiuddin, Major K. Lee, Meredith Chiaccio, HaiyingChen, Moh-Moh Lian, Robert Zhong, James F.Markmann, Shaoping Deng. Philadelphia, PA; London,ON, Canada.

5:00 PM AN ESSENTIAL REQUIREMENT FOR AN INTACTHOST MHC CLASS I PATHWAY IN ISLETALLOGRAFT SURVIVAL. (Abstract #1539)Joshua N. Beilke, Nathan R. Kuhl, Zachary A. Johnson,Ronald G. Gill. Denver, CO.

5:10 PM ANTI-CD40 LIGAND ANTIBODY AND ANTI-CD40ISOTYPE IgG

2B ANTIBODY INDUCE EQUIVALENT

MURINE CHIMERISM AND SKIN GRAFTTOLERANCE UNLIKE ANTI-CD40 ISOTYPE IgG

1ANTIBODY. (Abstract #1540)Zvonimir L. Milas, Andrew B. Adams, Thomas Jones,Meghan Durham, Thomas C. Pearson, Christian P.Larsen. Atlanta, GA.

5:20 PM LONG-TERM ACCEPTANCE OF HETEROTOPICCARDIAC ALLOGRAFTS BY CO-TRANSPLANTATION OF VASCULARIZEDTHYMIC LOBES IN FULLY MHC-MISMATCHEDMINIATURE SWINE. (Abstract #1541)Parsia A. Vagefi, Chisako Kamano, Shin Yamamoto,Katsuhito Teranishi, Stuart L. Houser, Joren C. Madsen,Emma Samelson-Jones, Akira Shimizu, David H. Sachs,Kazuhiko Yamada. Boston, MA.

5:45 PM AST Business MeetingBallroom A

4:20 PM THYMOGLOBULIN PRECONDITIONING ANDTACROLIMUS MONOTHERAPY WITHSUBSEQUENT WEANING IN RENAL TRANSPLANTRECIPIENTS: AN UPDATE. (Abstract #1526)Ron Shapiro, Amit Basu, Henkie P. Tan, Akhtar Khan,Edward A. Gray, Parmjeet S. Randhawa, Noriko Murase,Adriana Zeevi, Anthony J. Demetris, JenniferWoodward, Velma P. Scantlebury, Mark L. Jordan,Santosh Potdar, Carlos A. Vivas, Kristine M. Ruppert,Amadeo Marcos, John J. Fung, Thomas E. Starzl.Pittsburgh, PA.

4:30 PM CYCLOSPORINE WITHDRAWAL FROM AMYCOPHENOLATE MOFETIL-CONTAININGIMMUNOSUPPRESSIVE REGIMEN: RESULTS OF AFIVE-YEAR, PROSPECTIVE, RANDOMIZEDSTUDY. (Abstract #1527)Daniel Abramowicz, Nesrin Gafner, Peter Wijngaard.Bruxelles, Belgium; Basel, Switzerland.

4:40 PM A PROSPECTIVE, RANDOMIZED, DOUBLE BLINDMULTICENTER STUDY OF EARLY (7 DAY)CORTICOSTEROID CESSATION VS. LONG TERMLOW DOSE CORTICOSTEROID THERAPYUNDER TACROLIMUS AND MYCOPHENOLATEMOFETIL THERAPY WITH ANTIBODYINDUCTION IN RENAL TRANSPLANTRECIPIENTS. (Abstract #1528)E. S. Woodle, for the Fujisawa Steroid Withdrawal StudyGroup. Cincinnati, OH; Deerfield, IL.

Concurrent Session 60: Transplant Tolerance II4:00 - 5:30 PM

Room 309Chairs: Thomas Pearson and Angus W. Thomson

4:00 PM LONG TERM ALLOGRAFT SURVIVALFOLLOWING ATTENUATION OF THE EARLYINFLAMMATORY RESPONSE PLUS SHORT TERMCO-STIMULATORY MOLECULE BLOCKADE.(Abstract #1533)Tarek El-Sawy, John A. Belperio, Robert M. Strieter,Robert L. Fairchild. Cleveland, OH; Los Angeles, CA.

4:10 PM BLOCKING CD134 COSTIMULATION ISCRITICALLY IMPORTANT IN THE INDUCTION OFDONOR SPECIFIC ISLET ALLOGRAFTTOLERANCE. (Abstract #1534)Yon Su Kim, Minh Diem Vu, Mohamed H. Sayegh, TerryB. Strom, Xian C. Li. Seoul, Korea; Boston, MA.

4:20 PM NK CELL ALLOREACTIVITY IS AN IMPORTANTMEDIATOR OF COSTIMULATION-BLOCKADE-RESISTANT REJECTION DURING ALLOGENEICTRANSPLANTATION. (Abstract #1535)Leslie Kean, Shana Coley, Andrew Adams, Kelly Hamby,Eun Lee, Eric Heiss, Thomas Pearson, Christian Larsen.Atlanta, GA.

4:30 PM PREVENT TYPE I DIABETES IN NOD MICE BYGENE THERAPY. (Abstract #1536)Chaorui Tian, Jessamyn Bagley, Daron Forman, David H.Sachs, John Iacomini. Boston, MA.

150

AMERICAN TRANSPLANT CONGRESSDay-at-a-Glance, Wednesday, May 19, 2004

7:00 – 8:15 AM Concurrent Sunrise SymposiaPage 151 Sunrise Symposium I: Autoimmunity

and TransplantationBallroom A/B

Sunrise Symposium II: Update onInfectious Disease: Donor and RecipientScreening Issues, and EmergingInfectious AgentsBallroom C

7:00 – 8:15 AM Early Morning WorkshopsPage 151

8:30 – 9:30 AM Plenary Session IIIPage 151 Basic Science II

Ballroom C

Clinical Science IIBallroom A/B

9:45 – 11:15 AM Concurrent SessionsPage 152 Concurrent Session 61: Allorecognition

and Antigen PresentationRoom 310

Page 152 Concurrent Session 62: BK VirusRoom 312

Page 153 Concurrent Session 63: Growth Factors,Tissue Repair and Metabolic PathwaysRoom 309

Page 153 Concurrent Session 64: Kidney andPancreas Transplantation: Public Policyand EconomicsRoom 311

Page 154 Concurrent Session 65: KidneyTransplantation: Living DonorsRoom 302/304

Page 154 Concurrent Session 66: LiverTransplantation: Complications ofImmunosuppressionBallroom A/B

Page 155 Concurrent Session 67: LymphocyteActivation: Experimental TherapeuticsRoom 306

Page 155 Concurrent Session 68: Predictors ofKidney Graft Function and SurvivalBallroom C

11:30 – 12:30 PM Joint SessionPage 156 What’s Hot, What’s New?

Ballroom A/B

12:30 PM Adjourn

151

Wed

nesd

ay, May 19

Plenary Session: Basic Plenary II8:30 - 9:30 AM

Ballroom CChairs: A. Benedict Cosimi and Geraldine G. Miller

8:30 AM HUMAN PLATELET-DERIVED CD154 PLAYS ANIMPORTANT ROLE IN INITIATING ALLOGRAFTREJETION. (Abstract #1542)He Xu, Xiao-Jie Zhang, Frank Leopradi, Roslyn B.Mannon, Allan D. Kirk. Bethesda, MD.

8:45 AM ENGAGEMENT OF THE CHEMOKINE RECEPTORCXCR3 INDUCES TYROSINEPHOSPHORYLATION OF THE CRITICAL T-CELLSIGNALING MOLECULES LCK, ZAP-70, AND LAT.(Abstract #1543)Wasim A. Dar, Sandra Gould, Julie DeMartino, MajedHamawy, Stuart J. Knechtle. Madison, WI; Rahway, NJ.

9:00 AM GRAFT-SPECIFIC CD4 T CELL HELP INFLUENCESGRAFT SPECIFIC CD8 T CELL MIGRATION,CYTOTOXICITY AND THE GENERATION OFMEMORY BY CD154 DEPENDENT ANDINDEPENDENT MECHANISMS. (Abstract #1544)Dawn Taylor, Elizabeth Ingulli. Minneapolis, MN.

9:15 AM EFFECTS OF IMMUNOSUPPRESSIVE DRUGS ONREGULATORY T CELL FUNCTION.(Abstract #1545)Hee Gyung Kang, Yon Su Kim, Sophoclis Alexopoulos,Terry B. Strom, Xin Xiao Zheng. Boston, MA.

Plenary Session: Clinical Plenary II8:30 - 9:30 AM

Ballroom A/BChairs: Jeffrey S. Crippen and Goran B. Klintmalm

8:30 AM INCREASED PATIENT SURVIVAL AFTERSOLITARY PANCREAS TRANSPLANTS.(Abstract #1546)Rainer W. G. Gruessner, David E. R. Sutherland, AngelikaC. Gruessner. Minneapolis, MN.

8:45 AM FAVORABLE EFFECT OF EVEROLIMUS ONCARDIAC ALLOGRAFT VASCULOPATHY ISMAINTAINED THROUGH 24 MONTHS.(Abstract #1547)E. M. Tuzcu, J. A. Kobashigawa, H. J. Eisen, R. C.Starling, T. Crowe, K. Abeywickrama, J. Jaffe. Cleveland,OH; Los Angeles, CA; Philadelphia, PA; E. Hanover, NJ.

9:00 AM IVIG MODULATION OF ANTI-HLA CLASS I ANDII ANTIBODY PRODUCTION IN HIGHLYSENSITIZED PATIENTS IS SELECTIVE, BUT NOTRANDOM: AN ANALYSIS OF THE NIH IG02STUDY. (Abstract #1548)Mieko Toyoda, Anna Petrosyan, Lara Hilo, Andy Pao,Gail Rodich, Matthew McIntosh, Stanley C. Jordan. LosAngeles, CA; Rockville, MD.

9:15 AM A DOUBLE BLINDED RANDOMISED CONTROLTRIAL OF ZOLEDRONATE TO PREVENT BONELOSS IN LIVER TRANSPLANT PATIENTS.(Abstract #1549)G. McCaughan, S. Duke, C. Kam, A. Donaghy, J.Pavlovic, P. Angus, S. Strasser, B. Crawford. Sydney,NSW, Australia; Melbourne, VIC, Australia.

Wednesday, May 19, 2004

Concurrent Sunrise Symposia7:00 – 8:15 AM

Sunrise Symposium I: Autoimmunity and TransplantationBallroom A/BChair: Hugh Auchincloss

7:00 AM The role of AIRE protein in definingimmunological self

Diane Mathis7:25 AM The role of innate immunity in pathogenic CD8

and T cell responsesAndrew Lichtman

7:50 AM Autoreactivity to collagen V influences lungtransplant rejection

David Wilkes

Sunrise Symposium II: Update on Infectious Disease:Donor and Recipient Screening Issues, and EmergingInfectious AgentsBallroom CChair: Upton Allen

7:00 AM MRSA: Insights into pathogenesis andimplications for management

Nina Singh7:25 AM VRE

Emily Blumberg7:50 AM SARS and West Nile Virus

Atul Humar

Early Morning Workshops7:00 – 8:15 AM

Room locations will be printed in the onsite mini-program and onthe tickets.

14. Lymphocyte trafficking: Requirements in toleranceand rejection

Wayne W. Hancock15. Transplant genomics

Enver Akalin and Minnie Sarwal16. The endothelium in rejection

David Briscoe and Beatrice Charreau17. NK cells in transplantation

Sheri Krams and Robert Fairchild18. Costimulatory pathways in rejection and tolerance

Andrew Wells and Zhenhua Dai19. Donor selection for living donor liver transplant:

Expanding or limiting criteriaGlynn Morgan and James Trotter

21. Implementing extended criteria deceased kidney donorsystem

Francis L. Delmonico and James J. Wynn22. Early steroid withdrawal in kidney transplantation

Dixon Kaufman and Arthur Matas23. Pancreas after kidney and pancreas alone: Is it

justifiedHans Sollinger and Rainer Gruessner

24. Genomics and proteomics in solid organtransplantation: A basic topic, a clinicalapplication

Manikkam Suthanthiran and Peter Nickerson25. Video workshop: Maximizing islet recovery and

transplantation techniquesCamillo Ricordi

152

Concurrent Session 61: Allorecognition andAntigen Presentation9:45 - 11:15 AM

Room 310Chairs: Biagio (Bill) Pietra and Ana Maria Waaga-Gasser

9:45 AM RENAL DENDRITIC CELL-MEDIATED ANTIGENTRAFFICKING. (Abstract #1550)Xiangyang Dong, Lori A. Bachman, Matthew D. Griffin.Rochester, MN.

9:55 AM A TWO STEP MODEL OF ACUTE CD4-MEDIATEDCARDIAC ALLOGRAFT REJECTION.(Abstract #1551)Todd J. Grazia, Biagio A. Pietra, Zachary A. Johnson,Robert J. Plenter, Ronald G. Gill. Denver, CO.

10:05 AM PRETREATMENT WITH FIXED IMMATUREDENDRITIC CELLS OF DONOR STRAINPOWERFULLY PROMOTES ALLOGRAFTACCEPTANCE. (Abstract #1552)Yon Su Kim, James Kenny, Hee Gyung Kang, WendaGao, Terry B. Strom. Boston, MA.

10:15 AM ACQUISITION OF HLA-DR ANDCOSTIMULATORY MOLECULES BY T CELLSFROM ANTIGEN PRESENTING CELLS AMPLIFIESHUMAN ALLORESPONSES. (Abstract #1553)David S. Game, Nicola J. Rogers, Robert I. Lechler.Hammersmith Hospital, London, United Kingdom.

10:25 AM CD40-DEPENDENT SIGNALING IN ENDOTHELIALCELLS (EC) RESULTS IN THE ASSOCIATION OFTHE ADAPTOR PROTEINS TRAF2, TRAF3 ANDTRAF6 WITH THE RAS SIGNALING PATHWAY.(Abstract #1554)Jesse A. Flaxenburg, David M. Briscoe, Soumitro Pal.Boston, MA.

10:35 AM TARGETING OF ADHESION MOLECULES THATREGULATE CC CHEMOKINE-INDUCEDTRANSENDOTHELIAL MIGRATION OF DCSUBSETS. (Abstract #1555)B. L. Colvin, A. H. Lau, A. M. Schell, A. W. Thomson.Pittsburgh, PA.

10:45 AM INFLUENCE OF DIRECT AND INDIRECTALLORECOGNITION PATHWAYS ONCD4+CD25+ REGULATORY T CELL FUNCTION INTRANSPLANTATION. (Abstract #1556)Alberto Sanchez-Fueyo, Christoph Domenig, ChristophMariat, Sophoclis Alexopoulos, Terry B. Strom, XinXiao Zheng. Boston, MA.

10:55 AM A NEW MHC CLASS II-RESTRICTED TCRTRANSGENIC MOUSE MODEL FOR THE STUDYOF ALLOIMMUNITY. (Abstract #1557)Todd V. Brennan, Kym R. Garrod, Catherine K. Chang,Sang-Mo Kang. San Francisco, CA.

11:05 AM INDIVIDUAL ROLES OF DONOR AND HOST APCIN THE PRESENTATION TO CD8+ T CELLS OFDONOR-DERIVED CLASS I-RESTRICTED MHAG.(Abstract #1558)Stacy L. Dalheimer, David M. Richards, Daniel L.Mueller. Minneapolis, MN.

Concurrent Session 62: BK Virus9:45 - 11:15 AM

Room 312Chairs: Daniel C. Brennan and Oleh G. Pankewycz

9:45 AM NATIONAL SURVEY OF POLYOMA (BK) VIRUSIN RENAL TRANSPLANT RECIPIENTS (RTR).(Abstract #1559)P. Kadambi, R. Baliga, B. Javaid, H. Robert, W. James, J.Thistlethwaite, M. Josephson. Chicago, IL.

9:55 AM HISTOLOGIC GRADING OF PVN BIOPSIES:CORRELATION WITH VIRAL LOADMONITORING AND RENAL FUNCTION.(Abstract #1560)J. Trofe, E. Woodle, J. Gordon, G. Wadih, P. Succop, R.R. Alloway, G. Mutema, T. Cavallo, S. Heffelfinger, M.A. Cardi, J. Austin, S. Goel, S. Safdar, S. Huang, S. Raabe,R. Munda, J. Buell, M. Hanaway, J. W. Alexander, R.Boardman, C. Rogers, M. Kidd, A. Jain, E. Berilla, A.Demmey, K. Khalili, P. Roy-Chaudhury. OH; Phila, PA;Cincinnati, OH.

10:05 AM THE ADVERSE IMPACT OF PRETRANSPLANT BKPOLYOMA VIRUS INFECTION ON RENALALLOGRAFT FUNCTION. (Abstract #1561)Vivekanand Jha, Ashiq Hayat, Srinivasan Radhika,Manupdesh S. Sachdeva, Ritambhara Nada, Harbir S.Kohli, Kamal Sud, Krishan L. Gupta, Kusum Joshi, VinaySakhuja. Chandigarh, India.

10:15 AM FACTORS ASSOCIATED WITH DEVELOPMENTOF BK NEPHROPATHY AMONG PATIENTSRECEIVING KIDNEY TRANSPLANTS AT A SINGLECENTER DURING 2001. (Abstract #1562)Hasan A. Khamash, Adit Mahale, Christopher K.Buehrig, Fernando C. Cosio, Donna J. Lager, Mary E.Fidler, Thomas R. Schwab, James M. Gloor, Sandra J.Taler, Stephen C. Textor, Mark D. Stegall, Timothy S.Larson, Matthew D. Griffin. Rochester, MN.

10:25 AM POLYOMA NEPHROPATHY: LEFLUNOMIDEBLOOD LEVELS NEEDED FOR CONTROL OFTHIS INFECTION. (Abstract #1563)Michelle Josephson, Basit Javaid, Harland Robert, RajivvPoduval, Pradeep Kadambi, Preston Foster, GarfinkelMarc, Walter Atwood, Shane Meehan, Michael Millis,James Williams, Dick Thistlethwaite. Chicago, IL; SanAntonio, TX; Providence, RI.

10:35 AM USE OF FLUOROQUINOLONES TO TREAT BKINFECTION IN RENAL TRANSPLANT RECIPIENTS.(Abstract #1564)Anil Chandraker, Syed Ali, Cynthia B. Drachenberg,Ravinder Wali, Hans Hirsch, James DeCaprio, EmilioRamos. Boston, MA; Baltimore, MD; Basel, Switzerland.

10:45 AM URINE DECOY CELL SHEDDING IS LESSSENSITIVE THAN QUANTITATIVE PCR FORSCREENING POLYOMAVIRUS INFECTION INKIDNEY TRANSPLANT RECIPIENTS.(Abstract #1565)Parmjeet S. Randhawa, Andrew Ho, Abhay Vats, RonShapiro, Karen Weck. Pittsburgh, PA.

10:55 AM BK NEPHROPATHY MANAGED BY REDUCEDIMMUNOSUPPRESSION: PROGRESSIVE LOSSOF GRAFT FUNCTION IS DICTATED BY TIMINGOF DIAGNOSIS AND BY EXTENT OF THE INITIALFIBROTIC INJURY. (Abstract #1566)Hasan A. Khamash, Adit Mahale, Christopher K.Buehrig, Fernando C. Coisio, Donna J. Lager, Mary E.Fidler, Thomas R. Schwab, James M. Gloor, Sandra J.Taler, Stephen C. Textor, Mark D. Stegall, Timothy S.Larson, Matthew D. Griffin. Rochester, MN.

153

Wed

nesd

ay, May 19

11:05 AM BKV-SPECIFIC CELLULAR IMMUNITY INPEDIATRIC PATIENTS WITH ACTIVE BKVINFECTION AFTER KIDNEY TRANSPLANTATION.(Abstract #1567)Patrizia Comoli, Alberta Azzi, Sabrina Basso, GerardoBotti, Giancarlo Basile, Iris Fontana, Angela Cometa,Francesco Perfumo, Umberto Valente, Franco Locatelli,Rita Maccario, Fabrizio Ginevri. Pavia, Italy; Firenze,Italy; Genova, Italy.

Concurrent Session 63: Growth Factors, TissueRepair and Metabolic Pathways9:45 - 11:15 AM

Room 309Chairs: Duska Dragun and Luis H. Toledo-Pereyra

9:45 AM CARBON MONOXIDE EXPOSURE INDUCESUPREGULATION OF HIF/VEGF IN LONG TERMPRESERVED KIDNEY GRAFTS, AMELIORATES I/RINJURY, AND IMPROVES SURVIVAL.(Abstract #1568)Joao Seda Neto, Anna J. Romanosky, Kei Kimizuka,Atsunori Nakao, Donna B. Stolz, Noriko Murase.Pittsburgh, PA.

9:55 AM CONNECTIVE TISSUE GROWTH FACTOR(CTGF): A POTENTIAL EFFECTOR OF ISCHEMIA/REPERFUSION INJURY (IRI). (Abstract #1569)Xiaojie Zhang, Orlena H. Cheng, Roslyn B. Mannon.Bethesda, MD.

10:05 AM MIGRATION OF EXOGENOUS ENDOTHELIALCELLS AND BONE MARROW CELLS TODAMAGED ENDOTHELIUM. (Abstract #1570)Kathryn M. Verbanac, H. Keith Pittman, Bill T. Storey,Carl E. Haisch. Greenville, NC.

10:15 AM EXPRESSION OF KIDNEY INJURY ANDFUNCTIONAL GENES CORRELATE WITHREDUCED NEPHRON MASS IN CYCLOSPORINE-INDUCED NEPHROTOXICITY. (Abstract #1571)Ida Fernandes, Maria Hong, Mouer Wang, Ye Zhang,Hemangshu Podder, Richard Knight, Stanislaw M.Stepkowski, Barry D. Kahan. Houston, TX.

10:25 AM POTENTIAL OF REPAIRING ISCHEMICALLYDAMAGED KIDNEYS EX VIVO. (Abstract #1572)Lauren Brasile, Bart M. Stubenisky, Carl E. Haisch,Gauke Kootstra. Utrecht, Netherlands; Greenville, NC;Maastricht, Netherlands.

10:35 AM FTY720 ATTENUATES SMALL-FOR-SIZE LIVERGRAFT INJURY - THE SIGNIFICANCE OFACTIVAION OF CELL SURVIVAL SIGNALINGPATHWAY. (Abstract #1573)Yi Zhao, Kwan Man, Chung-Mau Lo, Kevin T. P. Ng,Xian-Liang Li, Chris K. W. Sun, Xian-Wei Dai, Sheung-Tat Fan. Hong Kong, China; Shen Yang, China.

10:45 AM METABOLIC SIGNATURES OF MILD AND SEVEREISCHEMIA/REPERFUSION INJURY IN RATKIDNEY TRANSPLANT MODEL BASED ON 1H-MRS METABONOMICS. (Abstract #1574)Natalie J. Serkova, Florian T. Fuller, Jost Klarwitter,Chris E. Freise, Ryutaro Hirose, Claus U. Niemann.Denver, CO; San Francicso, CA.

10:55 AM HEPATOCYTE GROWTH FACTOR IMPROVESSURVIVAL AFTER TRANSPLANTATION OF COLD-PRESERVED STEATOTIC LIVER IN RATS.(Abstract #1575)Xiangdong Zhao, Michihiro Hayashi, Satoshi Kaihara,Toshimi Kaido, Takaaki Koshiba, Ying Li, TatsuakiTsuruyama, Shigeki Arii, Hiroto Egawa, Koichi Tanaka.Kyoto, Japan; Osaka, Japan; Otsu, Shiga, Japan; Kyoto,Japan; Tokyo, Japan.

11:05 AM SIROLIMUS MODULATES INFLAMMATIONDURING POSTTRANSPLANT REPERFUSIONINJURY IN THE KIDNEY VIA UPREGULATION OFVEGF AND VEGF-R2. (Abstract #1576)Duska Dragun, Melina Nieminen-Kelhae, DeniseMarkmann, Anna Lizak, Jan H. Braesen, Lutz Liefeldt,Wolfgang Schneider, Harm Peters, Hans H. Neumayer,Klemens Budde. Berlin, Germany.

Concurrent Session 64: Kidney and PancreasTransplantation: Public Policy and Economics9:45 - 11:15 AM

Room 311Chairs: Marc W. Cavaille-Coll and Stuart M. Flechner

9:45 AM THE TIMING OF LIVING DONOR AND DECEASEDDONOR RENAL TRANSPLANTATION IN ELDERLYPATIENTS. (Abstract #1577)Aloke K. Mandal, Benjamin K. S. Chan. Portland, OR.

9:55 AM RISK FACTORS FOR DEATH AND GRAFTFAILURE IN RENAL TRANSPLANT RECIPIENTSOVER 65 YEARS: A MULTIVARIATE ANALYSIS OFUNOS DATABASE. (Abstract #1578)V. Ram Peddi, Steven Katznelson, Vish Halukurike,Timothy J. Baker, Maureen A. McBride. San Francisco,CA; Richmond, VA.

10:05 AM MEDICARE KIDNEY TRANSPLANT AND ORGANACQUISITION REIMBURSEMENT ECONOMICS:A FIVE YEAR TREND REVIEW. (Abstract #1579)E. Y. Zavala, B. Reeb, J. C. Rogers, C. W. Pinson.Nashville, TN; Baltimore, MD; San Diego, CA.

10:15 AM RACIAL DISPARITIES FOR PANCREASTRANSPLANTATION IN THE US. (Abstract #1580)Ross B. Isaacs, Peter I. Lobo, Wida Cherikh, RasheedBalogun. Charlottesville, VA.

10:25 AM COMPLICATIONS, COST, AND RESOURCEUTILIZATION OF LIVING-DONOR ABO-INCOMPATIBLE KIDNEY TRANSPLANTATIONVERSUS ABO-COMPATIBLE TRANSPLANTATION.(Abstract #1581)Jason Schwartz, Lynette Fix, Marco Covarrubias, JamesGloor, Mark Stegall. Rocester, MN; Rochester, MN.

10:35 AM IDENTIFICATION OF “HIGH-RISK” WAIT LISTCANDIDATES FOR KIDNEY TRANSPLANTATION.(Abstract #1582)Jesse D. Schold, Bruce Kaplan, Pamela R. Patton, TitteR. Srinivas, Richard J. Howard, Herwig-Ulf Meier-Kriesche. Gainesville, FL.

10:45 AM FTY720 VS. MYCOPHENOLATE MOFETIL,ECONOMIC IMPACT IN CYCLOSPORINE BASEDIMMUNOSUPRESSION FOR DE NOVO RENALTRANSPLANTATION. (Abstract #1583)Robert Balshaw, Paul Keown, Daniel E. Hricik, GerardoMachnicki, Zoltan Kalo. Burnaby, BC, Canada;Vancouver, BC, Canada; Cleveland, OH; Basle,Switzerland.

10:55 AM COMPLETION OF THE RENAL TRANSPLANTEVALUATION PROCESS BY PREEMPTIVE VS.DIALYSIS-DEPENDENT PATIENTS. (Abstract #1584)Francis L. Weng, Kevin C. Mange. Philadelphia, PA.

11:05 AM UNETHICAL OR HELPFUL?: KIDNEY DONORS’ATTITUDES ABOUT FINANCIAL COMPENSATIONFOR DONOR-SWAPPING. (Abstract #1585)Amy D. Waterman, Barry Hong, Daniel C. Brennan,Emily Schenk, Tonie Covelli, Anne Barrett, SarahStanley, Tracye Davis, Mark A. Schnitzler. Saint Louis,MO.

Concurrent Session 65: Kidney Transplantation:Living Donors9:45 - 11:15 AM

Room 302/304Chairs: Patricia L. Adams and Arthur J. Matas

9:45 AM COMPARATIVE OUTCOMES OF UNRELATEDLIVE DONOR AND IDEAL DECEASED DONORKIDNEY TRANSPLANTATION. (Abstract #1586)Francis L. Delmonico, Joshua McGowan, Akinlolu Ojo.Boston, MA; Ann Arbor, MI.

9:55 AM WHO IS THE BETTER LIVING KIDNEY DONOR? APREDICTIVE MODEL BASED ON SIMPLEDONOR-RECIPIENT DEMOGRAPHICS.(Abstract #1587)Todd V. Brennan, Stephen J. Tomlanovich, AlanBostrom, Sandy Feng. San Francisco, CA.

10:05 AM LONG TERM FOLLOW UP OF 800 LIVINGRELATED KIDNEY DONORS. (Abstract #1588)Adib Rizvi, Anwar Naqvi, Mirza Naqi Zafar. Karachi,Sindh, Pakistan.

10:15 AM ‘MINI NEPHRECTOMY’ AN IDEAL DONORNEPHRECTOMY PROCEDURE? (Abstract #1589)Surendra Shenoy, Martin Jendrisak, Jeffrey Lowell, NirajDesai, Anita Vijayan, Karen Hardinger, Debra Kemp,Mary Ann Laflin, William C. Chapman. St. Louis, MO.

10:25 AM EXCELLENT RENAL FUNCTION OBTAINED BYRETROPERITONEOSCOPIC LIVE DONORNEPHRECTOMY UNDER LOW CO

2 GAS

PRESSURE. (Abstract #1590)Kazunari Tanabe, Naoshi Miyamoto, TadahikoTokumoto, Hirofumi Yamamoto, Hideki Ishida,Tsunenori Kondo, Nobuo Ishikawa, Hiroaki Shimmura,Hiroki Shirakawa, Tomokazu Shimizu, KiyoshiSetoguchi, Hiroshi Toma. Shinjuku, Tokyo, Japan.

10:35 AM HAND-ASSISTED RETROPERITONEOSCOPICNEPHRECTOMY. EXPERIENCE WITH THE FIRST50 CONSECUTIVE CASES. (Abstract #1591)Jonas Wadström. Uppsala, Sweden.

10:45 AM ADAPTIVE RENAL HYPERFILTRATION ISPRESERVED IN OLDER LIVING KIDNEY DONORSFOLLOWING UNINEPHRECTOMY.(Abstract #1592)Anjali Bhatt, Bryan D. Myers, Geraldine C. Derby,Kristina L. Blouch, Jane C. Tan. Stanford, CA.

10:55 AM LIVING KIDNEY DONOR OUTCOMES INLAPAROSCOPIC VS. OPEN DONATION.(Abstract #1593)Jane S. Benjey, Leslie Trumbull, Jill E. Martin.Cincinnati, OH.

11:05 AM OBESITY IN LIVING RENAL DONORS: IMPACTON PERI-OPERATIVE AND SHORT-TERMRESULTS. (Abstract #1594)Julie K. Heimbach, Sandra J. Taler, Mikel Prieto,Fernando G. Cosio, Stephen C. Textor, Yogish C. Kudva,George K. Chow, Michael B. Ishitani, Timothy S.Larson, Mark D. Stegall. Rochester, MN.

Concurrent Session 66: Liver Transplantation:Complications of Immunosuppression9:45 - 11:15 AM

Ballroom A/BChairs: James D. Eason and Brendan M. McGuire

9:45 AM INTERIM ANALYSIS OF A PROSEPCTIVERANDOMIZED TRIAL TO ASSESS REVERSAL OFEARLY STAGE CALCINEURIN INHIBITORINDUCED NEPHROTOXICITY USING SIROLIMUSBASED IMMUNOSUPPRESSION IN STABLELONG TERM LIVER RECIPIENTS. (Abstract #1595)Surendra Shenoy, Karen L. Hardinger, Jeffrey Lowell,Niraj Desai, Thalachallour Mohanakumar, JeffreyCrippin, Maurico Lisker-Melman, Kevin Korenblat,Mary Ann Laflin, William Chapman. St. Louis, MO.

9:55 AM SUPERIOR RENAL FUNCTION FOLLOWINGCONVERSION TO SIROLIMUS AFTER LIVERTRANSPLANTATION - PRELIMINARY RESULTSFROM A RANDOMISED TRIAL. (Abstract #1596)Christopher J. Watson, Graeme J. Alexander, Michael E.Allison, Paul Gibbs, Jane C. Smith, Christopher R.Palmer, Alexander E. Gimson. Cambridge, UnitedKingdom.

10:05 AM STEROID-FREE REGIME VERSUS STANDARDTREATMENT IN LIVER TRANSPLANT RECIPIENTS.(Abstract #1597)Alejandra Otero, Evaristo Varo, Jorge Ortiz de Urbina,Rafael Martin-Vivaldi, Valentin Cuervas-Mons, IgnacioGonzalez-Pinto, Angel Bernardos, Rosa Dominguez-Granados MD on Behalf of the Investigators of StudyM67014. La Coruña, Spain; Santiago de Compostela, LaCoruña, Spain; Baracaldo, Vizcaya, Spain; Granada, Spain;Madrid, Spain; Oviedo, Asturias, Spain; Sevilla, Spain.

10:15 AM PERSPECTIVES IN CARDIOVASCULAR DISEASEAFTER LIVER TRANSPLANTATION.(Abstract #1598)Olaf Guckelberger, Alice Byram, Jochen Klupp, Ulf P.Neumann, Matthias Glanemann, Ruth Neuhaus, PeterNeuhaus. Berlin, Germany.

10:25 AM PRIMARY MANAGEMENT OF POST-TRANSPLANTDIABETES WITH ROSIGLITIZONE.(Abstract #1599)Griselda Villanueva, David Baldwin, Jr. Chicago, IL.

10:35 AM REDUCED RISK OF LIVER TRANSPLANTREJECTION IN THE ELDERLY. (Abstract #1600)Meelie A. DebRoy, Tempie E. Hulbert-Shearon, Dawn M.Dykstra, Robert A. Wolfe, Friedrich K. Port, Robert M.Merion. Ann Arbor, MI.

10:45 AM MYCOPHENOLATE MOFETIL IN LIVERTRANSPLANTATION FOR HEPATITIS C: EFFECTON RECURRENCE AND PHARMACOKINETICS.(Abstract #1601)Rafik M. Ghobrial, Curtis D. Holt, Theodore M. Sievers,Sammy Saab, Lucy Artinian, Suzanne V. McDiarmid,Ronald W. Busuttil. Los Angeles, CA.

10:55 AM CORRELATION OF CELL-MEDIATED IMMUNERESPONSE WITH LIVER ALLOGRAFT BIOPSY INLIVER TRANSPLANT RECIPIENTS WITHHEPATITIS C. (Abstract #1602)James Huang, Mayra Lopez-Cepero, James Mayes, AngelAlsina, David Bruce, John Leone, Victor Bowers. Tampa,FL.

155

Wed

nesd

ay, May 19

11:05 AM DRUG RESISTANCE MUTATION IN HUMANCYTOMEGALOVIRUS ISOLATED FROMPATIENTS AFTER LIVER TRANSPLANTATION.(Abstract #1603)Gregory A. Smallwood, Ling Lu, Todd Pillen, CurtHagedorn, Thomas G. Heffron. Atlanta, GA; KansasCity.

Concurrent Session 67: Lymphocyte Activation:Experimental Therapeutics9:45 - 11:15 AM

Room 306Chairs: Eugenia Fedoseyeva and Robert Zhong

9:45 AM CD95/CD95L ENGAGEMENT IS A REQUIREMENTFOR STABLE EMBRYONIC STEM CELLENGRAFTMENT IN ALLOGENEIC RECIPIENTS.(Abstract #1604)Dorit Fabricius, Sabrina Bonde, Nicholas Zavazava. IowaCity, IA.

9:55 AM PIGS LACKING THE ααααα-1,3GALACTOSYLTRANSFERASE GENE DEVELOPANTI-GAL ANTIBODIES THAT ARE CYTOTOXICTO WILD-TYPE (GAL+/+) MHC-MATCHED PIGCELLS: A POTENTIAL MODEL TO STUDYACCOMMODATION. (Abstract #1605)Frank J. M. F. Dor, Yau-Lin Tseng, Jane Cheng, KathleenMoran, Todd M. Sanderson, Courtney J. Lancos, AkiraShimizu, Michel Awwad, David H. Sachs, Henk-JanSchuurman, Robert Hawley, David K. C. Cooper. Boston,MA; Cambridge, MA.

10:05 AM INABILITY TO CLEAR POLYOMA VIRUS IN MHCDISPARATE MURINE KIDNEY TRANSPLANTMODEL RESULTS IN ACCELERATED GRAFTREJECTION. (Abstract #1606)Eun D. Han Lee, Jun Wang, Ying Dong, Aron E.Lukacher, Kenneth A. Newell, Tom C. Pearson,Christian P. Larsen. Atlanta, GA.

10:15 AM BLOCKADE OF CO-STIMULATORY MOLECULESUSING INTRACELLULAR FUSION PROTEINS.(Abstract #1607)Andrew J. T. George, Peng H. Tan, John Yates, Robert I.Lechler, Giovanna Lombardi. London, United Kingdom.

10:25 AM ROLE OF NFAT TRANSCRIPTION FACTORS INSKIN AND VASCULARIZED CARDIACALLOGRAFT REJECTION. (Abstract #1608)Takuya Ueno, Nader Najafian, Akira Yamada, Laurie H.Glimcher, Mohamed H. Sayegh, Hugh Auchincloss, Jr.Boston, MA.

10:35 AM THROMBOPHILIA ASSOCIATED WITH ANTI-CD154 MONOCLONAL ANTIBODY TREATMENTAND ITS PROPHYLAXIS IN NONHUMANPRIMATES. (Abstract #1609)Svetlan Boskovic, Tatsuo Kawai, David Andrews, IchiroKoyama, Ognjenka Nadazdin, Robert B. Colvin, DavidH. Sachs, A. Benedict Cosimi. Boston, MA; Miami, FL;Charlestown, MA.

10:45 AM IN VIVO IMMUNE MODULATION BY IN VITRO-GENERATED TOLEROGENIC DENDRITIC CELLSIN MURINE HEART TRANSPLANTATION.(Abstract #1610)Mu Li, Dameng Lian, Thomas E. Ichim, Robert Zhong,Wei-Ping Min. London, ON, Canada.

10:55 AM SINGLE INFUSION OF PHARMACOLOGICALLY-MODIFIED, ALLOANTIGEN PULSED RECIPIENTDC PROLONGS TRANSPLANT SURVIVAL BYINDUCING AG-SPECIFIC T CELLHYPORESPONSIVENESS. (Abstract #1611)T. Taner, H. Hackstein, Z. Wang, A. W. Thomson.Pittsburgh, PA.

11:05 AM THE ROLE OF CD30 IN ALLOIMMUNERESPONSES. (Abstract #1612)Jay Campisi, Monika Zwierzchoniewska, Eugenia V.Fedoseyeva, Sheri M. Krams, Robert C. Robbins, CarlosO. Esquivel, Olivia M. Martinez. Stanford, CA.

Concurrent Session 68: Predictors of KidneyGraft Function and Survival9:45 - 11:15 AM

Ballroom CChairs: Fernando Cosio and Robert S. Gaston

9:45 AM IMPACT ON CLINICAL STUDIES OF THECHOICE OF EQUATIONS TO ESTIMATE RENALFUNCTION. (Abstract #1613)Kevin C. Mange, Alden Doyle, Simin Goral, MartySellers, Roy D. Bloom. Philadelphia, PA.

9:55 AM FAVORABLE OUTCOME IN KIDNEYTRANSPLANT RECIPIENTS ENROLLED INCLINICAL TRIALS. (Abstract #1614)Sali Aswad, Ellen Liao, Fred Aswad, Shirley Mirador,Rafael G. Mendez, Hamid Shidban, Mazen Sabawi, RobertMendez. Los Angeles, CA.

10:05 AM NON-LINEAR ASSOCIATION BETWEEN ESRDDURATION AND GRAFT AND RECIPIENTSURVIVAL. (Abstract #1615)Donald Morris, Alfred K. Cheung, Lev Barenbaum, JohnHurdle, Bradley Baird, Alex S. Goldfarb-Rumyantzev. SaltLake City, UT.

10:15 AM SURROGATE MEASURES OF LONGTERM KIDNEYALLOGRAFT SURVIVAL. (Abstract #1616)Marcello Tonelli, Brian G. Pereira, John S. Gill.Vancouver, BC, Canada; Boston, MA; Edmonton, AB,Canada.

10:25 AM DONOR AGE AND IMPROVEMENT IN GRAFTSURVIVAL OVER TIME. (Abstract #1617)John S. Gill, Nathan Johnson, Brian J. G. Pereira,Sundaran Hariharan. Vancouver, BC, Canada; Boston,MA; Milwaukee, WI.

10:35 AM THE IMPACT OF DONOR AGE ON GFR AT SIXMONTH IN CADAVERIC KIDNEY RECIPIENTS.(Abstract #1618)Douglas S. Keith, Angelo deMattos, MuralikrishnaGolconda, Jonathan Prather, Douglas Norman. Portland,OR.

10:45 AM IMPACT OF ACUTE REJECTION, DELAY GRAFTFUNCTION, MAINTENANCEIMMUNOSUPPRESSION, AND HLA MISMATCHON SIX-MONTH RENAL FUNCTION INCADAVERIC RENAL TRANSPLANTS, ANANALYSIS OF OPTN DATA. (Abstract #1619)Douglas S. Keith, Angelo deMattos, MuralikrishnaGolconda, Jonathan Prather, Douglas Norman. Portland,OR.

10:55 AM THE ROLE OF PRE-TRANSPLANT RENALREPLACEMENT THERAPY (RRT) MODALITY INKIDNEY ALLOGRAFT AND RECIPIENTSURVIVAL. (Abstract #1620)Alex S. Goldfarb-Rumyantzev, John F. Hurdle, LevBarenbaum, Zhi Wang, Bradley Baird, John D. Scandling,Alfred K. Cheung. Salt Lake City, UT; Stanford, CA.

156

Adjourn

Joint Session9:45 – 10:45 AM

RoomChairs: Jay Fishman and Richard Howard

What’s Hot, What’s New: BasicAllan Kirk

What’s Hot, What’s New: ClinicalJeffrey Crippin

11:05 AM CYTOMEGALOVIRUS AND HLA-DRMISMATCHES IN US RENAL TRANSPLANTATION.(Abstract #1621)Mark A. Schnitzler, Karen L. Hardinger, Daniel C.Brennan. St. Louis, MO.

11:15 AM Break

157

Notes